

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF FLORIDA
WEST PALM BEACH DIVISION

CASE NO. 20-md-02924-ROSENBERG

IN RE: ZANTAC (RANITIDINE) .
PRODUCTS LIABILITY . West Palm Beach, FL
LITIGATION. . May 6, 2020
.
.

VIDEO CONFERENCING of
MDL LEADERSHIP APPLICATION INTERVIEWS
BEFORE THE HONORABLE ROBIN L. ROSENBERG
UNITED STATES DISTRICT JUDGE

Official Court Reporter: Pauline A. Stipes
HON. ROBIN L. ROSENBERG
Ft. Pierce/West Palm Beach, Fl
772.467.2337

1 *THE COURT:* Okay. Good morning, everyone. This is
2 not a test. We are finally ready to meet in person virtually,
3 at least some of us.

4 Now, let me just say it is a little uncomfortable. I
5 am looking at myself right now, you will see I will be turning
6 to my right many times, and that is because I have notes I have
7 prepared for today's proceeding. Pardon me if my eyes are
8 diverted, it is because I am looking at my other screen that
9 has my helpful notes.

10 As to the others, the non-applicants, I look forward
11 to meeting next week and over the course of this litigation.
12 That should be about a year or so, right? Someone said this
13 was a fast track case? Maybe it has felt that way since so
14 much work has been done in such a relatively short period of
15 time, but I do want to assure you that the Court is going to
16 give all of the parties the time, the commitment, and the
17 attention that the case warrants and deserves.

18 I do very much hope that this day goes smoothly. Lest
19 the record not be clear, all of you are appearing through Zoom
20 because of the COVID-19 pandemic. If all goes well, I will
21 give each of you credit for graciously giving up your time for
22 a testing session and our cohosts, Frank Maderal, Joanne
23 O'Connor and Melanie Richardson for indulging me not only in
24 Thursday's testing session, but also in a pretesting session we
25 held on Monday, and another one yesterday, just to be sure.

1 I do want to take a moment to thank our IT department
2 in helping me. I may be on one end of the spectrum of the high
3 maintenance judges who need a lot of tech support because
4 demands have been great in this case, but they have been
5 helping all of the judges in this district, and I am very
6 grateful. I want to thank Jamie Dodge for all of the work she
7 has been doing as a special master during this time as well.

8 I do not want to encroach on what is your time today,
9 that is, the leadership applicants' time, but I do have a few
10 brief comments I would like to share with you all before we get
11 underway with the interviews.

12 I want to thank all of the applicants for applying for
13 a leadership position. The applications were thoughtful,
14 informative, and they were thorough. I learned a lot not only
15 about each of you, but also about your experiences with other
16 cases, and your vision for leading this case. Your credentials
17 are outstanding, and I truly feel privileged to have all of you
18 as participants in this case.

19 Some of you shared your view of what a leadership
20 structure would look like, and I value those insights as well.
21 It is my intention to make a decision as to the leadership
22 structure and to make leadership appointments following all of
23 the interviews when they are completed at the end of the day on
24 Thursday, and that will be in order to allow the leadership
25 team that I select ample time to prepare for next week's

1 proceeding. I realize the word "ample" is a relative term, I
2 suppose. I hope that if you are not selected for leadership,
3 you will play an active role in the litigation, whether it be
4 in serving on a committee or sub-committee or engaging in
5 common benefit work. The case would certainly greatly benefit
6 from your skills, talent, and dedication that you have shown
7 thus far in submitting your applications.

8 I hope that if you are selected for leadership that
9 you remember the tremendous talent that you have in this pool
10 of applicants and you do everything you can to be inclusive and
11 engaged with all counsel.

12 As there are many seasoned MDL participants among this
13 group, I know that you appreciate and in fact many of you wrote
14 in your application about the need for the Court to employ a
15 leadership team that is diverse, a team that is representative
16 of the inevitable diversity of the Plaintiffs in this case, and
17 a team that affords younger and slightly less experienced
18 attorneys an opportunity to participate in a leadership role in
19 an MDL maybe for the first time. Because diversity is not
20 always apparent on the surface and may not have been showcased
21 in your application, that may be true of race,
22 sexual orientation, or disability, as well as unique life
23 experiences or diversity of thought, I do invite each of you to
24 share with me in your opening statement if you believe you are
25 a diverse applicant, rather than assuming I can tell,

1 especially with the limitations of Zoom.

2 The Court further recognizes the importance of
3 ensuring adequate representation in the leadership team for the
4 full range of cases currently pending in the MDL and
5 anticipated to be filed in the MDL, as reflected in the census
6 data gathered to date, including the economic injury putative
7 class action cases on behalf of consumers and third-party
8 payors; medical monitoring cases; and personal injury/wrongful
9 death cases.

10 I want to thank each of you for completing the initial
11 census forms, although, technically, you didn't have a choice
12 about the matter, but they have been incredibly informative to
13 the Court in understanding the broad parameters of the types of
14 cases filed and anticipated to be filed in this case.

15 While things did not go exactly as planned due to
16 COVID-19, that is we had to cancel our initial conference and
17 leadership applicant interviews that previously were scheduled
18 for March, one benefit of this delay is that I do have the
19 initial census data now and I can more accurately, I hope, put
20 together a leadership team that truly is representative of the
21 different types of cases represented in this MDL.

22 I also appreciated the time you took not only in
23 certifying to the Court the accuracy of your census data, but
24 also in completing your disclosure forms. These disclosures
25 provide the Court with the necessary added assurance that the

1 applicants do not have any conflicts that would compromise
2 their ability to carry out the important role of serving in a
3 leadership role in this litigation. The disclosures also
4 further the goal of instilling transparency in the overall
5 process of managing this case, and thereby promotes confidence
6 in the attorneys selected to act on behalf of so many others
7 who will rely greatly upon their good judgment and fair
8 dealing.

9 The disclosures I have asked the leadership applicants
10 to make are in the same vein as that which I would require of
11 myself that I have required of the vendors in this case, and
12 the special master, and what I anticipate I will tailor for the
13 Defense leadership team as well.

14 The matters sought in the disclosures are the subject
15 of professional rules of conduct and other ethical guidelines
16 and, quite frankly, are the subject of local rules nationwide,
17 and I am speaking specifically about third-party litigation
18 funding. It was never the intention of the Court to exclude
19 any applicant based on any disclosures, but rather, if needed,
20 to engage in a conversation about the disclosures if the Court
21 believed they could raise any question about an applicant's
22 ability to comport with the highest standards of conduct as to
23 all stakeholders and interests in this case.

24 The Court wanted to ensure that the people it was
25 selecting for leadership were the very people making the

1 litigation decisions without any influence from others, for it
2 is you in whom I am placing my trust to lead this litigation.

3 The Court is pleased to report that it gleaned no
4 issues involving any actual or perceived conflicts from the
5 disclosures, and that no applicant disclosed any third-party
6 litigation financing. I am hopeful that this sets at ease not
7 only the minds of those of you who made disclosures, but also
8 everyone involved in this litigation, that who is appointed
9 this week will have my utmost confidence and trust.

10 I am looking forward to not only your opening
11 statements, but to asking each of you some questions within
12 your areas of expertise as I understand it from your
13 applications and the many thoughtful comments of my colleagues
14 within the judiciary whom I have consulted. Fortunately, they
15 have all been available when I reach out to them. These
16 questions are not meant to be gotcha questions, it is not my
17 style or intention. I have an open mind. I really want to
18 give you an equal chance to share with me your thoughts on your
19 areas of expertise. To that end, I want to assure you that I
20 take these as your personal thoughts. I understand that once
21 leadership is in place, you will come together on your united
22 view of how the case will move forward. I will take anything
23 that you say as just your view on how we can best handle this
24 and not a binding statement on behalf of your colleagues. I
25 want to equally assure the Defense you will have an opportunity

1 to share your thoughts next week, and I thank you for your
2 patience and participation in observing today as we conduct the
3 application interviews.

4 So, with that, I hope that no one feels too nervous,
5 if it makes you feel any better, I was very nervous about
6 today.

7 I think a proceeding of this nature can engender
8 stress and anxiety among all participants, but with the added
9 layer of us all using new technology, that creates just a whole
10 new host of issues we haven't experienced.

11 When I related this to my daughter and she said, why
12 are you so nervous, I said I want to make sure the Zoom goes
13 all right. She said, mom, I have six Zoom meetings every day,
14 somebody pings me and I get on a Zoom meeting five minutes
15 later. What is the big deal?

16 I don't know, maybe a different generation. I want
17 you to know if you are feeling nervous about the technology and
18 platform with which we are communicating, I am, too. Relax, be
19 yourself and tell me what you want me to know.

20 With that, I will welcome our first applicant,
21 Ms. Fegan, to enable her video and her microphone, if she
22 would.

23 *MS. FEGAN:* Good morning, your Honor.

24 *THE COURT:* I want to congratulate you on your new
25 firm, I know the fortitude it must have taken. When I started

1 my own firm with my husband on a much smaller scale than yours,
2 it was exciting, exhilarating, and something we took great
3 pride in. Hopefully, starting off as the leadoff candidate
4 will be less stressful for you.

5 With that, let me allow you to move into your opening
6 statement. Don't mind my eyes diverting back and forth. I
7 want to keep a general time I spend with the applicants. I
8 said this, but please read no inferences for how little or long
9 I spend with one applicant, it is not intended to be anything
10 other than certain questions I may have for some and I may not
11 have for other candidates.

12 With that, let me turn it over to you, Ms. Fegan.

13 *MS. FEGAN:* I am here to apply for a position on the
14 Plaintiffs' Steering Committee. I think I can bring lots to
15 the case, and I would like to go back for a bit and tell you
16 how I got to this place and starting a firm, I am actually with
17 my husband.

18 I started with the defense side out of law school, and
19 while there I had a chance to do jury trials as well as bench
20 trials. The pinnacle for me pushing to the Plaintiffs side was
21 a special master's team with the waste management litigation.
22 Through that we got to sit in and watch how a class action
23 works in and out, we worked in discovery and settlement and the
24 Plaintiffs' applications. Through that experience, it was
25 really my first experience with class actions, it caused me to

1 go over to a Plaintiffs' firm here in Chicago.

2 In 2004, my husband and I decided we were not going to
3 open our own firm and approached Hagens Berman. Lucky enough
4 they took us on, and I spent my last 15 years there. While
5 there, I had the opportunity to lead class actions involving
6 pharmaceutical products, there was an over-the-counter drug
7 involving a breach of warranty in the Eastern District of New
8 York. I was part of a team that was developing the early
9 theories on pricing litigation in pharmaceutical cases,
10 including Vioxx. There we had a chance to explore the
11 difference between the benefit of the bargain, out-of-pocket
12 losses and how to make this work.

13 In cases that dealt with defects in pharmaceutical
14 products, I had an opportunity while there to be engaged in
15 multiple monitoring class action actions. I was a monitor in a
16 class action involving lead paint on children's toys that
17 ultimately successfully settled, and am currently involved,
18 with Hagens Berman, in several class actions now before the
19 Supreme Court on the question of whether medical monitoring is
20 a class action by law.

21 In May 2019, we had the opportunity of revisiting our
22 chance of opening a firm together with Tim Scott, hence Fegan
23 Scott. We were appointed counsel in the Allergan class action.
24 I realize that may cause the -- I am applying for a PSC
25 position, there is a lot of synergy in that case and this case,

1 they include the mass and class issues. We have personal
2 injury cases together with class action cases, and we can
3 figure out how to monitor those and bring those together in
4 terms of complaints, building a case together to fight
5 preemption issues, and ultimately create a cohesive team on
6 discovery.

7 I also have a great support team of lawyers at our new
8 firm, lawyers with class side experience as well as personal
9 injury side experience. We can bring those resources to bear
10 in a helpful way.

11 I pride myself in building relationships, working
12 together. I am working hard, frankly, in promoting and
13 mentoring women, this is something important to me, as I am
14 sure you can see from my application. I would appreciate the
15 opportunity to be appointed to the PSC. I welcome any
16 questions.

17 *THE COURT:* Thank you very much. You covered a number
18 of the topics I wanted to go over. Congratulations on your
19 colead appointment in Allergan, plus the new firm. So, I do
20 want to ask you about your time commitment.

21 You indicated you are seeking a PSC role here, and I
22 guess if you maybe can combine your answer, how can you assure
23 the Court that you have enough time for this case, even if it
24 is in a PSC role? I consider that to be a very important role,
25 and I don't think, also, we should get too bogged down with

1 labels because I treat everybody's contribution the same
2 whether with a label or not. In starting a new firm it is
3 exhilarating, you do everything, driving to the bank to deposit
4 the checks. I used to take great pleasure driving up to the
5 teller and depositing our checks. It is time consuming.

6 With that and a senior position as colead in Allergan,
7 tell me about your time commitment and what you see yourself
8 substantively being able to accomplish in this case and
9 contribute not only your expertise, but based on your time.

10 *MS. FEGAN:* From my experience, I have had the
11 opportunity over 15 years to think about and develop systems
12 for managing the administrative function of a law firm. When I
13 jumped into starting our firm, I quickly tried to put in place
14 the types of things that would take the administrative
15 functions off my plate with support staff, with a bookkeeper on
16 site, those types of things. I wasn't playing HR, IT, and all
17 of the roles and trying to lead cases. At this point, with a
18 year under our belt, I am comfortable that is not going to
19 distract. With my husband as a comanaging member, those
20 responsibilities are well shouldered between the two of us.

21 With respect to Allergan, that also has a large PSC,
22 large leadership group. I am going to have to spend time,
23 obviously, working on the case, but at the same time, because
24 of the synergy between the two, I feel that we can contribute
25 in a meaningful way. Some of the things I mean by that, we

1 have spent some time, without disclosing work product with
2 other pending class actions that currently involve class and
3 mass issues, and there are a lot of synergies to be had between
4 people working together, and a way to make sure that the class
5 complaints we are putting out work in tandem -- I am stumbling
6 over myself. I don't want to disclose the other litigations,
7 there are plenty out there right now that people can
8 understand.

9 I think with that work and the time this appointment
10 has, we have the class Complaint on file, we are waiting for
11 the Court's rulings on discovery, discovery is not completed at
12 this point, and I think there is a nice flow between these two
13 cases.

14 *THE COURT:* You spoke about it in your application and
15 mentioned it here, diversity. You have been in a major firm,
16 and you have your own firm. What can the Court do to promote a
17 diverse and inclusive environment within leadership? And I
18 will wrap into that question, being able to take pride in
19 working with people, not only diversity and inclusiveness,
20 being a nice person, working well with your colleagues and
21 those on the Defense, while still being a zealous advocate.

22 *MS. FEGAN:* I think fundamentally, when we talk about
23 civility among lawyers, it is important when working with your
24 colleagues and the defense side not getting caught up on minor
25 procedural issues versus agree to disagree on substantive

1 issues, and forge relationships with your co-counsel and
2 opposing counsel.

3 It is important to recognize there are a lot of young
4 lawyers who have had much less experience even than I have, and
5 haven't had the opportunity to stand up in court and argue
6 discovery motions and those types of things, have a leadership
7 that recognizes when there are big issues lead counsel are the
8 ones to present and argue, but also developing younger lawyers.
9 Working on motions for discovery, and allowing to bring that to
10 the Court will strengthen them the next time when they stand up
11 for a position like this of PSC. There are ways for
12 leadership, once appointed, to help develop the younger lawyers
13 so the next time around they have a fair shot.

14 *THE COURT:* Thank you.

15 And I guess I will conclude with a question at this
16 early juncture. Don't be thrown by it, it is okay if you don't
17 have answer with specificity, but do you have a vision of this
18 case?

19 *MS. FEGAN:* I think the vision is one working closely
20 at the outset with the personal injury side to ensure that we
21 have a cohesive set of facts that are going to survive 12(b)(6)
22 motions, thinking about the generic versus brand issues which I
23 think will weigh heavily at the outset.

24 If we can build that foundation now, and I know the
25 committees have been working on that and I appreciate the work

1 they have done, building that foundation now is going to be
2 critical to the next stage. If the time isn't spent at the
3 outset on development, that case can quickly devolve. My focus
4 is on what can be done on the front end to assure the case is
5 solid as the case went forward.

6 *THE COURT:* Excellent. Sit back, turn your mike off,
7 video off, get a cup of coffee, relax, and I thank you very
8 much.

9 At this point, if I could ask Ms. Wolfson to turn her
10 video on and her audio on. Good morning, Ms. Wolfson.

11 *MS. WOLFSON:* Good morning. Is it okay, can you see
12 me?

13 *THE COURT:* I can. I want to let you know I
14 appreciate you directly addressing your firm's finances in your
15 application. Not all firms, big and small, have the resources
16 to properly advocate for Plaintiffs here, I was impressed by
17 your statement and look forward to even more impressive remarks
18 from you now.

19 Let me turn it over, if I can, to you for your opening
20 remarks.

21 *MS. WOLFSON:* Thank you so much. I am applying for
22 the opportunity to serve the class as lead counsel in this
23 litigation. I want to thank you on behalf of the class and as
24 a citizen for your efforts and devotion to continuing to
25 provide access to justice in these trying times. I want to

1 thank the interim lead team in these trying circumstances.
2 Their professionalism and dedication are paramount and I have
3 gotten to know all of them.

4 I am qualified to join that team for three reasons:
5 Number one, the depth of my substantial experience in consumer
6 class act litigation. I have practiced in this area since I
7 founded my firm in 1998, it is an intricate, evolving area of
8 law, and it is very, very important to have someone in this
9 case with such experience.

10 I am well versed in the issues that will be seminal to
11 the success of this class action, and I look forward to
12 contributing those efforts.

13 Number two is my deep sense of permanent
14 accountability to the class and the Court. I do not apply for
15 every position, every mega class action, because in my 20 years
16 of experience, I am profoundly aware of the type of commitment
17 this case requires both financially and in terms of personal
18 focus. If you appoint me, you can expect me to live and
19 breathe this case, to see me, not a partner or associate, at
20 every conference, at every hearing, to have the final pen
21 stroke in every paper we present to you. I will be thoroughly
22 prepared and not just address, but participate in the issues
23 that arise in this complex litigation.

24 Finally, I think I can offer my effective leadership.
25 I pride myself in leading effectively and with an open mind, I

1 like people and join in the collaborative effort with senior
2 attorneys as well as younger attorneys. I know I can harness
3 all of the talent among the Plaintiffs' counsel here in
4 organizing in an efficient manner for the best outcome of the
5 case.

6 I would love to answer any questions you may have,
7 your Honor.

8 *THE COURT:* Thank you, Ms. Wolfson.

9 So, as I asked with Ms. Fegan, you, as I understand
10 it, are on the Allergan PSC, and so, similarly, I would like to
11 know about your time availability, your commitment to that
12 case, your availability to this case, and wrapped into that,
13 what role you envision for yourself in this case and what you
14 would substantively want to do.

15 So, let's start with kind of that bucket of questions.

16 *MS. WOLFSON:* Sure, your Honor. I am on the executive
17 committee, and I must say Ms. Fegan is doing an excellent job
18 in that case, in Allergan.

19 I described that currently my commitment is about ten
20 hours per month. That is because there is a large executive
21 committee available and we do what is asked of us, we
22 collaborate, but it is up to the lead counsel to make sure work
23 is allocated efficiently and nothing is duplicated. So, we
24 offer deep experience in that case, but it is a limited role.

25 The role of lead counsel here is different, it is just

1 as much applying your substantive knowledge to the case as well
2 as leading a team of lawyers. It is really like running the
3 firm, I take the same skills I have for running my firm, which
4 I have over two decades, to running a PSC, that is, to listen
5 to people and to understand what their talents are. I know
6 many of the members of this team already from working in other
7 cases, and I look forward to meeting the new ones and getting
8 to know them more.

9 I pride myself to be able to assess people's set of
10 skills and utilize that in an inclusive matter, but with an eye
11 toward efficiency so work is not duplicated. There are a lot
12 of management skills in a case like this.

13 The work I can do his the large acknowledger case, to
14 the granular of the class action issues. I am a class action
15 attorney, not a mass tears attorney, this involves a large
16 class and entitled to relief and subclass who people have
17 suffered devastating personal injuries, based okays he is luck
18 all irrelevant begin, I know how to combine the synergies of
19 the two teams. There are a lot of issues that would need to be
20 brought to this case so the larger class can be addressed
21 appropriately.

22 In terms of my vision for the case, I approach every
23 case as we are getting ready for trial, and so there is going
24 to be a long life, hopefully not too long, to this case that
25 has to do with, you know, the initial pleadings, and from that

1 getting -- I always prepare a case as if we are going to trial.

2 At the same time, I think communication with opposing
3 counsel, not just the Plaintiffs' team, is extremely important,
4 and to discuss the possibility of a resolution from the outset,
5 there are resolutions that need to be resolved before those
6 conversations can begin, but it is very important to build a
7 solid relationship in communication with opposing counsel.

8 I pride myself on collaborating with opposing counsel.
9 As set forth in my application, I participate in a lot of
10 boards as well as C will be events in conjunction with opposing
11 counsel and the judiciary. I have been invited by defense
12 counsel to speak at their own in-house marketing events and
13 present my trials, and things like that.

14 I hope that answers your question.

15 *THE COURT:* You answered my question and the next
16 three.

17 *MS. WOLFSON:* I'm trying to anticipate.

18 *THE COURT:* You have answered everything. I wanted
19 examples of your collaboration with opposing counsel, you have
20 spoken about that. I will conclude with any other thoughts,
21 anything else that you feel you would like me to know?

22 *MS. WOLFSON:* Um-m-m, well, your Honor, maybe on the
23 issue of diversity, it is in my application, what may not be
24 obvious just from looking and talking with me, I do have the
25 unique experience of being -- my family came to this country as

1 political refugees, and I do think this is my passion, this
2 work. I meet the appreciation for the rights of our judicial
3 system that maybe someone who is born in this country takes
4 more for granted.

5 I like to pride myself on the immigrant work ethic.
6 My family started from nothing, bringing themselves up by the
7 bootstraps in this country and bring that to the dedication to
8 the work I do.

9 *THE COURT:* That was very touching, reading about
10 that. Thank you for bringing it up in our conversation here
11 today. Thank you so much, you too can relax. I want to thank
12 you for your application and time, Ms. Wolfson.

13 *MS. WOLFSON:* It was very enjoyable, thank you, your
14 Honor.

15 *THE COURT:* Mr. Albert. There you are.

16 *MR. ALBERT:* Good morning.

17 *THE COURT:* Good morning.

18 *MR. ALBERT:* Good morning, your Honor.

19 *THE COURT:* As I recall from your application, you
20 spent about 11 years or so teaching the law --

21 *MR. ALBERT:* Not teaching the law, I was an elementary
22 school teacher.

23 *THE COURT:* Limiting your comments to two minutes, you
24 have to do a lot of talking, and hands-on work teaching
25 elementary or high school, that is incredible. I have always

1 had admiration for teachers, especially today seeing what
2 teachers are being called upon to do with students, having to
3 do it remotely.

4 So, with that, if you can squeeze your -- you know
5 what, actually, before you do your opening statement, I would
6 ask if we could pause for a moment because others wanted to be
7 admitted, and we were trying not to admit anybody during
8 anyone's interview unless somebody inadvertently came in. Let
9 me pause for a moment and give the cohosts an opportunity to
10 permit anyone else who is waiting in the waiting room.

11 I am told we are good.

12 With that, let me turn that over to you for your
13 opening statement.

14 *MR. ALBERT:* Thank you, your Honor. If someone told
15 me three months ago that I would be sitting here in a Zoom
16 conference in an interview with a judge over a Leadership
17 Steering Committee position, I probably would have said, what
18 is a Zoom conference?

19 As a seasoned attorney, when I started out we didn't
20 have computers, everything was by hand on paper, and things
21 have changed quite a lot over the years.

22 I understand that there are many, many excellent
23 candidates in this, and I know the judge will rule in this case
24 and it will be the right rulings.

25 I am Lee Albert, I am an attorney with Glancy Prongay

1 and Murray. I have been an attorney there since 2012, and I am
2 a candidate for the steering committee in the Zantac case. I
3 represent one individual who brought an economic class action
4 claim under consumer law.

5 I want to spend a minute telling you who I am.

6 I was an elementary school teacher for 11 years.
7 After 1986, I became an attorney, and I have been told by many
8 other lawyers, as well as clients, that you explained this to
9 me a lot better than any other lawyers can explain it to me,
10 you are good at what you do in terms of talking to clients,
11 talking to other lawyers.

12 I have used that experience of having been a teacher
13 in the law with dealing and mentoring young attorneys. There
14 are a number of young attorneys in my firm, I mentor them. And
15 I was part of the Avandia case, I was not in leadership in that
16 case, I had a number of attorneys beneath me looking at
17 documents. I explained how you are looking at documents, why
18 you are looking for it, how to look for it.

19 My role would be that continuing mentoring process. I
20 expect there should be a large number of younger attorneys in
21 this case that I can mentor and help along the way in the work,
22 in the bulk of the work being done by these attorneys.

23 Most recently, I held the position of lead counsel in
24 an antitrust case which is now completely concluded, Korean
25 Ramen Direct Antitrust in the Northern District of California,

1 before Judge York. I had that case prior to the Complaint to
2 the end of the jury verdict, class certification and summary
3 judgment.

4 I have worked in executive committee positions in
5 other cases. I am currently on an executive committee in July
6 in an antitrust drug matter, a paper delay matter, but I do
7 have the time to work on this case. The fact of the matter is,
8 if I didn't have the time to work on this case, I would not
9 have applied.

10 I understand that this Court can only select but a few
11 people, and if I don't get selected, hopefully I will continue
12 to work on the case and working with the younger people that
13 would be on the case.

14 I do think it is significant that members of the
15 steering committee be on -- have clients that have consumer
16 cases and do not have injuries, because both the mass court
17 clients and the class clients need to be developed in different
18 ways. There could be some conflicts, and therefore they both
19 need representation.

20 Finally, your Honor, whether I am on the leadership or
21 executive steering committee in this case, I would recommend
22 Mr. Steve Berman for a leadership position. Mr. Berman helped
23 develop this case, and I am working with him, and I think he
24 would be an excellent choice as well.

25 I think I did this for three minutes.

1 *THE COURT:* You might be more accurate. We have been
2 going for four minutes and 45 seconds, but some of that was my
3 time.

4 Thank you. I apologize, I did not get the teaching
5 role correctly, but I admire perhaps even more the work that
6 you previously did, and I think that is a very interesting
7 transition, to have been an elementary school teacher and now a
8 lawyer and one who is active in MDL litigation. I know you
9 were involved in the Yahoo case, which is, as I understand
10 it, a large MDL. Can you tell me the lessons you learned in
11 that?

12 *MR. ALBERT:* The Yahoo case, I had a tangential role
13 in it.

14 *THE COURT:* All right. So, what particular
15 substantive areas of expertise do you think you would bring to
16 this case?

17 *MR. ALBERT:* As I said, helping younger attorneys get
18 themselves involved in the case, telling them what the
19 questions are, telling them how they have to approach the case.

20 I, miss in a lot of cases I have been involved in
21 deposition work, quite frankly. As a member of the steering
22 committee, I believe the leadership that is in this case are
23 the ones that guide my way in what I should be doing in the
24 case. I don't see the steering committee position as a
25 leadership position, and I take my guidance from whoever is

1 leading the case.

2 *THE COURT:* Okay.

3 *MR. ALBERT:* I think one other issue worth mentioning,
4 it is important that the attorneys in this case work
5 efficiently. I see from the number of people on Zoom, there
6 are a lot of people here, work has to be done efficiently, and
7 that is something that I can work with people to make sure it
8 is done in a manner that is not overly spending too much time
9 on. Time has to be watched in cases such as this.

10 *THE COURT:* I appreciate that. I think that is very
11 important, I appreciate that very much. Okay. Mr. Albert, I
12 want to thank you for your time, for your application, and the
13 time you put into it.

14 We will move on to our next applicant whom you have
15 introduced in some respects, and that is Steve Berman.

16 So, Mr. Berman, you can turn your mike on and your
17 video on.

18 Good morning. You need to turn your audio on.

19 *MR. BERMAN:* Good morning, your Honor.

20 *THE COURT:* Okay, terrific.

21 You got a nice introduction from Mr. Albert, I don't
22 know if it was planned or not. You fell in the lineup as you
23 did. As I recall, you are on the West Coast, right?

24 *MR. BERMAN:* That is right.

25 *THE COURT:* A little bit earlier for you. Thank you

1 for getting up so early.

2 I would like to turn it over to your opening
3 statement, and your credentials are quite outstanding and I
4 read them carefully, maybe also addressing how you see yourself
5 assembling a team with others to best advocate for the
6 Plaintiff, and maybe you think of it as building a dream team,
7 and how you promote diversity. Since you are the
8 quintessential repeat player in the MDL world, I'd welcome
9 those to be included in your comments.

10 MR. BERMAN: Thank you, your Honor. I am glad you
11 mentioned nervousness. My daughter said, why are you nervous?
12 I said, well, it is an important matter, and I always get
13 nervous when there is something important.

14 In trying to decide leadership, you need lead counsel
15 to demonstrate a -- I'll give you one example as a testament to
16 my leadership skills. In the Toyota acceleration MDL, NASA
17 came up with a study and said there is nothing wrong with that
18 and moved to dismiss the case, and I said I don't agree with
19 NASA, I want to keep going. I convinced the leadership to keep
20 going and put in tens of millions of dollars, eventually we
21 got -- (unintelligible).

22 The second thing I want to mention is that I care
23 about what the client gets. Too often there is a pile of money
24 and the class members are told to make a claim. We at Hagen
25 Berman are -- \$350 million were distributed to people, all they

1 had to do is log on to the Amazon account and they got money.

2 So, in this case, I envision we have to do something
3 like that, and I have a team that we can bring to bear in this
4 case.

5 In terms of leadership style, your Honor, one thing I
6 would mention is my leadership style is such that I get respect
7 from people on my side, but after some of my hard fought cases,
8 defense lawyers are my best friends. I think that speaks to
9 what I bring to the Court, the respect of everyone involved.
10 I'd bring that leadership style here.

11 I also bring to the Court, I have been creative in
12 managing MDL's. Particularly on the MDL side, I was the first
13 lawyer in a class action to do a -- (unintelligible).

14 Now I can understand the issues, and so we have been
15 bringing these bellwether case management things to MDL courts
16 all over the country. I can bring that to the world.

17 The dream team. So, my vision of a dream team would
18 be co-leads on both sides working together, and in the General
19 Motors case just finished, we had in that case two co-leads on
20 the consumer side and two on the personal injury side.

21 We worked so well together, I co-tried with Mr.
22 Hilliard the first personal injury case. I see co-leadership
23 working together on common issues, but maintaining separate
24 lines of inquiry, and I envision on drawing on young lawyers to
25 get out there, do the depositions, help with the motions and to

1 be inclusive as much as possible.

2 I think diversity is important. Mentioning female
3 lawyers to be partners and lawyers in my firm, including
4 Ms. Fegan and Ms. Barnes, I know worked with jam lie dodge, and
5 those are inclusive.

6 Those are my items.

7 *THE COURT:* Thank you very much. You took one of the
8 first questions regarding diversity and as I -- tell me a
9 little bit about the state claims.

10 What do you see happening with state claims? Do you
11 anticipate state claims on the class side or do you think the
12 MDL will predominate? I realize it is early, but you have had
13 experience. From what you've gleaned so far.

14 *MR. BERMAN:* What I think is going to happen, your
15 Honor, we have interviewed just in my own firm 1700 class
16 members, and we filed a census form, 55 of us. What we are
17 trying to do is get a good representative from each of the
18 states. As I envision it there will be a master Complaint with
19 the state laws of all 50 states and decide and review how do
20 you handle motions to dismiss with the laws of 50 states, that
21 could be very complex, but I do believe consumer cases will
22 involve state law claims.

23 We brought those state law claims and dozens of class
24 actions. We are aware of what the requirements are for state
25 law, and we bring that knowledge to the master plan.

1 *THE COURT:* All right. I want to understand a little
2 more about what role you see for yourself.

3 You have explained to me a structure that you think
4 worked well in GM, and perhaps you believe that would work well
5 here, co-leads on the class, co-leads on the PSC side. Tell me
6 again, you don't have to repeat everything you said, what role
7 you see for yourself, how you interact with others with lesser
8 roles, and wrapped into that, if you are not selected as
9 co-lead, would you prefer a PSC position or have a colleague,
10 for example, on the PSC. As you indicated, you worked hard to
11 mentor many in your firm over the years.

12 *MR. BERMAN:* Your Honor, I see myself as one of the
13 co-leads focusing on the economic loss cases. There should be
14 more than one co-lead. I had a case with Judge Cohen with me
15 alone, and I said, no, I want another head, two heads are
16 better than one, and she went against the normal appointing one
17 and she appointed two, and it worked out very well.

18 I see myself being one of the co-leads. If I can't, I
19 am willing to serve on the PSC.

20 *THE COURT:* And lastly, could you share with me at
21 this juncture, above and beyond what you have said, insight you
22 have as to how to make this MDL successful? And maybe you can
23 even tell me what you think successful means so I don't have
24 any pre-conceived notion of what successful means.

25 *MR. BERMAN:* Successful on the Plaintiffs' side is

1 convincing the Court -- I know there would be perhaps
2 opposition to this, go to a bellwether approach, pick a couple
3 of states to test the sufficiency of those states and get those
4 states ready for trial. It is a massive task to certify, you
5 and us, for all 50 states, very few Courts have done that.

6 For me, success is getting the bellwethers up and
7 ready for trial as soon as possible, and if we have to, try the
8 case. The bellwether trial in a class case should give insight
9 as to the strengths and weaknesses and present a position --
10 place us in a position where we could resolve the case. To me,
11 that is success.

12 *THE COURT:* Any sense of, based on your experience,
13 how much time between now and when you would have a vision of
14 at least a class bellwether case going to trial?

15 *MR. BERMAN:* Realistically, if we work really hard, we
16 should be able to get to a class certification stage on a
17 bellwether in 12 to 15 months.

18 *THE COURT:* Okay. All right. So, those are all the
19 questions I have. Anything you feel you want to tell me that
20 you haven't had a chance to?

21 *MR. BERMAN:* One thing, and this is unusual, I am
22 blessed here in Seattle to be next to Amazon and Microsoft and
23 leading corporations in the world, and in the last week I have
24 had access to return to work, best practices that we are
25 working on here in Seattle. One thing I feel strongly about,

1 if we have to push the case forward, we have to do it safely,
2 so I hope to bring the knowledge I have and implement it and
3 how to do that. It is a complicated process, we have do to do
4 it securely. Plaintiff side, Defense side, all the witnesses
5 need protection, and I will bring that knowledge to this.

6 *THE COURT:* I appreciate that. Thank you for the work
7 you have done out there. I know you have struggled, as many of
8 us have, Seattle has COVID issues. So, you know the Court
9 feels the same way, put safety above anything else, if we can
10 do them simultaneously which is what the Court is attempting to
11 do. Thank you so much, have a nice rest of the day.

12 We'll turn to Mr. Gilbert who can turn on his video
13 and audio.

14 Good morning, Mr. Gilbert.

15 *MR. GILBERT:* Good morning, your Honor.

16 *THE COURT:* Different background than last time, not
17 virtual, but real.

18 *MR. GILBERT:* It is real. I may have misunderstood
19 your questions, I think you asked others if it is a virtual
20 background or not. It was my library, it was a photograph of
21 my library.

22 *THE COURT:* That counts as a virtual. So, I asked my
23 daughter the other day, should I have a virtual background for
24 the hearings today? She said, mom, that is ridiculous, you are
25 going to be in your courtroom. Just another stupid question by

1 somebody who hasn't had all of the Zoom experience that the
2 younger generation has.

3 I welcome you and I would like to now give you the
4 opportunity to give your opening statement.

5 *MR. GILBERT:* Thank you, your Honor. It is a honor to
6 be in your courtroom by Zoom.

7 First, I would like to express my gratitude for the
8 opportunity the Court afforded to me over the past several
9 months to work as part of the practices and procedures and
10 initial census teams and subsequently with the expanded
11 deliverable team.

12 It is a great experience for me and all of us, I
13 believe. I am proud to say that the lawyers who are part of
14 that team, most of them I didn't know before this case began,
15 are now my colleagues and friends, and that is a great way to
16 start a case.

17 I would like to add to that I believe we have evolved
18 from a group of individuals with different skill sets and
19 personalities to a great team already. I hope the Court
20 recognizes that we have accomplished a lot under trying and
21 difficult circumstances.

22 I would like to express appreciation to Special Master
23 Professor Dodge.

24 Your Honor, as I mentioned in my application, the
25 decision you will make after these interviews today and

1 tomorrow is a decision that is not the ordinary decision that
2 District Court Judges make in civil lawsuits, but an extremely
3 important decision that is going to impact this litigation from
4 now until the conclusion.

5 The Court is going to create a virtual law firm, a law
6 firm to represent in advance the best interests of the
7 Plaintiffs, putative class members, victims, people who
8 purchased, used, and in many cases were diagnosed with cancer
9 after using a drug that is now recalled from the market.

10 The law firm that you create to promote the advanced
11 interests of the Plaintiffs is going to square off against some
12 of the most powerful companies in the world who are represented
13 by outstanding legal talent at formidable law firms.

14 In order to advance the Plaintiffs' interests this law
15 firm that the Court will help create needs top-notch lawyers
16 with experience in many different areas, something I believe
17 and am proud to say our interim team members have already
18 demonstrated. The law firm needs managing partners, as Mr.
19 Berman alluded to and alluded to before, to lead the team as it
20 carries out the legal battle plan.

21 One more thing that I would submit, every lawyer who
22 is chosen for this team needs to have another quality, and that
23 is the ability to work cohesively, something our interim teams
24 have shown already in our work today.

25 Judge, this month marks my 34th year of practicing

1 law, it is hard for me to get my arms around it, but it is
2 true, and over those years I have had the opportunity to
3 develop, work up, and try many large and complex cases. I have
4 also had the honor to be appointed to teams on many different
5 positions in MDL's.

6 As your Honor knows, I am relentless when it comes to
7 the pursuit of justice for my clients. As Mr. Berman, my
8 colleague, mentioned, again, I know what it is to take more
9 than a decade to bring to victims the recovery that they are
10 entitled to.

11 I understand the commitment required to pursue justice
12 for the victims in this litigation, and as humbly as I can
13 express it to the Court and others on the call, I am confident
14 I have the experience, skills, and temperament to help with
15 this litigation as your Honor creates it, and if you elect me
16 to this responsibility, I vow to carry out the duties to the
17 best of my ability every day and I pledge confidently to the
18 team that you will have my undivided dedication until
19 concluded.

20 I am happy to answer questions.

21 *THE COURT:* Thank you. Financial questions, your
22 comfort level in taking on a case of this nature, the
23 standpoint of having resources available to you should you
24 serve in a leadership position, and more generally, what
25 resources do you think are needed on the class side?

1 MR. GILBERT: Let me answer it in two ways. I will
2 talk about human resources and financial resources. I'll take
3 the financial resources first, that is a more straightforward
4 question.

5 First, I can assure the Court, as I did in my
6 application, I and my firm have more than adequate financial
7 resources to shoulder our fair share of the burden that will be
8 imposed on the Plaintiffs' leadership team that the Court
9 creates.

10 Every member of the leadership group, whether the PSC,
11 PEC, co-lead counsel, every member of that leadership team will
12 have to shoulder his or her fair share of that financial burden
13 and leaders often times, if not always, have to shoulder a
14 larger financial burden than other members of the PSC, and I am
15 prepared to shoulder that burden.

16 On the human resource side, to directly answer your
17 question with regards to the class action, I am confident that
18 the team that is already working on an interim basis is ample,
19 is adequate, in fact, is in my view a dream team already, and
20 any additional resources that you add to that team will only
21 compliment what we already have.

22 Mr. Dearman, who you will interview shortly, and his
23 firm, Robbins Geller, not only have I worked with them for a
24 decade and know them personally, but they are for all intents
25 and purposes the equivalent of a big -- when we refer to big

1 law on the defense side, Robbins Geller has the human resources
2 to be the big law on the Plaintiffs' side. That he has
3 afforded to assist us is a tremendous asset.

4 Ms. Whitely, who is also part of the team and part of
5 the -- and has much experience as well, her firm is smaller,
6 closer to the size of ours. Ms. Whitely is involved in a
7 leadership capacity in a drug case that has quite a bit of
8 similarity to this case, the Valsartan case. Ms. Whitely's
9 experience and knowledge in that case will be invaluable as we
10 move forward with the class action process in this case as
11 well.

12 In addition to Mr. Dearman, Robbins Geller, and
13 Ms. Whitely, we have others on an interim team participating on
14 the class side, they are outstanding, extremely beneficial.
15 There are other applicants extremely well qualified. Should
16 the Court supplement others with additional ones, it would
17 further complement the team.

18 I see a class side of four or five firms who are
19 devoting largely all of their time to the class related work,
20 and there are others who are part of the interim leadership
21 group already who I refer to as utility players because they
22 have experience on the class side and personal injury side and
23 can be of great assistance to both sides.

24 *THE COURT:* Okay, thank you.

25 How many class Master Complaints do you think should

1 be filed if you were in a leadership position to make that
2 decision? If you are able to make that decision or -- again,
3 recognizing all of this is personal at this juncture, for the
4 class side, what are you thinking about for Master Complaints?

5 *MR. GILBERT:* I am thinking about two Master
6 Complaints at this point in time. One would be a Master
7 Complaint called the consumer economic loss medical monitoring
8 Complaint, those are individuals who are not yet diagnosed with
9 cancer and seeking economic loss and/or medical monitoring as a
10 result of their purchase and use of Zantac or other products.
11 That is Master Complaint number one.

12 Master Complaint two is a Complaint brought
13 exclusively by what are called third-party payors, and that
14 Master Complaint will seek economic loss only on behalf of the
15 putative class who paid for or were reimbursed for their
16 insureds' or members' purchases of this particular drug.

17 *THE COURT:* Okay, thank you.

18 You touched on the staffing, I think maybe as relates
19 to the class side. What about total staffing, what are your
20 thoughts as to the broader MDL as to total staffing?

21 *MR. GILBERT:* In terms of a leadership group as a
22 whole, I know in my application I mentioned a range of 12 to
23 18. Based on my experience of the two and a half months and
24 knowing what we know today, I would slightly increase that
25 number. I think PSC in total, or whatever you refer to it as,

1 leadership team -- I refer to it as PSC -- I would say 16 at
2 the low end and 20 at the top end is the ideal size of this
3 case at this time. I don't think we need a larger PSC at this
4 point in time, but recognizing how litigation evolves, I would
5 say that if we find -- if I am entrusted to be part of the
6 leadership of this MDL, this steering committee, if we found at
7 some point in the future more members of the leadership team
8 are necessary, I wouldn't hesitate in suggesting to the Court
9 that you expand it beyond others.

10 The 16 to 20, I fall into the sweet side of 18, that
11 is a number I like. There are a number of lawyers out there,
12 many of whom filed cases, some of whom applied for leadership
13 spots, some of them have not. They have resources, human
14 resources that we can call upon to assist us both on the class
15 side of this proceeding as well as the personal injury side of
16 the proceeding.

17 If the Court were to entrust me as one of the leaders
18 of this case, I can assure you I will be reaching out beyond
19 the leadership team to call upon those resources, particularly
20 younger members of the Bar, less experienced members of the
21 Bar, and diverse members of the Bar.

22 *THE COURT:* Okay, all right. Have you said everything
23 you wanted to say?

24 *MR. GILBERT:* I have, other than it is an honor always
25 to appear before the Court. As you and others have mentioned,

1 it was a little anxiety raising in anticipation of today. It
2 would be much easier to drive 45 miles up to your courthouse
3 and walk right in. That explains why I woke up at 4:15 in the
4 morning to get ready for the day. Thank you for giving me the
5 opportunity for the last two and a half months and for today.

6 *THE COURT:* Thank you, Mr. Gilbert.

7 We will now turn to Mr. Dearman who, like Mr. Berman,
8 already got an introduction from Mr. Gilbert, and you are the
9 most official looking of all of us there at a podium. Is that
10 for real or at your house? I welcome you, the Zoom podium is
11 yours. That is true.

12 *MR. DEARMAN:* Thank you, your Honor.

13 *THE COURT:* Good morning.

14 *MR. DEARMAN:* Good morning. I have to tell you a
15 story. My wife said, you are more nervous than you usually
16 are, and I said, of course we are, we have this technology that
17 we never had before. She said, my third graders do Zoom every
18 day.

19 *THE COURT:* I am in the same situation, my children
20 have said the same thing.

21 *MR. DEARMAN:* I am a partner at Robbins Geller in the
22 Boca Raton office. I am seeking a position on the PSC or
23 whatever capacity the Court desires.

24 I understand this is an individual appointment. If
25 appointed, the other members of the team will have my full

1 commitment and that of the unparalleled human resources of
2 Robbins Geller. We are over 200 lawyers and ten officers who
3 handle class action litigation.

4 If appointed, I will spend the time necessary to
5 advance this litigation. Upon my appointment to the teams, I
6 have done just that. I started to transition from other
7 responsibilities, many of my other responsibilities, and since
8 that time I have spent almost all of my time in furtherance of
9 my team responsibilities, case management, scheduling issues,
10 initial meet and confers, and to me of most importance,
11 strategizing regarding Master or consolidated Master
12 Complaints.

13 We have had discussions about it already. Mr.
14 Gilbert's strategy is one that I am in favor of, and what
15 facts, what legal theories, what class definitions are all
16 things we are continuing to work on.

17 These are tasks that I am intimately familiar with as
18 a direct result of my experience in other large MDL's,
19 Volkswagen, opioids, Apple devices and others. For the last
20 decade I have spent most of my career in the MDL context.

21 I am proud of my reputation, which is to always
22 collaborate and cooperate with my colleagues. MDL's are
23 unique, you mentioned this during the test, they are unique.
24 If appointed, you get the opportunity to work with many other
25 lawyers from different places, different cultures, with unique

1 perspectives on litigation. It is that organization that
2 properly managed with that collaboration leads to an efficient,
3 effective, and a successful MDL.

4 In this case already, with the Court's guidance, and
5 Special Master Dodge's guidance, we are advancing the
6 litigation. A lot has been done, I have only been doing it for
7 the past month, but the teams are working really hard. The
8 teams, besides Mr. Gilbert, I have never worked with before,
9 and I have come to learn to respect and enjoy collaborating
10 with them.

11 My class experience -- my MDL experience is set forth
12 in my application, doesn't include class -- we only included
13 class actions, doesn't include MDL's. I have served in many
14 roles in MDL's, I have been appointed and supported other
15 partners in my firm in cases they have been appointed in, and
16 cases that I have been appointed in, many members of the firm
17 supported me, which I see happening here.

18 I see cases start to finish. I am asking to be
19 involved on the class side, which is what I do. I understand
20 class certification, I recognize it will be hard fought, but I
21 am confident we can prepare the Court with a path to certify
22 classes. Without disclosing any privilege, I am happy to
23 discuss that.

24 I'm a team player, I have been doing this for 20
25 years. I make a commitment to the Court, the parties, and

1 other appointees that I will continue to spend the time
2 necessary to collaborate to effectively, efficiently, and
3 successfully litigate this MDL.

4 *THE COURT:* Thank you, Mr. Dearman. I understand you
5 have worked on the Apple and opioids case. How are you
6 balancing that?

7 *MR. DEARMAN:* Apple is an easy one, we have an
8 approval hearing next week, that is coming to conclusion. As
9 far as National Opioids, my partner, Paul Geller, was appointed
10 to the PEC. I am one of many lawyers in the firm who supported
11 him in that case, I have spent a significant amount of time in
12 that very important case. I began transitioning the majority
13 of my responsibilities to other members on the team. We have a
14 deep bench here, and that is one of the benefits. This case is
15 in my backyard, I am in Boca Raton. It is an important case.

16 I represent individuals who have been diagnosed with
17 cancer, I represent individuals in the economic loss case, and
18 I represent third-party payors, health and welfare plans, so it
19 is an important litigation, and I have the time to spend to
20 properly collaborate and litigate this case.

21 *THE COURT:* Okay. Why do you think your leadership
22 appointment will be important to the success of the MDL?

23 *MR. DEARMAN:* We are going to be going against the
24 largest companies in the world who have the biggest defense
25 firms in the world, and I think it is important to have an

1 equalizer and have firms on the other side who have the same
2 power.

3 A case I was involved with, Household, a securities
4 class action litigation, it lasted 14 years. We tried the case
5 once, ended up with roughly a two billion dollar judgment, and
6 for ten plus years we dealt with appeals as we were getting
7 ready for the second trial, and all during that time we had to
8 finance that litigation. If we were unable to do that, that
9 would be in the putative class' best interest. It is important
10 to have a firm who has a deep bench and sustaining power as
11 part of any team.

12 *THE COURT:* You spoke about civility and
13 professionalism in your application. How do you think it could
14 be fostered in the MDL?

15 *MR. DEARMAN:* Anybody involved in an MDL tells you
16 inclusion is very important, it is lawyers who are going to
17 seek the position in the future, the current lawyers who do it
18 all the time. I mentioned my reputation, I think it is
19 important to be inclusive and include everyone and anyone who
20 wants to work. You get a lot of unique perspectives in an MDL,
21 and those perspectives allow you to successfully litigate these
22 cases.

23 *THE COURT:* Thank you very much. Anything I didn't
24 ask you or you didn't say before we conclude?

25 *MR. DEARMAN:* Other than thank you very much, I

1 appreciate it.

2 *THE COURT:* Thank you, Mr. Dearman, have a nice rest
3 of the day.

4 With that, we'll turn it over to Ms. Whitely who can
5 turn on her video and audio.

6 *MS. WHITELEY:* Good morning.

7 *THE COURT:* How are you?

8 *MS. WHITELEY:* I am well, thank you.

9 *THE COURT:* I appreciate all of the work you have
10 done, and you heard Mr. Gilbert speak highly of that, and I
11 have been monitoring the best I can through my orders and
12 working with Special Master Dodge, so I am most appreciative of
13 the work that you and everyone have done.

14 So, let me turn it over to you for your opening
15 remarks.

16 *MS. WHITELEY:* I would like to thank you in particular
17 for all of the amount of work you have done to move this case
18 forward in the past several weeks. I have seen the opposite in
19 other courts and it has been refreshing to see how much work
20 that you and Special Master Dodge have been able to do, and we
21 very much appreciate that.

22 I want to thank you for the opportunity to serve on
23 the team. I compliment the comment in the amount of
24 cohesiveness and comradery we put together, we do make a good
25 team. I have learned a lot in this process and a lot from my

1 colleagues on the various teams we are working on now, and I
2 hope I am able to make some contributions as well.

3 There is an impressive skill set in the team you did
4 put together, and I learned a good bit from them.

5 I am applying to serve on the Plaintiffs' Steering
6 Committee, and I have adequate experience in pharmaceutical
7 litigation to add to that team. I currently, along with my
8 co-counsel, represent Plaintiffs in the four innovator
9 liability class actions that were filed in California,
10 Illinois, Vermont and Massachusetts, and I am co-counsel in the
11 Valsartan MDL, I can bring direct experience from that case
12 along to this one. There are similarities, and there are
13 differences, sometimes differences are even more important. I
14 believe that there are things that we learned there and that we
15 have done there that we can bring to bear here, and there are
16 many things in this case that are different, and before then we
17 started to work on those differences.

18 I mentioned I primarily have class action experience.
19 I started my first class action case along with my senior
20 partner in 1996, a RICO class action trial in San Juan which
21 was tried to verdict, which was a very interesting first case
22 to be on as an associate, and I have done class action work
23 since then.

24 For the past decade my work has switched from long
25 term care insurance litigation to pharmaceutical litigation,

1 both in the context of antitrust litigation in cases such as
2 this one. And I have -- through that litigation have developed
3 an understanding of third-party payor claims and state law
4 reimbursement claims, Medicaid. I represented the State of
5 Louisiana in several instances, including the Avandia case,
6 which we litigated before trial and it settled. It was a
7 meaningful case to our state. I believe I can bring that
8 experience to bear here.

9 With that, I would like to answer any questions you
10 may have for me.

11 *THE COURT:* Thank you, Ms. Whitely.

12 You touched on it, but any kind of major one or two
13 insights from the work you have done so far that come to mind
14 that you want to share?

15 *MS. WHITELEY:* Yes, your Honor. I believe that
16 because, you know, the significant differences between this
17 case and the Valsartan case that we are working on involve
18 over-the-counter medication and a significant amount of pills
19 here, and something --

20 *THE COURT:* Let me just -- there is noise in the
21 background, I don't know if it is coming on your end or
22 somebody else's. I remind you that we have a court reporter
23 here, I want to make sure everything is taken down. There is a
24 scratching noise.

25 You were talking about over-the-counter medications.

1 *MS. WHITELEY:* Yes. I agree with the comments
2 Ms. Fegan made about early on structuring the case to deal with
3 all of those issues. As we came into the case a lot of the
4 preliminary work had been done, and done very well, and in the
5 past four weeks to five weeks we have been building on that
6 work, focusing on the retailer issues. We have been
7 investigating the API issues, which are an important component
8 of this case, and I believe we really need to structure through
9 the Master Complaint and initial discovery every aspect of the
10 case so they can work in tandem inclusively in an appropriate
11 manner.

12 *THE COURT:* Touch on, if you would, the innovator
13 liability class actions in the four states.

14 *MS. WHITELEY:* Those are the four states that have
15 acknowledged this and it is -- basically, our class in those
16 four states are purchases of generics of the brand Defendants.
17 It is developing in other states as well, but those are the
18 states that have the clearest law where, because of the brand
19 manufacturing, what they put together early on, the generics
20 are required by law to rely on it and basically copy what they
21 are doing in their language.

22 The brands manufacturing at the outset said this would
23 happen. It is a blockbuster that once the patents had expired
24 they would develop generics. Their duties would be upheld not
25 only to consumers of their own products, but those of generics.

1 *THE COURT:* Okay, thank you.

2 I know you have spoken at some length in your opening
3 about your insights from Valsartan, and there are some
4 similarities and some differences. If you had to hone in on a
5 top level takeaway that you can bring from Valsartan to share
6 with me, as I know you would be able to share throughout the
7 litigation, kind of what comes to mind?

8 *MS. WHITELEY:* Well, the distribution chain is one of
9 the things that we are working on in the Valsartan case, and I
10 believe all of those things will be worked out before we need
11 to address them specifically in this case.

12 We have worked with the retailers and wholesalers'
13 counsel in that case to learn more about it and who is doing
14 exactly what. It has taken us quite awhile to unravel that,
15 but we are at that stage now where we can determine exactly who
16 is doing what, whether it be from the API manufacturer or the
17 finished manufacturer, down to the wholesalers and retailers,
18 we can save a lot of time in this case not having to reinvent
19 the wheel on those issues. We have a lot of the science in
20 common because of the MDMA that is common to both.

21 *THE COURT:* Okay. Given your role in Valsartan, can
22 you tell me what your time commitment is to Valsartan, and how
23 you have been able to balance your time in Valsartan with the
24 time in this case and how you see that going forward?

25 *MS. WHITELEY:* Yes, I have a significant time

1 commitment in the Valsartan case, I intend to keep that
2 commitment. The case is moving quickly, it is well managed by
3 the Court and by our group, but I do have the time to commit to
4 this case as well. I have done that through the April
5 deliverables team, and in my personal experience, I finished a
6 two-year commitment where I had a substantial obligation to a
7 non-profit and it ended in January. That freed up some of my
8 time.

9 My firm was gracious enough to allow me a significant
10 amount of time to serve with that non-profit. Now that that
11 ended, I have more time to devote to this case.

12 *THE COURT:* All right. Anything else you would like
13 to add?

14 *MS. WHITELY:* I would say this, in the Valsartan case
15 I worked closely with my team, Layne Hilton and Amneca Timez
16 (phon), we worked together over eight years, they were
17 paralegals with me. After they passed the Bar they became
18 attorneys here, and they are tremendous young women with a
19 great work ethic, and I would like to have the opportunity to
20 bring their services to bear in this case as well.

21 *THE COURT:* Thank you very much, Ms. Whitely, I thank
22 you for your time and application, and wish you a nice rest of
23 the day.

24 *MS. WHITELY:* Thank you.

25 *THE COURT:* Next we'll turn to Mr. Honik.

1 With that, I turn it over to you for your opening
2 statement. Good morning. How are you?

3 MR. HONIK: Good morning. Thank you very much for the
4 opportunity to appear before you, albeit virtually, and thank
5 you for your candor, it is refreshing in my 40 years of
6 practice. It is rare that a judge, let alone a Federal Judge,
7 conveys their own nervousness, and you have done a great deal
8 to make us feel comfortable in your courtroom and it bodes well
9 for the future.

10 In the limited amount of time, I would like to not
11 focus on my experience, which I think is laid out in my
12 submission to the Court, but to make four observations that I
13 think perhaps may be helpful to the Court in developing this
14 leadership structure.

15 Let me say in advance I don't presume that you or the
16 deliverables team had not thought about these matters, but I
17 think they are important for me to stress.

18 Point number one, I believe there should be close
19 coordination between whatever leadership structure is appointed
20 here and that of the Valsartan litigation. The science of MDMA
21 contamination, which is the issue in Valsartan in the context
22 of a medicine, and the one here is very similar. We have a
23 running start in Valsartan, almost a year and a half developing
24 four class experts who undoubtedly would comment on the
25 contamination both in the arts involved in Valsartan and

1 Zantac.

2 Another thing is the interplay between the class and
3 economic components in the case and the bodily injury
4 components, there are points of overlaps and differences. In a
5 small way in the last year and a half to serve as a co-lead in
6 Valsartan we were able to sort out where those differences
7 exist, and it would help mightily to incorporate in this
8 litigation.

9 Point number two, I want to encourage the Court not to
10 be afraid to have a large lead structure here. In Valsartan,
11 we have four co-leads. Ms. Whitely and I serve on the class
12 side and there are two bodily injury co-leads, we make
13 decisions jointly. That is important to the success of that
14 litigation thus far. I urge the Court to have an executive
15 committee, that is to say sort of a board where the co-leads
16 could serve as chair people in order to make strategic
17 decisions in the case.

18 In Valsartan, we have four. We have a relatively
19 large steering committee consisting of 26 members, soon to be
20 increased by four, or as many as five, because the MDL
21 includes -- we have functioned very effectively that way.

22 I think the third point I would like to stress is the
23 Court should ensure there is adequate representation in this
24 litigation for the TPP class. That is an extremely important
25 component for the economic position here, and it is an

1 excellent membership to the deliverable team. I would like you
2 to ensure there is an appropriate representation for the TPP
3 aspect of the case in this matter.

4 Finally, the fourth point is somewhat intangible. I
5 would encourage the Court to look for characteristics of
6 leadership that ensures trust, confidence, and harmony between
7 and among Plaintiffs' lawyers.

8 Take a moment and consider the obvious, all of the
9 applicants before you today, albeit the structure, you end up
10 appointing are all competitors and what we are being asked to
11 do is work collaboratively in an intense way for a protracted
12 period of time.

13 I think finding leadership that has the kind of human
14 intelligence and experience to instill confidence and instill
15 harmony is a very important characteristic.

16 I think one of the benefits of this time period where
17 we have been working in this informal interim leadership manner
18 is that the Court and the -- and Ms. Dodge have been able to
19 assess some of those human intelligence qualities, and I
20 encourage the Court to stress that.

21 There is nothing more dispiriting after working many
22 years on an MDL successfully where you get the parties on each
23 side to agree, and at the conclusion, when there is a
24 settlement and resolution you have back end litigation or
25 litigation between the Plaintiffs.

1 One of the ways you can avoid that, and we all can
2 avoid that, is to ensure we have the kind of leadership which
3 brings the characteristics to bear.

4 *THE COURT:* Thank you. Thank you for being so
5 thoughtful and sharing these four points with me. I appreciate
6 that and I have been listening carefully.

7 So, with your role in Valsartan, what type of time
8 commitment do you envision having in that case and how would
9 that dovetail with any commitment you envision being required
10 if you are appointed to a position in this case?

11 *MR. HONIK:* For many years now I have been circumspect
12 about what I put on my plate, I handle fewer than ten cases.
13 Valsartan is the only MDL case I am involved in. We have a
14 rather deep bench at my firm. I have worked with associates
15 for many years now who are invaluable to help me steer and
16 engender the work I am able to do. I am confident that in any
17 position except a co-lead position I could serve effectively in
18 this matter.

19 *THE COURT:* And I was going to ask you about innovator
20 liability class actions. I asked Ms. Whitely about that. Is
21 there anything more you want to add to what she said about
22 innovator liability class actions?

23 *MR. HONIK:* We are co-counsel in the innovator cases
24 we brought. Innovative liability is developed in the four
25 states where we brought those actions.

1 They result in the case -- there is a Supreme Court
2 case that ordinarily prohibits liability attaching to generic
3 manufacturers so long as the labeling mirrors the grant.
4 Recognizing the unfairness of that, the states developed
5 innovative liability to address innovative liability of the
6 brand for the generic because of the inadequacy of the label.

7 *THE COURT:* Okay. You express in your application you
8 have a reputation for working effectively with Defense counsel.
9 Why do you think you have that reputation? What is it you do
10 that has earned you that reputation?

11 *MR. HONIK:* I think, your Honor, that treating others
12 with candor and fairness and recognizing our vulnerability and
13 frailness has always pervaded how I approach what we do.

14 There is a somewhat unwanted reputation of Plaintiffs'
15 lawyers being aggressive or sharp. There is a way to be
16 effective and strong without being unkind. Candidly, for the
17 many years I have been doing this work I've treated folks I
18 work with in the manner I always like to be treated and I think
19 it pays dividends for effectiveness and congeniality and
20 results that everybody can live with.

21 *THE COURT:* Okay. Anything else you want the Court to
22 know that I haven't given you the opportunity to express?

23 *MR. HONIK:* No, your Honor, except thank you for
24 today.

25 *THE COURT:* Thank you so much, I appreciate your

1 application. Have a nice rest of the day.

2 MR. HONIK: You do the same.

3 THE COURT: All right. With that, we will ask Mr.
4 Martinez-Cir to turn your mike and video on. Good morning.

5 MR. MARTINEZ-CIR: Thank you for this opportunity.

6 THE COURT: You are welcome. Thank you for your
7 application. Without any further ado, let me turn it over to
8 you for your opening statement.

9 MR. MARTINEZ-CIR: Thank you, your Honor. I know the
10 Court has read all of the applications and submissions, and I
11 appreciate it.

12 I hope my dedication to this matter has come through
13 in other filings. I have been very committed to and worked
14 very hard in bringing together many of the great lawyers that
15 are before the Court today and collaborating with them and
16 organizing.

17 I also think I have a number of skills that would
18 benefit the leadership in this case. I typically work on very
19 complex product liability, wrongful death, and personal injury
20 cases from inception to trial, and I also have experience in
21 class action cases, economic loss and medical monitoring.

22 So, this case with that significant class component
23 and the thousands of personal injury death claims is one that I
24 have experience to bear.

25 When Mr. Gilbert spoke about the utility player role,

1 that is one that Special Master Dodge described me in and Mr.
2 Gilbert described me, too. It is an important role in this
3 case, it is important to bridge the gap wherever there is one,
4 and make sure that we are working together to benefit in a
5 collaborative efficient way the entire case and move it
6 forward.

7 I think -- I hope that experience and that involvement
8 in this case from the beginning is what -- is attributable to
9 something I am very proud of. I am among one of the most
10 recommended lawyers to your Honor, 11 of the 13 of the team
11 recommended me, that is why they asked me to become involved in
12 the important work the Court has put together. I worked
13 closely with the class action group Mr. Gilbert was talking
14 about earlier. We are a small group, but working effectively.

15 I have worked with the discovery committee very
16 closely. Particularly, I worked with just a few -- I won't get
17 into any work product, but I have been blessed with real
18 responsibility to take on a leadership role in that aspect, in
19 that work, and I have been working with the ESI team, and with
20 the legal research and briefing team, so it is something I hope
21 to continue to be able to do.

22 I think, you know -- I hope I would be recommended by
23 all 13. I would say without hesitation I would recommend all
24 13 that your Honor was wise to appoint. I have seen the way we
25 have worked so effectively and collaboratively together on the

1 litigation, so I am proud to be able to recommend all of them.

2 As far as going forward in this case, I think the
3 Court has heard from a few different folks on division of
4 leadership structure. I will give the Court a hybrid.

5 I suggest a three-person co-lead situation, one of a
6 consummate class action lawyer, and the Court has heard from
7 many very experienced, very good class action lawyers, one mass
8 tort personal injury, wrongful death lawyer, and the Court has
9 many fantastic ones to choose from, and I would like to humbly
10 suggest myself as that utility role player among the co-leads.

11 I think an odd number is always good, and I think
12 exactly what Mr. Honik was talking about a moment ago, the
13 ability to collaboratively bring people together, I think that
14 is my strong suit. I hope that has come out in the nice things
15 that were said in the appendices.

16 I worked early on in bringing the folks together
17 before the MDL hearing in Tampa, and when disagreements arose
18 among Plaintiffs' counsel to work and bring everyone together
19 to reach a consensus and make everyone actually not just feel
20 they were able to contribute, but honestly to bring in that
21 contribution to learn what everyone has to say is very
22 important. And so, I like Mr. Gilbert's idea of something
23 around 18 or 20 PSC members. Mr. Honik is not wrong, it could
24 be bigger. This is a very important piece of litigation and we
25 are going to need contribution from a lot of folks.

1 I think the PSC can be helpful. If the Court is
2 inclined to have an executive committee, that often helps
3 manage a case of this magnitude and this many firms involved.

4 So, I know the Court has talked about diversity. My
5 background being Latino is diverse, I have diverse experience
6 in having actually worked on the defense side of an MDL, having
7 a trial on the defense side as a very young associate in a
8 class action litigation, and my experience obviously on the
9 Plaintiffs' side going back to 2002. I have been here for 18
10 years, I am proud of having mentored young attorneys in the
11 community, but also in the firm.

12 I am very proud of having brought in Lea Valdez at the
13 time, now Bucciero, brought her in. She mentored, I trained
14 her and trained her and she is the first female partner my firm
15 had in 20 years. She continues to work closely with me. Were
16 the Court to appoint me, she would be involved in this case,
17 she is a fantastic attorney.

18 With that, I turn over the case --

19 *THE COURT:* Don't turn over the case to me, that is
20 your job. No. So, I do want to acknowledge and thank you for
21 the work that you have been doing volunteering, so to speak, on
22 a number of aspects, and without disclosing any attorney/client
23 work product matters, pick one, whether it be of the class
24 action work, discovery in the PSC, what you would like to tell
25 me about in terms of your role?

1 MR. MARTINEZ-CIR: On the discovery side, the Court
2 gave the team a clear directive in trying to develop as much as
3 possible very good work product that the leadership will be
4 able to take and run with, and I was given the responsibility
5 to work on third-party discovery very closely. I have worked
6 with a few members of the team and put together what I think
7 are solid draft discovery requests on a number of different
8 fronts, forms that can be adapted per individual third parties,
9 but on broad categories that are going to be needed in this
10 case, and so I think that is probably an easy one to discuss
11 with the Court.

12 THE COURT: Okay. And you have spoken about your
13 assets, among others, as being a utility player. It seems like
14 you have a diverse practice, less in the form of an MDL area.
15 I want to give you an opportunity to address that.

16 MR. MARTINEZ-CIR: Absolutely. I don't have a lot of
17 pharma experience, MDL's. I am very careful about getting into
18 very few MDL's. I typically will only work on one at a time
19 and certainly not all the time. But a lot of my work -- for
20 example, I worked in mass actions. I am currently on the
21 executive committee of the Ethiopia Air 302 case in Chicago,
22 that was not an MDL, cases in South Carolina and other states
23 were dismissed. It is a mass action, but I work in that area.
24 And I am board certified in aviation which has a lot of overlap
25 with dealing with regulators, dealing with arguments on

1 preemption, so many of the things we are dealing with in a
2 pharma case that we deal with.

3 Frankly, a lot of my strength is not in talking
4 specifically about a pharma case, but my strength is in
5 managing, my strength is in bringing a team together to
6 collaborate and making sure we get the right people. We have a
7 great pharma bench that the Court has before it, there is deep
8 experience on the Plaintiffs' Bar for that as well.

9 *THE COURT:* Okay. Is there anything that you wanted
10 to let me know that I haven't had a chance to ask you thus far?

11 *MR. MARTINEZ-CIR:* No, I think that covers it. I
12 appreciate the Court's time.

13 *THE COURT:* Thank you very much, Mr. Martinez-Cir, I
14 appreciate the work you have done and wish you a nice rest of
15 the day, although maybe you will sit on and watch.

16 I have gone a little bit out of order. I apologize if
17 I have thrown anybody. I think it is a result of the fact that
18 I have, among my additional organizational tools here, a screen
19 to the right which has the application folders in one note, and
20 I am told there is only one way in which so many names will
21 appear at the top right, and you have to scroll way over to the
22 right and do a drop down and the names appear.

23 Somehow I maybe have called people out of turn. That
24 is probably a horrible thing to do for those people I skipped
25 over and are probably feeling even maybe more nervous than they

1 should feel.

2 While I work in one note regularly, it is not often I
3 have 15 tabs going across the right screen while looking at
4 myself, and fortunately you when you pop on in front of me.

5 Again, more learning lessons. Don't worry, I haven't
6 forgotten about you. I apologize for calling some people out
7 of order. And have I outright skipped anybody? Yes, I skipped
8 two people.

9 Let's circle back and let's go to Mr. Mestre, if we
10 could, and that may have been why you were right there when
11 your video came on.

12 *MR. MESTRE:* I did jump on.

13 *THE COURT:* All right. Mystery resolved. No worries.
14 Just so you know, Ms. Westcot, same issue with you, so we will
15 get to you next.

16 So, with that being said, and not to take up any more
17 time, Mr. Mestre, let me allow you to address the Court.

18 *MR. MESTRE:* Thank you. The timing worked out well,
19 like everybody, I am learning this, and I have my two daughters
20 in high school about 15 feet away from me. Their break started
21 just when I got on, and got off. They were on a break, so it
22 worked out quite well.

23 *THE COURT:* Are they like co-counsel there? Are they
24 going to be joining you?

25 *MR. MESTRE:* Maybe at some point they will take over.

1 Funny enough, my wife is also a lawyer and she is doing a
2 conference as we speak.

3 *THE COURT:* Bring it all on.

4 *MR. MESTRE:* I appreciate the opportunity to
5 interview, your Honor. To answer your question first about
6 diversity, I am a diverse candidate, I am Hispanic, I am
7 president of the Hispanic National Foundation. During this
8 pandemic it is important so there is equality.

9 I have diverse experience, I have tried ICC cases in
10 Spanish in Mexico City. I have done internal investigations in
11 the United States, in Central American countries, and global
12 legal work in the Chevron case, ground work for filing 72
13 applications for discovery in the proceeding, and we have
14 discovery in this Court.

15 We had two matters relating to the Harvoni drug where
16 your Honor certified two different classes that permitted
17 coverage for 9,000 people who wanted to obtain the Harvoni drug
18 and were unable to obtain it. And coincidentally, we just had
19 a fairness hearing on Tuesday in front of Magistrate Judge
20 Becerra and we are expecting a class settlement any day now.

21 I also have been very involved in the Valsartan case,
22 and you met a lot of the team, and you get a sense we all like
23 each other very much and have developed a good working
24 relationship.

25 With that, I want to talk about my claim a little bit.

1 In the MDL, we are the only third party payor class
2 claim, third party payor meaning the entities that pay for the
3 drugs, which include traditional health care, health insurance
4 companies, HMO's, PPO's, self insured employers, Medicare
5 Advantage organizations. That is the claim, that is the
6 putative class.

7 Mr. Gilbert alluded to the fact that he thinks it
8 should be pled as a separate Master Complaint. We actually
9 debated this in Valsartan, and it could have gone either way.
10 We decided -- in Valsartan, we decided there to include it in
11 the Master Complaint, but it could have been a separate
12 Complaint and there are pros and cons to both. I am pleased to
13 hear that is being thought about and considered.

14 Your Honor, the reason it is important, until 1995,
15 this was exclusively a prescription drug for which the third
16 party payors would have paid the lion's share.

17 With my personal health insurance policy, when I go to
18 the pharmacy, it either pays 90 percent of the cost of the
19 prescription drug or there is a \$10 copay, and the third party
20 payors pay the rest. We have given after that date, post 1995,
21 we took it from my cuff I a, which is one of the standards for
22 this point of sale information, at least 15 percent of Zantac
23 after 2008 was still prescription based, and to give you an
24 idea of what those numbers look like, it is at least 40 million
25 prescriptions since that date. It is a significant number.

1 Beyond that, many of the plans -- you have probably
2 seen a lot of the MAO's, Medicare Advantage Organizations, they
3 have periods of enrollment and give benefits during the periods
4 of enrollment. Some of the benefits include supplemental
5 insurance coverage for over-the-counter medications.

6 Some health insurance, commercial health insurance
7 plans do that as well, it is plus, plus, plus, the prescription
8 amount, eight on or nine on percent of that, plus the over the
9 counter and, your Honor, we pled, I will not get into the
10 tolling consents, we plead totaling consents, delayed
11 discovery, concealment, if you go beyond the last four or five
12 years and we are able to go back to where we think we ought to
13 go back, these third party payors really have, if you think BS
14 he C material which is five to ten percent, we are way above
15 that.

16 So, what I am hearing in hearing Mr. Honik and Mr.
17 Gilbert talk about this, I can fairly say there is agreement
18 that the third party payors having a material stake in this
19 litigation is a class that needs to be represented, and we
20 believe that we are in the best position to do that.

21 I'm pretty good when I am the only person who filed
22 it, so -- but regardless, we think we are in a good position
23 having done this in Valsartan. We also have been representing
24 third party payors in antitrust pay for delay cases in San
25 Francisco, Delaware. We have been doing a lot of the third

1 party payor work for years.

2 Folks have been talking about sustaining power, I met
3 my law partner and my wife 22 years all, I am still practicing
4 law and I am still marry had to the same person. I think we
5 have sustaining power. I am trying to stay brief, I hope that
6 is okay.

7 *THE COURT:* Sure. You addressed the TPP claims. That
8 is something I wanted to ask you about.

9 What about what happened in the Seven Circuit with
10 MSP; can you comment on that?

11 *MR. MESTRE:* Yes. I think you are talking about the
12 assignment issue.

13 *THE COURT:* The sanctions that were ultimately
14 overturned.

15 *MR. MESTRE:* I am not sure I was personally involved
16 in that case. I thought your question was going in a different
17 direction. MSP is a company that has assignments from various
18 TPP's, maybe a hundred of them, Emblem Health from New York,
19 SummaCare, so major, major players in this field, and at the
20 beginning there was an issue that was litigated about the
21 assignments, first of all, that has now been upheld, number
22 one, and number two, it is different assignments.

23 That issue has gone away. The Seventh Circuit case --
24 I have a colleague who is texting me and listening. We weren't
25 the lead on that case, and that issue has been resolved by -- I

1 wasn't personally involved, but I would be happy to give you
2 more information separately, or talk to Special Magistrate
3 Dodge about it.

4 *THE COURT:* That would be fine. I did some research
5 and looked at what the Illinois Federal Court did. I
6 understand the Seventh Circuit pulled back the sanctions, but
7 if you didn't have a role in that, that is helpful, that is
8 helpful to know.

9 *MR. MESTRE:* I can tell you neither me nor any of my
10 law partners, and I have six law partners, have ever been
11 sanctioned.

12 *THE COURT:* So, your client has been MSP Recovery.

13 *MR. MESTRE:* I am representing MSP Recovery in this
14 case and MSP Recovery in other cases. The antitrust cases that
15 I referenced are on behalf of MSP Recovery, that is right.

16 *THE COURT:* Do you want to tell me anything about MSP
17 Recovery?

18 *MR. MESTRE:* Well, what they do is get assignments
19 from various third party payors, major entities like Emblem,
20 SummaCare and others, and they help recover moneys. In cases
21 like this one, based on these assignments, these are moneys
22 that, you know, they paid for a drug that wasn't what it was
23 supposed to be because of the MDMA contamination, and based on
24 the assignment, we're able to bring these claims and recover
25 this money on their behalf.

1 *THE COURT:* Okay.

2 *MR. MESTRE:* We mentioned some of the assignees in the
3 Complaint, so it is not a black box. In the Complaint we say
4 here are some example assignors that have claims in this
5 matter, and we did that in this Complaint.

6 In fact, in Valsartan, for instance, there have been
7 Plaintiffs' fact sheets, and the Plaintiffs' fact sheets --
8 there were specific Plaintiffs' fact sheets designed for the
9 third party payors.

10 It is very hard, a have different type of question,
11 akin to a census type of application. You have it narrowly
12 tailored to the third party payors, that was designed with our
13 input and negotiating with the Defendants, and within that, we
14 gave a lot of the data that we have which is a very important
15 component.

16 So, if you think about the amount of assignments they
17 have, they have a tremendous amount of data which is valuable
18 during class certification stages, summary judgment stages, if
19 you have a bellwether trial. If you have an economic class, be
20 it bellwether or not, there is a lot of information that will
21 be found out about the actual assignees during the course of
22 discovery in this case, I am sure.

23 *THE COURT:* Okay, all right, terrific. Thank you. I
24 hope our breaks are timing up with your daughters' so you can
25 be in sync with one another. Thank you for your information

1 that you shared with the Court, I appreciate it.

2 *MR. MESTRE:* Your Honor, I appreciate it. It is good
3 to see you again.

4 *THE COURT:* Now, Ms. Westcot. She jumped to the video
5 because she doesn't trust the Judge. I wouldn't either after
6 that.

7 Let me pull you up. You are very much here on my
8 screen. We have so many of you, you got pushed over to the
9 drop down.

10 Good morning. We will continue with the Valsartan
11 streak here. So, let me first allow you to give your opening
12 comments if you'd like to, and we will get into some questions.

13 *MS. WESTCOT:* Thank you, your Honor, I appreciate the
14 opportunity to be heard.

15 My name is Sarah Westcot, I am a partner with Bursor &
16 Fisher, we filed one of the first cases, we have three offices
17 in New York, San Francisco, and Miami. I am the managing
18 partner in the Miami office, we have 17 attorneys, we are not
19 short staffed. We have the manpower and financial resources to
20 take on a case like this.

21 I think I have the professional experience to take on
22 a role on the steering committee, most specifically I will
23 mention the Valsartan litigation. My firm is on the steering
24 committee there, we are also on the economic loss subcommittee
25 and the discovery committee.

1 We have been working extensively putting together the
2 class action economic Complaint, corresponding documents,
3 research, and thus heavily involved in the class certification
4 briefing shortly.

5 I am in a unique position here, I am a first-time
6 applicant for a leadership position, but in my role as a
7 partner of my firm I have been involved working with other
8 partners who had leadership roles, and was the person behind
9 the scenes doing the heavy lifting, research, briefing, taking
10 depositions. I have been doing all of the work behind the
11 scenes and not having my name on the leadership role.

12 In addition to Valsartan, I worked on a number of drug
13 cases, Zicam, an over-the-counter drug, Hyland's, all of which
14 settled in wide class settlements.

15 I want to touch briefly on the diversity you
16 mentioned. I bring as a younger applicant -- I am one of the
17 younger applicants in my firm, I think that would bring a
18 unique perspective particularly as we are dealing with the
19 current situation in the world, technology. I am definitely
20 familiar with all of the technological opportunities and how to
21 facilitate collaboration remotely. It is not something I am
22 uncomfortable doing at all.

23 Another point, my firm is the only firm filing cases
24 against the generic manufacturers, generic manufacturers like
25 Dr. Reddy, Arego (phon). I have been in a unique situation

1 because there is a lot of different discovery there, different
2 document requests received from Zantac, different depositions,
3 so I think that maybe there is a need to have a representative
4 that has some of the generic cases because there may need to be
5 a separate track for those Complaints.

6 And I welcome any other questions you have.

7 *THE COURT:* Are you doing okay with the technology?

8 *MS. WESTCOT:* Yes.

9 *THE COURT:* Okay. Let's see. So, you mentioned that
10 your firm was on the PSC in Valsartan. Let me clarify, what
11 has your role been?

12 *MS. WESTCOT:* My name is not on it, it's one of the
13 other partners in our firm, but I have been heavily doing the
14 work behind the scenes, document requests, Complaint drafting,
15 class certification research, documents, things like that.

16 *THE COURT:* Did you get the support of the partners in
17 your firm who otherwise served more visibly in leadership
18 roles?

19 *MS. WESTCOT:* Yes, they have requested and made known
20 they thought I would be a fit for this, and took a step back
21 and allowed me to apply for this position.

22 *THE COURT:* What do you think is the greatest strength
23 you may bring and one of the greatest challenges you may find?

24 *MS. WESTCOT:* One of the greatest strengths is that I
25 am no stranger to doing hard work, that is what I do

1 day-to-day, more of the, you know, down and dirty litigation
2 work, drafting, research, depositions, things like that.

3 Maybe it's not necessarily a weakness, but somewhere
4 where I could grow is organization of individuals at a high
5 level like this, which is where some of the other applicants
6 may have experience, in a co-leadership role managing as a
7 co-lead and managing on a Plaintiffs' steering committee. I
8 see my role as more of a -- not necessarily, you know, division
9 of labor and deciding what is going to happen, but to step
10 forward and doing that work in that role.

11 *THE COURT:* Given you have been doing a lot of work,
12 be it behind the scenes, in Valsartan, and you have other
13 cases, how are you going to manage your time commitment with
14 Valsartan with any role in this case?

15 *MS. WESTCOT:* I am busy, but I do not have another MDL
16 role, my role in Valsartan is behind the scenes.

17 Other applicants do have a role in Valsartan. I have
18 the support from other partners who are named in that Valsartan
19 role and I would step back and do more work on this.

20 *THE COURT:* They would call on you less to make sure
21 you have ample time in this case?

22 *MS. WESTCOT:* Yes. I am truly familiar with the
23 science and discovery and overlap that would occur in this
24 case.

25 *THE COURT:* Okay. It may be early, both just because

1 we haven't gotten off the ground and you haven't served on a
2 leadership role yet, just from what you have seen so far and
3 what you have seen in Valsartan, what vision do you have in
4 this case?

5 *MS. WESTCOT:* We need to get a strong foundation, kind
6 of get an idea how we want to structure things, what is going
7 to be on the Master Complaints, how things are going to be
8 divided. I would anticipate, as one of the applicants
9 mentioned, separating and doing a combination of the economic
10 class and monitoring on a separate Master Complaint and make
11 sure it is in place where we figure on getting off running.

12 *THE COURT:* All right. Anything else you want to say?

13 *MS. WESTCOT:* I don't think so. Thank you, your
14 Honor.

15 *THE COURT:* Thanks, have a nice rest of the day.

16 *MS. WESTCOT:* Thank you. You, too.

17 *THE COURT:* We are not going to call upon Mr.
18 Martinez-Cir again, that is where he would have fallen. Now
19 let me make sure I get the right tab up. Ms. Kelly Hyman.

20 Good morning, Ms. Hyman, how are you?

21 *MS. HYMAN:* I am doing well. Nice to see you.

22 *THE COURT:* Good to see you, too.

23 Okay. So, let me have you begin with your opening
24 statement.

25 *MS. HYMAN:* Thank you. Hello, my name is Kelly Hyman,

1 co-counsel for Plaintiffs Lynn White and Gregory Wayland.
2 While the first MDL was formed in 1968, it took almost 47 years
3 for the first PSC to have a majority of women. A recent study
4 released found that the over wait of woman in leadership
5 between 2011 and 2016 was only 16.5 percent. I encourage you
6 to appoint 50 percent of women in the leadership position.

7 The Duke Law Center study showed diversity in
8 experience and gender enhances creativity in leadership. I am
9 not asking you to appoint women because we are women; I am
10 asking you to appoint women because we are just as competent as
11 male attorneys in what we bring to leadership.

12 I bring the type of diversity that has been lacking in
13 MDL leadership. My mom was born in Australia, and my
14 grandfather in Lebanon. I was a professional actress, I
15 started acting at age five, and my mom, she asked if he could
16 get me an agent. After considering what he knew about me, he
17 had enough faith in me to give me a chance. He recommended me
18 to an agent who enabled me to get acting jobs.

19 My practice areas focus on consumer class actions and
20 mass court litigation. I represented hundreds of litigants on
21 the American Spirit case, I represented clients in water
22 contamination class actions with a medical monitoring claim. I
23 have been a member of trial teams defending the clients in
24 deposition, our expert deposition, and took the expert
25 depositions in these cases.

1 While I have extensive experience in this litigation,
2 I have yet to be appointed to a PSC. If I am selected, I will
3 work diligently and provide leadership based on my background
4 and diverse experience. I am hard working and organized. I
5 know the resolution of mass claims requires attorneys on both
6 sides of the case working together. I hope you have enough
7 faith in me to give me a chance.

8 As a final note, your Honor, I would not be applying
9 for a leadership position without the support of my co-counsel.
10 If there is one place in which Elizabeth and I are appropriate,
11 I would request you select Elizabeth, she has more experience
12 than me and is an amazing competent attorney who supports
13 women. Thank you.

14 *THE COURT:* Thank you. That was nice of you to say
15 about Ms. Fegan. Are you back from Colorado?

16 *MS. HYMAN:* I am in the -- we drove out to Colorado
17 and I am in my basement in my house in Colorado. Otherwise, I
18 would be in Florida.

19 *THE COURT:* From your experience, how do you see the
20 timing of motion practice in this case, in the consumer class
21 part of the case versus the PI cases, if you have had a chance
22 to give that any thought?

23 *MS. HYMAN:* I think it is important to have two
24 tracks, I think it is important to have class counsel and PI
25 counsel, but I urge the Court to consider having settlement

1 counsel as well. I know they have done that in other MDL
2 litigation, so there be that track moving the case forward in
3 regards to settlement, and that settlement group to handle that
4 and the class move forward, and also the PI, and work
5 cooperatively together. But I think the case is moving very
6 fast, your Honor.

7 *THE COURT:* Okay. What do you think about class
8 certification; do you think that should come before or after
9 general causation, Daubert issues?

10 *MS. HYMAN:* Yes, your Honor, I do think it should come
11 after. I think, from that perspective, it should come at that
12 point in time.

13 *THE COURT:* And how do you see discovery overlapping
14 or differing as between the class track and general PI track?

15 *MS. HYMAN:* I think there are issues, and I think it
16 is important for the team to work cooperatively and I think
17 class counsel should be a lead or co-lead position dealing with
18 the class certification, in those issues as well, and have the
19 PI as well. I also ask the Court to possibly consider doing --
20 on the PI actions, doing the bulk Complaints where they do it
21 in actions, rather than filing individual cases, file bulk
22 Complaints that have multiple Plaintiffs on it. It is very
23 beneficial for the Plaintiffs because they don't have to incur
24 additional filing fees for each case.

25 *THE COURT:* Okay. I will conclude with what is the

1 best insight or advice you would want to give the Court on an
2 MDL? I recognize you haven't served in a leadership role yet,
3 but with your background and experience, what would you want to
4 impart to the Court?

5 *MS. HYMAN:* Besides what I said, I have seen through
6 the Court's filing that there are a lot of pro se people filing
7 different letters with the Court. I know in Actos they had one
8 attorney as a liaison that helped the people that didn't have
9 an attorney, they didn't give them advice, but provided them
10 updates and was a point person to assist people that weren't
11 represented.

12 *THE COURT:* Okay. All right. Is there anything more
13 you wanted to share with the Court that I didn't give you an
14 opportunity to do?

15 *MS. HYMAN:* I want to thank you for the opportunity.
16 If I am selected, I will definitely work hard and I would
17 welcome the opportunity.

18 *THE COURT:* Thank you, Ms. Hyman, great to see you
19 again.

20 *MS. HYMAN:* Thank you, your Honor, nice to see you.

21 *THE COURT:* Now we have Mr. Lear next, Mr. Brad Lear.

22 *MR. LEAR:* Hello, your Honor. As nervous as I am, I
23 can imagine how that felt.

24 *THE COURT:* Yes. For everyone's sake, it is 11:30, we
25 have Mr. Lear, we have two others, and we will take our recess

1 for lunch.

2 Mr. Lear, let's see here, I wanted to point out that I
3 do appreciate your focus on giving candid advice to your
4 clients. You highlighted that in your application and I look
5 forward to your thoughts to this Court as well.

6 Let me allow to you present your opening statement.

7 MR. LEAR: I am here from Columbia, Missouri, it makes
8 my firm a little unique in the sense that we are something of a
9 small town law practice that just over the years evolved with
10 the pursuing of class action cases, not from the major city
11 centers, but more from the heartland.

12 I have always been just really interested in trying to
13 handle cases that I think are meaningful and could have a
14 meaningful impact for our clients. The Court indicated the
15 importance of candor, and that is something I do take
16 seriously.

17 In that vein, it is the case that I am a new entrant
18 to the MDL practice. I only applied one time previously for an
19 MDL, and that was the Apple performance device litigation, and
20 was selected to serve, albeit that was part of a slate process.
21 I was part of a group that presented to the Court and the Court
22 accepted that slate as opposed to this application process,
23 which I appreciate the Court taking the time to do. I
24 understand it is a lot more work, and it likely leads to better
25 results. Overall, the Apple case was a good experience.

1 The vast majority of my background is actually in
2 employment oriented class action cases. We recently started to
3 work on consumer cases, in which this is one, and that is the
4 type of case we are bringing here on behalf of a Missouri
5 class, but this is my first case as a so-called pharma case.

6 My background, I hope, would bring to the team that is
7 selected two things. One is the perspective of working in a
8 smaller office which requires a real focus on efficiency in
9 terms of maintaining a focus on what is important in the
10 litigation, putting our efforts to that work, and also a client
11 centered focus.

12 One of the things that is somewhat unique, not
13 entirely, the employment cases we bring opt in, opt out
14 classes, it is not unusual for me to work on cases with scores,
15 if not hundreds of individual clients that we are communicating
16 with all the time, managing their inter-relationship and not
17 how their various testimony would impact the class
18 certification of others, but what this case means to them
19 individually.

20 I think that background, I hope will be helpful.
21 Serving on the class action team is where I would best fit,
22 assuming the Court divvies up responsibility in that way.

23 And so, that is sort of my spiel.

24 I know we are trying to keep on track here. I don't
25 want to go too long there. If the Court has any questions, I

1 would be happy to answer.

2 THE COURT: Okay. I appreciate it. You told me
3 primarily your background in employment, now transitioning in
4 this case, hopefully -- well, you are, whether it is leadership
5 or not, into consumer. So, I would like maybe to hear about
6 just a couple of the skills that you think are most valuable
7 that you can offer to this litigation, the skills that you
8 bring.

9 MR. LEAR: Thank you. My real passion, your Honor, is
10 what ought to be characterized as the law and briefing side of
11 things. I think of myself first and foremost as a writer.
12 Nearly all of my cases are in Federal Court, that is the vast
13 majority of the way advocacy is done. I have multiple usage
14 books, and I have a passion for research and writing and I am
15 within a smaller firm.

16 If I was appointed to the leadership team, I
17 personally would be the one doing the work. It is a personal
18 employment supported by my firm. I am supported by a great
19 team, I would expect myself to do that work. That would be my
20 passion. I am not sure that is a distinguishing factor, I am
21 sure there are a lot of good writers and briefing teams.

22 The other area I think I could do is in vetting
23 potential class representatives for an omnibus Complaint and
24 working with the individual Plaintiffs, you know, within their
25 role of class representatives. That is something I have a lot

1 of experience and comfort with, and enjoy the process of
2 playing counselor, the attorney, counselor side. Those would
3 be the two things that I would bring to the Court's attention.

4 *THE COURT:* What do you think is most important in
5 that vetting process?

6 *MR. LEAR:* There are several things. The most
7 important thing is commitment to the case and the role. It is
8 very important for a class representative to understand that
9 they are not just bringing their individual case, they are
10 bringing a case on behalf of others. That is something that we
11 focus on a lot.

12 Another thing that I think is similar and very
13 important, it should go without saying, but it does, the lack
14 of conflict of interest so the class representative, the claim
15 they are standing in for -- the class is pursuing a single
16 claim with, you know, not a situation that can occur, or in
17 this case, where you have multiple potential injuries. Those
18 are the two things that I think are most important.

19 *THE COURT:* Okay. And since you are transitioning to
20 an MDL, can you share with me, and maybe hopefully for the
21 benefit of others both on this session and maybe others to come
22 in the future, what are the challenges you face and what advice
23 would you give to new entrants?

24 *MR. LEAR:* The challenges I face are coming to grips
25 with the unique procedures put into place by order on an MDL,

1 you know. Of course, we are all very well versed from law
2 school on the Federal Rules of Procedure. We learn to work
3 those rules, within those rules, and with an MDL, it strikes me
4 that each case has its own unique procedures that you have to
5 watch very carefully, and that has been something -- could be a
6 challenge for me, something I am beginning to learn, you know,
7 and also understanding that is something for new entrants.

8 I guess advice would be to be mindful of the Court's
9 orders, follow the Court's orders to the letter, and I hope,
10 also -- you know, one of the challenges I have seen in this
11 practice, and the Court is attuned to, it can be difficult to
12 break in, so to speak, into this practice area. I appreciate
13 the Court's time in allowing once such person, and there are
14 others on the call, and I am sure more to come that are in that
15 situation. I encourage new entrants to continue to raise their
16 hand and volunteer for some work, and eventually you will be
17 selected and you will have an opportunity to prove yourself
18 just as those who came before you have.

19 *THE COURT:* Thank you so much. Anything more you want
20 to share with the Court?

21 *MR. LEAR:* No. I appreciate your time, your Honor,
22 thank you so much.

23 *THE COURT:* Okay, thank you so much, Mr. Lear.

24 Mr. Krause. Good morning, Mr. Krause. I can hear and
25 see you very well. These are the new questions we ask over

1 Zoom that we don't necessarily ask in court.

2 So, good morning and -- let's see. I understand you
3 have changed teams and you used to be on the pharma side.

4 MR. KRAUSE: I did, yes.

5 THE COURT: So, maybe with that, let me turn over to
6 your opening statement and maybe talk about that.

7 MR. KRAUSE: May it please the Court, my name is Adam
8 Krause, and I first want to just say for the last seven, eight
9 months or so it was great working with a bunch of you all. It
10 has been a lot of fun.

11 I was at the JPML hearing and I got to speak, and it
12 was fun working with the group. A lot of them are in the group
13 you selected in the April deliverables team, and I got to work
14 with them and talk about this. I got to meet with them in
15 Miami and Tampa, and I think you have a hard job. First of
16 all, there are incredible applicants on here. I read every
17 resume', and I think there if they were baseball players, I
18 would have their baseball cards. This is a unique group, you
19 have a challenging job ahead.

20 I will highlight for myself, I suppose I would fall in
21 the diverse group. I may not look young, I have a one year old
22 son and he aged me a bit over the last year or so. It has been
23 a lot of fun. If I am not the youngest applicant, I am one of
24 the younger applicants here.

25 Before I was in law school I worked in a

1 pharmaceutical company like your Honor said. I worked in a
2 variety of different aspects, I worked at Eli Lilly Company.
3 While there, I worked on the sales team primarily focused on
4 the human science division. I worked on messaging, which is a
5 huge part, messaging is you talk to a physician. These
6 physicians were the physicians that actually we are going to be
7 deposing in this type of case as well, too. I worked with
8 primary care physicians, nurse practitioners, PA's,
9 pharmacists, psychology offices, and I worked on the messaging
10 with the doctors and companies.

11 I worked on the brand side, which is the labeling and
12 packaging, what you are allowed to say, contraindications,
13 black box warnings. All of those I worked on were not only the
14 legal aspect, but what would be the most persuasive when
15 talking with doctors, too.

16 And I trained a lot of folks, too, I trained on the
17 messaging, what you are allowed to say and not allowed to say.

18 Since then, I've worked in a variety of mass court
19 litigations, a lot of them I worked pro bono, I didn't get
20 paid. I volunteered my time to help folks and lawyers that
21 wanted to depose sales reps and medical device reps, and I have
22 taken a plethora of depositions there, too, myself. There are
23 a lot of things you want to talk about with the sales reps and
24 so, I would like to do that here as well, too.

25 Secondly, I also worked at Physicians Reference

1 Laboratory, I worked there for a year and a half, two years,
2 under Dr. Kensey. We did biopsies of skin samples, livers, all
3 sorts of body parts, and we were looking at them underneath the
4 microscope. Those two things are going to be beneficial in
5 this case.

6 I spent a lot of time dealing with -- not telling
7 patients they have cancer, but looking at the aspects of what
8 cancer looks like at least under the microscope.

9 I own my own firm, that is unique. When I started my
10 firm, we focused on pharmaceutical and medical device
11 litigation from the very start.

12 I will leave it there, but what I will say is that I
13 already really enjoyed working in this litigation on the
14 various aspects I have and I hope to continue to do that.

15 *THE COURT:* Okay, thank you.

16 So, tell me a little bit how you would describe
17 medical monitoring.

18 *MR. KRAUSE:* Medical monitoring, the class action of
19 medical monitoring -- class action medical monitoring of people
20 who took the drug and don't yet have cancer or diagnosed with
21 cancer. That is the general class action. I do believe, and I
22 know you touched on this with other candidates, too, it needs
23 its own track, but it needs to pair well with the PI side, too.
24 There needs to be coordination among all of the counsel there.
25 There is going to be discovery that is going to assist each

1 other, but there definitely needs to be coordination,
2 definitely needs to be a track. In Valsartan, that track is
3 the first trial.

4 I think there are strategic decisions along the way,
5 and Court decisions along the way that may be necessary in this
6 case as well, too.

7 *THE COURT:* Okay. Have you given any thought to,
8 given how many cancers have been alleged, what the relief would
9 look like?

10 *MR. KRAUSE:* Sure. I think this is going -- there are
11 a lot of cancers alleged right now, right, and I think
12 throughout the litigation the science will develop, our experts
13 will develop some, new studies will be coming out, too. That
14 may increase the amount of cancers alleged or decrease the
15 amount of cancers alleged.

16 And so, in other litigations there are various tiers
17 and payouts, we are talking about actual payouts. More severe
18 types of cancers might get more money than the less severe and
19 those that could be cured. Pancratic cancer of someone who
20 died, that individual would get more money than someone who is
21 in remission on a less severe cancer. There might be tiers.

22 And if there is a settlement, that is something we
23 need to be cognizant of. The cancers right now could increase
24 throughout the litigation or decrease once discovery comes out
25 and once new studies come out as well.

1 *THE COURT:* Okay, thank you.

2 Do you see any conflicts in counsel representing PI
3 Plaintiffs if also serving as class counsel?

4 *MR. KRAUSE:* No, I think -- I would say that I think
5 it is a benefit. I am not sure if you are able to see the
6 individual census, but I do -- I represent quite a few folks on
7 the PI side as well, too. I am a PI lawyer, I file class
8 actions. I am a PI lawyer, I've tried several PI cases. I
9 hope to assist in getting these cases to trial.

10 Whether it is the monitoring class action track or the
11 PI side, I hope I can be a helpful person in getting these
12 cases to trial. Getting a set trial date is what really moves
13 the cases along.

14 *THE COURT:* I have seen the census data, that is one
15 of the reasons for my question.

16 And what type of protections do you think need to be
17 put in at settlement for personal injury, or class if you have
18 both?

19 *MR. KRAUSE:* That is a great point. I really have
20 been in the class actions since the beginning of my firm, and
21 what I have seen in the class actions can be seen as an after
22 thought sometimes. The PI claims often predominate over the
23 class actions, be it medical monitoring or economic loss or
24 whatever it might be, that predominates sometimes. That is
25 where the tension is. Often times the media focuses on those

1 cases.

2 Having separate counsel in that is going to help
3 separate that. And I think also -- I think Mr. Berman had
4 indicated that setting bellwethers for the class action and PI
5 tracks will also facilitate that as well, too. If you do have
6 any type of settlement, having representatives on both sides
7 will help as well.

8 But the trial date -- having a trial date set for the
9 PI claims and also for the class action will keep it separate
10 and make sure we have representation for both and make sure we
11 have a settlement pool for both. The key is setting different
12 trials for both.

13 *THE COURT:* Okay. Is there anything else that you
14 would like to share with the Court that I have not had a chance
15 to ask you that you haven't said already?

16 *MR. KRAUSE:* No. It would be an honor to serve on
17 this case. It is difficult, it is like applying for a 747,
18 have you flown in a 747 before? No, I haven't. They want you
19 to have the experience, that is difficult.

20 I appreciate you giving someone who doesn't have a
21 huge background -- if I were on the PSC, I would be in it for
22 the long haul. There is a need for lawyers to do a lot of the
23 grunt work, some of the work people don't want to do, I will be
24 happy to do anything. I have done it in other litigations,
25 unpaid, and I would do it in this litigation, anything asked.

1 On the PI side or medical monitoring side, I am happy to be
2 here and happy to work with the lawyers that you select.

3 *THE COURT:* All right. Great, thank you so much. I
4 really appreciate that.

5 And we are going to break at this point. I am aware
6 of the schedule. I want to remind everyone, I ask that maybe
7 you come back at 12:50 because we'll start up again at 1:00.

8 Now, I encourage participants, if you know you are
9 coming back, if it is not taking over your computer in a way
10 that will interfere with your work, just stay connected to the
11 meeting.

12 Reminder, turn -- your mute should be on and video
13 should already be on. No one can hear you or see you if you
14 decide to keep your computer on during our break.

15 If you leave the meeting, that is not the worst thing
16 in the world, we will let you back in. It does require our
17 cohosts to let you back in. And let me double check if that is
18 the way we want to proceed. Yes, I think we will proceed in
19 that manner.

20 Let me double check.

21 So I guess, in sum, if you could leave it on mute and
22 stop video and break for lunch, that way you don't have to be
23 readmitted. If you need to use your computer and leave the
24 meeting, that is okay, too. For those people, be ready to be
25 asked to be back in at 12:50, presumably it won't take quite as

1 long, and we will get started at one o'clock.

2 With that being said, I will follow my own advice, I
3 will mute myself and stop my video and see you back at one
4 o'clock.

5 *(Thereupon, a luncheon recess was taken.)*

6 THE COURT: Okay. Good afternoon, everybody. We are
7 back for session two. I hope everybody had a nice break.

8 We are going to begin with Mr. Behram, Parekh. Good
9 afternoon.

10 MR. BEHRAM: Good afternoon.

11 THE COURT: Did I pronounce your name correctly?

12 MR. BEHRAM: Yes, your Honor, thank you.

13 THE COURT: Let me let you get started and kick off
14 our afternoon session.

15 MR. BEHRAM: Sure. I listed pretty much everything, I
16 would like to give you my background. I started out as a
17 lawyer 25 years ago doing Plaintiffs' securities and class
18 action litigation, and did that for about ten years, and moved
19 on to consumer litigation and mass court litigation. I have
20 done appellate arguments in the Ninth Circuit, Tenth Circuit,
21 Second Circuit, I have done trials as the first and second
22 chair, litigated in taking a number of depositions. I have done
23 Daubert hearings, expert witness depositions.

24 Although my current focus for purposes of this
25 litigation is the ESI aspects of it, I didn't want to give the

1 misimpression that is my overall skill set.

2 I have been lead counsel in class cases, on the PEC in
3 mass cases. I am serving on the PEC in Valsartan, as are a
4 number of other individuals. I have worked with many of the
5 lawyers here. I worked with Mr. Dearman on a class case a few
6 years ago when I was counsel. I worked with Mr. Wisner and
7 with Ms. Goldenberg on two different matters, and I have been
8 able to efficiently work with a lot of the attorneys from the
9 entire spectrum.

10 I also pride myself in both my professionalism and
11 being able to work with the Defense Bar. I believe especially
12 in ESI, you have to be pragmatic and practical rather than
13 piece oriented in what you are trying to achieve.

14 ESI consultants on the Plaintiff side and Defense side
15 think about the absolute, well, if we don't get all of this
16 information, we are missing something. That is not the key.
17 The key is what is practical in the litigation. Plaintiffs
18 don't want to review 400 million documents, because those are
19 going to get boiled down to a hundred, 200 documents at the end
20 of the day for purposes of deposition and trial. So, how do
21 you find the hundred or 200 documents, and how do you focus the
22 ESI process on those 200 documents without having to review
23 four million documents?

24 My background in computers and having done a lot of
25 ESI discovery and manual sitting in warehouses with paper

1 boxes, which is where I started, allows me to bring that
2 experience in the ESI aspects of it and documentary aspects of
3 it.

4 One of the things I have been able to institute that
5 has been helpful is a weekly document review for calls and not
6 Zoom meetings, where we have all of the people who are doing
7 document review get together once a week for about 15 minutes
8 or half an hour and talk about what are you looking at, what is
9 interesting, what questions do you have.

10 It allows us to recreate the experience that I grew up
11 with in sitting in a room with 40 other Plaintiffs' attorneys
12 and you are talking to them and you would be discussing what
13 everybody found. That has been lost over the years when we
14 moved to electronic discovery, so we tried to shift into that.

15 We also tried to make it fun because document review,
16 it is not really fun. So, we have done things like we play a
17 game on the Zoom, hot or not. We have a document and ask
18 document reviewers: Do you think it is hot or not? And we
19 talk about the document afterwards. We play trivia games where
20 we send out a white paper in a case and say, okay, what does
21 TEA mean in this case? Does it mean, you know, a brief range,
22 or does it mean a chemical name?

23 And so, we try and make things so that people are much
24 more comfortable doing it, they feel comfortable doing it, and
25 they know people are supervising them who understand what they

1 are doing. Looking through documents day in and day out may
2 not be the most exciting thing in the world, but it is
3 essential and crucial for litigation.

4 The last thing is, I have teen-agers ranging from 13
5 to 18, and they ask me the technical questions rather than I
6 asking them.

7 *THE COURT:* Impressive. I don't think they would want
8 to play the Zoom games you are talking about. Why do the
9 Plaintiffs like Tar so much?

10 *MR. BEHRAM:* It allows us to get to the goal, to the
11 documents. We like to review the problem with search terms and
12 they are too broad and too narrow.

13 They are too broad in the sense that the word, for
14 example, delete, right, the word delete could show up in a lot
15 of different ways. It could show up in a good way, the
16 Defendants deleted all of the test data we deleted. Why are we
17 shredding this stuff or deleting it? It could be a footer on
18 an email, if you get this email in error, this is
19 attorney/client information, make sure you delete it.

20 How do you differentiate between those two? The way
21 you differentiate, you look at Tar, Tar looks at each document,
22 the words in the document, how they are put together if used
23 correctly, and there is a lot of misuse of Tar. Don't get me
24 wrong, Tar is not a panacea for everything.

25 But if the documents are the ones you are looking for,

1 hey, why did we delete this test data, this is necessary,
2 subsuming in the pile that is considered low range and junk,
3 once they have a footer, hey, if you get this email, delete it.

4 *THE COURT:* Okay. Thank you. So, what do you think
5 are the challenges and strategy for managing from your end the
6 discovery ESI standpoint substantially over Defendants? Have
7 you thought about that? How does that work?

8 *MR. BEHRAM:* That is a huge challenge. Even with two
9 Defendants you could end up with millions and millions of
10 emails and documents, much less texts.

11 What we tried to do in the past, and what we did in
12 Valsartan, is tailor the discovery depending on who the
13 Defendant is, where they are in the chain. For example, are
14 they a generic name manufacturer, are they a name brand
15 manufacturer, are they a packager, a wholesaler. Depending on
16 where they are, they have different levels of discovery
17 obligations, different levels of what we are looking for, and
18 tailoring discovery for that particular information, the type
19 that the Defendant has versus the information that they may
20 not.

21 *THE COURT:* And I think you touched on it, that is,
22 obviously, you have a lot of experience in ESI. Are there any
23 other broader discovery and other skills in addition to what
24 you did incorporate in your opening statement or anything else
25 you would like to tell me?

1 MR. BEHRAM: I am sort of an all around, as stated
2 previously, a utility player. I have done class cases, I have
3 been lead counsel, I have done mass cases, individual business
4 litigation. I was temporarily internet startup counsel before
5 the crash. 95 percent of my experience is in class mass
6 litigation.

7 I also advise companies on how to deal with document
8 requests, so I have seen it from the other side as well, and
9 can understand in part how that works from the other side and
10 the means and restrictions that the client is placing on
11 Defense lawyers when Plaintiffs say we want everything under
12 the sun, and the clients say, why, why do we have to go through
13 all of that. I understand both sides.

14 THE COURT: I am sure that is music to the ears of the
15 defense attorneys on the Zoom, and they will probably hold you
16 to that. I don't disagree, a person having worked on both
17 sides and having a diversity, it gives you a demand placed on
18 both sides. Thank you so much.

19 MR. BEHRAM: Thank you, your Honor, it has been a
20 pleasure.

21 THE COURT: As well.

22 And let's see here. The next interview is Kristian
23 Rasmussen.

24 MR. RASMUSSEN: Yes, your Honor. It is telling me
25 that I cannot start the video because the host spot stopped it.

1 THE COURT: Okay. It might take a moment.

2 MR. RASMUSSEN: There it is.

3 THE COURT: Don't take it personally that anyone was
4 trying to keep you out. I don't think that is the case.

5 MR. RASMUSSEN: I don't think so, your Honor.

6 THE COURT: These sorts of things happen. I like your
7 DOJ sail there, I have one of those with all of the signatures
8 in the background.

9 Welcome. Let me turn it over to you for your opening
10 statement.

11 MR. RASMUSSEN: Thank you, good afternoon. I want to
12 say thank you very much for all of your hard work, to
13 Ms. Dodge, to Ms. Richardson, and all of the Court staff. I
14 know a lot of work goes into pulling something like this off
15 without a hitch, so, thank you.

16 The foundation that is being laid for this litigation
17 with the deliverables group and the bellwether and census data
18 I think is wonderful. At the end of the day, given the number
19 of Plaintiffs we have, and the length of time this drug was on
20 the market, laying this firm foundation early, regardless of
21 what you are doing, is going to be important forever. Thank
22 you for that.

23 Other than the information in the application, there
24 are a couple of things I want to touch on and highlight that I
25 didn't. Specifically, your Honor noted in pretrial order 1

1 that the added demands and burden of this type of litigation
2 places a premium on professionalism and requires counsel to
3 fulfill their obligations in a manner that would foster and
4 sustain good working relations.

5 I could not agree with that statement more. I think
6 it is imperative if this litigation is going to move swiftly
7 and efficiently, whatever that resolution might be. In order
8 to do that, it is going to take a lot of professionalism, a lot
9 of candor and honesty both in terms of how we assess ourselves
10 and also in terms of our ability to communicate with the -- I
11 have litigated with most of the Defense lawyers involved in
12 this litigation. Mr. Agneshwar and Ms. (inaudible) were lead
13 counsel. Mr. Petrosinelli, I have been on the other side of
14 him for one case or another, the same for Mr. Brown and Mr.
15 Holian. I mention that to you because if you take a stranger
16 from the opposite side and put them in a room and say figure it
17 out, it takes awhile to build up that trust.

18 I am not saying this is a determinative factor, but I
19 do think having some history helps in our ability to
20 communicate. So, I wanted to note that for the record.

21 And also, in terms of diversity, I am Norwegian, and I
22 am wearing pink today, I don't think that qualifies, but I was
23 active duty in the United States Navy. That does give me
24 something, it is a unique experience that most people don't
25 have. To the extent that that helps in terms of your

1 evaluation of who might be the most suitable, then that is
2 really diversity, it is for me.

3 In terms of my practice experience, I have been a
4 Federal prosecutor, I have been on the Defense side, commercial
5 litigation, PIP work in Florida for awhile, but primarily in
6 the products liability mass litigation.

7 I have been in cases where there is a large aspect of
8 the product liability allegation consumer class claims. The
9 people most interested in those particular claims work
10 cooperatively as a group and prosecute the claims together as
11 opposed to maybe staying one aspect of the litigation, and I
12 don't think that is going to be an issue with this Court, but
13 based on past experience, I think it has a way of unnecessarily
14 protracting it.

15 So, that said, I am going to try to anticipate what
16 some of your questions may be.

17 *THE COURT:* Are you looking at my screen?

18 *MR. RASMUSSEN:* I am going to go ahead --

19 *THE COURT:* Am I doing a screen share inadvertently?

20 *MR. RASMUSSEN:* I think the first question might be,
21 Ms. Rasmussen, how many cases have you had? Your census data
22 is nonexistent right now. That is true.

23 I gave -- I just started my firm, and so I told my
24 paralegal, I said, listen, let's go ahead and get everything
25 up, and so, she is excellent, she is wonderful, but I haven't

1 heard from her, and I called her three days before the
2 deadline, and I said, hey, where are we on this? She didn't
3 answer. I called her the next day. Long story short, she has
4 a very personal thing. If you need her information, I would be
5 happy to share that. There are people on this who are
6 adversaries who know who she is, and I told her, I said I am
7 not going to get into any of the details. Suffice it to say,
8 she did talk to me from California and she was in her house
9 locked up. She is back, she got back yesterday.

10 *THE COURT:* Okay.

11 *MR. RASMUSSEN:* The second thing you might want to ask
12 me about is financing.

13 I can assure you I am fully prepared to finance this
14 litigation, not only for my individual clients, but make my
15 capital contributions on a regular and recurring basis with the
16 full understanding that this litigation, despite our best
17 efforts, sometimes it may just drag out a little bit. I am in
18 it for the long run.

19 In fact, I can't tell you how many people tried to
20 force money on me. It is crazy how they want to loan me money.
21 In fact, this morning I had two different people hit me up, are
22 you sure you don't want to take money? You know, it is crazy.

23 In time, I have had four separate MDL's that have
24 recently wrapped up, including Invokana, Abilify, and right now
25 in the litigation my role is for all intents and purposes over,

1 right.

2 Now, that is not to say I might be more involved in
3 some more aspects of the litigation, but I don't expect it to
4 be much. This is my case that I am focused on.

5 I think there is one more question, expertise. I hate
6 to say jack of all trades, master of some, use whatever
7 phraseology you want, but I have had the benefit of a number of
8 different diversity students. I hate to be penalized, I am 43
9 years old, but I earned, I feel like, the trust of the
10 judiciary, I have been appointed. And I promise this Court if
11 you choose to select me, I will not let you down, and I take
12 this litigation seriously, I take my responsibility very
13 seriously.

14 And so, with that said, that is pretty much it.

15 *THE COURT:* Okay. You made my job easy, you
16 anticipated questions that I was going to ask, but it was
17 helpful, and I would be repetitive. Thank you, thank you for
18 your presentation and for anticipating questions and I
19 appreciate your applying for the position.

20 *MR. RASMUSSEN:* Thank you very much.

21 *THE COURT:* Okay. Thanks so much.

22 The next applicant is George Williamson.

23 Good afternoon, Mr. Williamson.

24 *MR. WILLIAMSON:* Good afternoon, your Honor.

25 *THE COURT:* Let's see. I want to make sure we have

1 the same right corridor. Let me let you -- I am paranoid about
2 making sure I am calling everybody in the right order.

3 Let me turn it over to you for your opening statement.

4 *MR. WILLIAMSON:* Thank you for allowing me to appear
5 before you this afternoon, your Honor, albeit by Zoom. I
6 appreciate your time and consideration for this position.

7 I woke up this morning at about 4:13 a.m. worried
8 about what I should say in the statement in light of all of the
9 excellent and very well qualified candidates that have applied
10 for these positions.

11 I know I'm one of the younger attorneys seeking an
12 important part in this MDL, but I do feel I could bring a
13 unique perspective to this case from my experience and
14 leadership on other pharmaceutical MDL's. I have been
15 practicing for ten years, I am a partner of our law firm, we
16 have 15 attorneys with active areas spread across three areas
17 in South Florida.

18 My individual practice is focused almost exclusively
19 on pharmaceutical medical litigation. I have had PSC positions
20 in the Abilify MDL, and Benicar, both concluded in resolutions.

21 What I would say is that over the course of my
22 appointments on these MDL's, my responsibilities have expanded
23 significantly now to include all aspects of the MDL process.

24 For example, when I started in the Benicar litigation
25 I was working on discovery and somewhat behind the scenes in

1 drafting discovery, document review and management, was
2 involved in taking some depositions of domestic and foreign
3 witnesses, and when I began working in the vilify MDL, I took
4 on a larger role in helping to manage all aspects of discovery
5 in that case from written discovery to depositions to arguments
6 before the Court.

7 I also co-led the ESI committee with Mr. Parekh who
8 you heard from earlier. We reviewed storage, management of
9 electronic adverse events, databases. Like Mr. Rasmussen said
10 earlier, I probably should mention that I have good working
11 relationships with many of the Defense counsel in this case.

12 I see Mr. Agneshwar, who is lead counsel for Sanofi,
13 and I'd say and hopefully he would say we worked
14 collaboratively in Abilify to bring that case to a successful
15 resolution. As I mentioned earlier, I served on the PEC MDL,
16 and I co-chaired the bellwether committee.

17 I see areas where I believe we have a chance to draw
18 on our experiences in Valsartan to, I believe, help propel the
19 Zantac litigation forward.

20 The first is that over the past, I would say, six to
21 eight months we carefully crafted and negotiated search terms
22 and requests for production. Those have been aimed at the API
23 dosage factors, and we are working on the requests to
24 retailers.

25 I think the search terms and requests that we crafted

1 in the Valsartan case can provide a solid foundation and a
2 starting point for the discovery in this case.

3 And then, I believe the example for your Honor, as
4 co-chair of the bellwether community, in consultation with our
5 retained experts, we have essentially developed a case criteria
6 for all of the Valsartan cases, for example, exposure to MDA,
7 MDA contamination the client was exposed to, the types of
8 cancers that persons developed, and when they developed the
9 cancer.

10 It also looks at the various risk factors and
11 morbidities that a person is exposed to, and we use the
12 criteria to score the cases filed in the MDL so we can identify
13 what the bellwether cases are, and what are our weakest cases,
14 and we encourage non PSC firms to use in evaluating whether or
15 not to file a case MDL.

16 We hope one day to be able to use this as the scoring
17 framework in the Valsartan cases when we reach a settlement,
18 but I do believe the vast majority of that scoring criteria can
19 be used in this case to help vet and review cases because we
20 are dealing with the same genotoxic substance, MDMA, and the
21 same general injuries.

22 Lastly, I would say that I am highly motivated and
23 excited about this case. I have been involved with this
24 project since its inception. I spoke in September at the first
25 public panel to discuss this case, I participated in MDL

1 meetings all over the country, I hosted them in Tampa. I
2 co-chaired the Zantac group, speaking at engagements with the
3 AAJ.

4 I believe the group of 13 you assembled so far has
5 done an excellent job on carrying the torch, so to speak, and I
6 hope to have the opportunity to rejoin them moving forward, and
7 I appreciate you giving me the opportunity to speak with you
8 this afternoon.

9 *THE COURT:* Thank you, Mr. Williamson.

10 Let me ask you two questions. How do you think in the
11 case selection criteria, because that is something that you
12 have spoken about -- I take it that is what you mean by a
13 scoring system that you have used. How would we leverage the
14 registry that is going to be set up in this case, sort of
15 comporting with that vision.

16 *MR. WILLIAMSON:* Sure. So, the case criteria and the
17 case scoring systems are somewhat different. We developed the
18 case criteria based upon what we believe are going to be good
19 cases down the line, and we vet the potential cases as clients
20 come to us based on that criteria.

21 As of now, the case scoring criteria takes into
22 consideration much more detailed information, the type of
23 information that will be in the registry, and for example, as
24 you look at a potential case, the information that we need to
25 score that case based upon what we know now is likely going to

1 be often in the registry.

2 The idea is that we assign a numerical value to
3 various data points that are contained within the registry.
4 So, for example, we have our experts tell us what they believe
5 to be the best types of cancers in this case.

6 So, for example, if that is testicular cancer, breast
7 cancer, or thyroid, whatever that may be, they get a certain
8 score based on the types of cancers they have. They get a
9 score on how long they have been taking the drug and how much
10 exposure to MDA they have been given, and apply that score to a
11 risk factor which reduces the value of the score. And at the
12 conclusion we have a number, and that number will -- we can
13 compare from case to case the value of each case within the
14 registry.

15 I think that is certainly something that can be
16 accomplished in this case based upon all of the information
17 that we are going to be taking and entering into the registry.

18 *THE COURT:* All right. Terrific, thank you so much,
19 very informative, and certainly you bring a lot of knowledge
20 and experience. I appreciate you sharing that with us during
21 this interview.

22 *MR. WILLIAMSON:* Thank you, your Honor.

23 *THE COURT:* Have a nice rest of the day, thank you for
24 your seeking a leadership position in this case.

25 *MR. WILLIAMSON:* Thank you, your Honor.

1 *THE COURT:* Okay, the next applicant is Carmen Scott.

2 *MS. SCOTT:* Good afternoon, thank you for the
3 opportunity to be here this afternoon. I appreciate the
4 opportunity to apply for this position as well. I see a number
5 of friends and colleagues on the list of applicants here, very
6 professional folks, and I am honored to be among them and I
7 hope I have the opportunity to work along with them in this
8 case.

9 I also have experience with Jaime Dodge, I have worked
10 with her and participated in her course at Emory, and with what
11 she has done before this in the MDL settings, but also in this
12 case, she is going to be a tremendous asset moving forward.

13 I have good working relationships with Defense counsel
14 that are involved already, and I suspect will be involved as
15 the case progresses.

16 This case is a super important one for a number of
17 reasons. There is such an important opportunity here to help
18 the tens of thousands of people that will be part of the case,
19 and part of those who have been injured by Zantac.

20 This case also has some important implications for not
21 only those individuals, but for other cases, because there are
22 so many interesting scientific facts, questions of fact and
23 law, and we have those intertwined and become issues in this
24 case. As you undoubtedly noticed, and we all do, science is
25 continually evolving, the literature offered has many facets in

1 this case.

2 The regulatory landscape has changed as well. The FDA
3 has repeatedly changed its stance on this and recently issued a
4 new position on Ranitidine products, and just as the changes
5 take place throughout this case, which I imagine will continue
6 to happen, so undoubtedly will the theories in this case, and I
7 imagine each of the theories will be hotly contested among the
8 parties, how MDA forms, whether it is a manufacturing process,
9 shipping, storage, congestion, how this product causes
10 problems, and what types of problems it causes, causation, what
11 are the scientific foundational issues that would lead to this
12 case.

13 That is what I and my firm are set up to do. We have
14 a history and reputation of doing just that, being involved in
15 these type of cases and dismantling these complex scientific
16 issues, propounding the right discovery, asking the right
17 questions of witnesses and people involved and the right
18 experts, and finding the right type of cases to build for you,
19 the Court, for the entirety of the litigation the right type of
20 case that is not wasting judicial time and one that serves the
21 purpose of cases in the right direction.

22 Those are the assets I bring. I have had experience
23 in each of those areas and in multiple types of litigation. I
24 will address what some of the other candidates have mentioned
25 as well.

1 My time is -- although I am still involved in the
2 steering committee, my other PEC commitments are not quite
3 over. We are nearing the end because of the resolutions in
4 those matters. I have the time, I have the ability, and my
5 firm has always been available and is willing to commit the
6 resources necessary, monetarily and in a human capacity, in
7 these cases.

8 I am happy to entertain any questions you have. I
9 appreciate the time this afternoon.

10 *THE COURT:* Thank you so much.

11 You have heard me ask the others how we think about
12 promoting diversity. Your career trajectory and information is
13 different from the others I asked. I would like to know what I
14 can do to better support an environment to bring in new
15 entrants and others with different perspectives.

16 *MS. SCOTT:* Certainly. I am different than other
17 candidates and I recognize there is movement to bring more
18 women and young people into the fold. I am not sure -- I had a
19 birthday this week.

20 *THE COURT:* We won't ask what birthday.

21 *MS. SCOTT:* I appreciate that and I think it is a
22 necessary tool.

23 I hope I would be considered outside of that just
24 based on my professionalism and the other objectives that I can
25 go into, and that is the intellectual capacity, ability and

1 willingness to participate in the case, but as a woman, one of
2 the things I pride myself on in the firm and outside the firm
3 is holding the letter down, and making sure that other women
4 have their voices heard and get positions and involve
5 themselves in meaningful ways in cases, to not just be a place
6 holder, to actually serve in roles that they are very qualified
7 for.

8 *THE COURT:* Okay, terrific. Can you talk a bit about
9 how I should think about protecting individuals and counsel who
10 are not selected for leadership in the context of settlement
11 without being unduly restrictive?

12 *MS. SCOTT:* Protecting those individuals?

13 *THE COURT:* Yes. In other words, there have been
14 discussions about concerns with settlements favoring
15 leadership, and Courts not wanting to create artificial
16 restrictions that prevent both sides from settling cases.

17 With your experience, without particularizing, but
18 conceptually what you would want the Court to be thinking about
19 in that arena?

20 *MS. SCOTT:* Certainly. Well, I would expect that
21 everyone that is on your list for a PSC application would want
22 to assist in a meaningful role, whether it is a PSC position or
23 an ad hoc manner throughout the litigation, everyone here. And
24 I know most of them bring to the table varying talents, so that
25 would be counted as benefit time, whether they have a PSC

1 position or not.

2 My experience has been that those who put in the most
3 effort and time and provide the most benefit certainly reap
4 benefits in the end. There are certain values placed on
5 particular aspects of cases, all of which have value, but I
6 wouldn't expect any PSC member be favored in a settlement, nor
7 would I expect someone who does an enormous amount of work and
8 is not a PSC participant be disfavored. The value that person
9 brings to the table regardless of that position should be added
10 for in making those decisions.

11 *THE COURT:* Thank you very much for your news and
12 application, have a nice next part of the afternoon.

13 *MS. SCOTT:* Thank you, I appreciate it.

14 *THE COURT:* The next applicant is Brent Wisner. Good
15 afternoon.

16 *MR. WISNER:* Good afternoon.

17 *THE COURT:* I understand that this case has been
18 keeping you busy. If you want to include that in your opening
19 statement or tack that on at the end, that is fine.

20 *MR. WISNER:* My internet started getting bad in the
21 last 20 minutes, which is a nightmare for me. I apologize if I
22 go out for a quick second.

23 *THE COURT:* I can see and hear you. I don't know if
24 you are plugged into the ethernet or not, that gets you off of
25 the internet or wifi as I understand, that is what I did to

1 hopefully avoid internet issues. That being said, I can see
2 and hear you fine.

3 MR. WISNER: Your Honor, it is wonderful to finally
4 meet you and hear you speak and ask questions here. I have
5 heard so much from my colleagues about you and Professor Dodge.
6 It is great to see you in action.

7 I know a lot of the applicants this morning and this
8 afternoon have focused a lot on like their credentials, what
9 they have done that is successful, where they have
10 accomplishments. I originally want to do the same, all of that
11 is laid out in my application. If you want to ask questions
12 about things I accomplished or not accomplished, I will answer
13 those questions.

14 What struck me this morning is your question about
15 vision and where this litigation is going. It struck me as
16 important because in the context of leadership, that is so
17 important, and I think I would like to give you my vision.

18 I have been heavily involved in this litigation from
19 the very beginning, I have been deeply committed to learning
20 everything. I have been sticking my nose in all aspects of the
21 case, and I think more importantly, I developed deep personal
22 relationships with many of my friends.

23 This is something I didn't -- when I commit myself to
24 an endeavor, I commit myself. My purpose in doing that is
25 pretty much singular, get the case in the best possible

1 position for the clients.

2 The way I see that happening here is pretty staggering
3 because this case is probably one of the largest cancer MDL's
4 in history. I say that knowing there is asbestos and talc and
5 Roundup, but I really do believe this case has the potential to
6 dwarf them because of the length of time this was in the
7 market, the staggering number of people who have gotten cancer
8 and died from cancer. That is not even any of the class
9 issues.

10 The way we get this case to a place where we properly
11 represent, not just my clients, but all of the clients, is by
12 getting a case to trial. My experience in trying these types
13 of cases, and frankly, in working with complex leadership
14 structures to get a case to trial, is really where I shine.
15 So, I think the vision here is about getting the story, a
16 client's story in front of a jury. That is for my opening.
17 Let me answer the question directly.

18 You asked an earlier applicant what they had worked on
19 so far, and I thought maybe I should have this listed out. I
20 will forget something if I don't.

21 I have primarily drafted the Plaintiffs' claim
22 statement, and I drafted master plans, negotiating all of the
23 discovery with the Defendant. I worked very carefully on the
24 ESI protocol, I have been helping her a lot on that. I have
25 been consulting on all of the complex class issues, most

1 specifically in the area of RICO where I have a lot of
2 experience, third party pharmaceutical class actions. I have
3 been working and drafting up confidentiality orders and
4 negotiating that with the Defendants for confidentiality
5 preservation.

6 Basically, I have been helping and advising various
7 people in this case whether it be in the context of science or
8 other terms.

9 One of the things about my application, 32 other
10 individuals said, hey, you should consider running for the PSC,
11 and I think that is pretty remarkable considering I am 36 years
12 old. That demonstrates that I have a very broad base view of
13 how to bring in others and hear them and listen to them and
14 incorporate really good ideas on what we do.

15 I am probably missing other things I've worked on so
16 far, but that is where I have been hitting the ground running.

17 *THE COURT:* Great, that is a comprehensive list, I
18 appreciate that.

19 In your application, you say that you get people to
20 put aside ego and get work done. How have you done that?

21 *MR. WISNER:* It requires listening. One of the things
22 I have learned is that we have all of these brilliant attorneys
23 who have all of this incredible experience, and to the extent
24 we listen, bring them in and incorporate them, and sometimes
25 you disagree, and say it doesn't make sense, and you explain

1 why it doesn't make sense, you get that dialogue going.

2 I have tried cases with people who have very, very
3 pronounced ideas of their thousand attorneys and work really
4 well together because I am willing to set aside my own ego for
5 the most part and get the job done. So much leadership, and I
6 really believe this, is demonstrated -- for example, there is
7 no job that I won't do, there is no deposition, no document
8 review, no ESI protocol, no discovery that I pawn off. I am
9 willing to do everything. That demonstrated willingness to put
10 in that extra effort translates into everyone trying to do the
11 same. That is how I hope to do that.

12 *THE COURT:* I hope I am not having people staying up
13 all night and off on other things.

14 What about your thoughts on leadership and counter
15 benefit? I have posed that question for some people. I say
16 for everybody's benefit, I haven't asked the same question to
17 everyone. Please don't take that as anything other than I am
18 trying to spread the questions around.

19 So, I have heard from a couple of people. What are
20 your thoughts on that?

21 *MR. WISNER:* I come from the viewpoint that titles are
22 not important. If someone is contributing substantial work in
23 that case, that is subject to a commendation. We have people
24 who have very substantial roles. Now, for the overall side of
25 leadership, whether it is executive committee or PSC, frankly,

1 for this case I think you will have to have a larger one for it
2 to be long-term sustainable.

3 Putting aside the finances, different firms have
4 different sums of money, my firm is successful, it is not an
5 issue for us, but it is important to get people to the table,
6 but there are so many different aspects of this case we are
7 learning about.

8 You heard people mention a PI. I don't know if you
9 are familiar with that issue, but the manufacturers, they don't
10 actually manufacture the pill, they buy the active
11 pharmaceutical ingredients from suppliers, and those suppliers
12 are based in China or India and doing things in the
13 manufacturing process that lead to a terrible thing.

14 We are seeing this in our discovery and investigation
15 and that brings in a whole area of another group of Defendants.
16 We have a lot of moving parts here, and I would suspect that at
17 least a three to four person co-lead structure makes sense. I
18 think a PEC makes sense, a PSC makes sense. Getting over 25 is
19 too big just to keep your head on straight. 20, 25 is the
20 Goldilocks zone of the solar system.

21 *THE COURT:* Thank you, as I expressed to the others,
22 for taking the time to put the work in on the interim team and
23 for sharing your thoughts with me today.

24 *MR. WISNER:* Great to meet you.

25 *THE COURT:* Nice to meet you as well.

1 Okay, Roopal Luhana is next.

2 *MS. LUHANA:* Thank you. Good afternoon, your Honor,
3 wonderful to appear before you.

4 *THE COURT:* Thank you. I am happy to meet everyone as
5 well, put faces to names and paperwork. I am enjoying it as
6 well.

7 So, I was impressed with reading your biography and
8 looking forward to getting to know more about you in your
9 opening statement, including your career path.

10 *MS. LUHANA:* Thank you, Judge. You appointed me to
11 the practices and procedures team approximately two and a half
12 months ago, and I want to thank you for that privilege of
13 serving on the interim team and working with dynamic
14 experienced dedicated attorneys. I have been practicing for
15 almost 19 years, and since my clerkship with Judge Martinez I
16 have been litigating mass cases.

17 This case came to your Honor at the end of February,
18 and we have been able to accomplish six months of work in two
19 months. This litigation moved at a record pace despite
20 COVID-19. I don't want to belabor my experience and my firm's
21 experience, I know you reviewed all of the papers.

22 I and my firm are ready, willing, and able to commit
23 to this litigation. We are invested in the case and represent
24 close to 3,000 clients. My actions in the past two and a half
25 months further confirm that commitment.

1 Judge, the work done to date is a huge undertaking and
2 a collaborative effort of everyone involved.

3 I was involved in the initial orders, drafting the
4 streamline service orders that pertain to certain Defendants, I
5 have assisted with confidentiality and preservation orders.

6 I was key in choosing the ESI vendor for this
7 litigation. I have been leading the charge on the ESI protocol
8 which is going to govern production of the discovery in this
9 case. I was responsible for and led the charge with Pfizer on
10 the initial discovery, was on team strategy calls and working
11 with the science and discovery team purely. I think the team
12 would attest that I am a team player and have a strong work
13 ethic. I move things forward and get them done successfully, a
14 strategic theory and asset in discovery.

15 I am well versed in science and I worked with experts
16 in MDL's and worked on every aspect of expert discovery. I
17 have expert skills to lead the team and collaborate with
18 others.

19 Judge, to the extent you have any questions, I am
20 happy to answer them now.

21 *THE COURT:* Thank you. Based on the interim
22 appointment and work you have done, what insights can you share
23 with me? Pick a few that you think would be important for me
24 to know about the case, not about the actual work that has been
25 done, which is remarkable, and I'm, you know, so impressed, but

1 what vision has come out of this work? What strategy, what
2 concept of how you see the case moving forward based on the
3 unique opportunity you have had to spend over the last period
4 of months?

5 *MS. LUHANA:* Judge, I think this case needs to be well
6 funded and well staffed. We have Defendants here with
7 unlimited resources. You need a large team in place, perhaps
8 16 to 20 firms on the PSC. You need permanent leadership
9 appointed immediately. That will trigger the census forum. I
10 know your Honor is planning to do that. You need a firm order
11 in place and a discovery order in place so production will move
12 forward.

13 We'll not engage in protracted motion practice and
14 Defendants produce documents to get to trial in the case. I
15 imagine a trial date two and a half years from here. Firm
16 deadlines and trial dates move the parties. More so,
17 importantly, we need Federal and State liaison counsel to
18 coordinate with the State proceedings we know will definitely
19 arise.

20 *THE COURT:* Okay. What is the biggest concern you
21 have about this MDL, either problems or challenges we'll face,
22 and what is your greatest hope for it?

23 *MS. LUHANA:* The sheer number of parties that are
24 going to be involved. There are multiple Defendants at the
25 table, and this product has been on the market for 37 years, we

1 are going to have to go back to the time of paper discovery.
2 It is important we get the key documents up front in place and,
3 of course, stagger discovery based on the import of the
4 Defendants, the brands would be separate from the retailer
5 Defendants and generic Defendants, so on and so forth.

6 It is going to be unruly, but in terms of the census
7 program, you are managing the number of cases. The Defendants
8 as a result will have so much key information on all of the
9 Plaintiffs that are filed as well as unified cases. You
10 haven't had that type of transparency in any other case
11 previously. Now we are moving the case forward and have that
12 transparency for the Plaintiffs as well.

13 *THE COURT:* What is your philosophy and/or experience
14 in promoting diversity given you have gone from a prominent
15 firm to opening up your own form? What experiences have you
16 had managing and monitoring your team?

17 *MS. LUHANA:* Your Honor, diversity and leadership is
18 key. We need to make sure that leadership reflects diversity
19 with gender, race, and sexual orientation. As a result, we
20 have different perspectives and different life experiences that
21 strengthens the case overall and brings the creativity you
22 wouldn't otherwise have.

23 I know I am a minority business owner, and I am one of
24 the very few out there. In terms of what I have done, I
25 brought associates along on my team. Kendra Goldhirsch is of

1 Asian descent. We do our part to incorporate diverse people in
2 leadership to be represented and represent the clients that we
3 are representing.

4 *THE COURT:* Terrific. Anything that I haven't asked
5 you that you want to make sure you shared with me?

6 *MS. LUHANA:* I think we covered it, thank you so much
7 for your time.

8 *THE COURT:* Thank you for your time and application.
9 Tracy Finken is our next applicant. Good afternoon.

10 *MS. FINKEN:* Thank you. How are you? Good afternoon.

11 *THE COURT:* I appreciate all of the work you have done
12 in the past weeks. It is very impressive what all of you have
13 accomplished substantively and just the quantity of work. So,
14 I look forward to hearing your opening statement, and to the
15 extent you want to include how it has been going and what you
16 have been doing and what you learned from it and what advice
17 you may be able to give the judge.

18 *MS. FINKEN:* First and foremost, I want to thank you
19 and Special Master Dodge for allowing our team to continue to
20 work and serve and move this case forward despite the issues we
21 have had with COVID-19 and the pandemic. Not every Court has
22 been taking the same approach, and I want you to know how much
23 we appreciate it on behalf of our clients.

24 I appreciate you giving me the opportunity to work to
25 move these cases forward, I don't take that honor lightly,

1 there are many to choose from, and giving me the opportunity to
2 work with Plaintiff's lawyers I have never worked with before
3 and Defense lawyers I have never worked with before and I truly
4 enjoyed getting to know on Zoom meetings and video conferences.
5 We are learning how to forge a new path forward in this
6 situation and anything -- if anything, I have met great new
7 colleagues who I now call friends.

8 That being said, on the Plaintiff side of things and
9 Defense side of things we have started to develop a very good
10 rapport to move the case forward. I believe it is a very solid
11 foundation at the beginning of this litigation. And because of
12 the way it has been laid out and we have done such an amount of
13 work in a short period of time, we have developed a trust and
14 good working relationship that I think will benefit all of us
15 as we move forward in this litigation.

16 With that being said, I request the opportunity to
17 continue in the leadership role on behalf of the Plaintiffs
18 here. I think the teams we have in place, despite we have a
19 good working relationship well provide needed continuity for
20 the litigation to proceed forward with the Defendants as well.

21 I believe I am uniquely qualified for a leadership
22 role in this litigation for a variety of reasons. One, I spent
23 four years working on the PPI MDL. It is a case similar to
24 this case in the sense that it is a complex MDL with multiple
25 Defendants, multiple products spanning over 30 years with

1 multiple formulations of those products. My experience has
2 been at a high level in that litigation, and I have been
3 involved in it from the beginning, drafting the initial orders,
4 discovery, all the motion practice, I have been involved in
5 over 20 corporately built depositions, and I have learned a lot
6 from that experience that I think would have a lot of benefit
7 in this particular MDL moving forward.

8 In addition, there is a lot of institutional knowledge
9 there. Because these products were competitors for so many
10 years, the science and regulatory history overlaps quite a bit
11 and enabled me to hit the ground running in this litigation. I
12 don't have the learning curve other people have because of the
13 substantial overlap between these products, and regulatory
14 history going back for over 30 years.

15 Secondly, this Saturday marks my 21st anniversary
16 working at Anapol Weiss doing liability cases as well as
17 catastrophic liability cases. I have been involved in mass
18 tort pharmaceutical cases from soup to nuts for the past 24
19 years and involved in every aspect of the litigation from the
20 beginning until we worked up a trial, and taking them to trial.
21 I am ready to get into the dirty work on this litigation and I
22 am experienced to do so.

23 My firm has been appointed as lead or co-lead counsel
24 in 24 MDL's, and I have the collective wisdom of many seasoned
25 attorneys at my disposal who fully back me in this litigation

1 and provide much needed advice if necessary.

2 The dynamic with the team that we have already has
3 very varied experiences, which I think has collectively given
4 me better work product already. I want you to know I do have
5 the full support of my firm and the collective wisdom of many,
6 many seasoned MDL lawyers behind me and their wisdom.

7 Last, I want to point out that I do have a
8 relationship with many of the opposing counsel in this case,
9 some of them on the line earlier, Matt Holian, Loren Brown,
10 Terry Henry. I have a good working relationship, and they can
11 attest that I am always approaching our differences in a
12 collaborative congenial manner, and they can attest I am
13 somebody who vets my cases.

14 I treat my clients as if they are family. That is
15 probably why many Defense lawyers that I have been across the
16 desk from in the past have actually referred me cases at the
17 conclusion of litigation, because they know my clients aren't a
18 number to me, that they are -- I take my responsibilities very
19 seriously on their behalf.

20 With that being said, I would appreciate the
21 opportunity to continue working on this case on behalf of the
22 collective Plaintiffs, and if your Honor has any questions for
23 me, I will be happy to answer them.

24 *THE COURT:* Okay. With your other leadership roles,
25 what can you do to reassure me that you have enough time for

1 this case?

2 *MS. FINKEN:* The PPI litigation is the main litigation
3 I am involved in, it is a mature litigation, it will be three
4 years this summer. The discovery deadline is set to expire
5 this summer, we are at the final stages of that litigation. A
6 lot of the initial work has been done there.

7 Frankly, I have been working full time on this
8 litigation, nights and weekends in the last two months, while
9 balancing my role in the PPI litigation, and it is not a
10 problem. I have a large staff, four associates and one junior
11 partner working for me, four out of five are women. I have two
12 paralegals. Many of the firms are laying off people right now,
13 and we are hiring. I have the full permission from the firm to
14 bring on additional staff if I need to.

15 Last, a little about me and my background. I started
16 working when I was 13, and when I was in high school I worked
17 nights and weekends. When I was in law school I worked three
18 jobs. When I graduated I was working as an attorney and
19 working weekends for the first year. Nothing has changed, I
20 work nights and weekends because I want to, not because I have
21 to. I take my responsibility for the clients very seriously
22 and I want to do a good job.

23 I have no doubt I will be able to balance my
24 responsibilities with the PPI litigation and this litigation as
25 well.

1 *THE COURT:* What is your view for staffing the MDL in
2 size and organization, structure?

3 *MS. FINKEN:* Well, I can tell you the PPI litigation
4 is similar in terms of size with multiple Defendants and
5 different types of product. In that litigation we have a PSC
6 of 23, that is inclusive of the co-leaders and PEC.

7 That has worked very well, we have not wanted for --
8 we haven't needed to -- we brought other people in, but we
9 haven't needed to. There has been enough involvement and
10 financial backing in that litigation, and that size is
11 comparable here and that would work well, 20 to 23.

12 As far as the PSC and PEC structure, there is value
13 both ways, I don't think there is a right or wrong way to do
14 it. If you are not going to have a PEC, you might want
15 additional co-leads so you have a higher extent -- if there are
16 20 people involved to have to make every single decision, it
17 helps to have a decision of hierarchy.

18 Regardless of the size of the PSC, if people want to
19 work on litigation and bring necessary skills and value to the
20 litigation they should be able to work on the litigation
21 whether they have a spot or not. If they want to be involved
22 in committee structures, that is something that could be done
23 and should be allowed.

24 I put this in my papers and I strongly believe that
25 the collective wisdom of many benefits the whole. Everybody

1 brings different strengths to the table, and it is certainly
2 helping, benefiting all of the Plaintiffs in a collective
3 manner.

4 *THE COURT:* Thank you so much, I have enjoyed getting
5 to see you and know you. Thank you for your work and for your
6 application.

7 *MS. FINKEN:* Thank you so much for your time, I
8 appreciate it.

9 *THE COURT:* Okay, Kristine Kraft, good afternoon. How
10 are you? Can you hear me?

11 *MS. KRAFT:* Yes, thank you for the opportunity to
12 speak with you today. In addition to my application, I want to
13 emphasize three primary points about myself for the Court's
14 consideration in terms of why I would be an asset to the
15 leadership structure.

16 First of all, I bring well-rounded diversity and
17 experience to the table, having worked both on the Defense and
18 the Plaintiff's side. I have a background that has
19 concentrated my entire career in MDL's and mass torts. I began
20 my career as a Defense attorney representing target Defendants
21 in the asbestos litigation, Defendants who manufactured pipe
22 insulation, were insulation contractors, so we were always on
23 the front line.

24 I started with the firm by understanding how to manage
25 a large number of cases in house, as well as developing issues

1 that were common to the litigation, not only for our clients,
2 but other Defendants as well, and did so in an effective way
3 and worked really well with other law firms in that regard, and
4 in fact, was one of a handful of attorneys responsible for
5 taking lead in depositions, whether it was fact witnesses,
6 expert witnesses, reporting on the cases to clients, arguing
7 before the Court on behalf of multiple parties, and eventually
8 became one of two other attorneys responsible for getting our
9 case off the ground which involved our largest inventory of
10 cases at that time.

11 So, I had a lot of responsibility from the very
12 beginning in terms of big litigation in this regard, in
13 epidemiology and other things that transferred over to the
14 Plaintiffs' side.

15 Then about 15 years ago, I transitioned to
16 representing Plaintiffs in branding litigation, which was the
17 pharmaceutical cases and medical device cases. In fact, I was
18 recruited by my current law firm to become part of their firm
19 and to develop their pharmaceutical practice, which was
20 branding at the time, it was in the infancy stages.

21 We just had a hand -- well, we had several Ortho
22 cases, and no presence in the MDL, and my responsibility was to
23 gain a presence in the MDL and represent our clients in our
24 practice, and I was very successful in doing that. I think it
25 is a testament to how I work well with other lawyers and how

1 hard I work. With no role whatsoever, I am an example of a
2 situation where I volunteered to do work in an MDL, DVG, high
3 level work, went above and beyond in many situations.

4 I had developed good relationships with counsel I
5 didn't know at all. I was a new person on the block. I worked
6 well with lead counsel and other PSC members and eventually
7 both myself and then my partner, who then became a bit more
8 involved after time went on, became part of the trial team for
9 the Ortho case. That was the case -- the first case set for
10 trial.

11 So, in that regard, I really have direct experience
12 with appreciating so much the willingness of lead counsel and
13 other PSC members to welcome somebody new to the litigation and
14 give them a chance to prove themselves. And I think that is
15 very much appreciated, and I have always taken that to heart.

16 Since that time, as well as before that time, I think
17 that is just part of my natural inclination, why I manage
18 things, I am easy going, a very well-rounded person who will
19 take on any task that is needed to get the job done.

20 So, over time I worked my name into PSC roles and have
21 had the privilege of serving as co-lead counsel and liaison
22 counsel in a couple of MDL's, and that experience is invaluable
23 to me. Those MDL's were smaller in comparison to what this one
24 would be and others, but it was a prime opportunity for me to
25 now have the opportunity on the Plaintiff's side to organize

1 litigation.

2 I worked with other terrific, well seasoned co-lead
3 counsel, and being part of a team to manage the litigation,
4 decided priorities of responsibilities while at the same time,
5 because it was relatively small overall, I was extremely active
6 in working up both of those cases, being an integral part of
7 discovery and expert committees, identifying brand new experts
8 that had never been part of an MDL and served as experts in the
9 past, and I think did a very effective job in those
10 litigations, with one of the litigations involving the filing
11 of Daubert motions and we survived on the Daubert motions.

12 All of those experiences transfer into who I am, and a
13 second reason why I would be a strong asset to the leadership
14 team is because I get it. I have had the opportunity to work
15 at the high level strategy aspect of the litigation and handle
16 whatever task needs to be done.

17 I am not one who has an ego that you have to worry
18 about, I will be the one who will work, do all the leg work to
19 workup a deposition. I can certainly take a deposition, and be
20 on that front firing line as well.

21 My goal is to advance the litigation because that is
22 so important to our clients, to the Court, to the rest of the
23 team, and we want to do so in a fair and thorough manner, and I
24 think I bring that to the table. I am very reliable in that
25 regard, I am committed to my obligations, and I take them

1 seriously.

2 Thirdly, I can assure the Court that I am committed to
3 this litigation. I have thought very carefully about the time
4 necessary to handle this role in conjunction with my other
5 responsibilities. One of my primary responsibilities is the
6 Juul litigation which I could not be more honored to receive
7 that appointment, and I have been a significant part of that
8 litigation thus far, and I very much intend to continue with
9 that obligation. I am cochair of a personal injury committee
10 concerning the bellwethers and handling the fact sheet, the
11 Plaintiffs' fact sheet, and part of the discovery and expert
12 committees in that litigation working on third party subpoenas
13 and other tasks, but I think I have just grown up as a person
14 with a really strong work ethic. I worked my way through law
15 school and have always managed a lot of responsibility and
16 actually consistently. I guess when evaluated I almost work
17 too hard sometimes.

18 I feel very confident that I can do PSC roles and I
19 would be honored to be part of such a great team that is going
20 to be part of the PSC team and leadership team, and I welcome
21 any questions you have.

22 *THE COURT:* When do you think the bellwethers will be
23 in the Juul litigation?

24 *MS. KRAFT:* It will be quite some time. We are at the
25 stage of proposing an initial plan, we haven't done that yet.

1 We have in place our thoughts on that process, but in terms of,
2 you know, when that selection, that cutoff deadline is going to
3 be we haven't firmly decided, and because we haven't had the
4 discussion with Defense counsel as to when that will be, I am
5 hesitant to really elaborate too much on our thought process,
6 but we do have some thoughts in place.

7 *THE COURT:* Given the background you have had with a
8 bellwether committee in Juul and the fact sheet, can you give
9 any thought to bellwether selections in this case or do you
10 think it is too early?

11 *MS. KRAFT:* I think in this case it is too early. We
12 want to see how the science develops and particularly with the
13 Sloan Kettering study that is going to come out. There will be
14 some priorities in terms of some of the cancers, but in terms
15 of which category of cases to put first in the type of cancer,
16 I think it is a bit early to make that decision, but I do think
17 there are going to be different categories for the different
18 cancers put in place.

19 *THE COURT:* Okay. All right. Thank you so much.
20 Nice to meet you, and thank you for your application.

21 *MS. KRAFT:* Thank you for the opportunity.

22 *THE COURT:* Take care.

23 Okay, Daniel Nigh is next.

24 *MR. NIGH:* Good afternoon, your Honor.

25 *THE COURT:* Good afternoon. How are you?

1 MR. NIGH: I want to start off by thanking you for
2 having a Zoom meeting for the interviews. I know it takes a
3 lot of planning. I appreciate the personal touch that is
4 added.

5 THE COURT: Thank you.

6 MR. NIGH: I want to tell you what I have been doing
7 thus far in the appointments you have been giving me, and I
8 appreciate that. We have been working on the April
9 deliverables team and meeting up with the experts. I have been
10 working with them, and that is helping us to define the scope
11 of the litigation, but we're preparing the scientist litigation
12 along with Tracy Finken.

13 I think my background has given me a head start in
14 this litigation. I was appointed one of four co-leads in the
15 Valsartan litigation by choosing the area I focus on in that
16 litigation. The main aspect I focus on is the science,
17 experts, and developing bellwether cases that George Williamson
18 spoke about previously. We have done a lot of work in terms of
19 this type of carcinogen. It is odd that we have MDA, which is
20 a rare carcinogen, come up, and so to be able to have the
21 experience already looking at the MDA carcinogen for over a
22 year with Valsartan, I can bring the expertise I gathered from
23 that case over to this case.

24 And also, in negotiating many of the protocols in
25 Valsartan, a lot of the issues will overlap here. Just like in

1 Valsartan, here we have a factor that George spoke about, we
2 are going to have generic manufacturers, name brands,
3 manufacturers that we had in Valsartan. There are important
4 issues that we have to grapple upon and think about how to
5 stage discovery to the best -- to best maximize the efforts.

6 I can draw upon a lot of that experience I have had.

7 I want to take a step back and talk about my other
8 experience I have had.

9 I worked with Levin Packer for 11 years, I have worked
10 almost exclusively on pharmaceutical litigation and medical
11 devices. I have been involved in multiple MDL's in leadership
12 roles, also working on the -- I have more cases than anybody
13 else in that litigation that I personally represented.

14 And the second most common benefit, just the amount of
15 work I put into that litigation in all aspects. One of the key
16 things is negotiating and developing the global resolution we
17 have in the case, and managing the claims process through to
18 finality.

19 One thing I can say is that I have had a significant
20 amount of time free up. That case is almost completely -- it
21 is not complete, but we only have about two hours that I spend
22 every month, and that is on a few liens that haven't resolved
23 yet, global issues. I have a lot of experience in all aspects
24 in that case.

25 What I have done here in Zantac, I have been able to

1 focus on the science and experts, I have been able to negotiate
2 and be involved in negotiations with Pfizer, with the
3 retailers. I have been involved with negotiating a
4 preservation order and hopefully I can be involved in many more
5 aspects of this litigation. I am very motivated.

6 Our firm, Levin Papantonio, is well-known, has a
7 fantastic reputation in terms of resources. We are committed
8 to every MDL we get involved in. I represent over 3,000 cases,
9 we believe resulting from Zantac.

10 And I will address any questions you have.

11 *THE COURT:* Terrific, thank you.

12 What is your vision for using or leveraging the
13 registry?

14 *MR. NIGH:* The registry -- at the time we were
15 negotiating the settlement, we were there 2500 times, the
16 settlement gets announced, and all of the claims behind the
17 curtain, law firms not involved in the case at all, come
18 forward for the first time, so it is discouraging. We had to
19 deal with that and we worked the settlement with 9,000
20 additional (inaudible). One way is that you assess the census
21 up front early on.

22 I am a data driven guy, data is extremely important as
23 you look at these types of litigations. We are going to get a
24 lot of data from the census program. We already have it.

25 In terms of the scoring system we developed in

1 Valsartan, the data we have put in, we can look and decipher
2 what are our very strong cases versus what are our weakest
3 cases. That is the type of scoring system helpful for initial
4 vetting, for filing a case. It is helpful for determining
5 which cases should be tried from a bellwether perspective on
6 the strong/weak basis and helpful because it lays a foundation
7 in terms of settlement. A lot of things we are talking about
8 in the scoring system leads the way.

9 *THE COURT:* What do you think leadership can do to
10 control the scope of the case other than some of the things
11 that have been put into place already?

12 *MR. NIGH:* Early discovery helps and scientific
13 studies help. We are trying to get our eyes on scientific
14 studies. We really at this point -- one of the issues on
15 trying to limit the scope, we can't limit the scope prematurely
16 in terms of the cancer, we are just finding out on the
17 Plaintiffs' side. We have Zantac which has been used for 35
18 years and we have a recall at the beginning of April, so a lot
19 of the data coming out of the FDA, testing data, a lot of the
20 EPI studies that are most informative are not the ones starting
21 out trying to look at -- there are EPI studies that look at
22 ulcers. And breaking out categories of information, pulling
23 together all of that information quicker is going to help us as
24 well.

25 *THE COURT:* Okay.

1 *MR. NIGH:* Discovery will be key in terms of the types
2 of like defects from, you know, from a PI, manufacturing
3 defects, from the shipping and storage angle, and in terms of
4 the knowledge, how it breaks down.

5 *THE COURT:* Thank you so much for your work and
6 presentation and taking the time to apply and for being here
7 today.

8 *MR. NIGH:* Thank you, your Honor.

9 *THE COURT:* Okay, take care.

10 Ms. Goldenberg.

11 *MS. GOLDENBERG:* Thank you, your Honor.

12 *THE COURT:* How are you?

13 *MS. GOLDENBERG:* I am well, thank you. How are you?

14 *THE COURT:* Good, thank you. Let's have you give us
15 your opening remarks and, again, I want to thank you, too, for
16 the work you have been doing, and to the extent that you
17 anticipate one of the first questions might be what have you
18 been doing and how has it been going, you can wrap that into
19 the other prepared remarks.

20 *MS. GOLDENBERG:* Thank you for giving me an
21 opportunity to audition, for lack of a better term, for the
22 leadership. I loved the opportunity to work with everyone on
23 the team so far. I told Mr. Dearman I would have to buy a
24 podium if I want to look half as impressive as him.

25 *THE COURT:* I like your picture in the background.

1 MS. GOLDENBERG: What I have had an opportunity to do,
2 I have been on the discovery team, where I spent the bulk of my
3 time. I have been on the leadership team as well, weighed in
4 on the master pleadings that Jennifer Moore and so many others
5 spent a lot of time on as well. I honed in on some of the
6 issues with the API manufacturers and preemptive issues, and I
7 talked about what I did in the previous MDL's in my
8 application. I won't go too far on that today. But I briefed
9 in these preemptive issues in several MDL's. I am ready to run
10 in that regard.

11 One of my passions, I want MDL's to run efficiently.
12 It is important to make things run smoothly at a legal level as
13 well as a lawyer level. Some of the things I have also worked
14 on include streamlining service of process a little further
15 than what we have already negotiated, and using our LMI portal
16 to transport data that is inputted for the Master Complaint and
17 carrying that over to other forms that you might have to
18 complete in the future. I have done some work with Frank
19 Maderal (phon). I think that covers most of what I have had
20 the opportunity to work on.

21 As far as just a couple of personal remarks, my
22 parents started Goldenberg Law when I was one year old, and
23 since I was able to read, I pretty much worked at the firm. I
24 announced at my bat-mitzvah that I was going to be a lawyer,
25 and every summer I was a file clerk, law clerk and paralegal,

1 and now where I am at as an attorney. I am a mom of a two
2 month old and four year old and it is fun to show my kids the
3 same thing, and they are ahead on the scale already.

4 I have had time to work on the personal injury cases,
5 to work on drug and medical device cases in both MDL work and I
6 handled pharma device cases on my own, which meant handling
7 every aspect of the case.

8 With that said, I know I discussed a lot of that in my
9 application and I know you read it. I am happy to answer any
10 questions you have.

11 *THE COURT:* What is the best lesson learned from the
12 Valsartan MDL and this MDL, in your opinion?

13 *MS. GOLDENBERG:* The important thing is so we
14 understand how much -- putting a lot of that together on the
15 administrative side it is how you manage so many Defendants. I
16 have been marginally in charge of a protocol where you have
17 Defendants and others that have been dismissed without
18 prejudice for now.

19 The attorneys on the other side appreciated that
20 because their clients weren't paying them to come for every
21 management conference. We were able to get discovery from
22 those entities up front, and that is helpful to prioritize
23 discovery and use resources on all sides very well.

24 *THE COURT:* You kind of wrapped into the discovery
25 question with so many different types of Defendants. What do

1 you think in terms of discovery structure -- you spoke about
2 prioritization, at least in Valsartan, and ultimately
3 dismissing some voluntarily without prejudice. Any thoughts on
4 discovery structure as relates to the number of Defendants we
5 have in this case?

6 *MS. GOLDENBERG:* Sure. Candidly, this idea came from
7 our judges in Valsartan, they said, look, you need to focus on
8 where the problem really started. That is going to be the bulk
9 of where we focus in this trial.

10 We focused on the manufacturers, and now we are
11 getting to the point where we are looking at retailers and
12 other entities down the distribution chain. A similar model
13 would make sense here. The company responsible for making the
14 active ingredient in the drug will be the focus, not to say the
15 others are not important, but probably it is important to start
16 in the same place we started in the Valsartan litigation.

17 *THE COURT:* What ideas do you have about diversity,
18 promoting the next generation of MDL attorneys and the concept
19 of mentoring and inclusiveness; how can that be effectuated in
20 this case?

21 *MS. GOLDENBERG:* Sure. I am the beneficiary of that
22 process already. I got to serve on some committees on MDL's,
23 and that was my introduction to MDL work. Doing document
24 review in the first MDL taught me about the case, what was
25 important for depositions, and everything went from there. And

1 similarly in this case, if we are able to give opportunities to
2 newer attorneys to serve on committees and help in assignments,
3 it gives them an opportunity to grow as well.

4 *THE COURT:* Thank you so much for your application and
5 for taking the time to speak with me today.

6 *MS. GOLDENBERG:* Thanks, your Honor, I appreciate the
7 time. Take care.

8 *THE COURT:* The next is Rosemarie Bogdan. How are
9 you?

10 *MS. BOGDAN:* I am good.

11 *THE COURT:* Thank you for taking the time and
12 submitting your application. I don't want to wear anybody out,
13 let me let you go into your comments.

14 *MS. BOGDAN:* It is my pleasure to be here today to
15 apply for a position on the steering committee and to let you
16 know about my background. I am a partner with Martin Harding,
17 my partners and I built our firm over the last 27 years here in
18 upstate New York, Vermont, and Massachusetts. Our practice is
19 limited exclusively to representing Plaintiffs, and that has
20 been my focus for my entire private practice career.

21 I actually started handling what are called mass tort
22 cases as opposed to single event cases. I never knew a single
23 event case, or an applied liability case with one person. I
24 started with mass torts when we realized so many of the clients
25 in the area we serve have a need for pharmaceutical

1 representation. I started into this arena about ten years ago
2 and found a way to take my talents which I developed over the
3 last 15, 17 years of practice and move them into this arena.

4 I applied for this position because I am co-science
5 chair on the Valsartan litigation, and my position with regard
6 to the PSC in that litigation has allowed me to become very,
7 very familiar with the carcinogen that is the issue in this
8 litigation. I have spent over two years understanding MDMA,
9 learning about MDMA. I have dealt in everything from the
10 animal studies to the characteristics of this chemical, toxic,
11 genotoxic, understanding the oncology aspects, understanding
12 the latency aspects, and essentially that all has a crossover
13 to this litigation.

14 One of the reasons I have sought out a leadership
15 position in the Valsartan litigation is, although I wanted to
16 move into the mass tort arena, I recognized early that I have a
17 strong drive to want to continue practicing law. By serving on
18 the PSC, it allows me to practice in this arena, to be involved
19 in the litigation, be involved in the strategy and science, and
20 my interest in science which goes back a long, long way.

21 And one of the reasons I think I became interested in
22 personal injury law, it allows me the framework to liability
23 and damages as pertains to these types of litigations. My
24 position on the Valsartan PSC dovetails into what I would be
25 doing in this litigation. I served on the one PSC, I have the

1 time to devote to this. Starting in 2016, I decided to go a
2 hundred percent into MDL's and mass torts.

3 We have a full service law firm here, but I did that
4 because I became really aware of how this particular area of
5 the law and what I could do in it would benefit the Plaintiffs
6 as a whole and, you know, to -- just to put it in a common type
7 of, you know, situation here, you have moms and dads who, when
8 they go through the kids' Halloween candy, if they see it is
9 made in China, they throw it out, they don't know if it is
10 safe.

11 When you realize pharmaceuticals have a chemical made
12 overseas without the quality control, and with the assumption
13 that it is safe, these active ingredients could have a
14 carcinogen in it. They are so trusting that the drug is safe
15 and medical device is safe, and that can be misplaced if the
16 manufacturers are not doing what they are supposed to be doing.
17 That is why I moved over to doing a hundred percent mass torts.

18 We have a law firm over 150 members strong, we have
19 the resources to be involved in litigation, I have the drive to
20 be involved in this litigation. We are already committed to
21 litigation with regard to agreeing to represent clients and,
22 you know, I welcome any questions that you have.

23 *THE COURT:* Okay. Given the evolving science and, you
24 know, the importance of case selection, what do you think about
25 screening in a case where science is evolving?

1 MS. BOGDAN: The screening is everything, especially
2 in a litigation like this, or any cancer litigation. You have
3 multiple aspects of screening. With some medical device
4 litigation, was the device in place and caused this particular
5 injury? But when you are looking at this type of litigation,
6 the screening is crucial. It was crucial in Valsartan. It is
7 about dose and response, how much of the carcinogen did the
8 person ingest over what period of time, and what particular
9 cancer are you speaking of.

10 With regard to MDMA, there could be ways cancer
11 develops pertaining to both of those different phenomena
12 going on simultaneously, and what goes on in each person's
13 body, it is an individual thing. You have to look at each case
14 individually, but have the idea of what those factors are, how
15 they interrelate. And that is one thing when we were dealing
16 with Valsartan and developing a scoring system that Daniel Nigh
17 referred to earlier and Mr. Williamson, taking all of those
18 factors, but screening is crucial.

19 I filed our census, and we have about 150 clients on
20 there. I probably have actually screened over 800 or 900 calls
21 with regard to this litigation, and it is understanding that
22 criteria.

23 Most important, as part of leadership, what is
24 important is that all of the attorneys that want to be involved
25 in the litigation and represent individual Plaintiffs

1 understand that criteria so they can be doing that type of
2 evaluation to make a decision with regard to whether or not
3 that particular Plaintiff has a viable claim, and that is the
4 role of the leadership committee.

5 And one of the things at the science fair I do, I
6 field questions from all of the attorneys throughout the
7 country asking about their specific client, giving me the facts
8 of the case with regard to the manufacturer, the dose they were
9 on, and the kind of cancer they had, and giving them an idea
10 how to use the criteria that we know so they can make a good
11 decision for their client.

12 *THE COURT:* Okay. How young do you see people
13 reporting Zantac use?

14 *MS. BOGDAN:* How young? They do use it in children as
15 well. But as far as my client base, I see people using it
16 starting in their teens, and then the drug has been on the
17 market for so long at this point, there is a wide range of
18 people that have taken it, and the period of time they have
19 taken it, but it's not that the 18 year old usually has a sour
20 stomach, it is not typical. We have seen it in teens, and
21 through 20's, and it is in conjunction with having GERD or one
22 of the other conditions that it would treat.

23 *THE COURT:* Lastly, any mentoring ideas for new
24 lawyers?

25 *MS. BOGDAN:* Having practiced for 27 years and being a

1 woman, I think mentoring is so important with young attorneys,
2 and with regard to how that would work in an MDL, I see for
3 young attorneys the opportunity would be working on committees,
4 working under the -- in the structure under one of the more
5 experienced attorneys.

6 On a personal note, being up here in New York and
7 practicing in New York, Vermont, and Massachusetts, I noticed
8 as I enter the MDL world that there are not a ton of law firms
9 from my geographic area that are actually involved in this type
10 of work. And so, as I entered into the MDL landscape, and I am
11 not a young attorney, I found it, how do I navigate in, how do
12 I meet the different attorneys involved, how do I actually get
13 to practice in this area that I have become so passionate
14 about.

15 And if there is a framework within MDL's to allow
16 young attorneys to get involved, to get those stepping stones,
17 especially if it is from a firm that has not done MDL's
18 forever -- there are firms where that is their main practice, a
19 new associate in one of those firms has a nice path to follow
20 in their career, but for someone who wants to enter into the
21 MDL world who doesn't work for one of those firms, it would be
22 wonderful if the structure in the MDL would provide
23 opportunities for attorneys who have a passion to be able to
24 serve in a role that would be commensurate at their level to
25 allow them to grow and learn.

1 We do that in our individual firms, they work under
2 one of the senior litigators. In MDL's, at least I haven't
3 seen that they provide for that. So, I think what we do, we
4 bring in a new associate that would be adopted in an MDL.

5 *THE COURT:* Terrific, thank you so much, I appreciate
6 you sharing your time and thoughts with me.

7 *MS. BOGDAN:* Thank you for the time and opportunity.

8 *THE COURT:* I think what we will do now is take a
9 short break. We are well on schedule. We have six applicants
10 left.

11 It is five minutes to 3:00, so why don't we take a 15
12 minute break, and why don't we come back at 3:10. When I say
13 come back, again, I don't mean leave the meeting. For this
14 short period of time, if the 88 of you are still on, if you
15 want to be here in 15 minutes, just stay on, keep your mute
16 button on, keep your stop video. I will turn mine on in a
17 moment and we will come back at ten minutes after 3:00. Thanks
18 so much.

19 *(Thereupon, a short recess was taken.)*

20 *THE COURT:* We are going on to Steve Rotman.

21 Okay. We are back and our next applicant is Steve
22 Rotman.

23 *MR. ROTMAN:* Good afternoon.

24 *THE COURT:* Good afternoon. How are you?

25 *MR. ROTMAN:* Thank you very much, your Honor. I want

1 to join the others who have expressed their appreciation for
2 all of the work accomplished so far in a short period of time
3 by this Court, by Special Master Dodge and by the interim
4 committees. It is really setting a model for all Courts on how
5 to move litigation at a time when we are facing the kind of
6 restrictions that we are.

7 My contribution to this litigation for the PSC would
8 be in the area of science and experts. This is my strength and
9 has been my focus for the past 20 plus years, even prior to
10 that.

11 My first experience with pharmaceutical litigation was
12 with the Bendectin litigation, I was an associate with the law
13 firm Davis Polk and Wardwell. I worked with a former retired
14 judge who had been the special counsel in Iran-Contra, he was
15 representing the manufacturer in the Bendectin litigation.
16 That litigation was the litigation that gave rise to the
17 Daubert principle.

18 Since the late '90's, my focus in all of the cases I
19 have worked on has been working with experts and working with
20 science, recruiting experts and working with them to develop
21 their reports, prepare them for depositions, defend them on
22 Daubert challenges, take depositions of Defense experts, and
23 prepare Daubert challenges to defense expert opinions where
24 appropriate, and to explain present scientific evidence
25 pertaining to general and specific causation to judges and to

1 juries.

2 I'm not generally comfortable tooting my own horn, but
3 I have been told by colleagues and Defense lawyers I am very
4 good at this. In the next few minutes I would like to talk
5 about my approach in dealing with experts and science in these
6 cases.

7 I view my role as a liaison or bridge between the
8 expert witness and the courtroom. We are dealing with science
9 in the courtroom which is very different for these experts than
10 just dealing with the peer review process. We are dealing with
11 the adversarial process where they are challenged in ways that
12 they are not used to being challenged, and there is a big
13 difference between an excellent expert on cancer, and an
14 excellent expert witness on that same subject matter.

15 So, it is my job to find the excellent expert and help
16 that expert navigate how to apply the area of expertise to fit
17 the needs of the case, to meet the Daubert standards, and to
18 address the specific questions that need to be answered in the
19 case, and to be able to present the evidence in an
20 understandable way to nonscientists.

21 I have worked with experts in numerous medical and
22 non-medical specialties in my career. In recent years, I
23 worked with the type of experts that I would expect would be
24 involved in a litigation like this, epidemiology,
25 biostatistics, toxicology, oncology, pathology, radiology,

1 molecular biology.

2 I've worked on several mass torts involving cancer,
3 lung cancer, ovarian cancer, breast cancer. I am familiar with
4 the kinds of science issues of latency, the issues involving
5 the different types of carcinogens, and different medical and
6 scientific disciplines that can help and aid the Court in
7 understanding these issues.

8 In my work I find the Federal Judicial Center's
9 scientific evidence to be an extremely valuable guide, I refer
10 to it and use it often. I spend more time reading medical
11 literature than I do case law, I find the details in medical
12 literature, not just the conclusions of a particular study, but
13 the details can provide a great resource for use in depositions
14 and briefing.

15 I am a team player, I enjoy working with others. I
16 see the next after me is Dr. Restaino. I worked with John for
17 years in a number of cases and we worked well together. Before
18 the break, Marlene Goldenberg was before the Court, and we
19 think so highly of her and her father and their firm that my
20 firm is referring our Zantac cases to them.

21 Your Honor, I strive to practice law with integrity.
22 I am always thinking about maintaining my credibility and the
23 credibility of my case with expert Defense counsel, with the
24 Court and jury and my own colleagues, and I believe that if
25 there is a battle between Plaintiffs and Defendants on

1 credibility, I want to win that battle.

2 I think about paying attention to the scientific
3 evidence that cumulatively will create a picture where
4 causation is the most likely explanation. I take effective
5 legal writing very seriously on science issues, I take pride in
6 my writing. My goal is to be clear, easy to understand to a
7 nonscientist without over simplification, and I am comfortable
8 with the basic principles of epidemiology, design, sample size,
9 power, statistical significance, bias and confounding.

10 We use these concepts to interpret studies and to
11 assimilate the results of one study with the other scientific
12 evidence in the case.

13 Your Honor, I see I have gone a long time already, I
14 have more that I could talk about, but I am going to stop here,
15 other than just to say that I can devote an extensive amount of
16 time to this case. I would like very much to be able to work
17 with this Court, with Special Master Dodge and with the very
18 talented lawyers that have already been working on this and
19 that will be continuing to work on the case.

20 *THE COURT:* Thank you very much, Mr. Rotman. I
21 appreciate your sharing your area of expertise, that has come
22 through in your application.

23 So, maybe just one question about how you see science
24 interacting with a class action. Are all types of Zantac
25 created equal or are there differences in how much MDMA there

1 is that would impact class certification?

2 MR. ROTMAN: I was involved in one monitoring class
3 action involving a medical device. I understand in a class
4 action there needs to be a common denominator and the science,
5 general causation of science would be a common denominator.

6 Individual cases are difficult to fit into a class,
7 but the general causation evidence that we develop in this MDL
8 should serve individual injury cases and class action
9 Plaintiffs alike to the extent that the issue is going to be
10 does this medication cause any type of cancer or specific types
11 of cancer.

12 I don't know if I answered your question, but I can
13 certainly go further if you have a followup.

14 THE COURT: No, thank you, I appreciate that.

15 So, now maybe speaking on the individual personal
16 injury side as we move forward with individuals who have
17 perhaps unique usage patterns, any thoughts on how you see
18 science interacting with case management in the way we get from
19 here to resolution, whatever resolution looks like?

20 MR. ROTMAN: Yes. So, generally what we do in these
21 types of cases, what we start with is general causation, does
22 the exposure cause the injury, and what is the injury. There
23 are many different types of cancer, what types of cancer. Does
24 the exposure cause ovarian cancer, stomach cancer,
25 gastrointestinal cancer, liver cancer.

1 So, the Plaintiffs would need to identify the types of
2 injury that they are going to target and develop general
3 causation evidence for.

4 Then we move to specific causation. Of course, from
5 the beginning, we are thinking about specific causation for all
6 of our cases as we screen them. The things we want to think
7 about, has this individual, this Plaintiff, this client had the
8 exposure? How long has been the exposure? When did the
9 symptoms -- when was the cancer diagnosed? When did the
10 symptoms first manifest? Is it the type of cancer for which we
11 can prove general causation? Are there any latency issues?
12 What are the confounding questions in the person's medical
13 history?

14 For example, if the person has other risk factors in
15 their medical history separate from their medication use, can
16 we prove specific causation, and how will we prove specific
17 causation given that array of presentation?

18 One thing we may see as we develop the case, I have
19 seen this in other cases, is there anything in the pathology,
20 anything in the medical chart that would be distinctive about
21 this type of cancer so that it can be a signature for the
22 exposure? If that is the case, that really is a significant
23 element of case specific causation.

24 Case specific causation can certainly be proved where
25 that does not exist, but where it does exist, it can become a

1 game changer.

2 *THE COURT:* Okay, thank you so much. Thanks for
3 sharing your knowledge, time, and applying for the interview
4 here today. I appreciate that.

5 Okay, our next applicant is John Restaino. I hope I
6 pronounced your name correctly, if you are there.

7 There you are. Gosh, I thought we were going to break
8 the streak here.

9 *DR. RESTAINO:* I was going to call my ten year old
10 grandson to come in and help me.

11 *THE COURT:* I am glad we did not need him.

12 *DR. RESTAINO:* Thank you for the opportunity. My name
13 is John Restaino, I am joined in this conference by two of my
14 named partners who will be working with us on the PSC or the
15 various committees. I will give you some representation of my
16 firm if you have any questions about my firm.

17 Dalimonte Rueb Stoller is one of the largest mass tort
18 firms in the United States, we have over 150 people working
19 with us. We have no problem putting as many staff members and
20 attorneys on the litigation as necessary. We have significant
21 financial liquidity and access to credit lines if needed to
22 assist the litigation in going forward.

23 The firm is made up of trial lawyers, we have over 250
24 with trial experience collectively. We have been in the lead
25 in Plaintiffs' steering committees, various discovery and

1 science committees for years, we have taken thousands of expert
2 depositions, Daubert and, of course, the trials, and we have
3 multiple doctors and lawyers on our staff from which we can
4 draw their expertise.

5 Right now, as to Zantac itself, we have 3,472 clients
6 in the census system, and as of yesterday, 4,217 clients under
7 retainer. We continue to actively acquire and have cases
8 referred to us, and we anticipate we'll ultimately be
9 representing 10,000 clients or so.

10 We have been very active also in developing and
11 retaining numerous experts, including toxicology, epidemiology
12 in this country, Canada, and Europe, and lecturing to our
13 colleagues on science, case selection, and epidemiology
14 litigation, I have experience in that regard.

15 Based upon past experience, we find it important to
16 identify firms in PSC's we work with that have a strong
17 invested interest in the litigation, have substantial
18 experience in trying these cases, and I include in that Daubert
19 hearings, and I am a member of the talc PSC, and PSC members,
20 my colleagues, asked me to cross-examine the Defense cancer
21 expert in the talc case at the Daubert hearing in July.

22 I have worked in the past with eight of the
23 individuals who have been here this afternoon. Steve Rotman --

24 *THE COURT:* Somehow I put you together, back to back.

25 *DR. RESTAINO:* We appreciate it.

1 *THE COURT:* It worked out that way.

2 *DR. RESTAINO:* Your Honor, you have a fabulous slate
3 of individuals to work from, they are all worthy applicants and
4 good lawyers who put the profession of law first.

5 I can give Steve a little grief, but I can do that at
6 a different time.

7 We have a positive relationship with Defense counsel
8 and consider some of them friends. We have the ability to
9 handle any and all aspects of this litigation.

10 One of my partners, Paul Stoller, who is on this
11 listening to me, sent me a text when you asked a question to
12 Steve about class actions, and how many class action cases he
13 has handled, if there is a class action committee, how he would
14 volunteer to be on that committee.

15 As far as myself, I have a little bit of an eclectic
16 background, I practiced surgery in foot and ankles from 1980 to
17 1990, I started law in January 1991. In September of 1991, a
18 woman came in and complained of neurological problems in both
19 of her arms that she thought were due to ruptured silicone
20 breast implants. I discussed this and in 48 hours I was on an
21 interview, and I was put on the Plaintiffs' Steering Committee
22 for the diet pill litigation and many of the different mass
23 torts since then.

24 I practice mass torts one hundred percent with my day
25 job. I semi facetiously like to say in my night job I am an

1 adjunct associate professor at the Medical College of Virginia.
2 If I could tease Mr. Rotman, I read the medical literature
3 every day, but twice a day I am asked from the university how
4 to read the medical literature.

5 Epidemiology is very important in this litigation,
6 along with the toxicology, the dose, duration, and confounding
7 of those. It takes some experience to look at that and one of
8 my favorite sayings is, experience is what you think about
9 after you need it.

10 I was an associate professor, taught a surgical
11 residency program for 13 years, and I've worked with many
12 associates teaching them in various aspects how to conduct
13 themselves in the practice of law.

14 Do you have any questions of me?

15 *THE COURT:* Yes. So, I understand that talc has a
16 unique pathology. How will we know which of these cancers are
17 caused by Zantac versus people who happen to get cancer because
18 it is, sadly, common?

19 *DR. RESTAINO:* It is, sadly, common. There is serious
20 cancer associated with talc, I don't believe we are going to
21 see that.

22 With everything I have seen so far, with Zantac,
23 Ranitidine, nitrites and MDMA, I am not seeing a signature in
24 any of the cancers which will make the epidemiology of it all
25 that more important. Looking at the strength of association,

1 lack of confounding, and yes, it is common, but also the tenant
2 that while genes load the gun, the environment pulls the
3 trigger. There is that interplay between genetics and
4 environments in probably all cancers mainly, mostly in medical
5 conditions.

6 That is the strength I have had over the years,
7 whether I am on the PSC or working along with the PSC, keeping
8 one foot in science and one foot in discovery, assisting in the
9 evaluation of document review, providing outlines for what
10 individuals should be looking for in document review that is
11 science based, and quite frankly, teaching some of the
12 attorneys working on the case about the epidemiological aspects
13 of some of the -- I am not going to say -- I have to say
14 minutia. I am blanking on the word right now.

15 Confounding by indication two years after developing
16 the cancer, the manifesting symptom is heartburn, they start
17 taking Zantac or the PPI. They are taking the PPI to treat the
18 symptoms from the cancer, that is confounding by indication,
19 and that is important. So, we want to look at the latency of
20 studies, many times they exclude individuals who are diagnosed
21 within a year, sometimes more, preferably more. That has to be
22 looked at carefully. I enjoy teaching that to not only
23 students, but attorneys.

24 *THE COURT:* Did I see you have a filing in California
25 State Court, and if so, can you tell me about that, or am I

1 mistaken?

2 *DR. RESTAINO:* A Zantac filing?

3 *THE COURT:* Do you know whether you have any in State
4 Court in California?

5 *DR. RESTAINO:* No, we do not.

6 *THE COURT:* Okay. Well, I think you covered
7 everything in your thorough presentation, so I appreciate that.
8 Certainly, your expertise, given your background and your
9 unique background and knowledge of the sciences is very helpful
10 and instructive to the Court even at this early stage.

11 *DR. RESTAINO:* Thank you, your Honor. I want to take
12 30 seconds, I want to give a shout out to my alma mater, Johns
13 Hopkins, with the COVID-19. This week I loss a colleague that
14 I trained with to the virus. I want to give a shout out to all
15 health care workers and first responders, thank you for your
16 time and stay safe.

17 *THE COURT:* Thank you. I extend my condolences for
18 your loss. Thank you so much.

19 Okay, our next applicant is Nicola Larmond-Harvey.

20 *MS. HARVEY:* Yes.

21 *THE COURT:* Good afternoon. How are you?

22 *MS. HARVEY:* I am doing well, thank you.

23 *THE COURT:* Good, good. Let me give you the podium,
24 so to speak, the Zoom podium, and let me know about you and I
25 am intrigued by your story. Share that with me as you would

1 like.

2 Hold on a second, I don't think we are hearing this as
3 clearly as I think we would like to.

4 (Audio difficulties.)

5 *THE COURT:* Talk for a moment. Why don't we say hello
6 again, how are you doing?

7 Is there another device that is on that might cause an
8 echo. Why don't you proceed, and if I am not hearing you well,
9 I will tell you right away. I want you to have the benefit of
10 me hearing everything.

11 I had somebody stay on the video, but they called in
12 and actually spoke on the phone, if it comes to that, but I can
13 still see you.

14 Why don't you begin and let me see how it goes.

15 I am sorry if this is adding stress upon stress, don't
16 worry, I am not put out at all about it, I want to make sure I
17 hear you, that is all.

18 *MS. HARVEY:* I have applied for a position to advocate
19 for Plaintiffs with a smaller firm, I believe the
20 representation of all firms is vital to ensure mass settlement
21 agreements are comprehensive and takes care of all Plaintiffs.
22 It is my experience -- the opinions (unintelligible) dominate
23 the decision making that can weaken the smaller firms,
24 specifically working in the trans -- I have experience
25 (unintelligible) that Plaintiff can lose their voice and

1 bargaining powers.

2 I have not worked on a PSC before, and while I
3 currently do not possess some of the finite skills for the
4 position, I believe it his important to have advocates like me
5 to work with that leadership.

6 Also, I am a registered nurse, I am passionate as to
7 the importance of an MDL that holds manufacturers accountable
8 for deceit, deceit for Plaintiffs who took medication and
9 deceit for the medical professionals who administered drugs to
10 those Plaintiffs, I hold (inaudible) -- paramount, and I strive
11 -- (inaudible) so, having heard my clients say my doctor, my
12 nurse, the pharmacist has never mentioned that risk to me,
13 makes me want to be part of a team to make the drug company do
14 better.

15 *THE COURT:* Okay. I could hear you, it worked.

16 You have an amazing life story of having been a nurse
17 and now an attorney, and so, you are working for Saunders &
18 Walker, is that my understanding?

19 *MS. HARVEY:* Yes, I have been working with them since
20 2013. I worked as a nurse in several areas of nursing through
21 various states, and one of the concerns that afforded me was
22 the fact that I don't like putting bandaids on people's
23 problems. I couldn't get, with a lot of assistance, them
24 affording the drugs or making them follow a doctor long term,
25 specifically with cystic fibrosis, and certain people who could

1 not afford certain medications. I went from bedside nursing to
2 working with insurance companies, and I also worked in
3 long-term care, in a long-term care unit for the elderly
4 population in rehab, and my curiosity kept going.

5 I didn't understand the legal side of things, and that
6 is when I went to law school in 2010. I graduated in 2013, and
7 I joined the firm as a law student, and they took me on as an
8 associate, that is where I have been, and I have been working
9 with medical injury cases, drug injury cases.

10 I am pretty sure I administered Zantac to my patients
11 over the years, and to see the harm that has been done, I want
12 to make sure that when someone (inaudible) -- the outlying
13 cases are considered, that the decision-making is not made by
14 firms who have a large inventory, that everyone is considered.

15 *THE COURT:* Okay. So, as I understand it, there were
16 product identification challenges in Taxotere, and are there
17 lessons to learn from that for Zantac, in your opinion?

18 *MS. HARVEY:* Definitely. The Taxotere litigation has
19 been just very time consuming, I am very hands on with that in
20 the firm. What we found was there should have been a system in
21 place to document product I.D.'s, and they should have put in
22 place again for -- if you are a Medicare patient, you are to
23 document that.

24 We are finding these facilities were not doing that.
25 Okay, for five, six years, we didn't have to document that at

1 all. As a consequence, there are a lot of problems, and there
2 are a lot of things you can do with the Zantac litigation so
3 that you can overcome that problem. Hopefully the Zantac
4 litigation is bringing that to light, and we wouldn't have that
5 problem going forward, and I could bring that to the PSC to
6 fine tune the process and effect that in this litigation.

7 *THE COURT:* Okay. Do you think there are any other
8 proof issues in this case, and what ideas do you have on how we
9 might address them? Maybe you can pick one, if there are any
10 others that you have come across or thought about.

11 *MS. HARVEY:* One of the proof issues I see is the
12 patients who purchased over the counter, and they have
13 conversations with their doctors, telling the doctors, I am
14 taking this medication, and it is documented in the notes.

15 That is something going forward that we have to
16 consider.

17 *THE COURT:* Okay. Any ideas that you want to share
18 with me on the concept I have spoken about with mentoring with
19 an MDL.

20 *MS. HARVEY:* I will be a beneficiary of mentoring with
21 the MDL. In transitioning from nursing to law, there were a
22 lot of things I had to learn in transitioning, the legal
23 language. The way you write as a nurse is not as an attorney.
24 Yes, I think I would be one that could benefit from that
25 mentorship. I am eager, ready to learn, and I am ready to do

1 the hard work.

2 I did some work, document review, that was my
3 introduction to MDL's. When I started as a clerk I did that
4 work and it sparked my interest in product liability and I
5 stayed on with the firm upon graduation from the law school,
6 and my experience has been in the MDL research for them, entry
7 of a micro bacteria during surgery, and that was beneficial to
8 the case itself.

9 *THE COURT:* Okay, perfect, thank you. I am glad we
10 got through that successfully. I appreciate it. Thank you for
11 your application, and taking your time to present here today.

12 *MS. HARVEY:* Thank you for your attention today.

13 *THE COURT:* Absolutely.

14 Our next application is Mr. Rodal. Good afternoon,
15 how are you?

16 *MR. RODAL:* It is common that I get called by my last
17 name as well.

18 *THE COURT:* Yes, that was purposeful. How do you
19 pronounce that?

20 *MR. RODAL:* Yechezkel.

21 *THE COURT:* I will ask how you became a Thai
22 restaurant owner and transitioned to this.

23 *MR. RODAL:* I will start with that. I began working
24 at eight years old, one of 11 children, born and raised in
25 Pittsburgh. I went into the local store and just down the

1 block one of my late father's good friends owned a Chinese
2 restaurant, and I used to hang out there a lot. I used to cook
3 Chinese food when I was 18. I managed a Chinese restaurant and
4 I wanted to go into a different business.

5 I wanted to go to Thai food. As much as Jewish people
6 like Chinese food, I thought I am going to be different. My
7 timing was bad, it was before a few bad hurricanes in 2006,
8 2007 or so, but I did that for a few years. That is how I
9 ended up opening a Thai restaurant.

10 *THE COURT:* I don't want that to take the entirety of
11 your opening remarks, but I found that different, to say the
12 least, and intriguing.

13 What would you like to tell me?

14 *MR. RODAL:* That story is really important here. One
15 of my best customers was a personal injury lawyer, that is how
16 I ended up getting into law. He used to come two, three times
17 a week and tell me about the stories in court, and I would
18 listen. We would argue and debate and that sparked my love of
19 law and litigation, and I ended up going to law school a few
20 years later.

21 More importantly, being a business owner was defining
22 for me, and it is important, talking about diversity, in my
23 restaurant one of the things, I made sure I knew how to do
24 everything, washing the floor, preparing every dish, opening,
25 closing, it is important to know that. When I hire associates

1 and paralegals, they have to know how to file, they can't rely
2 on the paralegals to do everything, they have to know the
3 basics. What if they don't have someone available? This
4 hands-on approach that one only gets from owning your own
5 business, it is very valuable to me.

6 I don't want to rehash what I put in my submissions.
7 Thank you for the opportunity. I would say there are a few
8 candidates here that have no leadership experience. I think I
9 am the only candidate without any MDL cases at all. I have
10 some cases on talc and consumer MDL, my cases got something, I
11 have no MDL experience, something that the Zantac case came
12 across our desk, and is what I want to define myself by, this
13 is not a case where I saw Zantac and say I would jump on the
14 ship. We were working on this well before September.

15 We already had a cancer patient with medical records.
16 We filed the first case -- there is some debate whether we
17 filed the first case. We filed the first personal injury case
18 after the balance even ship case came out, we had been working
19 on this for some time, we had to get a jump on it. We were not
20 expecting the news to break from Europe, my father-in-law was
21 an oncologist, I talked to him before. We developed the
22 science behind it, and we were the only attorneys that brought
23 breast cancer cases that relied on per review cases. I spoke
24 to so many clients that were so grateful we took their case
25 because so many attorneys did not take the case because cancer

1 did not show up -- the control was had two walkers.

2 So, you know, I really thought long and hard about
3 whether I should be applying here, it is a little bit of
4 chutzpah, I can't tell you my accomplishments in the MDL field.
5 I am doing it here because I show -- okay, show what I put into
6 this, I show my effort and actual results with Judge Bloom in
7 one of my cases. I believe I was the first case and possibly
8 the only case that served discovery on Defendants, we had a 26
9 if and joint schedule report out, I turned over those documents
10 in Word form to the April deliverables team, and yes, I turned
11 them over to help them out and my subpoenas in discovery.

12 I am keenly aware of the Court's need to balance
13 experience with -- this panel is phenomenal, I am hoping the
14 Court has one seat for someone who would not traditionally get
15 on. I know that is one of the negatives in talking of MDL's,
16 they say the club is hard to break into. I hope I can be the
17 poster child. One of the things I am most proud of and what I
18 want to talk about, even though I have no MDL experience and
19 leadership experience, over ten percent of the candidates
20 listed me on their appendixes. People say the best complement
21 you can give is a referral. To have over ten percent of the
22 greatest minds in MDL's think I would be suitable for this team
23 is humbling and made all the work worth it.

24 And every single one of them except for one mentioned
25 science or scientific. Mr. Wisner, who was on earlier, Mr.

1 Odal, on multiple occasions demonstrated a deep understanding
2 of the science in this case and valuable in working this up,
3 and Mr. Nigh leading the science team, and Tracy Finken also on
4 the science team stated I am exceptionally well versed in the
5 science in this case. They didn't have to say that. It is
6 because I presented with them and I showed the substance, and
7 they saw my work. I filed the first Complaint, I didn't have
8 the benefit of copying anyone's Complaint, I had to do it all
9 from scratch.

10 As far as science, one of the things I looked at in
11 interviewing the clients -- we didn't take any money for
12 marketing, we focused on the quality of cases. We don't have
13 as many cases as everyone else does. I asked my clients about
14 their diet, because science shows an increase in nitrites and
15 nitrates can break down MDMA. I asked them about their diet,
16 smoked meats, that kind of thing, did you keep your pills in
17 vehicles, based on the Emory study showing the heat would break
18 down Zantac and MDA.

19 As far as the point system, those are things that are
20 ready to go, diet, location, being in South Florida.

21 So, my background has always been in consumer
22 protection. I have done that for many years and now my
23 focus -- I have been a Plaintiffs' attorney for my entire
24 career. I am talking to you from Fort Lauderdale in the
25 unknown of what is going to be in the next few months. I am

1 local to the extent I can jump up to the courthouse, and I am
2 happy to, you know, answer any other questions.

3 And I think one of the Court's questions is going to
4 be about funding and our ability and sustaining power. We
5 thought long and hard about this, whether we should even get
6 into it, and I spoke with many of the people on this Zoom
7 meeting right now about, you know, what I should expect as a
8 member of the PSC, what kind of monetary commitment, what kind
9 of marketing budget, before we get into the heart and thick of
10 things. So, we made an informed decision before we jumped into
11 it, and we are -- we are not here to see how it goes, we are in
12 this for the long haul.

13 I signed up right away and, unfortunately, it got
14 canceled two days before. The last I spoke with them, they are
15 waiting to see if it is going to be done remotely or live.
16 They haven't made a decision yet. I am in it for the long
17 haul. I am passionate about this. I feel like when I became a
18 lawyer I got this energy again of the mass torts, and I am
19 hoping the Court has room for a newbie to have a place.

20 *THE COURT:* Okay, thank you.

21 So, what is your thinking on any cases that are not
22 cancer cases, that is, if most here are cancer cases, how would
23 the MDL address those other cases so the case is not so broad
24 that parties cannot get a sufficient resolution of the claims?

25 *MR. RODAL:* This is a question I have been grappling

1 with. To highlight the fact I am a team player and I know my
2 place, I have been in extensive talks with the census team, I
3 am ready to file. I held up filing to figure those things out,
4 and those are things that we talked about in understanding that
5 this is a team effort, in understanding my place. I really
6 didn't want to make any moves that would jeopardize anyone's
7 claims. I haven't filed any of that. We have multiple of
8 cases specifically tied to scientific studies related to
9 Zantac. Now, you know, the question is going to be, frankly,
10 some of the science is going to be the same, NDMA. After that,
11 it diversifies, and I think that is what I have been waiting
12 for, for leadership to address that. I will adhere to what the
13 expert says, whether it is a separate track or whether it is
14 included in the personal injury. Whether it is a separate
15 case, that is something I decided to wait for leadership, that
16 is a question that will affect people.

17 *THE COURT:* All right. Thank you so much for
18 presenting and taking the time to submit an application in this
19 case, and for your energy and passion that you expressed today
20 and in your application. I appreciate it very much.

21 Okay, Melanie Muhlstock, good afternoon. How are you?

22 *MS. MUHLSTOCK:* Good afternoon, your Honor. How are
23 you?

24 *THE COURT:* Good, thanks. Hopefully we haven't worn
25 you out having to wait this long.

1 MS. MUHLSTOCK: I can wait with the best of them.

2 THE COURT: And I can listen with the best of them, I
3 am all ears. I don't want you to feel you won't be heard by
4 where you are coming on the list of the applicants today. I
5 look forward to hearing from you. I will turn it over to you.

6 MS. MUHLSTOCK: Thank you for having me and
7 considering my application. I am somewhat a veteran to the
8 mass tort Bar, but at the same time I have not yet had a PSC
9 position of my own. My firm has had lots of them, Akerman has
10 had a seat on many, many PSC's over the last several decades,
11 and I have been the beneficiary of those appointments of my
12 partners, and I have had some committee positions of my own.

13 So, I have had a lot of MDL experience both in Federal
14 MDL's and State Court proceedings, but I think one of the
15 things that I would like the Court to know, and reminiscent of
16 some of the questions you asked today, my upbringing in this
17 business is very relevant to the questions you have been asking
18 today.

19 I started my career in this business, I have only done
20 mass tort work in my career. I started on the Defense side,
21 like a lot of people who have spoken today, and then I
22 transitioned over to the Plaintiffs' side coming up on 15 years
23 now.

24 And when I was on the Defense side, a young baby
25 lawyer, I did not feel that I got a lot of the mentoring that I

1 see with young lawyers today that I mentor. When I moved over
2 to the Plaintiffs' side I was lucky enough to find my home in
3 Parker Waichman, that will be my forever home. I work for the
4 position I wanted whether I have the title I wanted or not, I
5 started as a associate and became managing attorney at the mass
6 tort department and then a managing member of the mass tort
7 department there.

8 Whether I had an individual assignment on a particular
9 case or an individual assignment from a PSC, or co-chair
10 position on an individual committee, I always worked for the
11 position I wanted whether it was given to me or not.

12 I work the same way with my team, everybody has a
13 voice. Whether they are a first year lawyer or seasoned
14 attorney, everybody has a voice, and everybody has an opinion,
15 and everybody's opinion is heard.

16 Mr. Rodal said a moment ago opportunity should be
17 given to people that haven't had experience, and I haven't met
18 Mr. Rodal, and I hope to in the future, but he made reference
19 to this undercurrent of criticism that's been swirling in the
20 news about firms that have opportunity after opportunity after
21 opportunity, and I think there is a reason for that.

22 In big pharma litigation we are coming up against the
23 most experienced and the biggest companies in the world, and to
24 handle that type of litigation you need vast experience, but
25 that does not mean we have to exclude younger lawyers or less

1 experienced lawyers, and we do want diversity in our panels,
2 diversity in thought, diversity in experience, but led by a
3 leadership that has gone from the inception of a case all the
4 way through trial, all the way through settlement if that is
5 how the case is resolved.

6 I don't think we can presume at one stage in the
7 litigation, whether we go through one trial or ten or
8 immediately resolve cases, we have to be prepared to go through
9 every phase of that litigation. When we talk about committee
10 structure or how cases are going to go, I think every team has
11 to have cogs in the wheel that are good at every phase. That
12 is how I build my teams. There are people who develop experts,
13 people who are good at briefing, there are people who are good
14 at doing discovery, or ESI. You build your team with the right
15 parts, and with the people that have diversity of thought. You
16 build a very strong team that, with the right leaders, can
17 combat any issue, the right thought can combat any issue.

18 So, I, too, am a proponent of diversity in all
19 aspects, but I also am a proponent of experienced leaders,
20 people who have the depth in their bench in their own offices,
21 who can withstand the time that it would take to meet
22 litigation of this size, that have the experience, finances and
23 where-with-all to stand the test of time, and within that
24 process can mentor those with less experience that are younger
25 and bring those lawyers up through the ranks so that they can

1 learn how to do this as the leaders in the next one and the
2 next one and the next one.

3 That is how my last 15 years have been at Parker
4 Waichman. Quite frankly, in the beginning of my career I was
5 discouraged by not having that experience. The fact that I
6 pivoted, I considered myself to be lucky to make that pivot
7 from the Defense side to the Plaintiffs and found people to
8 having mentored me and the position I have today and sit before
9 you in a Zoom conference and talk to you about my experience
10 today.

11 I am happy to answer any questions that you have that
12 are not addressed in my application or you just want me to
13 address personally.

14 *THE COURT:* Okay, thank you very much.

15 Given your management role at the firm, any concerns
16 on your part about the time commitment that would be required
17 to assume a leadership position in this case?

18 *MS. MUHLSTOCK:* No, not at all. I am much more
19 efficient the more I have on my plate, I am good at having a
20 lot on my plate. I have a large team behind me that will
21 support me in both what I have to do at the firm and what I
22 have to do in this litigation. I plan on bringing members of
23 my team with me to work on this litigation as well.

24 Like I said to you before, mentoring young members and
25 members of my internal team is very, very important to me. At

1 Parker Waichman, this is not something that is in my papers, we
2 have had multiple individuals that have worked for us that have
3 started out as paralegals or in other positions, nonlawyer
4 positions in our office, that are now lawyers in our office,
5 that went to law school at night or left and went to law school
6 and came back and worked for us for many, many years. It is
7 important that we see our lawyers succeed through the ranks and
8 keep our lawyers with us for a long time. We have had
9 paralegals with us for almost the whole time I have been at the
10 firm and some were at the firm at its inception. We have a
11 track record of keeping staff with us, and that staff is
12 heavily involved in everything we do. I do have the support of
13 my team to successfully take part in this PSC.

14 *THE COURT:* Your thoughts on what novel discovery and
15 trial methods we might want to consider incorporating in this
16 litigation.

17 *MS. MUHLSTOCK:* Any team not to consider novel methods
18 is not thinking into the future, anything from ESI to novel
19 methods of conducting trials, is stuck in the past. A good
20 example of that, and one of the roles I played in the Actos
21 litigation was having witnesses appear remotely, not by Zoom,
22 but almost the same thing during the trial, having remote
23 testimony from live witnesses, which was an enormous
24 undertaking to coordinate, but was ultimately very successful.
25 Judge Doherty was very accommodating in allowing the Plaintiffs

1 to embark on that venture, but COVID-19 is not the perfect
2 example of that.

3 We do have the ability to work remotely, we do have
4 the ability to bring people together remotely, if that is an
5 efficient way, whether we are forced to do it or whether it
6 makes it economically feasible to the parties to litigate
7 cases, whether it be by deposition or document review or
8 discovery or ultimately by trials, to have trials run more
9 efficiently and economically feasible for everybody, the option
10 is something we should consider. As the technology gets
11 better, those are viable options for everybody.

12 *THE COURT:* Terrific, thank you so much. Thank you
13 for your patience waiting, it is a pleasure getting to know
14 you.

15 *MS. MUHLSTOCK:* You, too, thank you.

16 *THE COURT:* And you as well.

17 Okay, last, but certainly not least, we still have
18 tomorrow, Mr. Woodson. How are you?

19 *MR. WOODSON:* Good afternoon. When your name starts
20 with W, you know you are always last.

21 *THE COURT:* That is what happens, like being tall and
22 when you line up for recess you are at the end of the line. It
23 is your turn.

24 *MR. WOODSON:* I am Frank Woodson, I am with the law
25 firm of Beasley Allen in Atlanta, Georgia. We have 81 lawyers

1 in our law firm, 200 support staff, we have a mass tort section
2 which I work in with about 35 to 37 lawyers at any one time
3 with a large staff to handle a great number of cases that we
4 typically get.

5 I find it interesting to talk about the young lawyers
6 today and getting involved, and I practiced for 17 years in
7 Mobile before I got to Beasley Allen. I litigated against
8 Beasley Allen in the '90's, and they enticed me to move to
9 Montgomery, and they said we want you to pursue pharmaceutical
10 work, and I said I am not a pharmaceutical lawyer, and they
11 said, name someone who is, and there wasn't.

12 I had no idea what an MDL was until we got involved in
13 Vioxx several years later. My first assignments came in that
14 litigation on committees and doing work with many various
15 lawyers. That was a very large litigation with 55,000 filed
16 cases at some point, so it took a large team to get that work
17 done. So, in committee work, it was very good work for me, and
18 ultimately being involved in several of the trials that we had
19 in the MDL.

20 Since then, I have been able to serve as a PSC member
21 on several other litigations, Bextra, Celebrex, Lipitor, I got
22 to litigate with Mark Chevreau (phon), on the line today, and I
23 had the opportunity to work with a great number of lawyers in
24 our firm who have been appointed to over 30 MDL positions,
25 cancer litigations. One of my partners was on the PSC for the

1 hormone litigation in Arkansas and I ended up taking over and
2 trying three of the breast cancer cases for our firm, one in
3 Nebraska, one in Utah, and the last MDL trial in Arkansas. So,
4 I have some experience with cancer patients.

5 Our law firm is very involved in the talcum powder
6 litigation, another cancer. One of my other partners was
7 involved in the Actos litigation, a cancer litigation, in
8 several of those. One of the things that our firm thinks has
9 been beneficial is, I think one of the other candidates was
10 talking about storing cases and it sounded to me similar to
11 what we have taken the lead on in various litigations or worked
12 very hard on in Vioxx and Actos in developing a grid system.

13 When you have a grid system to evaluate cases across
14 the board using your medical records and other information
15 concerning each individual case, and each individual case is
16 evaluated on their merits, they can be included and hopefully
17 what we will see in this case ultimately is a global settlement
18 and not picking off leadership firms and leaving people behind,
19 if you will.

20 So, that is my experience. I have a great firm behind
21 me, they want me to do this. I have recently resolved some
22 cases I was concerned about taking up an inordinate amount of
23 my time, I will be settling those in the next month or so,
24 which would free me up to spend a large amount of time on the
25 litigation given the opportunity.

1 *THE COURT:* Okay, thank you. So, clearly you have
2 substantial MDL experience, you touched on some of the insights
3 that you have gained from those.

4 Let me point you to vetting in the case selection
5 process. Can you share with me thoughts on that, whether it
6 comes from other cases or what you have seen about this case so
7 far?

8 *MR. WOODSON:* What I really like is what the team has
9 done so far, setting up the registry so you don't get surprised
10 at the end where cases are showing up all of a sudden. This
11 registry is great for that. So, you have a great registry on
12 the cases.

13 What we have done in the past in Vioxx, Xarelto, we
14 have developed one of the grids to try to measure and evaluate
15 a case and so you get to the end of the day and you can see and
16 you help the Defendants. Actually, that is what we did in
17 Actos, they wanted to resolve the litigation and we ended up
18 doing what is a clinical trial on our client database.

19 You might be able to use the registry if there is
20 enough information available there, and in looking at the other
21 cases, see what a typical type of Zantac case ought to be
22 resolved for, and you can extrapolate that information into
23 determining how much is it going to take to actually resolve in
24 the entire litigation knowing we have X number of cases at the
25 end of the day.

1 And your registry is a great thing, hopefully a lot of
2 law firms will take advantage of that and register their cases.

3 *THE COURT:* Okay.

4 *MR. WOODSON:* The diversity question, we have 81
5 lawyers, and we are a diverse group, we buy into what the Court
6 is considering with the diversity question today.

7 *THE COURT:* What is your style in working with
8 opposing counsel? Do you have a style?

9 *MR. WOODSON:* I like lawyers and I get along with
10 lawyers, I don't really have a problem. I saw Matt Holian
11 earlier. Back in the Celebrex days, one of our lawyers left
12 and I took his spot on the Celebrex PSC, and I asked for the
13 opportunity to help work up the deposition cuts for the trial.
14 Judge Fallon just about killed me and a team of about ten other
15 lawyers.

16 In the Vioxx cases, there was a lot of video being
17 played in those things. Judge Fallon liked to do it during the
18 trial. He was up all hours of the night along with us ruling
19 on objections to get those deposition cuts ready to play, and I
20 talked to Judge Breyer, I said, please, let's do it up front,
21 and we started doing that about eight months before the first
22 trial.

23 I was working a lot with Matt, I probably annoyed him
24 a little bit because I was sending him cuts all the time and he
25 was getting back with me on it.

1 I worked with Mr. Sheffield (phon) before in the
2 Lipitor litigation, I don't think he would say that I was ugly
3 or unprofessional to him. We did a lot of negotiations later
4 in the litigation regarding business reference, and I actually
5 emailed Mr. McGlamry and Mr. Watts about that issue after you
6 had appointed them to see if we could handle that up front. I
7 think they have been having conversations about trying to get
8 the authenticity issues taken care of before it gets too far
9 down the road in the litigation.

10 *THE COURT:* Okay. Well, I think that is a good place
11 to end. You said you really liked today, and I like lawyers,
12 and those are two good themes to end our session on today.

13 Thank you very much, Mr. Woodson, and unless my tabs
14 or numbers are off, I think you were the last one for today,
15 so, I thank you.

16 *MR. WOODSON:* Thank you, your Honor. I will get rid
17 of my video.

18 *THE COURT:* I want to thank everyone. That does
19 conclude today's session. Phew, that was an accomplishment for
20 all of us. Tomorrow should be a breeze. I am going to start
21 tomorrow -- I am checking the instructions. The drill is, if
22 you want to join the meeting -- if you are an applicant you
23 should want to join the meeting -- you should be in the waiting
24 room at 8:45, and the cohost will seamlessly let you in. They
25 did an amazing job today. Thank you.

1 For the rest of you who are watching and listening and
2 really enjoying this because you don't have to do the work, so
3 to speak, other than absorbing everything, you come in five
4 minutes later, at 8:50, and we will get started at 9:00 with
5 session three.

6 So, with that, everybody have a -- we ended a little
7 early, that is a good thing, too. Thank you, everyone, thank
8 you for your time and patience. Most of you stayed on, not all
9 of you. We have 82 participants. I am watching, there is no
10 requirement that everybody stay on, we were up to 90 at some
11 point.

12 Have a nice rest of the afternoon and evening, and I
13 look forward to seeing the applicants who will be presenting
14 tomorrow. I am most appreciative of the time, preparation,
15 patience, and thought that everyone has put into this
16 proceeding. It could not happen without everyone's
17 cooperation, I am very grateful for that.

18 At this point I am going to mute, stop video, I am
19 going to leave the meeting. We will start a new one tomorrow
20 with the same -- if I am not mistaken, it is the same, just so
21 everybody knows, the same ID, same password that we used today.

22 Okay, good evening.

23 *(Thereupon, the hearing was concluded.)*

24 * * *

25 I certify that the foregoing is a correct transcript

1 from the record of proceedings in the above matter.

2
3 Date: May 9, 2020

4 /s/ Pauline A. Stipes, Official Federal Reporter

5 Signature of Court Reporter

6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
Pauline A. Stipes, Official Federal Reporter

DR. RESTAINO: [8] 152/8 152/11 153/24 154/1 155/18 157/1 157/4 157/10 MR. ALBERT: [7] 20/15 20/17 20/20 21/13 24/11 24/16 25/2 MR. BEHRAM: [7] 89/9 89/11 89/14 92/9 93/7 93/25 94/18 MR. BERMAN: [8] 25/18 25/23 26/9 28/13 29/11 29/24 30/14 30/20 MR. DEARMAN: [7] 39/11 39/13 39/20 42/6 42/22 43/14 43/24 MR. GILBERT: [7] 31/14 31/17 32/4 34/25 37/4 37/20 38/23 MR. HONIK: [6] 50/2 53/10 53/22 54/10 54/22 55/1 MR. KRAUSE: [7] 82/3 82/6 84/17 85/9 86/3 86/18 87/15 MR. LEAR: [6] 76/21 77/6 79/8 80/5 80/23 81/20 MR. MARTINEZ-CIR: [5] 55/4 55/8 58/25 59/15 60/10 MR. MESTRE: [11] 61/11 61/17 61/24 62/3 65/10 65/14 66/8 66/12 66/17 67/1 68/1 MR. NIGH: [7] 130/23 130/25 131/5 133/13 134/11 134/25 135/7 MR. RASMUSSEN: [8] 94/23 95/1 95/4 95/10 97/17 97/19 98/10 99/19 MR. RODAL: [5] 162/15 162/19 162/22 163/13 167/24 MR. ROTMAN: [4] 145/22 145/24 150/1 150/19 MR. WILLIAMSON: [5] 99/23 100/3 103/15 104/21 104/24 MR. WISNER: [6] 109/15 109/19 110/2 112/20 113/20 114/23 MR. WOODSON: [6] 174/18 174/23 177/7 178/3 178/8 179/15 MS. BOGDAN: [6] 139/9 139/13 141/25 143/13 143/24 145/6 MS. FEGAN: [5] 8/22 9/12 12/9 13/21 14/18 MS. FINKEN: [5] 119/9 119/17 123/1 124/2 125/6 MS. GOLDENBERG: [8] 135/10 135/12 135/19 135/25 137/12 138/5 138/20 139/5 MS. HARVEY: [8] 157/19 157/21 158/17 159/18 160/17 161/10 161/19 162/11 MS. HYMAN: [9] 72/20 72/24 74/15 74/22 75/9 75/14 76/4 76/14 76/19 MS. KRAFT: [4] 125/10 129/23 130/10 130/20 MS. LUHANA: [6] 115/1 115/9 117/4 117/22 118/16 119/5 MS. MUHLSTOCK: [6] 168/21	168/25 169/5 172/17 173/16 174/14 MS. SCOTT: [6] 105/1 107/15 107/20 108/11 108/19 109/12 MS. WESTCOT: [10] 68/12 70/7 70/11 70/18 70/23 71/14 71/21 72/4 72/12 72/15 MS. WHITELY: [10] 44/5 44/7 44/15 46/14 46/25 47/13 48/7 48/24 49/13 49/23 MS. WOLFSON: [6] 15/10 15/20 17/15 19/16 19/21 20/12 THE COURT: [213]	1/3 200 [5] 40/2 90/19 90/21 90/22 175/1 2002 [1] 58/9 2004 [1] 10/2 2006 [1] 163/7 2007 [1] 163/8 2008 [1] 63/23 2010 [1] 160/6 2011 [1] 73/5 2012 [1] 22/1 2013 [2] 159/20 160/6 2016 [2] 73/5 141/1 2019 [1] 10/21 2020 [2] 1/5 181/3 21st [1] 121/15 22 [1] 65/3 23 [2] 124/6 124/11 24 [2] 121/18 121/24 25 [3] 89/17 114/18 114/19 250 [1] 152/23 2500 [1] 133/15 26 [2] 51/19 165/8 27 [2] 139/17 143/25
	\$ \$10 [1] 63/19 \$350 [1] 26/25 \$350 million [1] 26/25	
	' '90's [2] 146/18 175/8	
	/ /s [1] 181/4	
	1 10,000 [1] 153/9 11 [5] 20/20 22/6 56/10 132/9 162/24 11:30 [1] 76/24 12 [3] 14/21 30/17 37/22 12:50 [2] 88/7 88/25 13 [7] 56/10 56/23 56/24 92/4 103/4 123/16 155/11 14 [1] 43/4 15 [12] 10/4 12/11 30/17 61/3 91/7 100/16 126/15 140/3 145/11 145/15 169/22 172/3 15 feet [1] 61/20 15 percent [1] 63/22 150 [3] 141/18 142/19 152/18 16 [3] 38/1 38/10 117/8 16.5 percent [1] 73/5 17 [3] 68/18 140/3 175/6 1700 [1] 28/15 18 [7] 37/23 38/10 57/23 58/9 92/5 143/19 163/3 19 [7] 2/20 5/16 115/15 115/20 119/21 157/13 174/1 1968 [1] 73/2 1980 [1] 154/16 1986 [1] 22/7 1990 [1] 154/17 1991 [2] 154/17 154/17 1995 [2] 63/14 63/20 1996 [1] 45/20 1998 [1] 16/7 1:00 [1] 88/7	
	2 20 [13] 16/15 38/2 38/10 41/24 57/23 58/15 109/21 114/19 117/8 121/5 124/11 124/16 146/9 20's [1] 143/21 20-md-02924-ROSENBERG [1]	
	3 3,000 [2] 115/24 133/8 3,472 [1] 153/5 30 [4] 120/25 121/14 157/12 175/24 302 [1] 59/21 32 [1] 112/9 34th [1] 33/25 35 [2] 134/17 175/2 36 [1] 112/11 37 [2] 117/25 175/2 3:00 [2] 145/11 145/17 3:10 [1] 145/12	
	4 4,217 [1] 153/6 40 [2] 50/5 91/11 40 million [1] 63/24 400 million [1] 90/18 43 [1] 99/8 45 [1] 24/2 45 miles [1] 39/2 47 [1] 73/2 48 [1] 154/20 4:13 [1] 100/7 4:15 [1] 39/3	
	5 50 [3] 28/19 28/20 30/5 50 percent [1] 73/6 55 [1] 28/16 55,000 [1] 175/15	
	7 72 [1] 62/12 747 [2] 87/17 87/18 772.467.2337 [1] 1/14	
	8 800 [1] 142/20 81 [2] 174/25 178/4 82 [1] 180/9 88 [1] 145/14	

8	above [5] 29/21 31/9 64/14 127/3 181/1 absolute [1] 90/15 Absolutely [2] 59/16 162/13 absorbing [1] 180/3 acceleration [1] 26/16 accepted [1] 77/22 access [3] 15/25 30/24 152/21 accommodating [1] 173/25 accomplish [2] 12/8 115/18 accomplished [6] 32/20 104/16 110/12 110/12 119/13 146/2 accomplishment [1] 179/19 accomplishments [2] 110/10 165/4 account [1] 27/1 accountability [1] 16/14 accountable [1] 159/7 accuracy [1] 5/23 accurate [1] 24/1 accurately [1] 5/19 achieve [1] 90/13 acknowledge [1] 58/20 acknowledged [1] 47/15 acknowledger [1] 18/13 acquire [1] 153/7 across [6] 61/3 100/16 122/15 161/10 164/12 176/13 act [2] 6/6 16/6 acting [2] 73/15 73/18 action [46] 5/7 9/22 10/15 10/16 10/20 10/23 11/2 16/11 16/15 18/14 18/14 22/3 27/13 35/17 36/10 40/3 43/4 45/18 45/19 45/20 45/22 55/21 56/13 57/6 57/7 58/8 58/24 59/23 69/2 77/10 78/2 78/21 84/18 84/19 84/21 86/10 87/4 87/9 89/18 110/6 149/24 150/3 150/4 150/8 154/12 154/13 actions [24] 9/25 10/5 10/15 10/18 13/2 28/24 41/13 45/9 47/13 53/20 53/22 53/25 59/20 73/19 73/22 75/20 75/21 86/8 86/20 86/21 86/23 112/2 115/24 154/12 active [9] 4/3 24/8 96/23 100/16 114/10 128/5 138/14 141/13 153/10 actively [1] 153/7 Actos [5] 76/7 173/20 176/7 176/12 177/17 actress [1] 73/14 actual [5] 7/4 67/21 85/17 116/24 165/6 actually [19] 9/16 21/5 57/19 58/6 63/8 78/1 83/6 108/6 114/10 122/16 129/16 139/21 142/20 144/9 144/12 158/12 177/16 177/23 179/4 ad [1] 108/23 Adam [1] 82/7 adapted [1] 59/8 add [5] 32/17 35/20 45/7 49/13 53/21	added [5] 5/25 8/8 96/1 109/9 131/4 adding [1] 158/15 addition [5] 36/12 69/12 93/23 121/8 125/12 additional [7] 35/20 36/16 60/18 75/24 123/14 124/15 133/20 address [12] 16/22 48/11 54/5 59/15 61/17 106/24 133/10 147/18 161/9 167/23 168/12 172/13 addressed [3] 18/20 65/7 172/12 addressing [2] 15/14 26/4 adequate [5] 5/3 35/6 35/19 45/6 51/23 adhere [1] 168/12 adjunct [1] 155/1 administered [2] 159/9 160/10 administrative [3] 12/12 12/14 137/15 admiration [1] 21/1 admire [1] 24/5 admit [1] 21/7 admitted [1] 21/7 ado [1] 55/7 adopted [1] 145/4 advance [5] 33/6 33/14 40/5 50/15 128/21 advanced [1] 33/10 advancing [1] 41/5 advantage [3] 63/5 64/2 178/2 adversarial [1] 147/11 adversaries [1] 98/6 adverse [1] 101/9 advice [8] 76/1 76/9 77/3 80/22 81/8 89/2 119/16 122/1 advise [1] 94/7 advising [1] 112/6 advocacy [1] 79/13 advocate [4] 13/21 15/16 26/5 158/18 advocates [1] 159/4 affect [1] 168/16 afford [1] 160/1 afforded [3] 32/8 36/3 159/21 affording [1] 159/24 affords [1] 4/17 afraid [1] 51/10 after [23] 22/7 27/7 32/25 33/9 49/17 52/21 63/20 63/23 68/5 73/16 75/8 75/11 86/21 127/8 145/17 148/16 155/9 156/15 164/18 168/10 170/20 170/20 179/5 afternoon [31] 89/6 89/9 89/10 89/14 95/11 99/23 99/24 100/5 103/8 105/2 105/3 107/9 109/12 109/15 109/16 110/8 115/2 119/9 119/10 125/9 130/24 130/25 145/23 145/24 153/23 157/21 162/14 168/21 168/22 174/19 180/12
9		
9,000 [2] 62/17 133/19		
90 [2] 63/18 180/10		
900 [1] 142/20		
95 percent [1] 94/5		
9:00 [1] 180/4		
A		
a.m [1] 100/7		
AAJ [1] 103/3		
Abilify [3] 98/24 100/20 101/14		
ability [13] 6/2 6/22 33/23 34/17 57/13 96/10 96/19 107/4 107/25 154/8 167/4 174/3 174/4		
able [39] 12/8 13/18 18/9 30/16 37/2 44/20 45/2 48/6 48/23 51/6 52/18 53/16 56/21 57/1 57/20 59/4 64/12 66/24 86/5 90/8 90/11 91/4 102/16 115/18 115/22 119/17 123/23 124/20 131/20 132/25 133/1 136/23 137/21 139/1 144/23 147/19 149/16 175/20 177/19		
about [165] 2/12 3/15 3/15 4/14 5/12 6/17 6/20 6/21 8/5 8/17 11/20 12/7 12/11 13/14 13/22 14/22 17/11 17/19 19/20 20/9 20/20 26/23 28/9 29/2 30/25 35/2 37/4 37/5 37/19 40/13 43/12 46/25 47/2 48/3 48/13 50/16 53/12 53/19 53/20 53/21 55/25 56/14 57/12 58/4 58/25 59/12 59/17 60/4 61/6 61/20 62/5 62/25 63/13 64/17 65/2 65/8 65/9 65/11 65/20 66/3 66/16 67/16 67/21 73/16 74/15 75/7 79/5 82/6 82/14 83/23 85/17 89/18 90/15 91/7 91/8 91/19 92/8 93/7 98/12 100/1 100/7 100/8 102/23 103/12 107/11 108/8 108/9 108/14 108/18 110/5 110/12 110/14 111/15 112/9 113/14 114/7 115/8 116/24 116/24 117/21 123/15 125/13 126/15 128/18 129/3 131/18 132/1 132/4 132/7 132/21 134/7 136/7 138/1 138/17 138/24 139/16 140/1 140/9 141/24 142/7 142/19 143/7 144/14 147/5 148/22 149/2 149/14 149/23 151/5 151/7 151/20 152/16 154/12 155/8 156/12 156/25 157/24 158/16 161/10 161/18 163/17 163/22 165/2 165/18 166/13 166/15 167/4 167/5 167/7 167/17 168/4 170/20 171/9 172/9 172/16 175/2 175/5 176/10 176/22 177/6 178/14 178/14 178/21 179/5 179/7		

A afterwards [1] 91/19 again [13] 29/6 34/8 37/2 61/5 68/3 72/18 76/19 88/7 135/15 145/13 158/6 160/22 167/18 against [6] 29/16 33/11 42/23 69/24 170/22 175/7 age [1] 73/15 aged [1] 82/22 agent [2] 73/16 73/18 agers [1] 92/4 aggressive [1] 54/15 Agneshwar [2] 96/12 101/12 ago [8] 21/15 57/12 89/17 90/6 115/12 126/15 140/1 170/16 agree [5] 13/25 26/18 47/1 52/23 96/5 agreeing [1] 141/21 agreement [1] 64/17 agreements [1] 158/21 ahead [4] 82/19 97/18 97/24 137/3 aid [1] 148/6 aimed [1] 101/22 Air [1] 59/21 Akerman [1] 169/9 akin [1] 67/11 albeit [4] 50/4 52/9 77/20 100/5 Albert [4] 20/15 21/25 25/11 25/21 alike [1] 150/9 all [154] 2/16 2/19 2/20 3/5 3/6 3/10 3/12 3/17 3/22 4/11 6/23 7/15 8/8 8/9 8/13 12/16 15/15 16/3 17/3 18/18 24/14 26/25 27/16 28/19 29/1 30/5 30/18 30/18 31/4 32/1 32/12 35/24 36/19 37/3 38/22 39/9 40/8 40/15 43/7 43/18 44/9 44/17 47/3 48/10 49/12 52/8 52/10 53/1 55/3 55/10 56/23 56/23 57/1 59/19 61/13 62/3 62/22 65/3 65/21 67/23 69/10 69/13 69/20 69/22 72/12 76/12 78/16 79/12 81/1 82/9 82/16 83/13 84/2 84/24 88/3 90/15 91/6 92/16 94/1 94/13 95/7 95/12 95/13 98/25 99/6 100/8 100/23 101/4 102/6 103/1 104/16 104/18 105/24 109/5 110/10 110/20 111/11 111/22 111/25 112/22 112/23 113/13 115/21 118/8 119/11 119/12 120/14 121/4 125/2 125/16 127/5 128/12 128/18 130/19 132/15 132/23 133/16 133/17 134/23 137/23 140/12 142/17 142/24 143/6 146/2 146/4 146/18 149/24 151/5 154/3 154/9 155/24 156/4 157/14 158/16 158/17 158/20 158/21 161/1 164/9 165/23 166/8 168/17 169/3 171/3 171/4 171/18 171/23 172/18	177/10 178/18 178/24 179/20 180/8 allegation [1] 97/8 alleged [4] 85/8 85/11 85/14 85/15 Allen [3] 174/25 175/7 175/8 Allergan [6] 10/23 11/19 12/6 12/21 17/10 17/18 allocated [1] 17/23 allow [9] 3/24 9/5 43/21 49/9 61/17 68/11 77/6 144/15 144/25 allowed [6] 70/21 83/12 83/17 83/17 124/23 140/6 allowing [5] 14/9 81/13 100/4 119/19 173/25 allows [5] 91/1 91/10 92/10 140/18 140/22 alluded [3] 33/19 33/19 63/7 alma [1] 157/12 almost [10] 40/8 50/23 73/2 100/18 115/15 129/16 132/10 132/20 173/9 173/22 alone [2] 29/15 50/6 along [14] 22/21 45/7 45/12 45/19 85/4 85/5 86/13 105/7 118/25 131/12 155/6 156/7 178/9 178/18 already [27] 18/6 32/19 33/17 33/24 35/18 35/19 35/21 36/21 39/8 40/13 41/4 84/13 87/15 88/13 105/14 122/2 122/4 131/21 133/24 134/11 136/15 137/3 138/22 141/20 149/13 149/18 164/15 also [50] 2/24 3/15 5/22 5/24 6/3 7/7 11/7 11/25 12/21 14/8 26/4 27/11 34/4 36/4 55/17 55/20 58/11 62/1 62/21 64/23 68/24 75/4 75/19 78/10 81/7 81/10 83/25 86/3 87/3 87/5 87/9 90/10 91/15 94/7 96/10 96/21 101/7 102/10 105/9 105/11 105/20 131/24 132/12 136/13 153/10 156/1 159/6 160/2 166/3 171/19 although [5] 5/11 60/15 89/24 107/1 140/15 always [20] 4/20 19/1 20/25 26/12 35/13 38/24 40/21 54/13 54/18 57/11 77/12 107/5 122/11 125/22 127/15 129/15 148/22 166/21 170/10 174/20 am [243] amazing [3] 74/12 159/16 179/25 Amazon [2] 27/1 30/22 American [2] 62/11 73/21 Amneca [1] 49/15 among [13] 4/12 8/8 13/23 17/3 52/7 56/9 57/10 57/18 59/13 60/18 84/24 105/6 106/7 amount [18] 42/11 44/17 44/23 46/18 49/10 50/10 64/8 67/16 67/17 85/14 85/15	109/7 120/12 132/14 132/20 149/15 176/22 176/24 ample [4] 3/25 4/1 35/18 71/21 Anapol [1] 121/16 and Benicar [1] 100/20 and right [1] 98/24 and/or [2] 37/9 118/13 angle [1] 135/3 animal [1] 140/10 ankles [1] 154/16 anniversary [1] 121/15 announced [2] 133/16 136/24 annoyed [1] 178/23 another [13] 2/25 29/15 31/25 33/22 51/2 67/25 69/23 71/15 80/12 96/14 114/15 158/7 176/6 answer [17] 11/22 14/17 17/6 34/20 35/1 35/16 46/9 62/5 79/1 98/3 110/12 111/17 116/20 122/23 137/9 167/2 172/11 answered [4] 19/15 19/18 147/18 150/12 answers [1] 19/14 anticipate [7] 6/12 19/17 28/11 72/8 97/15 135/17 153/8 anticipated [3] 5/5 5/14 99/16 anticipating [1] 99/18 anticipation [1] 39/1 antitrust [6] 22/24 22/25 23/6 46/1 64/24 66/14 anxiety [2] 8/8 39/1 any [74] 6/1 6/19 6/19 6/21 7/1 7/4 7/5 8/5 11/15 17/6 19/20 22/9 29/24 30/12 35/20 41/22 43/11 46/9 46/12 53/9 53/16 55/7 56/17 58/22 61/16 62/20 66/9 70/6 71/14 74/22 78/25 85/7 86/2 87/6 93/22 98/7 107/8 109/6 111/8 116/19 118/10 122/22 127/19 129/21 130/9 133/10 137/9 138/3 141/22 142/2 143/23 150/10 150/17 151/11 152/16 154/9 155/14 155/24 157/3 161/7 161/9 161/17 164/9 166/11 167/2 167/21 168/6 168/7 171/17 171/17 172/11 172/15 173/17 175/2 anybody [6] 21/7 43/15 60/17 61/7 132/12 139/12 anyone [3] 21/10 43/19 95/3 anyone's [3] 21/8 166/8 168/6 anything [25] 7/22 9/9 19/21 30/19 31/9 43/23 49/12 53/21 54/21 60/9 66/16 72/12 76/12 81/19 87/13 87/24 87/25 93/24 113/17 119/4 120/6 120/6 151/19 151/20 173/18 API [4] 47/7 48/16 101/22 136/6 apologize [4] 24/4 60/16 61/6 109/21
--	---	---

<p>A</p> <p>apparent [1] 4/20</p> <p>appeals [1] 43/6</p> <p>appear [7] 38/25 50/4 60/21 60/22 100/4 115/3 173/21</p> <p>appearing [1] 2/19</p> <p>appellate [1] 89/20</p> <p>appendices [1] 57/15</p> <p>appendixes [1] 165/20</p> <p>Apple [5] 40/19 42/5 42/7 77/19 77/25</p> <p>applicant [19] 4/25 5/17 6/19 7/5 8/20 9/9 25/14 69/6 69/16 82/23 99/22 105/1 109/14 111/18 119/9 145/21 152/5 157/19 179/22</p> <p>applicant's [1] 6/21</p> <p>applicants [20] 2/10 3/12 4/10 6/1 6/9 9/7 36/15 52/9 69/17 71/5 71/17 72/8 82/16 82/24 105/5 110/7 145/9 154/3 169/4 180/13</p> <p>applicants' [1] 3/9</p> <p>application [46] 1/9 4/14 4/21 8/3 11/14 13/14 15/15 19/9 19/23 20/12 20/19 25/12 32/24 35/6 37/22 41/12 43/13 49/22 54/7 55/1 55/7 60/19 67/11 77/4 77/22 95/23 108/21 109/12 110/11 112/9 112/19 119/8 125/6 125/12 130/20 136/8 137/9 139/4 139/12 149/22 162/11 162/14 168/18 168/20 169/7 172/12</p> <p>applications [6] 3/13 4/7 7/13 9/24 55/10 62/13</p> <p>applied [7] 23/9 38/12 77/18 100/9 139/23 140/4 158/18</p> <p>apply [8] 9/13 16/14 70/21 104/10 105/4 135/6 139/15 147/16</p> <p>applying [10] 3/12 10/24 15/21 18/1 45/5 74/8 87/17 99/19 152/3 165/3</p> <p>appoint [6] 16/18 56/24 58/16 73/6 73/9 73/10</p> <p>appointed [24] 7/8 10/23 11/15 14/12 29/17 34/4 39/25 40/4 40/24 41/14 41/15 41/16 42/9 50/19 53/10 74/2 79/16 99/10 115/10 117/9 121/23 131/14 175/24 179/6</p> <p>appointees [1] 42/1</p> <p>appointing [2] 29/16 52/10</p> <p>appointment [7] 11/19 13/9 39/24 40/5 42/22 116/22 129/7</p> <p>appointments [4] 3/22 100/22 131/7 169/11</p> <p>appreciate [51] 4/13 11/14 14/25 15/14 25/10 25/11 31/6 44/1 44/9 44/21 53/5 54/25 55/11 60/12 60/14 62/4 68/1 68/2 68/13 77/3 77/23 79/2 81/12 81/21 87/20 88/4 99/19 100/6 103/7 104/20 105/3 107/9 107/21 109/13 112/18</p>	<p>119/11 119/23 119/24 122/20 125/8 131/3 131/8 139/6 145/5 149/21 150/14 152/4 153/25 157/7 162/10 168/20</p> <p>appreciated [3] 5/22 127/15 137/19</p> <p>appreciating [1] 127/12</p> <p>appreciation [3] 20/2 32/22 146/1</p> <p>appreciative [2] 44/12 180/14</p> <p>approach [7] 18/22 24/19 30/2 54/13 119/22 147/5 164/4</p> <p>approached [1] 10/3</p> <p>approaching [1] 122/11</p> <p>appropriate [4] 47/10 52/2 74/10 146/24</p> <p>appropriately [1] 18/21</p> <p>approval [1] 42/8</p> <p>approximately [1] 115/11</p> <p>April [5] 49/4 82/13 131/8 134/18 165/10</p> <p>are [391]</p> <p>area [16] 16/6 16/7 59/14 59/23 79/22 81/12 112/1 114/15 131/15 139/25 141/4 144/9 144/13 146/8 147/16 149/21</p> <p>areas [10] 7/12 7/19 24/15 33/16 73/19 100/16 100/16 101/17 106/23 159/20</p> <p>Arego [1] 69/25</p> <p>aren't [1] 122/17</p> <p>arena [5] 108/19 140/1 140/3 140/16 140/18</p> <p>argue [3] 14/5 14/8 163/18</p> <p>arguing [1] 126/6</p> <p>arguments [3] 59/25 89/20 101/5</p> <p>arise [2] 16/23 117/19</p> <p>Arkansas [2] 176/1 176/3</p> <p>arms [2] 34/1 154/19</p> <p>arose [1] 57/17</p> <p>around [5] 14/13 34/1 57/23 94/1 113/18</p> <p>array [1] 151/17</p> <p>artificial [1] 108/15</p> <p>arts [1] 50/25</p> <p>as [271]</p> <p>asbestos [2] 111/4 125/21</p> <p>Asian [1] 119/1</p> <p>aside [3] 112/20 113/4 114/3</p> <p>ask [23] 11/20 15/9 21/6 43/24 53/19 55/3 60/10 65/8 75/19 81/25 82/1 87/15 88/6 91/17 92/5 98/11 99/16 103/10 107/11 107/20 110/4 110/11 162/21</p> <p>asked [22] 6/9 17/9 17/21 31/19 31/22 52/10 53/20 56/11 73/15 87/25 88/25 107/13 111/18 113/16 119/4 153/20 154/11 155/3 166/13 166/15 169/16 178/12</p> <p>asking [8] 7/11 41/18 73/9 73/10 92/6 106/16 143/7 169/17</p>	<p>aspect [11] 47/9 52/3 56/18 83/14 97/7 97/11 116/16 121/19 128/15 131/16 137/7</p> <p>aspects [23] 58/22 83/2 84/7 84/14 89/25 91/2 91/2 99/3 100/23 101/4 109/5 110/20 114/6 132/15 132/23 133/5 140/11 140/12 142/3 154/9 155/12 156/12 171/19</p> <p>assembled [1] 103/4</p> <p>assembling [1] 26/5</p> <p>assess [4] 18/9 52/19 96/9 133/20</p> <p>asset [5] 36/3 105/12 116/14 125/14 128/13</p> <p>assets [2] 59/13 106/22</p> <p>assign [1] 104/2</p> <p>assignees [2] 67/2 67/21</p> <p>assignment [4] 65/12 66/24 170/8 170/9</p> <p>assignments [8] 65/17 65/21 65/22 66/18 66/21 67/16 139/2 175/13</p> <p>assignors [1] 67/4</p> <p>assimilate [1] 149/11</p> <p>assist [7] 36/3 38/14 76/10 84/25 86/9 108/22 152/22</p> <p>assistance [2] 36/23 159/23</p> <p>assisted [1] 116/5</p> <p>assisting [1] 156/8</p> <p>associate [10] 16/19 45/22 58/7 144/19 145/4 146/12 155/1 155/10 160/8 170/5</p> <p>associated [1] 155/20</p> <p>associates [5] 53/14 118/25 123/10 155/12 163/25</p> <p>association [1] 155/25</p> <p>assume [1] 172/17</p> <p>assuming [2] 4/25 78/22</p> <p>assumption [1] 141/12</p> <p>assurance [1] 5/25</p> <p>assure [9] 2/15 7/19 7/25 11/22 15/4 35/5 38/18 98/13 129/2</p> <p>Atlanta [1] 174/25</p> <p>attaching [1] 54/2</p> <p>attempting [1] 31/10</p> <p>attention [4] 2/17 80/3 149/2 162/12</p> <p>attest [3] 116/12 122/11 122/12</p> <p>attorney [22] 18/15 18/15 21/19 21/25 22/1 22/7 58/17 58/22 74/12 76/8 76/9 80/2 92/19 123/18 125/20 137/1 144/11 159/17 161/23 166/23 170/5 170/14</p> <p>attorney/client [2] 58/22 92/19</p> <p>attorneys [43] 4/18 6/6 17/2 17/2 22/13 22/14 22/16 22/20 22/22 24/17 25/4 49/18 58/10 68/18 73/11 74/5 90/8 91/11 94/15 100/11 100/16 112/22 113/3 115/14 121/25 126/4 126/8 137/19 138/18 139/2 142/24 143/6 144/1 144/3 144/5 144/12 144/16 144/23</p>
---	---	---

A attorneys... [5] 152/20 156/12 156/23 164/22 164/25 attributable [1] 56/8 attuned [1] 81/11 audio [5] 15/10 25/18 31/13 44/5 158/4 audition [1] 135/21 Australia [1] 73/13 authenticity [1] 179/8 availability [2] 17/11 17/12 available [6] 7/15 17/21 34/23 107/5 164/3 177/20 Avandia [2] 22/15 46/5 aviation [1] 59/24 avoid [3] 53/1 53/2 110/1 aware [5] 16/16 28/24 88/5 141/4 165/12 away [4] 61/20 65/23 158/9 167/13 awhile [3] 48/14 96/17 97/5	bat [1] 136/24 bat-mitzvah [1] 136/24 battle [3] 33/20 148/25 149/1 be [296] BEACH [3] 1/2 1/5 1/14 bear [7] 11/9 27/3 45/15 46/8 49/20 53/3 55/24 Beasley [3] 174/25 175/7 175/8 became [10] 22/7 49/17 126/8 127/7 127/8 140/21 141/4 162/21 167/17 170/5 because [60] 2/6 2/8 2/20 3/3 4/19 12/1 12/23 16/15 17/20 21/6 23/16 36/21 46/16 47/18 48/20 51/20 54/6 66/23 68/5 70/1 70/4 71/25 73/9 73/10 75/23 88/7 90/18 91/15 94/25 96/15 102/19 103/11 105/21 107/3 110/16 111/3 111/6 113/4 120/11 121/9 121/12 122/17 123/20 123/20 128/5 128/14 128/21 130/3 134/6 137/20 140/4 141/4 155/17 164/25 164/25 165/5 166/6 166/14 178/24 180/2 Becerra [1] 62/20 become [6] 56/11 105/23 126/18 140/6 144/13 151/25 bedside [1] 160/1 been [170] 2/14 3/4 3/4 3/7 4/20 5/12 7/15 13/15 14/25 19/11 22/1 22/7 22/12 24/1 24/7 24/20 27/11 27/14 41/6 41/6 41/14 41/15 41/16 41/24 42/16 44/11 44/19 44/20 47/4 47/5 47/6 48/23 52/17 52/18 53/6 53/11 54/17 55/13 56/17 56/19 58/9 58/21 61/10 62/21 63/11 64/23 64/25 65/2 65/21 65/25 66/10 66/12 67/6 69/1 69/7 69/10 69/25 70/11 70/13 71/11 73/12 73/23 77/12 81/5 82/10 82/22 85/8 86/20 90/2 90/7 91/4 91/5 91/13 94/3 94/19 96/13 97/3 97/4 97/7 99/10 100/14 101/22 102/23 104/9 104/10 105/19 107/5 108/13 109/2 109/17 110/18 110/19 110/20 111/24 111/25 112/3 112/6 112/16 115/14 115/16 115/18 116/7 116/24 117/25 119/15 119/16 119/22 120/12 121/2 121/2 121/4 121/17 121/23 122/15 123/6 123/7 124/9 128/8 129/7 131/6 131/7 131/8 131/9 132/11 132/25 133/1 133/3 134/11 134/17 135/16 135/18 135/18 136/2 136/3 137/16 137/17 139/20 143/16 146/9 146/14 146/19 147/3 149/18 151/8 152/24 153/10 153/23 159/16 159/19 160/8 160/8 160/11 160/19 160/20 162/6 164/18 166/21 166/23 167/25 168/2 168/11 169/11 169/17	170/19 172/3 173/9 175/20 175/24 176/9 179/7 before [49] 1/10 3/10 10/18 19/5 21/5 23/1 32/14 33/19 38/25 39/17 41/8 43/24 45/16 46/6 48/10 50/4 52/9 55/15 57/17 60/7 75/8 81/18 82/25 87/18 94/4 98/1 100/5 101/6 105/11 115/3 120/2 120/3 126/7 127/16 148/17 148/18 159/2 163/7 164/14 164/21 167/9 167/10 167/14 172/8 172/24 175/7 178/21 179/1 179/8 began [5] 32/14 42/12 101/3 125/19 162/23 begin [5] 18/18 19/6 72/23 89/8 158/14 beginning [12] 56/8 65/20 81/6 86/20 110/19 120/11 121/3 121/20 126/12 134/18 151/5 172/4 behalf [14] 5/7 6/6 7/24 15/23 37/14 66/15 66/25 78/4 80/10 119/23 120/17 122/19 122/21 126/7 behind [12] 69/8 69/10 70/14 71/12 71/16 100/25 122/6 133/16 164/22 172/20 176/18 176/20 Behram [1] 89/8 being [37] 12/8 13/18 13/20 13/21 19/25 21/2 22/22 29/18 52/10 53/4 53/9 54/15 54/16 58/5 59/13 61/16 63/13 89/2 90/11 95/16 106/14 108/11 110/1 120/8 120/16 122/20 128/3 128/6 135/6 143/25 144/6 147/12 163/21 166/20 174/21 175/18 178/16 belabor [1] 115/20 believe [34] 4/24 24/22 28/21 29/4 32/13 32/17 33/16 45/14 46/7 46/15 47/8 48/10 50/18 64/20 84/21 90/11 101/17 101/18 102/3 102/18 103/4 103/18 104/4 111/5 113/6 120/10 120/21 124/24 133/9 148/24 155/20 158/19 159/4 165/7 believed [1] 6/21 bellwether [15] 27/15 30/2 30/8 30/14 30/17 67/19 67/20 95/17 101/16 102/4 102/13 130/8 130/9 131/17 134/5 bellwethers [4] 30/6 87/4 129/10 129/22 belt [1] 12/18 bench [6] 9/19 42/14 43/10 53/14 60/7 171/20 Bendectin [2] 146/12 146/15 beneath [1] 22/16 beneficial [5] 36/14 75/23 84/4 162/7 176/9 beneficiary [3] 138/21 161/20 169/11 benefit [20] 4/5 4/5 5/18 10/11 55/18 56/4 80/21 86/5
B baby [1] 169/24 back [35] 9/6 9/15 15/6 52/24 58/9 61/9 64/12 64/13 66/6 70/20 71/19 74/15 88/7 88/9 88/16 88/17 88/25 89/3 89/7 98/9 98/9 118/1 121/14 121/25 132/7 140/20 145/12 145/13 145/17 145/21 153/24 153/24 173/6 178/11 178/25 background [25] 31/16 31/20 31/23 46/21 58/5 74/3 76/3 78/1 78/6 78/20 79/3 87/21 89/16 90/24 95/8 123/15 125/18 130/7 131/13 135/25 139/16 154/16 157/8 157/9 166/21 backing [1] 124/10 backyard [1] 42/15 bacteria [1] 162/7 bad [3] 109/20 163/7 163/7 balance [4] 48/23 123/23 164/18 165/12 balancing [2] 42/6 123/9 bandaids [1] 159/22 bank [1] 12/3 Bar [7] 38/20 38/21 38/21 49/17 60/8 90/11 169/8 bargain [1] 10/11 bargaining [1] 159/1 Barnes [1] 28/4 base [2] 112/12 143/15 baseball [2] 82/17 82/18 based [23] 6/19 12/9 18/17 30/12 37/23 63/23 66/21 66/23 74/3 97/13 103/18 103/20 103/25 104/8 104/16 107/24 114/12 116/21 117/2 118/3 153/15 156/11 166/17 basement [1] 74/17 basic [1] 149/8 basically [3] 47/15 47/20 112/6 basics [1] 164/3 basis [3] 35/18 98/15 134/6		

<p>B</p> <p>benefit... [12] 99/7 108/25 109/3 113/15 113/16 120/14 121/6 132/14 141/5 158/9 161/24 166/8</p> <p>benefiting [1] 125/2</p> <p>benefits [6] 42/14 52/16 64/3 64/4 109/4 124/25</p> <p>Benicar [2] 100/20 100/24</p> <p>Berman [11] 10/3 10/18 23/22 23/22 25/15 25/16 26/25 33/19 34/7 39/7 87/3</p> <p>besides [2] 41/8 76/5</p> <p>best [22] 7/23 17/4 26/5 27/8 30/24 33/6 34/17 43/9 44/11 64/20 76/1 78/21 98/16 104/5 110/25 132/5 132/5 137/11 163/15 165/20 169/1 169/2</p> <p>better [9] 8/5 22/9 29/16 77/24 107/14 122/4 135/21 159/14 174/11</p> <p>between [19] 10/11 12/20 12/24 13/3 13/12 30/13 46/16 50/19 51/2 52/6 52/25 73/5 75/14 92/20 121/13 147/7 147/13 148/25 156/3</p> <p>Bextra [1] 175/21</p> <p>beyond [6] 29/21 38/9 38/18 64/1 64/11 127/3</p> <p>bias [1] 149/9</p> <p>big [10] 8/15 14/7 15/15 35/25 35/25 36/2 114/19 126/12 147/12 170/22</p> <p>bigger [1] 57/24</p> <p>biggest [3] 42/24 117/20 170/23</p> <p>billion [1] 43/5</p> <p>binding [1] 7/24</p> <p>biography [1] 115/7</p> <p>biology [1] 148/1</p> <p>biopsies [1] 84/2</p> <p>biostatistics [1] 147/25</p> <p>birthday [2] 107/19 107/20</p> <p>bit [17] 9/15 25/25 28/9 36/7 45/4 60/16 62/25 82/22 84/16 98/17 108/8 121/10 127/7 130/16 154/15 165/3 178/24</p> <p>black [2] 67/3 83/13</p> <p>blanking [1] 156/14</p> <p>blessed [2] 30/22 56/17</p> <p>block [2] 127/5 163/1</p> <p>blockbuster [1] 47/23</p> <p>Bloom [1] 165/6</p> <p>board [3] 51/15 59/24 176/14</p> <p>boards [1] 19/10</p> <p>Boca [2] 39/22 42/15</p> <p>bodes [1] 50/8</p> <p>bodily [2] 51/3 51/12</p> <p>body [2] 84/3 142/13</p> <p>Bogdan [1] 139/8</p> <p>bogged [1] 11/25</p> <p>boiled [1] 90/19</p> <p>bono [1] 83/19</p> <p>bookkeeper [1] 12/15</p> <p>books [1] 79/14</p>	<p>bootstraps [1] 20/7</p> <p>born [3] 20/3 73/13 162/24</p> <p>both [34] 16/17 23/16 23/18 27/18 36/23 38/14 46/1 48/20 50/25 63/12 71/25 74/5 80/21 86/18 87/6 87/10 87/11 87/12 90/10 94/13 94/16 94/18 96/9 100/20 108/16 124/13 125/17 127/7 128/6 137/5 142/11 154/18 169/13 172/21</p> <p>box [2] 67/3 83/13</p> <p>boxes [1] 91/1</p> <p>Brad [1] 76/21</p> <p>brand [7] 14/22 47/16 47/18 54/6 83/11 93/14 128/7</p> <p>branding [2] 126/16 126/20</p> <p>brands [3] 47/22 118/4 132/2</p> <p>breach [1] 10/7</p> <p>break [15] 61/20 61/21 81/12 88/5 88/14 88/22 89/7 145/9 145/12 148/18 152/7 164/20 165/16 166/15 166/17</p> <p>breaking [1] 134/22</p> <p>breaks [2] 67/24 135/4</p> <p>breast [5] 104/6 148/3 154/20 164/23 176/2</p> <p>breathe [1] 16/19</p> <p>breeze [1] 179/20</p> <p>Brent [1] 109/14</p> <p>Breyer [1] 178/20</p> <p>bridge [2] 56/3 147/7</p> <p>brief [3] 3/10 65/5 91/21</p> <p>briefed [1] 136/8</p> <p>briefing [7] 56/20 69/4 69/9 79/10 79/21 148/14 171/13</p> <p>briefly [1] 69/15</p> <p>brilliant [1] 112/22</p> <p>bring [53] 9/14 11/3 11/9 14/9 20/7 24/15 27/3 27/9 27/10 27/11 27/16 28/25 31/2 31/5 34/9 45/11 45/15 46/7 48/5 49/20 57/13 57/18 57/20 62/3 66/24 69/16 69/17 70/23 73/11 73/12 78/6 78/13 79/8 80/3 91/1 100/12 101/14 104/19 106/22 107/14 107/17 108/24 112/13 112/24 123/14 124/19 125/16 128/24 131/22 145/4 161/5 171/25 174/4</p> <p>bringing [11] 20/6 20/10 27/15 55/14 57/16 60/5 78/4 80/9 80/10 161/4 172/22</p> <p>brings [5] 53/3 109/9 114/15 118/21 125/1</p> <p>broad [6] 5/13 59/9 92/12 92/13 112/12 167/23</p> <p>broader [2] 37/20 93/23</p> <p>brought [11] 18/20 22/3 28/23 37/12 53/24 53/25 58/12 58/13 118/25 124/8 164/22</p> <p>Brown [2] 96/14 122/9</p> <p>BS [1] 64/13</p> <p>Bucciero [1] 58/13</p> <p>bucket [1] 17/15</p> <p>budget [1] 167/9</p> <p>build [7] 14/24 19/6 96/17 106/18 171/12 171/14 171/16</p>	<p>building [5] 11/4 11/11 15/1 26/6 47/5</p> <p>built [2] 121/5 139/17</p> <p>bulk [5] 22/22 75/20 75/21 136/2 138/8</p> <p>bunch [1] 82/9</p> <p>burden [5] 35/7 35/12 35/14 35/15 96/1</p> <p>Bursor [1] 68/15</p> <p>business [8] 94/3 118/23 163/4 163/21 164/5 169/17 169/19 179/4</p> <p>busy [2] 71/15 109/18</p> <p>but COVID-19 [1] 174/1</p> <p>button [1] 145/16</p> <p>buy [3] 114/10 135/23 178/5</p> <tr> <td colspan="3" data-bbox="180 533 630 562">C</td></tr> <p>California [5] 22/25 45/9 98/8 156/24 157/4</p> <p>call [8] 34/13 38/14 38/19 71/20 72/17 81/14 120/7 152/9</p> <p>called [10] 21/2 37/7 37/13 60/23 78/5 98/1 98/3 139/21 158/11 162/16</p> <p>calling [2] 61/6 100/2</p> <p>calls [3] 91/5 116/10 142/20</p> <p>came [13] 19/25 21/8 26/17 47/3 61/11 81/18 115/17 138/6 154/18 164/11 164/18 173/6 175/13</p> <p>can [142] 4/10 4/25 5/19 7/23 8/7 9/14 11/2 11/9 11/14 11/22 11/22 12/24 13/7 13/16 14/24 15/3 15/4 15/11 15/13 15/19 16/18 16/24 17/2 18/13 18/20 19/6 20/11 21/4 22/9 22/21 23/10 24/10 25/7 25/16 27/3 27/14 27/16 29/22 31/9 31/12 34/12 35/5 36/23 38/14 38/18 41/21 44/4 44/11 45/11 45/15 46/7 47/10 48/5 48/15 48/18 48/21 53/1 53/1 54/20 58/1 59/8 64/17 65/10 66/9 67/24 76/23 79/7 80/16 80/20 81/11 81/24 86/11 86/21 88/13 94/9 98/13 102/1 102/12 102/18 104/12 104/15 107/14 107/24 108/8 109/23 110/1 116/22 122/10 122/12 122/25 124/3 125/10 128/19 129/2 129/18 130/8 131/22 132/6 132/19 133/4 134/1 134/9 135/18 138/19 141/15 143/1 143/10 148/6 148/13 149/15 150/12 151/11 151/15 151/21 151/24 151/25 153/3 154/5 154/5 156/25 158/12 158/23 158/25 161/2 161/3 161/9 165/16 165/21 166/15 167/1 169/1 169/2 171/6 171/16 171/17 171/21 171/24 171/25 176/16 177/5 177/15 177/22</p> <p>can't [5] 29/18 98/19 134/15 164/1 165/4</p> <p>Canada [1] 153/12</p>	C		
C					

C cancel [1] 5/16 canceled [1] 167/14 cancer [52] 33/8 37/9 42/17 84/7 84/8 84/20 84/21 85/19 85/21 102/9 104/6 104/7 111/3 111/7 111/8 130/15 134/16 142/2 142/9 142/10 143/9 147/13 148/2 148/3 148/3 148/3 150/10 150/11 150/23 150/23 150/24 150/24 150/25 150/25 151/9 151/10 151/21 153/20 155/17 155/20 156/16 156/18 164/15 164/23 164/25 167/22 167/22 175/25 176/2 176/4 176/6 176/7 cancers [14] 85/8 85/11 85/14 85/15 85/18 85/23 102/8 104/5 104/8 130/14 130/18 155/16 155/24 156/4 candid [1] 77/3 candidate [4] 9/3 22/2 62/6 164/9 candidates [9] 9/11 21/23 84/22 100/9 106/24 107/17 164/8 165/19 176/9 Candidly [2] 54/16 138/6 candor [4] 50/5 54/12 77/15 96/9 candy [1] 141/8 cannot [2] 94/25 167/24 capacity [4] 36/7 39/23 107/6 107/25 capital [1] 98/15 carcinogen [6] 131/19 131/20 131/21 140/7 141/14 142/7 carcinogens [1] 148/5 cards [1] 82/18 care [12] 26/22 45/25 63/3 83/8 130/22 135/9 139/7 157/15 158/21 160/3 160/3 179/8 career [12] 40/20 107/12 115/9 125/19 125/20 139/20 144/20 147/22 166/24 169/19 169/20 172/4 careful [1] 59/17 carefully [7] 26/4 53/6 81/5 101/21 111/23 129/3 156/22 Carmen [1] 105/1 Carolina [1] 59/22 carries [1] 33/20 carry [2] 6/2 34/16 carrying [2] 103/5 136/17 case [319] cases [155] 3/16 5/4 5/7 5/8 5/9 5/14 5/21 10/9 10/13 11/2 11/2 12/17 13/13 18/7 23/5 23/16 24/20 25/9 27/7 28/21 29/13 33/8 34/3 38/12 41/15 41/16 41/18 43/22 46/1 53/12 53/23 55/20 55/21 59/22 62/9 64/24 66/14 66/14 66/20 68/16 69/13 69/23 70/4 71/13 73/25 74/21 75/21 77/10 77/13 78/2 78/3 78/13 78/14 79/12 86/8 86/9 86/12	86/13 87/1 90/2 90/3 94/2 94/3 97/7 97/21 102/6 102/12 102/13 102/13 102/17 102/19 103/19 103/19 105/21 106/15 106/18 106/21 107/7 108/5 108/16 109/5 111/13 113/2 115/16 118/7 118/9 119/25 121/16 121/17 121/18 122/13 122/16 125/25 126/6 126/10 126/17 126/17 126/22 128/6 130/15 131/17 132/12 133/8 134/2 134/3 134/5 137/4 137/5 137/6 139/22 139/22 146/18 147/6 148/17 148/20 150/6 150/8 150/21 151/6 151/19 153/7 153/18 154/12 160/9 160/9 160/13 164/9 164/10 164/10 164/23 164/23 165/7 166/12 166/13 167/21 167/22 167/22 167/23 168/8 171/8 171/10 174/7 175/3 175/16 176/2 176/10 176/13 176/22 177/6 177/10 177/12 177/21 177/24 178/2 178/16 catastrophic [1] 121/17 categories [3] 59/9 130/17 134/22 category [1] 130/15 caught [1] 13/24 causation [15] 75/9 106/10 146/25 149/4 150/5 150/7 150/21 151/3 151/4 151/5 151/11 151/16 151/17 151/23 151/24 cause [5] 10/24 150/10 150/22 150/24 158/7 caused [3] 9/25 142/4 155/17 causes [2] 106/9 106/10 Celebrex [3] 175/21 178/11 178/12 census [18] 5/5 5/11 5/19 5/23 28/16 32/10 67/11 86/6 86/14 95/17 97/21 117/9 118/6 133/20 133/24 142/19 153/6 168/2 Center [1] 73/7 Center study [1] 73/7 Center's [1] 148/8 centered [1] 78/11 centers [1] 77/11 Central [1] 62/11 certain [6] 9/10 104/7 109/4 116/4 159/25 160/1 certainly [13] 4/5 59/19 104/15 104/19 107/16 108/20 109/3 125/1 128/19 150/13 151/24 157/8 174/17 certification [10] 23/2 30/16 41/20 67/18 69/3 70/15 75/8 75/18 78/18 150/1 certified [2] 59/24 62/16 certify [3] 30/4 41/21 180/25 certifying [1] 5/23 chain [3] 48/8 93/13 138/12 chair [5] 51/16 89/22 102/4 140/5 170/9 chaired [2] 101/16 103/2	challenge [2] 81/6 93/8 challenged [2] 147/11 147/12 challenges [9] 70/23 80/22 80/24 81/10 93/5 117/21 146/22 146/23 160/16 challenging [1] 82/19 chance [12] 7/18 9/19 10/10 10/22 30/20 60/10 73/17 74/7 74/21 87/14 101/17 127/14 changed [5] 21/21 82/3 106/2 106/3 123/19 changer [1] 152/1 changes [1] 106/4 characteristic [1] 52/15 characteristics [3] 52/5 53/3 140/10 characterized [1] 79/10 charge [3] 116/7 116/9 137/16 chart [1] 151/20 check [2] 88/17 88/20 checking [1] 179/21 checks [2] 12/4 12/5 chemical [3] 91/22 140/10 141/11 Chevreaux [1] 175/22 Chevron [1] 62/12 Chicago [2] 10/1 59/21 child [1] 165/17 children [3] 39/19 143/14 162/24 children's [1] 10/16 China [2] 114/12 141/9 Chinese [4] 163/1 163/3 163/3 163/6 choice [2] 5/11 23/24 choose [3] 57/9 99/11 120/1 choosing [2] 116/6 131/15 chosen [1] 33/22 chutzpah [1] 165/4 Cir [3] 55/4 60/13 72/18 circle [1] 61/9 Circuit [6] 65/9 65/23 66/6 89/20 89/20 89/21 circumspect [1] 53/11 circumstances [2] 16/1 32/21 citizen [1] 15/24 city [2] 62/10 77/10 civil [1] 33/2 civility [2] 13/23 43/12 claim [10] 22/4 26/24 62/25 63/2 63/5 73/22 80/14 80/16 111/21 143/3 claims [21] 28/9 28/10 28/11 28/22 28/23 46/3 46/4 55/23 65/7 66/24 67/4 74/5 86/22 87/9 97/8 97/9 97/10 132/17 133/16 167/24 168/7 clarify [1] 70/10 class [139] 5/7 9/22 9/25 10/5 10/15 10/16 10/18 10/20 10/23 11/1 11/2 11/8 13/2 13/2 13/4 13/10 15/22 15/23 16/6 16/11 16/14 16/15 18/14 18/14 18/16 18/20 22/3 23/2 23/17 26/24 27/13 28/11 28/15 28/23 29/5 30/8 30/14 30/16 33/7 34/25 35/17 36/10
--	---	--

<p>C</p> <p>class... [97] 36/14 36/18 36/19 36/22 36/25 37/4 37/15 37/19 38/14 40/3 40/15 41/11 41/12 41/13 41/19 41/20 43/4 45/9 45/18 45/19 45/20 45/22 47/13 47/15 50/24 51/2 51/11 51/24 53/20 53/22 55/21 55/22 56/13 57/6 57/7 58/8 58/23 62/20 63/1 63/6 64/19 67/18 67/19 69/2 69/3 69/14 70/15 72/10 73/19 73/22 74/20 74/24 75/4 75/7 75/14 75/17 75/18 77/10 78/2 78/5 78/17 78/21 79/23 79/25 80/8 80/14 80/15 84/18 84/19 84/21 86/3 86/7 86/10 86/17 86/20 86/21 86/23 87/4 87/9 89/17 90/2 90/5 94/2 94/5 97/8 111/8 111/25 112/2 149/24 150/1 150/2 150/3 150/6 150/8 154/12 154/12 154/13</p> <p>class' [1] 43/9</p> <p>classes [3] 41/22 62/16 78/14</p> <p>clear [3] 2/19 59/2 149/6</p> <p>clearest [1] 47/18</p> <p>clearly [2] 158/3 177/1</p> <p>clerk [3] 136/25 136/25 162/3</p> <p>clerkship [1] 115/15</p> <p>client [12] 26/23 58/22 66/12 78/10 92/19 94/10 102/7 143/7 143/11 143/15 151/7 177/18</p> <p>client's [1] 111/16</p> <p>clients [38] 22/8 22/10 23/15 23/17 23/17 34/7 73/21 73/23 77/4 77/14 78/15 94/12 98/14 103/19 111/1 111/11 111/11 115/24 119/2 119/23 122/14 122/17 123/21 126/1 126/6 126/23 128/22 137/20 139/24 141/21 142/19 153/5 153/6 153/9 159/11 164/24 166/11 166/13</p> <p>clinical [1] 177/18</p> <p>close [2] 50/18 115/24</p> <p>closely [6] 14/19 49/15 56/13 56/16 58/15 59/5</p> <p>closer [1] 36/6</p> <p>closing [1] 163/25</p> <p>club [1] 165/16</p> <p>co [41] 14/1 27/18 27/19 27/21 27/22 29/5 29/5 29/9 29/13 29/14 29/18 35/11 45/8 45/10 51/5 51/11 51/12 51/15 53/17 53/23 57/5 57/10 61/23 71/6 71/7 73/1 74/9 75/17 101/7 101/16 102/4 103/2 114/17 121/23 124/6 124/15 127/21 128/2 131/14 140/4 170/9</p> <p>co-chair [2] 102/4 170/9</p> <p>co-chaired [2] 101/16 103/2</p> <p>co-counsel [7] 14/1 45/8</p>	<p>45/10 53/23 61/23 73/1 74/9</p> <p>co-lead [12] 29/9 29/14 35/11 51/5 53/17 57/5 71/7 75/17 114/17 121/23 127/21 128/2</p> <p>co-leaders [1] 124/6</p> <p>co-leadership [2] 27/22 71/6</p> <p>co-leads [12] 27/18 27/19 29/5 29/5 29/13 29/18 51/11 51/12 51/15 57/10 124/15 131/14</p> <p>co-led [1] 101/7</p> <p>co-science [1] 140/4</p> <p>co-tried [1] 27/21</p> <p>Coast [1] 25/23</p> <p>cochair [1] 129/9</p> <p>coffee [1] 15/7</p> <p>cognizant [1] 85/23</p> <p>cogs [1] 171/11</p> <p>Cohen [1] 29/14</p> <p>cohesive [2] 11/5 14/21</p> <p>cohesively [1] 33/23</p> <p>cohesiveness [1] 44/24</p> <p>cohost [1] 179/24</p> <p>cohosts [3] 2/22 21/9 88/17</p> <p>coincidentally [1] 62/18</p> <p>colead [2] 11/19 12/6</p> <p>collaborate [6] 17/22 40/22 42/2 42/20 60/6 116/17</p> <p>collaborating [3] 19/8 41/9 55/15</p> <p>collaboration [3] 19/19 41/2 69/21</p> <p>collaborative [4] 17/1 56/5 116/2 122/12</p> <p>collaboratively [4] 52/11 56/25 57/13 101/14</p> <p>colleague [4] 29/9 34/8 65/24 157/13</p> <p>colleagues [14] 7/13 7/24 13/20 13/24 32/15 40/22 45/1 105/5 110/5 120/7 147/3 148/24 153/13 153/20</p> <p>collective [5] 121/24 122/5 122/22 124/25 125/2</p> <p>collectively [2] 122/3 152/24</p> <p>College [1] 155/1</p> <p>Colorado [3] 74/15 74/16 74/17</p> <p>Columbia [1] 77/7</p> <p>comanaging [1] 12/19</p> <p>combat [2] 171/17 171/17</p> <p>combination [1] 72/9</p> <p>combine [2] 11/22 18/18</p> <p>come [27] 7/21 41/9 46/13 55/12 57/14 75/8 75/10 75/11 80/21 81/14 85/25 88/7 103/20 113/21 117/1 130/13 131/20 133/17 137/20 145/12 145/13 145/17 149/21 152/10 161/10 163/16 180/3</p> <p>comes [5] 34/6 48/7 85/24 158/12 177/6</p> <p>comfort [2] 34/22 80/1</p> <p>comfortable [6] 12/18 50/8 91/24 91/24 147/2 149/7</p> <p>coming [9] 42/8 46/21 80/24</p>	<p>85/13 88/9 134/19 169/4 169/22 170/22</p> <p>commendation [1] 113/23</p> <p>commensurate [1] 144/24</p> <p>comment [3] 44/23 50/24 65/10</p> <p>comments [7] 3/10 7/13 20/23 26/9 47/1 68/12 139/13</p> <p>commercial [2] 64/6 97/4</p> <p>commit [5] 49/3 107/5 110/23 110/24 115/22</p> <p>commitment [20] 2/16 11/20 12/7 16/16 17/11 17/19 34/11 40/1 41/25 48/22 49/1 49/2 49/6 53/8 53/9 71/13 80/7 115/25 167/8 172/16</p> <p>commitments [1] 107/2</p> <p>committed [6] 55/13 110/19 128/25 129/2 133/7 141/20</p> <p>committee [40] 4/4 4/4 9/14 17/17 17/21 21/17 22/2 23/4 23/5 23/15 23/21 24/22 24/24 38/6 45/6 51/15 51/19 56/15 58/2 59/21 68/22 68/24 68/25 71/7 101/7 101/16 107/2 113/25 124/22 129/9 130/8 139/15 143/4 154/13 154/14 154/21 169/12 170/10 171/9 175/17</p> <p>committees [11] 14/25 128/7 129/12 138/22 139/2 144/3 146/4 152/15 152/25 153/1 175/14</p> <p>common [13] 4/5 27/23 48/20 48/20 126/1 132/14 141/6 150/4 150/5 155/18 155/19 156/1 162/16</p> <p>communicate [2] 96/10 96/20</p> <p>communicating [2] 8/18 78/15</p> <p>communication [2] 19/2 19/7</p> <p>community [2] 58/11 102/4</p> <p>companies [7] 33/12 42/24 63/4 83/10 94/7 160/2 170/23</p> <p>company [5] 65/17 83/1 83/2 138/13 159/13</p> <p>comparable [1] 124/11</p> <p>compare [1] 104/13</p> <p>comparison [1] 127/23</p> <p>competent [2] 73/10 74/12</p> <p>competitors [2] 52/10 121/9</p> <p>complained [1] 154/18</p> <p>Complaint [23] 13/10 23/1 28/18 37/7 37/8 37/11 37/12 37/12 37/14 47/9 63/8 63/11 63/12 67/3 67/3 67/5 69/2 70/14 72/10 79/23 136/16 166/7 166/8</p> <p>complaints [10] 11/4 13/5 36/25 37/4 37/6 40/12 70/5 72/7 75/20 75/22</p> <p>complement [2] 36/17 165/20</p> <p>complete [2] 132/21 136/18</p> <p>completed [2] 3/23 13/11</p> <p>completely [2] 22/24 132/20</p> <p>completing [2] 5/10 5/24</p> <p>complex [8] 16/23 28/21 34/3 55/19 106/15 111/13 111/25 120/24</p>
--	---	---

<p>C</p> <p>complicated [1] 31/3</p> <p>compliment [2] 35/21 44/23</p> <p>component [4] 47/7 51/25 55/22 67/15</p> <p>components [2] 51/3 51/4</p> <p>comport [1] 6/22</p> <p>comporting [1] 103/15</p> <p>comprehensive [2] 112/17 158/21</p> <p>compromise [1] 6/1</p> <p>computer [3] 88/9 88/14 88/23</p> <p>computers [2] 21/20 90/24</p> <p>comradery [1] 44/24</p> <p>concealment [1] 64/11</p> <p>conceived [1] 29/24</p> <p>concentrated [1] 125/19</p> <p>concept [3] 117/2 138/18 161/18</p> <p>concepts [1] 149/10</p> <p>conceptually [1] 108/18</p> <p>concern [1] 117/20</p> <p>concerned [1] 176/22</p> <p>concerning [2] 129/10 176/15</p> <p>concerns [3] 108/14 159/21 172/15</p> <p>conclude [5] 14/15 19/20 43/24 75/25 179/19</p> <p>concluded [4] 22/24 34/19 100/20 180/23</p> <p>conclusion [5] 33/4 42/8 52/23 104/12 122/17</p> <p>conclusions [1] 148/12</p> <p>conditions [2] 143/22 156/5</p> <p>condolences [1] 157/17</p> <p>conduct [4] 6/15 6/22 8/2 155/12</p> <p>conducting [1] 173/19</p> <p>conference [8] 5/16 16/20 21/16 21/18 62/2 137/21 152/13 172/9</p> <p>conference and [1] 5/16</p> <p>conferences [1] 120/4</p> <p>CONFERENCING [1] 1/9</p> <p>confers [1] 40/10</p> <p>confidence [4] 6/5 7/9 52/6 52/14</p> <p>confident [5] 34/13 35/17 41/21 53/16 129/18</p> <p>confidentiality [3] 112/3 112/4 116/5</p> <p>confidently [1] 34/17</p> <p>confirm [1] 115/25</p> <p>conflict [1] 80/14</p> <p>conflicts [4] 6/1 7/4 23/18 86/2</p> <p>confounding [6] 149/9 151/12 155/6 156/1 156/15 156/18</p> <p>congenial [1] 122/12</p> <p>congeniality [1] 54/19</p> <p>congestion [1] 106/9</p> <p>congratulate [1] 8/24</p> <p>Congratulations [1] 11/18</p> <p>conjunction [3] 19/10 129/4 143/21</p> <p>connected [1] 88/10</p>	<p>cons [1] 63/12</p> <p>consensus [1] 57/19</p> <p>consents [2] 64/10 64/10</p> <p>consequence [1] 161/1</p> <p>consider [10] 11/24 52/8 74/25 75/19 112/10 154/8 161/16 173/15 173/17 174/10</p> <p>consideration [3] 100/6 103/22 125/14</p> <p>considered [6] 63/13 93/2 107/23 160/13 160/14 172/6</p> <p>considering [4] 73/16 112/11 169/7 178/6</p> <p>consistently [1] 129/16</p> <p>consisting [1] 51/19</p> <p>consolidated [1] 40/11</p> <p>consultants [1] 90/14</p> <p>consultation [1] 102/4</p> <p>consulted [1] 7/14</p> <p>consulting [1] 111/25</p> <p>consumer [14] 16/5 22/4 23/15 27/20 28/21 37/7 73/19 74/20 78/3 79/5 89/19 97/8 164/10 166/21</p> <p>consumers [2] 5/7 47/25</p> <p>consuming [2] 12/5 160/19</p> <p>consummate [1] 57/6</p> <p>contained [1] 104/3</p> <p>contamination [5] 50/21 50/25 66/23 73/22 102/7</p> <p>contested [1] 106/7</p> <p>context [6] 40/20 46/1 50/21 108/10 110/16 112/7</p> <p>continually [1] 105/25</p> <p>continue [13] 23/11 42/1 56/21 68/10 81/15 84/14 106/5 119/19 120/17 122/21 129/8 140/17 153/7</p> <p>continues [1] 58/15</p> <p>continuing [4] 15/24 22/19 40/16 149/19</p> <p>continuity [1] 120/19</p> <p>Contra [1] 146/14</p> <p>contractors [1] 125/22</p> <p>contraindications [1] 83/12</p> <p>contribute [3] 12/9 12/24 57/20</p> <p>contributing [2] 16/12 113/22</p> <p>contribution [4] 12/1 57/21 57/25 146/7</p> <p>contributions [2] 45/2 98/15</p> <p>control [3] 134/10 141/12 165/1</p> <p>conversation [2] 6/20 20/10</p> <p>conversations [3] 19/6 161/13 179/7</p> <p>conveys [1] 50/7</p> <p>convinced [1] 26/19</p> <p>convincing [1] 30/1</p> <p>cook [1] 163/2</p> <p>cooperate [1] 40/22</p> <p>cooperation [1] 180/17</p> <p>cooperatively [3] 75/5 75/16 97/10</p> <p>coordinate [2] 117/18 173/24</p> <p>coordination [3] 50/19 84/24 85/1</p>	<p>copay [1] 63/19</p> <p>copy [1] 47/20</p> <p>copying [1] 166/8</p> <p>corporately [1] 121/5</p> <p>corporations [1] 30/23</p> <p>correct [1] 180/25</p> <p>correctly [4] 24/5 89/11 92/23 152/6</p> <p>corresponding [1] 69/2</p> <p>corridor [1] 100/1</p> <p>cost [1] 63/18</p> <p>could [41] 6/21 15/9 21/6 23/18 28/21 29/20 30/10 43/13 51/16 53/17 57/23 61/10 63/9 63/11 71/4 73/15 77/13 79/22 81/5 85/19 85/23 88/21 92/14 92/15 92/17 93/9 96/5 100/12 124/22 129/6 141/5 141/13 142/10 149/14 155/2 159/15 159/25 161/5 161/24 179/6 180/16</p> <p>couldn't [1] 159/23</p> <p>counsel [59] 4/11 10/23 14/1 14/2 14/7 15/22 17/3 17/22 17/25 19/3 19/7 19/8 19/11 19/12 19/19 22/23 26/14 35/11 45/8 45/10 48/13 53/23 54/8 57/18 61/23 73/1 74/9 74/24 74/25 75/1 75/17 84/24 86/2 86/3 87/2 90/2 90/6 94/3 94/4 96/2 96/13 101/11 101/12 105/13 108/9 117/17 121/23 122/8 127/4 127/6 127/12 127/21 127/22 128/3 130/4 146/14 148/23 154/7 178/8</p> <p>counselor [2] 80/2 80/2</p> <p>counted [1] 108/25</p> <p>counter [8] 10/6 46/18 46/25 64/5 64/9 69/13 113/14 161/12</p> <p>countries [1] 62/11</p> <p>country [7] 19/25 20/3 20/7 27/16 103/1 143/7 153/12</p> <p>counts [1] 31/22</p> <p>couple [6] 30/2 79/6 95/24 113/19 127/22 136/21</p> <p>course [9] 2/11 39/16 67/21 81/1 100/21 105/10 118/3 151/4 153/2</p> <p>court [117] 1/1 1/13 2/15 4/14 5/2 5/13 5/23 5/25 6/18 6/20 6/24 7/3 10/19 11/23 13/16 14/5 14/10 16/14 23/10 23/16 27/9 27/11 30/1 31/8 31/10 32/8 32/19 33/2 33/5 33/15 34/13 35/5 35/8 36/16 38/8 38/17 38/25 39/23 41/21 41/25 46/22 49/3 50/12 50/13 51/9 51/14 51/23 52/5 52/18 52/20 54/1 54/21 55/10 55/15 56/12 57/3 57/4 57/6 57/8 58/1 58/4 58/16 59/1 59/11 60/7 61/17 62/14 66/5 68/1 73/20 74/25 75/19 76/1 76/4 76/7 76/13 77/5 77/14 77/21 77/21 77/23 78/22 78/25 79/12 81/11 81/20 82/1 82/7</p>
---	---	--

C	D	decrease [2] 85/14 85/24
court... [29] 83/18 85/5	dads [1] 141/7	dedicated [1] 115/14
87/14 89/19 95/13 97/12	Dalimonte [1] 152/17	dedication [5] 4/6 16/2 20/7
99/10 101/6 106/19 108/18	damages [1] 140/23	34/18 55/12
119/21 126/7 128/22 129/2	Daniel [2] 130/23 142/16	deep [8] 16/13 17/24 42/14
146/3 148/6 148/18 148/24	data [18] 5/6 5/19 5/23	43/10 53/14 60/7 110/21
149/17 156/25 157/4 157/10	67/14 67/17 86/14 92/16 93/1	166/1
163/17 165/14 167/19 169/14	95/17 97/21 104/3 133/22	deeply [1] 110/19
169/15 178/5 181/5	133/22 133/24 134/1 134/19	defects [3] 10/13 135/2
Court's [11] 13/11 41/4	134/19 136/16	135/3
60/12 76/6 80/3 81/8 81/9	database [1] 177/18	defend [1] 146/21
81/13 125/13 165/12 167/3	databases [1] 101/9	Defendant [3] 93/13 93/19
courthouse [2] 39/2 167/1	date [9] 5/6 63/20 63/25	111/23
courtroom [5] 31/25 32/6	86/12 87/8 87/8 116/1 117/15	Defendants [28] 47/16 67/13
50/8 147/8 147/9	181/3	92/16 93/6 93/9 112/4 114/15
courts [5] 27/15 30/5 44/19	dates [1] 117/16	116/4 117/6 117/14 117/24
108/15 146/4	Daubert [11] 75/9 89/23	118/4 118/5 118/5 118/7
coverage [2] 62/17 64/5	128/11 128/11 146/17 146/22	120/20 120/25 124/4 125/20
covered [3] 11/17 119/6	146/23 147/17 153/2 153/18	125/21 126/2 137/15 137/17
157/6	153/21	137/25 138/4 148/25 165/8
covers [2] 60/11 136/19	daughter [3] 8/11 26/11	177/16
COVID [7] 2/20 5/16 31/8	31/23	defending [1] 73/23
115/20 119/21 157/13 174/1	daughters [1] 61/19	defense [36] 6/13 7/25 9/18
COVID-19 [5] 2/20 5/16	daughters' [1] 67/24	13/21 13/24 19/11 27/8 31/4
115/20 119/21 157/13	Davis [1] 146/13	36/1 42/24 54/8 58/6 58/7
crafted [2] 101/21 101/25	day [28] 2/18 3/23 8/13	90/11 90/14 94/11 94/15
crash [1] 94/5	31/11 31/23 34/17 39/4 39/18	96/11 97/4 101/11 105/13
crazy [2] 98/20 98/22	44/3 49/23 55/1 60/15 62/20	120/3 120/9 122/15 125/17
create [6] 11/5 33/5 33/10	71/1 71/1 72/15 90/20 92/1	125/20 130/4 146/22 146/23
33/15 108/15 149/3	92/1 95/18 98/3 102/16	147/3 148/23 153/20 154/7
created [1] 149/25	104/23 154/24 155/3 155/3	169/20 169/24 172/7
creates [3] 8/9 34/15 35/9	177/15 177/25	define [2] 131/10 164/12
creative [1] 27/11	day-to-day [1] 71/1	defining [1] 163/21
creativity [2] 73/8 118/21	days [3] 98/1 167/14 178/11	definitely [6] 69/19 76/16
credentials [3] 3/16 26/3	deadline [3] 98/2 123/4	85/1 85/2 117/18 160/18
110/8	130/2	definitions [1] 40/15
credibility [3] 148/22	deadlines [1] 117/16	Delaware [1] 64/25
148/23 149/1	deal [6] 8/15 47/2 50/7 60/2	delay [3] 5/18 23/6 64/24
credit [2] 2/21 152/21	94/7 133/19	delayed [1] 64/10
criteria [11] 102/5 102/12	dealing [14] 6/8 22/13 59/25	delete [5] 92/14 92/14 92/19
102/18 103/11 103/16 103/18	59/25 60/1 69/18 75/17 84/6	93/1 93/3
103/20 103/21 142/22 143/1	102/20 142/15 147/5 147/8	deleted [2] 92/16 92/16
143/10	147/10 147/10	deleting [1] 92/17
critical [1] 15/2	dealt [3] 10/13 43/6 140/9	deliverable [2] 32/11 52/1
criticism [1] 170/19	Dearman [7] 35/22 36/12 39/7	deliverables [6] 49/5 50/16
cross [1] 153/20	42/4 44/2 90/5 135/23	82/13 95/17 131/9 165/10
cross-examine [1] 153/20	death [4] 5/9 55/19 55/23	demand [1] 94/17
crossover [1] 140/12	57/8	demands [2] 3/4 96/1
crucial [4] 92/3 142/6 142/6	debate [2] 163/18 164/16	demonstrate [1] 26/15
142/18	debated [1] 63/9	demonstrated [4] 33/18 113/6
cuff [1] 63/21	decade [4] 34/9 35/24 40/20	113/9 166/1
cultures [1] 40/25	45/24	demonstrates [1] 112/12
cumulatively [1] 149/3	decades [2] 18/4 169/10	denominator [2] 150/4 150/5
cup [1] 15/7	deceit [3] 159/8 159/8 159/9	department [3] 3/1 170/6
cured [1] 85/19	decide [3] 26/14 28/19 88/14	170/7
curiosity [1] 160/4	decided [7] 10/2 63/10 63/10	depending [2] 93/12 93/15
current [4] 43/17 69/19	128/4 130/3 141/1 168/15	depos [1] 89/22
89/24 126/18	deciding [1] 71/9	depose [1] 83/21
currently [8] 5/4 10/17 13/2	decipher [1] 134/1	deposing [1] 83/7
17/19 23/5 45/7 59/20 159/3	decision [16] 3/21 32/25	deposit [1] 12/3
curtain [1] 133/17	33/1 33/1 33/3 37/2 37/2	depositing [1] 12/5
curve [1] 121/12	124/16 124/17 130/16 143/2	deposition [10] 24/21 73/24
customers [1] 163/15	143/11 158/23 160/13 167/10	73/24 90/20 113/7 128/19
cutoff [1] 130/2	167/16	128/19 174/7 178/13 178/19
cuts [3] 178/13 178/19	decision-making [1] 160/13	depositions [16] 27/25 69/10
178/24	decisions [6] 7/1 51/13	70/2 71/2 73/25 83/22 89/23
cystic [1] 159/25	51/17 85/4 85/5 109/10	101/2 101/5 121/5 126/5
		138/25 146/21 146/22 148/13

<p>D</p> <p>depositions... [1] 153/2</p> <p>depth [2] 16/5 171/20</p> <p>descent [1] 119/1</p> <p>describe [1] 84/16</p> <p>described [3] 17/19 56/1 56/2</p> <p>deserves [1] 2/17</p> <p>design [1] 149/8</p> <p>designed [2] 67/8 67/12</p> <p>desires [1] 39/23</p> <p>desk [2] 122/16 164/12</p> <p>despite [4] 98/16 115/19 119/20 120/18</p> <p>detailed [1] 103/22</p> <p>details [3] 98/7 148/11 148/13</p> <p>determinative [1] 96/18</p> <p>determine [1] 48/15</p> <p>determining [2] 134/4 177/23</p> <p>devastating [1] 18/17</p> <p>develop [15] 12/11 14/12 23/23 34/3 47/24 59/2 85/12 85/13 120/9 126/19 146/20 150/7 151/2 151/18 171/12</p> <p>develop generics [1] 47/24</p> <p>developed [16] 23/17 46/2 53/24 54/4 62/23 102/5 102/8 102/8 103/17 110/21 120/13 127/4 133/25 140/2 164/21 177/14</p> <p>developing [12] 10/8 14/8 47/17 50/13 50/23 125/25 131/17 132/16 142/16 153/10 156/15 176/12</p> <p>development [1] 15/3</p> <p>develops [2] 130/12 142/11</p> <p>device [11] 77/19 83/21 84/10 126/17 137/5 137/6 141/15 142/3 142/4 150/3 158/7</p> <p>devices [2] 40/19 132/11</p> <p>devolve [1] 15/3</p> <p>devote [3] 49/11 141/1 149/15</p> <p>devoting [1] 36/19</p> <p>devotion [1] 15/24</p> <p>diagnosed [6] 33/8 37/8 42/16 84/20 151/9 156/20</p> <p>dialogue [1] 113/1</p> <p>did [40] 5/15 23/25 24/4 24/6 25/23 35/5 45/3 61/12 66/4 66/5 67/5 70/16 82/4 84/2 89/11 89/18 93/1 93/11 93/24 98/8 109/25 126/2 128/9 136/7 141/3 142/7 151/8 151/9 152/11 156/24 162/2 162/3 163/8 164/25 165/1 166/16 169/25 177/16 179/3 179/25</p> <p>didn't [22] 5/11 21/19 23/8 32/14 43/23 43/24 66/7 76/8 76/9 76/13 83/19 89/25 95/25 98/2 110/23 127/5 160/5 160/25 166/5 166/7 166/11 168/6</p> <p>died [2] 85/20 111/8</p>	<p>diet [4] 154/22 166/14 166/15 166/20</p> <p>difference [2] 10/11 147/13</p> <p>differences [9] 45/13 45/13 45/17 46/16 48/4 51/4 51/6 122/11 149/25</p> <p>different [54] 5/21 8/16 17/25 23/17 31/16 32/18 33/16 34/4 40/25 40/25 45/16 57/3 59/7 62/16 65/16 65/22 67/10 70/1 70/1 70/2 76/7 83/2 87/11 90/7 92/15 93/16 93/17 98/21 99/8 103/17 107/13 107/15 107/16 114/3 114/4 114/6 118/20 118/20 124/5 125/1 130/17 130/17 137/25 142/11 144/12 147/9 148/5 148/5 150/23 154/6 154/22 163/4 163/6 163/11</p> <p>differentiate [2] 92/20 92/21</p> <p>differing [1] 75/14</p> <p>difficult [5] 32/21 81/11 87/17 87/19 150/6</p> <p>difficulties [1] 158/4</p> <p>diligently [1] 74/3</p> <p>direct [4] 22/25 40/18 45/11 127/11</p> <p>direction [2] 65/17 106/21</p> <p>directive [1] 59/2</p> <p>directly [3] 15/14 35/16 111/17</p> <p>dirty [2] 71/1 121/21</p> <p>disability [1] 4/22</p> <p>disagree [3] 13/25 94/16 112/25</p> <p>disagreements [1] 57/17</p> <p>disciplines [1] 148/6</p> <p>disclose [1] 13/6</p> <p>disclosed [1] 7/5</p> <p>disclosing [3] 13/1 41/22 58/22</p> <p>disclosure [1] 5/24</p> <p>disclosures [8] 5/24 6/3 6/9 6/14 6/19 6/20 7/5 7/7</p> <p>discouraged [1] 172/5</p> <p>discouraging [1] 133/18</p> <p>discovery [66] 9/23 11/6 13/11 13/11 14/6 14/9 47/9 56/15 58/24 59/1 59/5 59/7 62/13 62/14 64/11 67/22 68/25 70/1 71/23 75/13 84/25 85/24 90/25 91/14 93/6 93/12 93/16 93/18 93/23 100/25 101/1 101/4 101/5 102/2 106/16 111/23 113/8 114/14 116/8 116/10 116/11 116/14 116/16 117/11 118/1 118/3 121/4 123/4 128/7 129/11 132/5 134/12 135/1 136/2 137/21 137/23 137/24 138/1 138/4 152/25 156/8 165/8 165/11 171/14 173/14 174/8</p> <p>discuss [4] 19/4 41/23 59/10 102/25</p> <p>discussed [2] 137/8 154/20</p> <p>discussing [1] 91/12</p> <p>discussion [1] 130/4</p>	<p>discussions [2] 40/13 108/14</p> <p>disfavored [1] 109/8</p> <p>dish [1] 163/24</p> <p>dismantling [1] 106/15</p> <p>dismiss [2] 26/18 28/20</p> <p>dismissed [2] 59/23 137/17</p> <p>dismissing [1] 138/3</p> <p>dispiriting [1] 52/21</p> <p>disposal [1] 121/25</p> <p>distinctive [1] 151/20</p> <p>distinguishing [1] 79/20</p> <p>distract [1] 12/19</p> <p>distributed [1] 26/25</p> <p>distribution [2] 48/8 138/12</p> <p>district [7] 1/1 1/1 1/10 3/5 10/7 22/25 33/2</p> <p>diverse [13] 4/15 4/25 13/17 38/21 58/5 58/5 59/14 62/6 62/9 74/4 82/21 119/1 178/5</p> <p>diversifies [1] 168/11</p> <p>diversity [32] 4/16 4/19 4/23 13/15 13/19 19/23 26/7 28/2 28/8 58/4 62/6 69/15 73/7 73/12 94/17 96/21 97/2 99/8 107/12 118/14 118/17 118/18 125/16 138/17 163/22 171/1 171/2 171/2 171/15 171/18 178/4 178/6</p> <p>diverted [1] 2/8</p> <p>diverting [1] 9/6</p> <p>divided [1] 72/8</p> <p>dividends [1] 54/19</p> <p>division [4] 1/2 57/3 71/8 83/4</p> <p>divvies [1] 78/22</p> <p>do [189]</p> <p>doctor [2] 159/11 159/24</p> <p>doctors [5] 83/10 83/15 153/3 161/13 161/13</p> <p>document [21] 70/2 70/14 91/5 91/7 91/15 91/17 91/18 91/19 92/21 92/22 94/7 101/1 113/7 138/23 156/9 156/10 160/21 160/23 160/25 162/2 174/7</p> <p>documentary [1] 91/2</p> <p>documented [1] 161/14</p> <p>documents [16] 22/17 22/17 69/2 70/15 90/18 90/19 90/21 90/22 90/23 92/1 92/11 92/25 93/10 117/14 118/2 165/9</p> <p>dodge [14] 3/6 28/4 32/23 44/12 44/20 52/18 56/1 66/3 95/13 105/9 110/5 119/19 146/3 149/17</p> <p>Dodge's [1] 41/5</p> <p>does [16] 80/13 88/16 91/20 91/21 91/22 93/7 96/23 109/7 150/10 150/21 150/23 151/25 151/25 166/13 170/25 179/18</p> <p>doesn't [7] 41/12 41/13 68/5 87/20 112/25 113/1 144/21</p> <p>Doherty [1] 173/25</p> <p>doing [55] 3/7 17/17 24/23 41/6 41/24 47/21 48/13 48/16 54/17 58/21 62/1 64/25 69/9 69/10 69/22 70/7 70/13 70/25 71/10 71/11 72/9 72/21 75/19</p>
---	---	--

<p>D</p> <p>doing... [32] 75/20 79/17 89/17 91/6 91/24 91/24 92/1 95/21 97/19 106/14 110/24 114/12 119/16 121/16 126/24 131/6 135/16 135/18 138/23 140/25 141/16 141/16 141/17 143/1 157/22 158/6 160/24 165/5 171/14 175/14 177/18 178/21</p> <p>DOJ [1] 95/7</p> <p>dollar [1] 43/5</p> <p>dollars [1] 26/20</p> <p>domestic [1] 101/2</p> <p>dominate [1] 158/22</p> <p>don't [70] 8/16 9/6 11/25 13/6 14/16 14/16 23/11 24/24 25/21 26/18 29/6 29/23 38/3 46/21 50/15 58/19 59/16 61/5 72/13 75/23 78/24 82/1 84/20 87/23 88/22 90/15 90/18 92/7 92/23 94/16 95/3 95/4 95/5 96/22 96/24 97/12 98/22 99/3 109/23 111/20 113/17 114/8 114/9 115/20 119/25 121/12 124/13 139/12 141/9 145/11 145/12 145/13 150/12 155/20 158/2 158/5 158/8 158/14 158/15 159/22 163/10 164/3 164/6 166/12 169/3 171/6 177/9 178/10 179/2 180/2</p> <p>done [62] 2/14 15/1 15/4 22/22 25/6 25/8 30/5 31/7 40/6 41/6 44/10 44/13 44/17 45/15 45/22 46/13 47/4 47/4 49/4 50/7 60/14 62/10 64/23 75/1 79/13 87/24 89/20 89/21 89/22 90/24 91/16 94/2 94/3 103/5 105/11 110/9 112/20 112/20 113/5 116/1 116/13 116/22 116/25 118/24 119/11 120/12 123/6 124/22 127/19 128/16 129/25 131/18 132/25 136/18 144/17 160/11 166/22 167/15 169/19 175/17 177/9 177/13</p> <p>dosage [1] 101/23</p> <p>dose [3] 142/7 143/8 155/6</p> <p>double [2] 88/17 88/20</p> <p>doubt [1] 123/23</p> <p>dovetail [1] 53/9</p> <p>dovetails [1] 140/24</p> <p>down [16] 11/25 46/23 48/17 60/22 68/9 71/1 90/19 99/11 103/19 108/3 135/4 138/12 162/25 166/15 166/18 179/9</p> <p>dozens [1] 28/23</p> <p>Dr [3] 69/25 84/2 148/16</p> <p>draft [1] 59/7</p> <p>drafted [2] 111/21 111/22</p> <p>drafting [6] 70/14 71/2 101/1 112/3 116/3 121/3</p> <p>drag [1] 98/17</p> <p>draw [3] 101/17 132/6 153/4</p> <p>drawing [1] 27/24</p> <p>dream [4] 26/6 27/17 27/17 35/19</p>	<p>drill [1] 179/21</p> <p>drive [3] 39/2 140/17 141/19</p> <p>driven [1] 133/22</p> <p>driving [2] 12/3 12/4</p> <p>drop [2] 60/22 68/9</p> <p>drove [1] 74/16</p> <p>drug [21] 10/6 23/6 33/9 36/7 37/16 62/15 62/17 63/15 63/19 66/22 69/12 69/13 84/20 95/19 104/9 137/5 138/14 141/14 143/16 159/13 160/9</p> <p>drugs [3] 63/3 159/9 159/24</p> <p>due [2] 5/15 154/19</p> <p>Duke [1] 73/7</p> <p>duplicated [2] 17/23 18/11</p> <p>duration [1] 155/6</p> <p>during [13] 3/7 21/7 40/23 43/7 62/7 64/3 67/18 67/21 88/14 104/20 162/7 173/22 178/17</p> <p>duties [2] 34/16 47/24</p> <p>duty [1] 96/23</p> <p>DVG [1] 127/2</p> <p>dwarf [1] 111/6</p> <p>dynamic [2] 115/13 122/2</p> <p>E</p> <p>each [19] 2/21 3/15 4/23 5/10 7/11 28/17 52/22 62/23 75/24 81/4 84/25 92/21 104/13 106/7 106/23 142/12 142/13 176/15 176/15</p> <p>eager [1] 161/25</p> <p>earlier [10] 25/25 56/14 101/8 101/10 101/15 111/18 122/9 142/17 165/25 178/11</p> <p>early [17] 10/8 14/16 26/1 28/12 47/2 47/19 57/16 71/25 95/20 130/10 130/11 130/16 133/21 134/12 140/16 157/10 180/7</p> <p>earned [2] 54/10 99/9</p> <p>ears [2] 94/14 169/3</p> <p>ease [1] 7/6</p> <p>easier [1] 39/2</p> <p>Eastern [1] 10/7</p> <p>easy [5] 42/7 59/10 99/15 127/18 149/6</p> <p>echo [1] 158/8</p> <p>eclectic [1] 154/15</p> <p>economic [15] 5/6 22/3 29/13 37/7 37/9 37/14 42/17 51/3 51/25 55/21 67/19 68/24 69/2 72/9 86/23</p> <p>economically [2] 174/6 174/9</p> <p>effect [1] 161/6</p> <p>effective [6] 16/24 41/3 54/16 126/2 128/9 149/4</p> <p>effectively [7] 16/25 42/2 51/21 53/17 54/8 56/14 56/25</p> <p>effectiveness [1] 54/19</p> <p>effectuated [1] 138/19</p> <p>efficiency [2] 18/11 78/8</p> <p>efficient [5] 17/4 41/2 56/5 172/19 174/5</p> <p>efficiently [8] 17/23 25/5 25/6 42/2 90/8 96/7 136/11</p>	<p>174/9</p> <p>effort [6] 17/1 109/3 113/10 116/2 165/6 168/5</p> <p>efforts [5] 15/24 16/12 78/10 98/17 132/5</p> <p>ego [3] 112/20 113/4 128/17</p> <p>eight [7] 49/16 64/8 82/8 101/21 153/22 162/24 178/21</p> <p>either [4] 63/9 63/18 68/5 117/21</p> <p>elaborate [1] 130/5</p> <p>elderly [1] 160/3</p> <p>elect [1] 34/15</p> <p>electronic [2] 91/14 101/9</p> <p>element [1] 151/23</p> <p>elementary [4] 20/21 20/25 22/6 24/7</p> <p>Eli [1] 83/2</p> <p>Elizabeth [2] 74/10 74/11</p> <p>else [10] 19/21 21/10 31/9 49/12 54/21 72/12 87/13 93/24 132/13 166/13</p> <p>else's [1] 46/22</p> <p>email [3] 92/18 92/18 93/3</p> <p>emailed [1] 179/5</p> <p>emails [1] 93/10</p> <p>embark [1] 174/1</p> <p>Emblem [2] 65/18 66/19</p> <p>Emory [2] 105/10 166/17</p> <p>emphasize [1] 125/13</p> <p>employ [1] 4/14</p> <p>employers [1] 63/4</p> <p>employment [4] 78/2 78/13 79/3 79/18</p> <p>enable [1] 8/21</p> <p>enabled [2] 73/18 121/11</p> <p>encourage [7] 51/9 52/5 52/20 73/5 81/15 88/8 102/14</p> <p>encroach [1] 3/8</p> <p>end [24] 3/2 3/23 7/19 15/4 23/2 38/2 38/2 46/21 52/9 52/24 90/19 93/5 93/9 95/18 107/3 109/4 109/19 115/17 174/22 177/10 177/15 177/25 179/11 179/12</p> <p>endeavor [1] 110/24</p> <p>ended [9] 43/5 49/7 49/11 163/9 163/16 163/19 176/1 177/17 180/6</p> <p>energy [2] 167/18 168/19</p> <p>engage [2] 6/20 117/13</p> <p>engaged [2] 4/11 10/14</p> <p>engagements [1] 103/2</p> <p>engaging [1] 4/4</p> <p>engender [2] 8/7 53/16</p> <p>enhances [1] 73/8</p> <p>enjoy [4] 41/9 80/1 148/15 156/22</p> <p>enjoyable [1] 20/13</p> <p>enjoyed [3] 84/13 120/4 125/4</p> <p>enjoying [2] 115/5 180/2</p> <p>enormous [2] 109/7 173/23</p> <p>enough [10] 10/3 11/23 49/9 62/1 73/17 74/6 122/25 124/9 170/2 177/20</p> <p>enrollment [2] 64/3 64/4</p> <p>ensure [6] 6/24 14/20 51/23</p>
--	---	---

E ensure... [3] 52/2 53/2 158/20 ensures [1] 52/6 ensuring [1] 5/3 enter [2] 144/8 144/20 entered [1] 144/10 entering [1] 104/17 entertain [1] 107/8 enticed [1] 175/8 entire [6] 56/5 90/9 125/19 139/20 166/23 177/24 entirely [1] 78/13 entirety [2] 106/19 163/10 entities [4] 63/2 66/19 137/22 138/12 entitled [2] 18/16 34/10 entrant [1] 77/17 entrants [4] 80/23 81/7 81/15 107/15 entrust [1] 38/17 entrusted [1] 38/5 entry [1] 162/6 environment [3] 13/17 107/14 156/2 environments [1] 156/4 envision [6] 17/13 27/2 27/24 28/18 53/8 53/9 EPI [2] 134/20 134/21 epidemiological [1] 156/12 epidemiology [7] 126/13 147/24 149/8 153/11 153/13 155/5 155/24 equal [2] 7/18 149/25 equality [1] 62/8 equalizer [1] 43/1 equally [1] 7/25 equivalent [1] 35/25 error [1] 92/18 ESI [16] 56/19 89/25 90/12 90/14 90/22 90/25 91/2 93/6 93/22 101/7 111/24 113/8 116/6 116/7 171/14 173/18 especially [5] 5/1 21/1 90/11 142/1 144/17 essential [1] 92/3 essentially [2] 102/5 140/12 ethernet [1] 109/24 ethic [4] 20/5 49/19 116/13 129/14 ethical [1] 6/15 Ethiopia [1] 59/21 Europe [2] 153/12 164/20 evaluate [2] 176/13 177/14 evaluated [2] 129/16 176/16 evaluating [1] 102/14 evaluation [3] 97/1 143/2 156/9 even [14] 11/23 14/4 15/17 24/5 29/23 45/13 60/25 93/8 111/8 146/9 157/10 164/18 165/18 167/5 evening [2] 180/12 180/22 event [2] 139/22 139/23 events [3] 19/10 19/12 101/9 eventually [4] 26/20 81/16 126/7 127/6	ever [1] 66/10 every [29] 8/13 16/15 16/15 16/20 16/20 16/21 18/22 33/21 34/17 35/10 35/11 39/17 47/9 82/16 116/16 119/21 121/19 124/16 132/22 133/8 136/25 137/7 137/20 155/3 163/24 165/24 171/9 171/10 171/11 everybody [15] 54/20 61/19 89/6 89/7 91/13 100/2 124/25 170/12 170/14 170/14 174/9 174/11 180/6 180/10 180/21 everybody's [3] 12/1 113/16 170/15 everyone [21] 2/1 7/8 27/9 43/19 44/13 57/18 57/19 57/21 88/6 108/21 108/23 113/10 113/17 115/4 116/2 135/22 160/14 166/13 179/18 180/7 180/15 everyone's [2] 76/24 180/16 everything [23] 4/10 12/3 19/18 21/20 29/6 38/22 46/23 89/15 92/24 94/11 97/24 110/20 113/9 138/25 140/9 142/1 155/22 157/7 158/10 163/24 164/2 173/12 180/3 evidence [7] 146/24 147/19 148/9 149/3 149/12 150/7 151/3 evolved [2] 32/17 77/9 evolves [1] 38/4 evolving [4] 16/7 105/25 141/23 141/25 exactly [4] 5/15 48/14 48/15 57/12 examine [1] 153/20 example [17] 26/15 29/10 59/20 67/4 92/14 93/13 100/24 102/3 102/6 103/23 104/4 104/6 113/6 127/1 151/14 173/20 174/2 examples [1] 19/19 excellent [11] 15/6 17/17 21/22 23/24 52/1 97/25 100/9 103/5 147/13 147/14 147/15 except [3] 53/17 54/23 165/24 exceptionally [1] 166/4 excited [1] 102/23 exciting [2] 9/2 92/2 exclude [3] 6/18 156/20 170/25 exclusively [5] 37/13 63/15 100/18 132/10 139/19 executive [9] 17/16 17/20 23/4 23/5 23/21 51/14 58/2 59/21 113/25 exhilarating [2] 9/2 12/3 exist [3] 51/7 151/25 151/25 expand [1] 38/9 expanded [2] 32/10 100/22 expect [9] 16/18 22/20 79/19 99/3 108/20 109/6 109/7 147/23 167/7 expecting [2] 62/20 164/20 experience [105] 9/24 9/25	11/8 11/9 12/10 14/4 16/5 16/9 16/16 17/24 19/25 22/12 28/13 30/12 32/1 32/12 33/16 34/14 36/5 36/9 36/22 37/23 40/18 41/11 41/11 45/6 45/11 45/18 46/8 49/5 50/11 52/14 55/20 55/24 56/7 58/5 58/8 59/17 60/8 62/9 68/21 71/6 73/8 74/1 74/4 74/11 74/19 76/3 77/25 80/1 87/19 91/2 91/10 93/22 94/5 96/24 97/3 97/13 100/13 104/20 105/9 106/22 108/17 109/2 111/12 112/2 112/23 115/20 115/21 118/13 121/1 121/6 125/17 127/11 127/22 131/21 132/6 132/8 132/23 146/11 152/24 153/14 153/15 153/18 155/7 155/8 158/22 158/24 162/6 164/8 164/11 165/13 165/18 165/19 169/13 170/17 170/24 171/2 171/22 171/24 172/5 172/9 176/4 176/20 177/2 experienced [10] 4/17 8/10 38/20 57/7 115/14 121/22 144/5 170/23 171/1 171/19 experiences [7] 3/15 4/23 101/18 118/15 118/20 122/3 128/12 expert [18] 73/24 73/24 89/23 116/16 116/17 126/6 128/7 129/11 146/23 147/8 147/13 147/14 147/15 147/16 148/23 153/1 153/21 168/13 expertise [10] 7/12 7/19 12/9 24/15 99/5 131/22 147/16 149/21 153/4 157/8 experts [21] 50/24 85/12 102/5 104/4 106/18 116/15 128/7 128/8 131/9 131/17 133/1 146/8 146/19 146/20 146/22 147/5 147/9 147/21 147/23 153/11 171/12 expire [1] 123/4 expired [1] 47/23 explain [3] 22/9 112/25 146/24 explained [3] 22/8 22/17 29/3 explains [1] 39/3 explanation [1] 149/4 explore [1] 10/10 exposed [2] 102/7 102/11 exposure [7] 102/6 104/10 150/22 150/24 151/8 151/8 151/22 express [5] 32/7 32/22 34/13 54/7 54/22 expressed [3] 114/21 146/1 168/19 extend [1] 157/17 extensive [3] 74/1 149/15 168/2 extensively [1] 69/1 extent [8] 96/25 112/23 116/19 119/15 124/15 135/16 150/9 167/1 extra [1] 113/10
---	--	---

<p>E</p> <p>extrapolate [1] 177/22</p> <p>extremely [8] 19/3 33/2 36/14 36/15 51/24 128/5 133/22 148/9</p> <p>eye [1] 18/10</p> <p>eyes [3] 2/7 9/6 134/13</p> <p>F</p> <p>fabulous [1] 154/2</p> <p>face [3] 80/22 80/24 117/21</p> <p>faces [1] 115/5</p> <p>facetiously [1] 154/25</p> <p>facets [1] 105/25</p> <p>facilitate [2] 69/21 87/5</p> <p>facilities [1] 160/24</p> <p>facing [1] 146/5</p> <p>fact [21] 4/13 23/7 35/19 60/17 63/7 67/6 67/7 67/7 67/8 98/19 98/21 105/22 126/4 126/5 126/17 129/10 129/11 130/8 159/22 168/1 172/5</p> <p>factor [4] 79/20 96/18 104/11 132/1</p> <p>factors [5] 101/23 102/10 142/14 142/18 151/14</p> <p>facts [4] 14/21 40/15 105/22 143/7</p> <p>fair [6] 6/7 14/13 35/7 35/12 128/23 143/5</p> <p>fairly [1] 64/17</p> <p>fairness [2] 54/12 62/19</p> <p>faith [2] 73/17 74/7</p> <p>fall [2] 38/10 82/20</p> <p>fallen [1] 72/18</p> <p>Fallon [2] 178/14 178/17</p> <p>familiar [6] 40/17 69/20 71/22 114/9 140/7 148/3</p> <p>family [3] 19/25 20/6 122/14</p> <p>fantastic [3] 57/9 58/17 133/7</p> <p>far [26] 4/7 28/13 42/9 46/13 51/14 57/2 60/10 72/2 103/4 111/19 112/16 124/12 129/8 131/7 135/23 136/8 136/21 143/15 146/2 154/15 155/22 166/10 166/19 177/7 177/9 179/8</p> <p>fast [2] 2/13 75/6</p> <p>father [2] 148/19 164/20</p> <p>father's [1] 163/1</p> <p>father-in-law [1] 164/20</p> <p>favor [1] 40/14</p> <p>favored [1] 109/6</p> <p>favoring [1] 108/14</p> <p>favorite [1] 155/8</p> <p>FDA [2] 106/2 134/19</p> <p>feasible [2] 174/6 174/9</p> <p>February [1] 115/17</p> <p>Federal [9] 50/6 66/5 79/12 81/2 97/4 117/17 148/8 169/13 181/4</p> <p>feel [16] 3/17 8/5 12/24 19/21 30/19 30/25 50/8 57/19 61/1 91/24 99/9 100/12 129/18 167/17 169/3 169/25</p>	<p>feeling [2] 8/17 60/25</p> <p>feels [2] 8/4 31/9</p> <p>fees [1] 75/24</p> <p>feet [1] 61/20</p> <p>Fegan [8] 8/21 9/12 10/22 17/9 17/17 28/4 47/2 74/15</p> <p>fell [1] 25/22</p> <p>felt [2] 2/13 76/23</p> <p>female [2] 28/2 58/14</p> <p>few [18] 3/9 23/10 30/5 56/16 57/3 59/6 59/18 86/6 90/5 116/23 118/24 132/22 147/4 163/7 163/8 163/19 164/7 166/25</p> <p>fewer [1] 53/12</p> <p>fibrosis [1] 159/25</p> <p>field [3] 65/19 143/6 165/4</p> <p>fight [1] 11/4</p> <p>figure [4] 11/3 72/11 96/16 168/3</p> <p>file [7] 13/10 75/21 86/7 102/15 136/25 164/1 168/3</p> <p>filed [18] 5/5 5/14 5/14 28/16 37/1 38/12 45/9 64/21 68/16 102/12 118/9 142/19 164/16 164/17 164/17 166/7 168/7 175/15</p> <p>filing [11] 62/12 69/23 75/21 75/24 76/6 76/6 128/10 134/4 156/24 157/2 168/3</p> <p>filings [1] 55/13</p> <p>final [3] 16/20 74/8 123/5</p> <p>finality [1] 132/18</p> <p>finally [5] 2/2 16/24 23/20 52/4 110/3</p> <p>finance [2] 43/8 98/13</p> <p>finances [3] 15/14 114/3 171/22</p> <p>financial [9] 34/21 35/2 35/3 35/6 35/12 35/14 68/19 124/10 152/21</p> <p>financially [1] 16/17</p> <p>financing [2] 7/6 98/12</p> <p>find [9] 38/5 70/23 90/21 147/15 148/8 148/11 153/15 170/2 175/5</p> <p>finding [4] 52/13 106/18 134/16 160/24</p> <p>fine [4] 66/4 109/19 110/2 161/6</p> <p>finish [1] 41/18</p> <p>finished [3] 27/19 48/17 49/5</p> <p>finite [1] 159/3</p> <p>Finken [3] 119/9 131/12 166/3</p> <p>firing [1] 128/20</p> <p>firm [96] 8/25 9/1 9/16 10/1 10/3 10/22 11/8 11/19 12/2 12/12 12/13 13/15 13/16 16/7 18/3 18/3 22/14 28/3 28/15 29/11 33/5 33/6 33/10 33/15 33/18 35/6 35/23 36/5 41/15 41/16 42/10 43/10 49/9 53/14 58/11 58/14 68/23 69/7 69/17 69/23 69/23 70/10 70/13 70/17 77/8 79/15 79/18 84/9 84/10 86/20 95/20 97/23</p>	<p>100/15 106/13 107/5 108/2 108/2 114/4 115/22 117/10 117/15 118/15 121/23 122/5 123/13 125/24 126/18 126/18 133/6 136/23 139/17 141/3 141/18 144/17 146/13 148/19 148/20 152/16 152/16 152/23 158/19 160/7 160/20 162/5 169/9 172/15 172/21 173/10 173/10 174/25 175/1 175/24 176/2 176/5 176/8 176/20</p> <p>firm's [2] 15/14 115/20</p> <p>firmly [1] 130/3</p> <p>firms [25] 15/15 33/13 36/18 42/25 43/1 58/3 102/14 114/3 117/8 123/12 126/3 133/17 144/8 144/18 144/19 144/21 145/1 152/18 153/16 158/20 158/23 160/14 170/20 176/18 178/2</p> <p>first [48] 4/19 8/20 9/25 27/12 27/22 28/8 32/7 35/3 35/5 45/19 45/21 58/14 62/5 65/21 68/11 68/16 69/5 73/2 73/3 78/5 79/11 82/8 82/15 85/3 89/21 97/20 101/20 102/24 119/18 123/19 125/16 127/9 130/15 133/18 135/17 138/24 146/11 151/10 154/4 157/15 164/16 164/17 164/17 165/7 166/7 170/13 175/13 178/21</p> <p>first-time [1] 69/5</p> <p>Fisher [1] 68/16</p> <p>fit [4] 70/20 78/21 147/16 150/6</p> <p>five [11] 8/14 36/18 47/5 51/20 64/11 64/14 73/15 123/11 145/11 160/25 180/3</p> <p>FL [2] 1/5 1/14</p> <p>floor [1] 163/24</p> <p>FLORIDA [5] 1/1 74/18 97/5 100/17 166/20</p> <p>flow [1] 13/12</p> <p>flown [1] 87/18</p> <p>focus [21] 15/3 16/18 50/11 73/19 77/3 78/8 78/9 78/11 80/11 89/24 90/21 131/15 131/16 133/1 138/7 138/9 138/14 139/20 146/9 146/18 166/23</p> <p>focused [7] 83/3 84/10 99/4 100/18 110/8 138/10 166/12</p> <p>focuses [1] 86/25</p> <p>focusing [2] 29/13 47/6</p> <p>fold [1] 107/18</p> <p>folders [1] 60/19</p> <p>folks [9] 54/17 57/3 57/16 57/25 65/2 83/16 83/20 86/6 105/6</p> <p>follow [4] 81/9 89/2 144/19 159/24</p> <p>following [1] 3/22</p> <p>followup [1] 150/13</p> <p>food [3] 163/3 163/5 163/6</p> <p>foot [3] 154/16 156/8 156/8</p> <p>footer [2] 92/17 93/3</p> <p>force [1] 98/20</p>
---	---	--

F forced [1] 174/5 foregoing [1] 180/25 foreign [1] 101/2 foremost [2] 79/11 119/18 forever [3] 95/21 144/18 170/3 forge [2] 14/1 120/5 forget [1] 111/20 forgotten [1] 61/6 form [4] 28/16 59/14 118/15 165/10 formed [1] 73/2 former [1] 146/13 formidable [1] 33/13 forms [5] 5/11 5/24 59/8 106/8 136/17 formulations [1] 121/1 Fort [1] 166/24 forth [4] 9/6 19/9 41/11 118/5 fortitude [1] 8/25 fortunately [2] 7/14 61/4 forum [1] 117/9 forward [40] 2/10 7/10 7/22 15/5 15/17 16/11 18/7 31/1 36/10 44/18 48/24 56/6 57/2 71/10 75/2 75/4 77/5 101/19 103/6 105/12 115/8 116/13 117/2 117/12 118/11 119/14 119/20 119/25 120/5 120/10 120/15 120/20 121/7 133/18 150/16 152/22 161/5 161/15 169/5 180/13 foster [1] 96/3 fostered [1] 43/14 fought [2] 27/7 41/20 found [9] 38/6 67/21 73/4 91/13 140/2 144/11 160/20 163/11 172/7 foundation [9] 14/24 15/1 62/7 72/5 95/16 95/20 102/1 120/11 134/6 foundational [1] 106/11 founded [1] 16/7 four [23] 24/2 36/18 45/8 47/5 47/13 47/14 47/16 50/12 50/24 51/11 51/18 51/20 53/5 53/24 64/11 90/23 98/23 114/17 120/23 123/10 123/11 131/14 137/2 fourth [1] 52/4 frailness [1] 54/13 framework [3] 102/17 140/22 144/15 Francisco [2] 64/25 68/17 Frank [3] 2/22 136/18 174/24 frankly [10] 6/16 11/12 24/21 60/3 111/13 113/25 123/7 156/11 168/9 172/4 free [2] 132/20 176/24 freed [1] 49/7 friends [7] 27/8 32/15 105/5 110/22 120/7 154/8 163/1 front [11] 15/4 61/4 62/19 111/16 118/2 125/23 128/20 133/21 137/22 178/20 179/6	fronts [1] 59/8 Ft [1] 1/14 fulfill [1] 96/3 full [7] 5/4 39/25 98/16 122/5 123/7 123/13 141/3 fully [2] 98/13 121/25 fun [6] 82/10 82/12 82/23 91/15 91/16 137/2 function [1] 12/12 functioned [1] 51/21 functions [1] 12/15 fundamentally [1] 13/22 funded [1] 117/6 funding [2] 6/18 167/4 Funny [1] 62/1 further [7] 5/2 6/4 36/17 55/7 115/25 136/14 150/13 furtherance [1] 40/8 future [7] 38/7 43/17 50/9 80/22 136/18 170/18 173/18 G gain [1] 126/23 gained [1] 177/3 game [2] 91/17 152/1 games [2] 91/19 92/8 gap [1] 56/3 gastrointestinal [1] 150/25 gathered [2] 5/6 131/22 gave [4] 59/2 67/14 97/23 146/16 Geller [6] 35/23 36/1 36/12 39/21 40/2 42/9 gender [2] 73/8 118/19 general [12] 9/7 27/18 75/9 75/14 84/21 102/21 146/25 150/5 150/7 150/21 151/2 151/11 generally [3] 34/24 147/2 150/20 generation [3] 8/16 32/2 138/18 generic [9] 14/22 54/2 54/6 69/24 69/24 70/4 93/14 118/5 132/2 generics [4] 47/16 47/19 47/24 47/25 genes [1] 156/2 genetics [1] 156/3 genotoxic [2] 102/20 140/11 geographic [1] 144/9 George [3] 99/22 131/17 132/1 Georgia [1] 174/25 GERD [1] 143/21 get [87] 3/10 8/14 11/25 15/7 23/11 24/4 24/17 26/12 27/6 27/25 28/17 30/3 30/16 34/1 39/4 40/24 43/20 52/22 56/16 60/6 61/15 62/22 64/9 66/18 68/12 70/16 72/5 72/6 72/19 73/16 73/18 83/19 85/18 85/20 89/1 89/13 90/15 90/19 91/7 92/10 92/18 92/23 93/3 97/24 98/7 104/7 104/8 108/4 110/25 111/10 111/14 112/19 112/20 113/1 113/5 114/5 116/13 117/14 118/2	121/21 127/19 128/14 133/8 133/23 134/13 137/21 144/12 144/16 144/16 150/18 155/17 159/23 162/16 164/19 165/14 167/5 167/9 167/24 175/4 175/16 177/9 177/15 178/9 178/19 179/7 179/16 180/4 gets [6] 26/23 109/24 133/16 164/4 174/10 179/8 getting [25] 13/24 18/7 18/23 19/1 26/1 30/6 43/6 59/17 72/11 86/9 86/11 86/12 109/20 111/12 111/15 114/18 115/8 120/4 125/4 126/8 138/11 163/16 174/13 175/6 178/25 Gilbert [11] 31/12 31/14 39/6 39/8 41/8 44/10 55/25 56/2 56/13 63/7 64/17 Gilbert's [2] 40/14 57/22 give [36] 2/16 2/21 7/18 21/9 26/15 30/8 32/3 32/4 57/4 59/15 63/23 64/3 66/1 68/11 73/17 74/7 74/22 76/1 76/9 76/13 80/23 89/16 89/25 96/23 110/17 119/17 127/14 130/8 135/14 139/1 152/15 154/5 157/12 157/14 157/23 165/21 given [20] 48/21 54/22 59/4 63/20 71/11 85/7 85/8 95/18 104/10 118/14 122/3 130/7 131/13 141/23 151/17 157/8 170/11 170/17 172/15 176/25 given after [1] 63/20 gives [2] 94/17 139/3 giving [11] 2/21 39/4 77/3 87/20 103/7 119/24 120/1 131/7 135/20 143/7 143/9 glad [3] 26/10 152/11 162/9 Glancy [1] 21/25 gleaned [2] 7/3 28/13 global [4] 62/11 132/16 132/23 176/17 GM [1] 29/4 go [29] 5/15 9/15 10/1 11/18 30/2 61/9 63/17 64/11 64/12 64/13 78/25 80/13 94/12 97/18 97/24 107/25 109/22 118/1 136/8 139/13 141/1 141/8 150/13 163/4 163/5 166/20 171/7 171/8 171/10 goal [4] 6/4 92/10 128/21 149/6 goes [8] 2/18 2/20 8/12 95/14 140/20 142/12 158/14 167/11 going [101] 2/15 10/2 12/18 12/22 14/21 15/1 18/23 19/1 24/2 26/19 26/20 28/14 30/14 31/25 33/3 33/5 33/11 42/23 42/23 43/16 48/24 53/19 57/2 57/25 58/9 59/9 61/3 61/24 65/16 71/9 71/13 72/6 72/7 72/17 83/6 84/4 84/25 84/25 85/10 87/2 88/5 89/8 90/19 95/21 96/6 96/8 97/12 97/15 97/18 98/7 99/16 103/14
--	--	---

<p>G</p> <p>going... [49] 103/18 103/25 104/17 105/12 110/15 113/1 116/8 117/24 118/1 118/6 119/15 121/14 124/14 127/18 129/19 130/2 130/13 130/17 132/2 133/23 134/23 135/18 136/24 138/8 142/12 145/20 149/14 150/9 151/2 152/7 152/9 152/22 155/20 156/13 160/4 161/5 161/15 163/6 163/19 166/25 167/3 167/15 168/9 168/10 171/10 177/23 179/20 180/18 180/19</p> <p>Goldenberg [4] 90/7 135/10 136/22 148/18</p> <p>Goldhirsch [1] 118/25</p> <p>Goldilocks [1] 114/20</p> <p>gone [6] 60/16 63/9 65/23 118/14 149/13 171/3</p> <p>good [90] 2/1 6/7 8/23 15/10 15/11 20/16 20/17 20/18 21/11 22/10 25/18 25/19 28/17 31/14 31/15 39/13 39/14 44/6 44/24 45/4 50/2 50/3 55/4 57/7 57/11 59/3 62/23 64/21 64/22 68/2 68/10 72/20 72/22 77/25 79/21 81/24 82/2 89/6 89/8 89/10 92/15 95/11 96/4 99/23 99/24 101/10 103/18 105/2 105/13 109/14 109/16 112/14 115/2 119/9 119/10 120/9 120/14 120/19 122/10 123/22 125/9 127/4 130/24 130/25 135/14 139/10 143/10 145/23 145/24 147/4 154/4 157/21 157/23 157/23 162/14 163/1 168/21 168/22 168/24 171/11 171/13 171/13 172/19 173/19 174/19 175/17 179/10 179/12 180/7 180/22</p> <p>Gosh [1] 152/7</p> <p>got [22] 9/16 9/22 25/21 26/21 27/1 39/8 61/21 61/21 68/8 82/11 82/13 82/14 98/9 138/22 162/10 164/10 167/13 167/18 169/25 175/7 175/12 175/21</p> <p>gotcha [1] 7/16</p> <p>gotten [3] 16/3 72/1 111/7</p> <p>govern [1] 116/8</p> <p>gracious [1] 49/9</p> <p>graciously [1] 2/21</p> <p>graders [1] 39/17</p> <p>graduated [2] 123/18 160/6</p> <p>graduation [1] 162/5</p> <p>grandfather [1] 73/14</p> <p>grandson [1] 152/10</p> <p>grant [1] 54/3</p> <p>granted [1] 20/4</p> <p>granular [1] 18/14</p> <p>grapple [1] 132/4</p> <p>grappling [1] 167/25</p> <p>grateful [3] 3/6 164/24 180/17</p> <p>gratitude [1] 32/7</p>	<p>great [29] 3/4 9/2 11/7 12/4 32/12 32/15 32/19 36/23 49/19 50/7 55/14 60/7 76/18 79/18 82/9 86/19 88/3 110/6 112/17 114/24 120/6 129/19 148/13 175/3 175/23 176/20 177/11 177/11 178/1</p> <p>greatest [5] 70/22 70/23 70/24 117/22 165/22</p> <p>greatly [2] 4/5 6/7</p> <p>Gregory [1] 73/1</p> <p>grew [1] 91/10</p> <p>grid [2] 176/12 176/13</p> <p>grids [1] 177/14</p> <p>grief [1] 154/5</p> <p>grips [1] 80/24</p> <p>ground [5] 62/12 72/1 112/16 121/11 126/9</p> <p>group [21] 4/13 12/22 32/18 35/10 36/21 37/21 49/3 56/13 56/14 75/3 77/21 82/12 82/12 82/18 82/21 95/17 97/10 103/2 103/4 114/15 178/5</p> <p>grow [3] 71/4 139/3 144/25</p> <p>grown [1] 129/13</p> <p>grunt [1] 87/23</p> <p>guess [5] 11/22 14/15 81/8 88/21 129/16</p> <p>guidance [3] 24/25 41/4 41/5</p> <p>guide [2] 24/23 148/9</p> <p>guidelines [1] 6/15</p> <p>gun [1] 156/2</p> <p>guy [1] 133/22</p> <p>H</p> <p>had [97] 5/16 9/19 10/5 10/10 10/14 10/21 12/10 13/3 14/4 14/5 21/1 22/16 23/1 24/12 27/1 27/19 28/12 29/14 30/20 30/24 32/1 34/2 34/4 39/17 40/13 43/7 47/4 47/23 48/4 49/6 50/16 58/15 60/10 62/15 62/18 65/4 69/8 73/17 74/21 76/7 87/3 87/14 89/7 97/21 98/21 98/23 99/7 100/19 106/22 107/18 111/18 117/3 118/10 118/16 119/21 126/11 126/21 126/21 127/4 127/21 128/8 128/14 130/3 130/7 132/3 132/6 132/8 132/19 133/18 136/1 136/19 137/4 143/9 146/14 151/7 156/6 158/11 161/22 164/15 164/18 164/19 165/1 165/8 166/8 169/8 169/9 169/10 169/12 169/13 170/8 170/17 173/2 173/8 175/12 175/18 175/23 179/6</p> <p>Hagen [1] 26/24</p> <p>Hagens [2] 10/3 10/18</p> <p>half [10] 37/23 39/5 50/23 51/5 84/1 91/8 115/11 115/24 117/15 135/24</p> <p>Halloween [1] 141/8</p> <p>hand [3] 21/20 81/16 126/21</p> <p>handful [1] 126/4</p> <p>handle [12] 7/23 28/20 40/3 53/12 75/3 77/13 128/15</p>	<p>129/4 154/9 170/24 175/3 179/6</p> <p>handled [2] 137/6 154/13</p> <p>handling [3] 129/10 137/6 139/21</p> <p>hands [3] 20/24 160/19 164/4</p> <p>hands-on [2] 20/24 164/4</p> <p>hang [1] 163/2</p> <p>happen [7] 28/14 47/23 71/9 95/6 106/6 155/17 180/16</p> <p>happened [1] 65/9</p> <p>happening [3] 28/10 41/17 111/2</p> <p>happens [1] 174/21</p> <p>happy [15] 34/20 41/22 66/1 79/1 87/24 88/1 88/2 98/5 107/8 115/4 116/20 122/23 137/9 167/2 172/11</p> <p>hard [21] 11/12 27/7 29/10 30/15 34/1 41/7 41/20 55/14 67/10 70/25 74/4 76/16 82/15 95/12 127/1 129/17 162/1 165/2 165/16 167/5 176/12</p> <p>Harding [1] 139/16</p> <p>harm [1] 160/11</p> <p>harmony [2] 52/6 52/15</p> <p>harness [1] 17/2</p> <p>Harvey [1] 157/19</p> <p>Harvoni [2] 62/15 62/17</p> <p>has [120] 2/9 2/13 2/14 3/7 12/21 13/10 18/25 25/6 25/9 31/8 32/2 36/1 36/2 36/5 36/7 41/6 43/10 44/19 45/24 48/14 52/13 54/10 54/13 55/10 55/12 56/12 57/3 57/6 57/8 57/14 57/21 58/4 59/24 60/7 60/19 65/17 65/21 65/23 65/25 66/12 70/4 70/11 73/12 74/11 78/25 81/4 81/5 82/10 82/22 91/5 91/13 93/19 94/19 97/13 98/3 103/4 105/11 105/20 105/25 106/2 106/3 107/5 109/2 109/17 111/5 116/24 117/1 117/25 119/15 119/21 120/12 121/1 121/23 122/2 122/3 122/22 123/6 123/19 124/7 124/9 125/18 128/17 131/13 133/6 134/17 135/18 139/19 140/6 140/12 143/3 143/16 143/19 144/17 144/19 146/9 146/19 149/21 151/7 151/8 151/14 154/13 155/15 156/21 159/12 160/11 160/18 162/6 165/14 166/21 167/19 169/9 169/9 170/12 170/14 170/14 171/3 171/10 176/8 177/8 180/15</p> <p>hasn't [1] 32/1</p> <p>hate [2] 99/5 99/8</p> <p>haul [3] 87/22 167/12 167/17</p> <p>have [718]</p> <p>haven't [27] 8/10 14/5 30/20 54/22 60/10 61/5 72/1 72/1 76/2 87/15 87/18 97/25 113/16 118/10 119/4 124/8 124/9 129/25 130/3 130/3 132/22 145/2 167/16 168/7 168/24 170/17 170/17</p>
---	---	--

<p>H</p> <p>having [36] 21/2 22/12 34/23 48/18 53/8 58/6 58/6 58/10 58/12 64/18 64/23 69/11 74/25 87/2 87/6 87/8 90/22 90/24 94/16 94/17 96/19 113/12 125/17 131/2 143/21 143/25 159/11 159/16 168/25 169/6 172/5 172/8 172/19 173/21 173/22 179/7</p> <p>he [21] 18/17 19/10 23/23 36/2 63/7 64/14 72/18 73/15 73/16 73/16 73/17 82/22 101/13 146/14 154/12 154/13 163/16 170/18 178/18 178/24 179/2</p> <p>head [3] 29/15 114/19 131/13</p> <p>heads [1] 29/15</p> <p>health [8] 42/18 63/3 63/3 63/17 64/6 64/6 65/18 157/15</p> <p>hear [11] 63/13 79/5 81/24 88/13 109/23 110/2 110/4 112/13 125/10 158/17 159/15</p> <p>heard [14] 44/10 57/3 57/6 68/14 98/1 101/8 107/11 108/4 110/5 113/19 114/8 159/11 169/3 170/15</p> <p>hearing [14] 16/20 42/8 57/17 62/19 64/16 64/16 82/11 119/14 153/21 158/2 158/8 158/10 169/5 180/23</p> <p>hearings [3] 31/24 89/23 153/19</p> <p>heart [2] 127/15 167/9</p> <p>heartburn [1] 156/16</p> <p>heartland [1] 77/11</p> <p>heat [1] 166/17</p> <p>heavily [5] 14/23 69/3 70/13 110/18 173/12</p> <p>heavy [1] 69/9</p> <p>held [3] 2/25 22/23 168/3</p> <p>hello [3] 72/25 76/22 158/5</p> <p>help [23] 14/12 22/21 27/25 33/15 34/14 51/7 53/15 66/20 83/20 87/2 87/7 101/18 102/19 105/17 134/13 134/23 139/2 147/15 148/6 152/10 165/11 177/16 178/13</p> <p>helped [2] 23/22 76/8</p> <p>helpful [15] 2/9 11/10 50/13 58/1 66/7 66/8 78/20 86/11 91/5 99/17 134/3 134/4 134/6 137/22 157/9</p> <p>helping [8] 3/2 3/5 24/17 101/4 111/24 112/6 125/2 131/10</p> <p>helps [5] 58/2 96/19 96/25 124/17 134/12</p> <p>hence [1] 10/22</p> <p>Henry [1] 122/10</p> <p>her [22] 8/21 8/21 15/9 15/10 35/12 36/5 44/5 58/13 58/14 58/14 98/1 98/1 98/3 98/4 98/6 98/8 105/10 105/10 111/24 148/19 148/19 154/19</p> <p>here [76] 9/13 10/1 11/21 13/15 15/16 17/3 17/25 20/10</p>	<p>21/15 25/6 27/10 29/5 30/22 30/25 41/17 42/14 45/15 46/8 46/19 46/23 49/18 50/20 50/22 51/10 51/25 58/9 60/18 67/4 68/7 68/11 69/5 77/2 77/7 78/4 78/24 82/16 82/24 83/24 88/2 90/5 94/22 105/3 105/5 105/17 108/23 110/4 111/2 111/15 114/16 117/6 117/15 120/18 124/11 131/25 132/1 132/25 135/6 138/13 139/14 139/17 141/3 141/7 144/6 145/15 149/14 150/19 152/4 152/8 153/23 162/11 163/14 164/8 165/3 165/5 167/11 167/22</p> <p>hesitant [1] 130/5</p> <p>hesitate [1] 38/8</p> <p>hesitation [1] 56/23</p> <p>hey [4] 93/1 93/3 98/2 112/10</p> <p>hierarchy [1] 124/17</p> <p>high [8] 3/2 20/25 61/20 71/4 121/2 123/16 127/2 128/15</p> <p>higher [1] 124/15</p> <p>highest [1] 6/22</p> <p>highlight [3] 82/20 95/24 168/1</p> <p>highlighted [1] 77/4</p> <p>highly [3] 44/10 102/22 148/19</p> <p>Hilliard [1] 27/22</p> <p>Hilton [1] 49/15</p> <p>him [9] 23/23 42/11 96/14 135/24 152/11 164/21 178/23 178/24 179/3</p> <p>hire [1] 163/25</p> <p>hiring [1] 123/13</p> <p>his [6] 18/13 31/12 35/12 35/22 159/4 178/12</p> <p>Hispanic [2] 62/6 62/7</p> <p>history [7] 96/19 106/14 111/4 121/10 121/14 151/13 151/15</p> <p>hit [2] 98/21 121/11</p> <p>hitch [1] 95/15</p> <p>hitting [1] 112/16</p> <p>HMO's [1] 63/4</p> <p>hoc [1] 108/23</p> <p>hold [3] 94/15 158/2 159/10</p> <p>holder [1] 108/6</p> <p>holding [1] 108/3</p> <p>holds [1] 159/7</p> <p>Holian [3] 96/15 122/9 178/10</p> <p>home [2] 170/2 170/3</p> <p>HON [1] 1/13</p> <p>hone [1] 48/4</p> <p>honed [1] 136/5</p> <p>honestly [1] 57/20</p> <p>honesty [1] 96/9</p> <p>Honik [4] 49/25 57/12 57/23 64/16</p> <p>honor [72] 8/23 17/7 17/16 19/22 20/14 20/18 21/14 23/20 25/19 26/10 27/5 28/15 29/12 31/15 32/5 32/5 32/24</p>	<p>34/4 34/6 34/15 38/24 39/12 46/15 54/11 54/23 55/9 56/10 56/24 62/5 62/16 63/14 64/9 68/2 68/13 72/14 74/8 75/6 75/10 76/20 76/22 79/9 81/21 83/1 87/16 89/12 94/19 94/24 95/5 95/25 99/24 100/5 102/3 104/22 104/25 110/3 115/2 115/17 117/10 118/17 119/25 122/22 130/24 135/8 135/11 139/6 145/25 148/21 149/13 154/2 157/11 168/22 179/16</p> <p>HONORABLE [1] 1/10</p> <p>honored [3] 105/6 129/6 129/19</p> <p>hope [34] 2/18 4/2 4/8 5/19 8/4 19/14 31/2 32/19 45/2 55/12 56/7 56/20 56/22 57/14 65/5 67/24 74/6 78/6 78/20 81/9 84/14 86/9 86/11 89/7 102/16 103/6 105/7 107/23 113/11 113/12 117/22 152/5 165/16 170/18</p> <p>hopeful [1] 7/6</p> <p>hopefully [12] 9/3 18/24 23/11 79/4 80/20 101/13 110/1 133/4 161/3 168/24 176/16 178/1</p> <p>hoping [2] 165/13 167/19</p> <p>Hopkins [1] 157/13</p> <p>hormone [1] 176/1</p> <p>horn [1] 147/2</p> <p>horrible [1] 60/24</p> <p>host [2] 8/10 94/25</p> <p>hosted [1] 103/1</p> <p>hot [2] 91/17 91/18</p> <p>hotly [1] 106/7</p> <p>hour [1] 91/8</p> <p>hours [4] 17/20 132/21 154/20 178/18</p> <p>house [5] 19/12 39/10 74/17 98/8 125/25</p> <p>Household [1] 43/3</p> <p>how [128] 7/22 7/23 9/8 9/16 9/22 10/12 11/3 11/22 18/18 22/17 22/18 24/19 26/4 26/7 28/19 29/7 29/22 30/13 31/3 36/25 38/4 42/5 43/13 44/7 44/19 48/22 48/24 50/2 53/8 54/13 69/20 71/13 72/6 72/7 72/20 74/19 75/13 76/23 78/17 84/16 85/8 90/20 90/21 92/20 92/22 93/7 94/7 94/9 96/9 97/21 98/19 98/20 103/10 103/13 104/9 104/9 106/8 106/9 107/11 108/9 112/13 112/20 113/11 117/2 119/10 119/15 119/22 120/5 125/9 125/24 126/25 126/25 130/12 130/25 132/4 135/4 135/12 135/13 135/18 137/14 137/15 138/19 139/8 141/4 142/7 142/14 143/10 143/12 143/14 144/2 144/11 144/11 144/12 145/24 146/4 147/16 149/23 149/25 150/17 151/8 151/16 154/12 154/13 155/3 155/12 155/16 157/21 158/6</p>
---	---	---

H how... [20] 158/14 161/8 162/15 162/18 162/21 163/8 163/15 163/23 164/1 167/11 167/22 168/21 168/22 171/5 171/10 171/12 172/1 172/3 174/18 177/23 HR [1] 12/16 huge [4] 83/5 87/21 93/8 116/1 human [9] 35/2 35/16 36/1 38/13 40/1 52/13 52/19 83/4 107/6 humbling [1] 165/23 humbly [2] 34/12 57/9 hundred [6] 65/18 90/19 90/21 141/2 141/17 154/24 hundreds [2] 73/20 78/15 hurricanes [1] 163/7 husband [4] 9/1 9/17 10/2 12/19 hybrid [1] 57/4 Hyland's [1] 69/13 Hyman [4] 72/19 72/20 72/25 76/18	52/15 56/2 56/3 56/12 57/22 57/24 62/8 63/14 67/14 74/23 74/24 75/16 78/9 80/4 80/7 80/8 80/13 80/18 95/21 100/12 105/16 105/17 105/20 110/16 110/17 113/22 114/5 116/23 118/2 128/22 132/3 133/22 136/12 137/13 138/15 138/15 138/25 142/23 142/24 144/1 153/15 155/5 155/25 156/19 159/4 163/14 163/22 163/25 172/25 173/7 importantly [3] 110/21 117/17 163/21 imposed [1] 35/8 impressed [3] 15/16 115/7 116/25 impressive [5] 15/17 45/3 92/7 119/12 135/24 in-house [1] 19/12 inadequacy [1] 54/6 inadvertently [2] 21/8 97/19 inaudible [5] 96/12 133/20 159/10 159/11 160/12 inception [4] 55/20 102/24 171/3 173/10 inclination [1] 127/17 inclined [1] 58/2 include [12] 11/1 41/12 41/13 43/19 63/3 63/10 64/4 100/23 109/18 119/15 136/14 153/18 included [4] 26/9 41/12 168/14 176/16 includes [1] 51/21 including [7] 5/6 10/10 28/3 46/5 98/24 115/9 153/11 inclusion [1] 43/16 inclusive [7] 4/10 13/17 18/10 28/1 28/5 43/19 124/6 inclusively [1] 47/10 inclusiveness [2] 13/19 138/19 incorporate [5] 51/7 93/24 112/14 112/24 119/1 incorporating [1] 173/15 increase [4] 37/24 85/14 85/23 166/14 increased [1] 51/20 incredible [3] 20/25 82/16 112/23 incredibly [1] 5/12 incur [1] 75/23 India [1] 114/12 indicated [4] 11/21 29/10 77/14 87/4 indication [2] 156/15 156/18 individual [24] 22/3 39/24 59/8 75/21 78/15 79/24 80/9 85/20 86/6 94/3 98/14 100/18 142/13 142/25 145/1 150/6 150/8 150/15 151/7 170/8 170/9 170/10 176/15 176/15 individually [2] 78/19 142/14 individuals [16] 32/18 37/8 42/16 42/17 71/4 90/4 105/21 108/9 108/12 112/10 150/16	153/23 154/3 156/10 156/20 173/2 indulging [1] 2/23 inevitable [1] 4/16 infancy [1] 126/20 inferences [1] 9/8 influence [1] 7/1 informal [1] 52/17 information [21] 63/22 66/2 67/20 67/25 90/16 92/19 93/18 93/19 95/23 98/4 103/22 103/23 103/24 104/16 107/12 118/8 134/22 134/23 176/14 177/20 177/22 informative [4] 3/14 5/12 104/19 134/20 informed [1] 167/10 ingest [1] 142/8 ingredient [1] 138/14 ingredients [2] 114/11 141/13 initial [13] 5/10 5/16 5/19 18/25 32/10 40/10 47/9 116/3 116/10 121/3 123/6 129/25 134/3 injured [1] 105/19 injuries [4] 18/17 23/16 80/17 102/21 injury [29] 5/6 5/8 11/2 11/9 14/20 27/20 27/22 36/22 38/15 51/3 51/12 55/19 55/23 57/8 86/17 129/9 137/4 140/22 142/5 150/8 150/16 150/22 150/22 151/2 160/9 160/9 163/15 164/17 168/14 injury/wrongful [1] 5/8 innovative [3] 53/24 54/5 54/5 innovator [5] 45/8 47/12 53/19 53/22 53/23 inordinate [1] 176/22 input [1] 67/13 inputted [1] 136/16 inquiry [1] 27/24 insight [3] 29/21 30/8 76/1 insights [5] 3/20 46/13 48/3 116/22 177/2 instance [1] 67/6 instances [1] 46/5 instill [2] 52/14 52/14 instilling [1] 6/4 institute [1] 91/4 institutional [1] 121/8 instructions [1] 179/21 instructional [1] 157/10 insulation [2] 125/22 125/22 insurance [7] 45/25 63/3 63/17 64/5 64/6 64/6 160/2 insured [1] 63/4 insureds' [1] 37/16 intangible [1] 52/4 integral [1] 128/6 integrity [1] 148/21 intellectual [1] 107/25 intelligence [2] 52/14 52/19 intend [2] 49/1 129/8 intended [1] 9/9 intense [1] 52/11
I I'd [3] 26/8 27/10 101/13 I'll [2] 26/15 35/2 I'm [6] 19/17 41/24 64/21 100/11 116/25 147/2 I've [6] 54/17 83/18 86/8 112/15 148/2 155/11 I.D.'s [1] 160/21 ICC [1] 62/9 ID [1] 180/21 idea [8] 57/22 63/24 72/6 104/2 138/6 142/14 143/9 175/12 ideal [1] 38/2 ideas [6] 112/14 113/3 138/17 143/23 161/8 161/17 identification [1] 160/16 identify [3] 102/12 151/1 153/16 identifying [1] 128/7 Illinois [2] 45/10 66/5 imagine [4] 76/23 106/5 106/7 117/15 immediately [2] 117/9 171/8 immigrant [1] 20/5 impact [4] 33/3 77/14 78/17 150/1 impart [1] 76/4 imperative [1] 96/6 implants [1] 154/20 implement [1] 31/2 implications [1] 105/20 import [1] 118/3 importance [5] 5/2 40/10 77/15 141/24 159/7 important [77] 6/2 11/13 11/24 13/23 14/3 16/8 19/3 19/6 25/4 25/11 26/12 26/13 28/2 33/3 42/12 42/15 42/19 42/22 42/25 43/9 43/16 43/19 45/13 47/7 50/17 51/13 51/24		

I intention [3] 3/21 6/18 7/17 intents [2] 35/24 98/25 inter [1] 78/16 inter-relationship [1] 78/16 interact [1] 29/7 interacting [2] 149/24 150/18 interest [5] 43/9 80/14 140/20 153/17 162/4 interested [3] 77/12 97/9 140/21 interesting [5] 24/6 45/21 91/9 105/22 175/5 interests [4] 6/23 33/6 33/11 33/14 interfere [1] 88/10 interim [11] 16/1 33/17 33/23 35/18 36/13 36/20 52/17 114/22 115/13 116/21 146/3 internal [2] 62/10 172/25 internet [4] 94/4 109/20 109/25 110/1 interplay [2] 51/2 156/3 interpret [1] 149/10 interrelate [1] 142/15 intertwined [1] 105/23 interview [8] 21/8 21/16 35/22 62/5 94/22 104/21 152/3 154/21 interviewed [1] 28/15 interviewing [1] 166/11 interviews [7] 1/9 3/11 3/23 5/17 8/3 32/25 131/2 intimately [1] 40/17 intricate [1] 16/7 intrigued [1] 157/25 intriguing [1] 163/12 introduced [1] 25/15 introduction [4] 25/21 39/8 138/23 162/3 invaluable [3] 36/9 53/15 127/22 inventory [2] 126/9 160/14 invested [2] 115/23 153/17 investigating [1] 47/7 investigation [1] 114/14 investigations [1] 62/10 invite [1] 4/23 invited [1] 19/11 Invokana [1] 98/24 involve [4] 13/2 28/22 46/17 108/4 involved [64] 7/8 10/17 24/9 24/18 24/20 27/9 36/6 41/19 43/3 43/15 50/25 53/13 56/11 58/3 58/16 62/21 65/15 66/1 69/3 69/7 96/11 99/2 101/2 102/23 105/14 105/14 106/14 106/17 107/1 110/18 116/2 116/3 117/24 121/3 121/4 121/17 121/19 123/3 124/16 124/21 126/9 127/8 132/11 133/2 133/3 133/4 133/8 133/17 140/18 140/19 141/19 141/20 142/24 144/9 144/12	144/16 147/24 150/2 173/12 175/6 175/12 175/18 176/5 176/7 involvement [2] 56/7 124/9 involves [1] 18/15 involving [8] 7/4 10/5 10/7 10/16 128/10 148/2 148/4 150/3 Iran [1] 146/14 Iran-Contra [1] 146/14 irrelevant [1] 18/18 is [706] isn't [1] 15/2 issue [16] 19/23 25/3 50/21 61/14 65/12 65/20 65/23 65/25 97/12 114/5 114/9 140/7 150/9 171/17 171/17 179/5 issued [1] 106/3 issues [47] 7/4 8/10 11/1 11/5 13/3 13/25 14/1 14/7 14/22 16/10 16/22 18/14 18/19 27/14 27/23 31/8 40/9 47/3 47/6 47/7 48/19 75/9 75/15 75/18 105/23 106/11 106/16 110/1 111/9 111/25 119/20 125/25 131/25 132/4 132/23 134/14 136/6 136/6 136/9 148/4 148/4 148/7 149/5 151/11 161/8 161/11 179/8 it [422] it's [3] 70/12 71/3 143/19 items [1] 28/6 its [5] 81/4 84/23 102/24 106/3 173/10 itself [2] 153/5 162/8	178/17 178/20 judges [5] 3/3 3/5 33/2 138/7 146/25 judgment [4] 6/7 23/3 43/5 67/18 judicial [3] 20/2 106/20 148/8 judiciary [3] 7/14 19/11 99/10 July [2] 23/5 153/21 jump [4] 61/12 164/13 164/19 167/1 jumped [3] 12/13 68/4 167/10 junction [3] 14/16 29/21 37/3 junior [1] 123/10 junk [1] 93/2 juries [1] 147/1 jury [4] 9/19 23/2 111/16 148/24 just [55] 2/4 2/25 7/23 8/9 16/22 17/25 19/3 19/24 27/19 28/15 31/25 40/6 46/20 56/16 57/19 61/14 61/21 62/18 71/25 72/2 73/10 77/9 77/12 79/6 80/9 81/18 82/8 88/10 97/23 98/17 106/4 106/14 107/23 108/5 111/11 114/19 119/13 126/21 127/17 129/13 131/25 132/14 134/16 136/21 141/6 145/15 147/10 148/12 149/15 149/23 160/19 162/25 172/12 178/14 180/20 justice [3] 15/25 34/7 34/11 Juul [3] 129/6 129/23 130/8
	J jack [1] 99/6 Jaime [1] 105/9 jam [1] 28/4 Jamie [1] 3/6 January [2] 49/7 154/17 Jennifer [1] 136/4 jeopardize [1] 168/6 Jewish [1] 163/5 Joanne [1] 2/22 job [15] 17/17 58/20 82/15 82/19 99/15 103/5 113/5 113/7 123/22 127/19 128/9 147/15 154/25 154/25 179/25 jobs [2] 73/18 123/18 John [3] 148/16 152/5 152/13 Johns [1] 157/12 join [5] 16/4 17/1 146/1 179/22 179/23 joined [2] 152/13 160/7 joining [1] 61/24 joint [1] 165/9 jointly [1] 51/13 JPML [1] 82/11 Juan [1] 45/20 judge [22] 1/10 21/16 21/23 23/1 29/14 33/25 50/6 50/6 62/19 68/5 115/10 115/15 116/1 116/19 117/5 119/17 146/14 165/6 173/25 178/14	K keenly [1] 165/12 keep [13] 9/7 26/19 26/19 49/1 78/24 87/9 88/14 95/4 114/19 145/15 145/16 166/16 173/8 keeping [3] 109/18 156/7 173/11 Kelly [2] 72/19 72/25 Kendra [1] 118/25 Kensey [1] 84/2 kept [1] 160/4 Kettering [1] 130/13 key [9] 87/11 90/16 90/17 116/6 118/2 118/8 118/18 132/15 135/1 kick [1] 89/13 kids [1] 137/2 kids' [1] 141/8 killed [1] 178/14 kind [12] 17/15 46/12 48/7 52/13 53/2 72/5 137/24 143/9 146/5 166/16 167/8 167/8 kinds [1] 148/4 knew [3] 73/16 139/22 163/23 know [106] 4/13 8/16 8/17 8/19 8/25 14/24 15/13 16/3 17/2 17/11 18/5 18/8 18/18 18/25 19/21 21/4 21/23 24/8 25/22 28/4 30/1 31/7 31/8 32/14 34/8 35/24 37/22 37/24 46/16 46/21 48/2 48/6 54/22

K know... [73] 55/9 56/22 58/4 60/10 61/14 66/8 66/22 71/1 71/8 74/5 75/1 76/7 78/24 79/24 80/16 81/1 81/6 81/10 84/22 88/8 91/21 91/25 95/14 98/6 98/22 100/11 103/25 107/13 108/24 109/23 110/7 114/8 115/8 115/21 116/24 116/25 117/10 117/18 118/23 119/22 120/4 122/4 122/17 125/5 127/5 130/2 131/2 135/2 137/8 137/9 139/16 141/6 141/7 141/9 141/22 141/24 143/10 150/12 155/16 157/3 157/24 163/25 164/1 164/2 165/2 165/15 167/2 167/7 168/1 168/9 169/15 174/13 174/20 knowing [3] 37/24 111/4 177/24 knowledge [10] 18/1 28/25 31/2 31/5 36/9 104/19 121/8 135/4 152/3 157/9 known [2] 70/19 133/6 knows [2] 34/6 180/21 Korean [1] 22/24 Kraft [1] 125/9 Krause [3] 81/24 81/24 82/8 Kristian [1] 94/22 Kristine [1] 125/9	latency [4] 140/12 148/4 151/11 156/19 later [5] 8/15 163/20 175/13 179/3 180/4 Latino [1] 58/5 Lauderdale [1] 166/24 law [67] 9/18 10/20 12/12 16/8 20/20 20/21 22/4 22/13 28/22 28/23 28/25 33/5 33/5 33/10 33/13 33/14 33/18 34/1 36/1 36/2 46/3 47/18 47/20 65/3 65/4 66/10 66/10 73/7 77/9 79/10 81/1 82/25 100/15 105/23 123/17 126/3 126/18 129/14 133/17 136/22 136/25 140/17 140/22 141/3 141/5 141/18 144/8 146/12 148/11 148/21 154/4 154/17 155/13 160/6 160/7 161/21 162/5 163/16 163/19 163/19 164/20 173/5 173/5 174/24 175/1 176/5 178/2 laws [2] 28/19 28/20 lawsuits [1] 33/2 lawyer [16] 24/8 27/13 33/21 57/6 57/8 62/1 86/7 86/8 89/17 136/13 136/24 163/15 167/18 169/25 170/13 175/10 lawyers [62] 11/7 11/8 13/23 14/4 14/8 14/12 18/2 22/8 22/9 22/11 27/8 27/24 28/3 28/3 32/13 33/15 38/11 40/2 40/25 42/10 43/16 43/17 52/7 54/15 55/14 56/10 57/7 83/20 87/22 88/2 90/5 94/11 96/11 120/2 120/3 122/6 122/15 126/25 143/24 147/3 149/18 152/23 153/3 154/4 170/1 170/25 171/1 171/25 173/4 173/7 173/8 174/25 175/2 175/5 175/15 175/23 178/5 178/9 178/10 178/11 178/15 179/11 layer [1] 8/9 laying [2] 95/20 123/12 Layne [1] 49/15 lays [1] 134/6 Lea [1] 58/12 lead [40] 7/2 10/5 10/16 12/17 14/7 15/22 16/1 17/22 17/25 22/23 26/14 29/9 29/14 33/19 35/11 51/5 51/10 53/17 57/5 65/25 71/7 75/17 75/17 90/2 94/3 96/12 101/12 106/11 114/13 114/17 116/17 121/23 121/23 126/5 127/6 127/12 127/21 128/2 152/24 176/11 leaders [6] 35/13 38/17 124/6 171/16 171/19 172/1 leadership [111] 1/9 3/9 3/13 3/19 3/21 3/22 3/24 4/2 4/8 4/15 4/18 5/3 5/17 5/20 6/3 6/9 6/13 6/25 7/21 12/22 13/17 14/6 14/12 16/24 21/16 22/15 23/20 23/22 24/22 24/25 26/14 26/16 26/19 27/5 27/6 27/10 27/22 34/24 35/8	35/10 35/11 36/7 36/20 37/1 37/21 38/1 38/6 38/7 38/12 38/19 42/21 50/14 50/19 52/6 52/13 52/17 53/2 55/18 56/18 57/4 59/3 69/6 69/8 69/11 70/17 71/6 72/2 73/4 73/6 73/8 73/11 73/13 74/3 74/9 76/2 79/4 79/16 100/14 104/24 108/10 108/15 110/16 111/13 113/5 113/14 113/25 117/8 118/17 118/18 119/2 120/17 120/21 122/24 125/15 128/13 129/20 132/11 134/9 135/22 136/3 140/14 142/23 143/4 159/5 164/8 165/19 168/12 168/15 171/3 172/17 176/18 leading [7] 3/16 16/25 18/2 25/1 30/23 116/7 166/3 leadoff [1] 9/3 leads [15] 27/18 27/19 29/5 29/5 29/13 29/18 41/2 51/11 51/12 51/15 57/10 77/24 124/15 131/14 134/8 Lear [5] 76/21 76/21 76/25 77/2 81/23 learn [10] 41/9 48/13 57/21 81/2 81/6 144/25 160/17 161/22 161/25 172/1 learned [9] 3/14 24/10 44/25 45/4 45/14 112/22 119/16 121/5 137/11 learning [7] 61/5 61/19 110/19 114/7 120/5 121/12 140/9 least [10] 2/3 30/14 63/22 63/24 84/8 114/17 138/2 145/2 163/12 174/17 leave [6] 84/12 88/15 88/21 88/23 145/13 180/19 leaving [1] 176/18 Lebanon [1] 73/14 lecturing [1] 153/12 led [3] 101/7 116/9 171/2 Lee [1] 21/25 left [3] 145/10 173/5 178/11 leg [1] 128/18 legal [10] 33/13 33/20 40/15 56/20 62/12 83/14 136/12 149/5 160/5 161/22 length [3] 48/2 95/19 111/6 less [11] 4/17 9/4 14/4 38/20 59/14 71/20 85/18 85/21 93/10 170/25 171/24 lesser [1] 29/7 lesson [1] 137/11 lessons [3] 24/10 61/5 160/17 Lest [1] 2/18 let [43] 2/4 9/5 9/12 15/13 15/19 21/8 21/12 35/1 44/14 46/20 50/6 50/15 55/7 60/10 61/17 68/7 68/11 70/10 72/19 72/23 77/6 82/5 88/16 88/17 88/17 88/20 89/13 89/13 95/9 99/11 100/1 100/1 100/3 103/10 111/17 139/13 139/13 139/15 157/23 157/24 158/14
L label [2] 12/2 54/6 labeling [2] 54/3 83/11 labels [1] 12/1 labor [1] 71/9 Laboratory [1] 84/1 lack [3] 80/13 135/21 156/1 lacking [1] 73/12 laid [4] 50/11 95/16 110/11 120/12 landscape [2] 106/2 144/10 language [2] 47/21 161/23 large [21] 12/21 12/22 17/20 18/13 18/15 22/20 24/10 34/3 40/18 51/10 51/19 97/7 117/7 123/10 125/25 160/14 172/20 175/3 175/15 175/16 176/24 largely [1] 36/19 larger [5] 18/20 35/14 38/3 101/4 114/1 largest [4] 42/24 111/3 126/9 152/17 Larmond [1] 157/19 Larmond-Harvey [1] 157/19 last [25] 10/4 30/23 31/16 39/5 40/19 51/5 64/11 82/8 82/22 92/4 109/21 117/3 122/7 123/8 123/15 139/17 140/3 162/16 167/14 169/10 172/3 174/17 174/20 176/3 179/14 lasted [1] 43/4 lastly [3] 29/20 102/22 143/23 late [2] 146/18 163/1		

<p>L</p> <p>let... [2] 177/4 179/24</p> <p>let's [11] 17/15 61/9 61/9 70/9 77/2 82/2 94/22 97/24 99/25 135/14 178/20</p> <p>letter [2] 81/9 108/3</p> <p>letters [1] 76/7</p> <p>level [9] 34/22 48/5 71/5 121/2 127/3 128/15 136/12 136/13 144/24</p> <p>levels [2] 93/16 93/17</p> <p>leverage [1] 103/13</p> <p>leveraging [1] 133/12</p> <p>Levin [2] 132/9 133/6</p> <p>liability [17] 1/5 45/9 47/13 53/20 53/22 53/24 54/2 54/5 54/5 55/19 97/6 97/8 121/16 121/17 139/23 140/22 162/4</p> <p>liaison [4] 76/8 117/17 127/21 147/7</p> <p>library [2] 31/20 31/21</p> <p>lie [1] 28/4</p> <p>liens [1] 132/22</p> <p>life [4] 4/22 18/24 118/20 159/16</p> <p>lifting [1] 69/9</p> <p>light [2] 100/8 161/4</p> <p>lightly [1] 119/25</p> <p>like [85] 3/10 3/20 9/15 14/11 17/1 17/10 18/2 18/12 19/13 19/21 20/5 26/2 27/3 32/3 32/7 32/17 32/22 38/11 39/7 44/16 46/9 49/12 49/19 50/10 51/22 52/1 54/18 57/9 57/22 58/24 59/13 61/19 61/23 62/22 63/24 66/19 66/21 68/12 68/20 69/24 70/15 71/2 71/5 79/5 83/1 83/24 84/8 85/9 87/14 87/17 89/16 91/16 92/9 92/11 93/25 95/6 95/14 99/9 101/9 107/13 110/8 110/17 131/25 135/2 135/25 142/2 147/4 147/24 149/16 150/19 154/25 158/1 158/3 159/4 159/22 163/6 163/13 167/17 169/15 169/21 172/24 174/21 177/8 178/9 179/11</p> <p>liked [2] 178/17 179/11</p> <p>likely [3] 77/24 103/25 149/4</p> <p>Lilly [1] 83/2</p> <p>limit [2] 134/15 134/15</p> <p>limitations [1] 5/1</p> <p>limited [3] 17/24 50/10 139/19</p> <p>Limiting [1] 20/23</p> <p>line [7] 103/19 122/9 125/23 128/20 174/22 174/22 175/22</p> <p>lines [2] 27/24 152/21</p> <p>lineup [1] 25/22</p> <p>lion's [1] 63/16</p> <p>Lipitor [2] 175/21 179/2</p> <p>liquidity [1] 152/21</p> <p>list [4] 105/5 108/21 112/17 169/4</p>	<p>listed [3] 89/15 111/19 165/20</p> <p>listen [6] 18/4 97/24 112/13 112/24 163/18 169/2</p> <p>listening [5] 53/6 65/24 112/21 154/11 180/1</p> <p>literature [5] 105/25 148/11 148/12 155/2 155/4</p> <p>litigants [1] 73/20</p> <p>litigate [5] 42/3 42/20 43/21 174/6 175/22</p> <p>litigated [5] 46/6 65/20 89/22 96/11 175/7</p> <p>litigating [1] 115/16</p> <p>litigation [191]</p> <p>litigations [11] 13/6 83/19 85/16 87/24 128/10 128/10 133/23 140/23 175/21 175/25 176/11</p> <p>litigators [1] 145/2</p> <p>little [18] 2/4 9/8 25/25 28/9 29/1 39/1 60/16 62/25 77/8 84/16 98/17 123/15 136/14 154/5 154/15 165/3 178/24 180/6</p> <p>live [4] 16/18 54/20 167/15 173/23</p> <p>liver [1] 150/25</p> <p>livers [1] 84/2</p> <p>LMI [1] 136/15</p> <p>load [1] 156/2</p> <p>loan [1] 98/20</p> <p>local [3] 6/16 162/25 167/1</p> <p>location [1] 166/20</p> <p>locked [1] 98/9</p> <p>log [1] 27/1</p> <p>long [26] 9/8 18/24 18/24 45/24 54/3 78/25 87/22 89/1 98/3 98/18 104/9 114/2 140/20 140/20 143/17 149/13 151/8 159/24 160/3 160/3 165/2 167/5 167/12 167/16 168/25 173/8</p> <p>long-term [3] 114/2 160/3 160/3</p> <p>look [25] 2/10 3/20 15/17 16/11 18/7 22/18 52/5 63/24 77/4 82/21 85/9 92/21 103/24 119/14 133/23 134/1 134/21 134/21 135/24 138/7 142/13 155/7 156/19 169/5 180/13</p> <p>looked [3] 66/5 156/22 166/10</p> <p>looking [23] 2/5 2/8 7/10 19/24 22/16 22/17 22/18 39/9 61/3 84/3 84/7 91/8 92/1 92/25 93/17 97/17 115/8 131/21 138/11 142/5 155/25 156/10 177/20</p> <p>looks [4] 84/8 92/21 102/10 150/19</p> <p>Loren [1] 122/9</p> <p>lose [1] 158/25</p> <p>loss [10] 29/13 37/7 37/9 37/14 42/17 55/21 68/24 86/23 157/13 157/18</p> <p>losses [1] 10/12</p> <p>lost [1] 91/13</p>	<p>lot [92] 3/3 3/14 10/25 13/3 14/3 18/11 18/19 19/9 20/24 21/21 22/9 24/20 25/6 32/20 41/6 43/20 44/25 44/25 47/3 48/18 48/19 57/25 59/16 59/19 59/24 60/3 62/22 64/2 64/25 67/14 67/20 70/1 71/11 76/6 77/24 79/21 79/25 80/11 82/10 82/12 82/23 83/16 83/19 83/23 84/6 85/11 87/22 90/8 90/24 92/14 92/23 93/22 95/14 96/8 96/8 104/19 110/7 110/8 111/24 112/1 114/16 121/5 121/6 121/8 123/6 126/11 129/15 131/3 131/18 131/25 132/6 132/23 133/24 134/7 134/18 134/19 136/5 137/8 137/14 159/23 161/1 161/2 161/22 163/2 169/13 169/21 169/25 172/20 178/1 178/16 178/23 179/3</p> <p>lots [2] 9/14 169/9</p> <p>Louisiana [1] 46/5</p> <p>love [2] 17/6 163/18</p> <p>loved [1] 135/22</p> <p>low [2] 38/2 93/2</p> <p>luck [1] 18/17</p> <p>lucky [3] 10/3 170/2 172/6</p> <p>Luhana [1] 115/1</p> <p>lunch [2] 77/1 88/22</p> <p>luncheon [1] 89/5</p> <p>lung [1] 148/3</p> <p>Lynn [1] 73/1</p> <hr/> <p>M</p> <p>made [13] 7/7 47/2 70/19 99/15 141/9 141/11 152/23 160/13 163/23 165/23 167/10 167/16 170/18</p> <p>Maderal [2] 2/22 136/19</p> <p>Magistrate [2] 62/19 66/2</p> <p>magnitude [1] 58/3</p> <p>main [3] 123/2 131/16 144/18</p> <p>mainly [1] 156/4</p> <p>maintaining [3] 27/23 78/9 148/22</p> <p>maintenance [1] 3/3</p> <p>major [6] 13/15 46/12 65/19 65/19 66/19 77/10</p> <p>majority [5] 42/12 73/3 78/1 79/13 102/18</p> <p>make [50] 3/21 3/22 6/10 8/12 10/12 13/4 17/22 25/7 26/24 29/22 32/25 33/2 37/1 37/2 41/25 44/24 45/2 46/23 50/8 50/12 51/12 51/16 56/4 57/19 71/20 72/10 72/19 87/10 87/10 91/15 91/23 92/19 98/14 99/25 112/25 113/1 118/18 119/5 124/16 130/16 136/12 138/13 143/2 143/10 155/24 158/16 159/13 160/12 168/6 172/6</p> <p>makes [7] 8/5 77/7 114/17 114/18 114/18 159/13 174/6</p> <p>making [9] 6/25 60/6 100/2 108/3 109/10 138/13 158/23 159/24 160/13</p>
--	---	--

<p>M</p> <p>male [1] 73/11</p> <p>manage [7] 58/3 71/13 101/4 125/24 127/17 128/3 137/15</p> <p>managed [4] 41/2 49/2 129/15 163/3</p> <p>management [9] 9/21 18/12 27/15 40/9 101/1 101/8 137/21 150/18 172/15</p> <p>managing [15] 6/5 12/12 27/12 33/18 60/5 68/17 71/6 71/7 78/16 93/5 118/7 118/16 132/17 170/5 170/6</p> <p>manifest [1] 151/10</p> <p>manifesting [1] 156/16</p> <p>manner [11] 17/4 25/8 47/11 52/17 54/18 88/19 96/3 108/23 122/12 125/3 128/23</p> <p>manpower [1] 68/19</p> <p>manual [1] 90/25</p> <p>manufacture [1] 114/10</p> <p>manufactured [1] 125/21</p> <p>manufacturer [6] 48/16 48/17 93/14 93/15 143/8 146/15</p> <p>manufacturers [10] 54/3 69/24 69/24 114/9 132/2 132/3 136/6 138/10 141/16 159/7</p> <p>manufacturing [5] 47/19 47/22 106/8 114/13 135/2</p> <p>many [77] 2/6 4/12 4/13 6/6 7/13 18/6 21/22 21/22 22/7 29/11 31/7 33/8 33/16 34/3 34/4 36/25 38/12 40/7 40/24 41/13 41/16 42/10 45/16 51/20 52/21 53/11 53/15 54/17 55/14 57/7 57/9 58/3 60/1 60/20 64/1 68/8 85/8 90/4 97/21 98/19 101/11 105/22 105/25 110/22 114/6 120/1 121/9 121/24 122/5 122/6 122/8 122/15 123/12 124/25 127/3 131/24 133/4 136/4 137/15 137/25 139/24 150/23 152/19 154/12 154/22 155/11 156/20 164/24 164/25 166/13 166/22 167/6 169/10 169/10 173/6 173/6 175/14</p> <p>MAO's [1] 64/2</p> <p>March [1] 5/18</p> <p>marginally [1] 137/16</p> <p>Mark [1] 175/22</p> <p>market [5] 33/9 95/20 111/7 117/25 143/17</p> <p>marketing [3] 19/12 166/12 167/9</p> <p>marks [2] 33/25 121/15</p> <p>Marlene [1] 148/18</p> <p>marry [1] 65/4</p> <p>Martin [1] 139/16</p> <p>Martinez [4] 55/4 60/13 72/18 115/15</p> <p>Martinez-Cir [3] 55/4 60/13 72/18</p> <p>mass [34] 11/1 13/3 18/15 23/16 57/7 59/20 59/23 73/20 74/5 83/18 89/19 90/3 94/3</p>	<p>94/5 97/6 115/16 121/17 125/19 139/21 139/24 140/16 141/2 141/17 148/2 152/17 154/22 154/24 158/20 167/18 169/8 169/20 170/5 170/6 175/1</p> <p>Massachusetts [3] 45/10 139/18 144/7</p> <p>massive [1] 30/4</p> <p>master [30] 3/7 6/12 28/18 28/25 32/22 36/25 37/4 37/5 37/6 37/11 37/12 37/14 40/11 40/11 41/5 44/12 44/20 47/9 56/1 63/8 63/11 72/7 72/10 99/6 111/22 119/19 136/4 136/16 146/3 149/17</p> <p>master's [1] 9/21</p> <p>mater [1] 157/12</p> <p>material [2] 64/14 64/18</p> <p>Matt [3] 122/9 178/10 178/23</p> <p>matter [12] 5/12 18/10 23/6 23/6 23/7 26/12 52/3 53/18 55/12 67/5 147/14 181/1</p> <p>matters [6] 6/14 50/16 58/23 62/15 90/7 107/4</p> <p>mature [1] 123/3</p> <p>maximize [1] 132/5</p> <p>may [31] 1/5 3/2 4/20 4/21 9/10 9/10 10/21 10/24 17/6 19/23 31/18 46/10 50/13 61/10 70/4 70/23 70/23 71/6 71/25 82/7 82/21 85/5 85/14 92/1 93/19 97/16 98/17 104/7 119/17 151/18 181/3</p> <p>maybe [28] 2/13 4/19 8/16 11/22 19/22 20/3 26/4 26/6 29/22 37/18 60/15 60/23 60/25 61/25 65/18 70/3 71/3 79/5 80/20 80/21 82/5 82/6 88/6 97/11 111/19 149/23 150/15 161/9</p> <p>McGlamry [1] 179/5</p> <p>md [1] 1/3</p> <p>MDA [7] 102/6 102/7 104/10 106/8 131/19 131/21 166/18</p> <p>MDL [92] 1/9 4/12 4/19 5/4 5/5 5/21 24/8 24/10 26/8 26/16 27/12 27/15 28/12 29/22 37/20 38/6 40/20 41/3 41/11 42/3 42/22 43/14 43/15 43/20 45/11 51/20 52/22 53/13 57/17 58/6 59/14 59/22 63/1 71/15 73/2 73/13 75/1 76/2 77/18 77/19 80/20 80/25 81/3 100/12 100/20 100/23 101/3 101/15 102/12 102/15 102/25 105/11 117/21 120/23 120/24 121/7 122/6 124/1 126/22 126/23 127/2 128/8 133/8 137/5 137/12 137/12 138/18 138/23 138/24 144/2 144/8 144/10 144/21 144/22 145/4 150/7 159/7 161/19 161/21 162/6 164/9 164/10 164/11 165/4 165/18 167/23 169/13 175/12 175/19 175/24 176/3 177/2</p> <p>MDL's [30] 27/12 34/5 40/18</p>	<p>40/22 41/13 41/14 59/17 59/18 98/23 100/14 100/22 111/3 116/16 121/24 125/19 127/22 127/23 132/11 136/7 136/9 136/11 138/22 141/2 144/15 144/17 145/2 162/3 165/15 165/22 169/14</p> <p>MDMA [10] 48/20 50/20 66/23 102/20 140/8 140/9 142/10 149/25 155/23 166/15</p> <p>me [197]</p> <p>mean [7] 12/25 91/21 91/21 91/22 103/12 145/13 170/25</p> <p>meaning [1] 63/2</p> <p>meaningful [6] 12/25 46/7 77/13 77/14 108/5 108/22</p> <p>means [4] 29/23 29/24 78/18 94/10</p> <p>meant [2] 7/16 137/6</p> <p>measure [1] 177/14</p> <p>meats [1] 166/16</p> <p>media [1] 86/25</p> <p>Medicaid [1] 46/4</p> <p>medical [37] 5/8 10/19 37/7 37/9 55/21 73/22 83/21 84/10 84/17 84/18 84/19 84/19 86/23 88/1 100/19 126/17 132/10 137/5 141/15 142/3 147/21 147/22 148/5 148/10 148/11 150/3 151/12 151/15 151/20 155/1 155/2 155/4 156/4 159/9 160/9 164/15 176/14</p> <p>Medicare [3] 63/4 64/2 160/22</p> <p>medication [5] 46/18 150/10 151/15 159/8 161/14</p> <p>medications [3] 46/25 64/5 160/1</p> <p>medicine [1] 50/22</p> <p>meet [12] 2/2 20/2 40/10 82/14 110/4 114/24 114/25 115/4 130/20 144/12 147/17 171/21</p> <p>meeting [13] 2/11 8/14 18/7 88/11 88/15 88/24 131/2 131/9 145/13 167/7 179/22 179/23 180/19</p> <p>meetings [4] 8/13 91/6 103/1 120/4</p> <p>mega [1] 16/15</p> <p>Melanie [2] 2/23 168/21</p> <p>member [10] 12/19 24/21 35/10 35/11 73/23 109/6 153/19 167/8 170/6 175/20</p> <p>members [25] 18/6 23/14 26/24 28/16 33/7 33/17 35/14 38/7 38/20 38/20 38/21 39/25 41/16 42/13 51/19 57/23 59/6 127/6 127/13 141/18 152/19 153/19 172/22 172/24 172/25</p> <p>members' [1] 37/16</p> <p>membership [1] 52/1</p> <p>mention [6] 26/22 27/6 68/23 96/15 101/10 114/8</p> <p>mentioned [17] 13/15 26/11 32/24 34/8 37/22 38/25 40/23 43/18 45/18 67/2 69/16 70/9</p>
---	--	---

M	170/16	moves [2] 86/12 168/6
mentioned... [5] 72/9 101/15	moms [1] 141/7	moving [9] 49/2 75/2 75/5
106/24 159/12 165/24	Monday [1] 2/25	103/6 105/12 114/16 117/2
mentioning [2] 25/3 28/2	monetarily [1] 107/6	118/11 121/7
mentor [5] 22/14 22/21 29/11	monetary [1] 167/8	Mr [72] 20/15 23/22 23/22
170/1 171/24	money [10] 26/23 27/1 66/25	25/11 25/16 25/21 27/21
mentored [3] 58/10 58/13	85/18 85/20 98/20 98/20	31/12 31/14 33/18 34/7 35/22
172/8	98/22 114/4 166/11	36/12 39/6 39/7 39/7 39/8
mentoring [10] 11/13 22/13	moneys [2] 66/20 66/21	40/13 41/8 42/4 44/2 44/10
22/19 138/19 143/23 144/1	monitor [2] 10/15 11/3	49/25 55/3 55/25 56/1 56/13
161/18 161/20 169/25 172/24	monitoring [18] 5/8 10/15	57/12 57/22 57/23 60/13 61/9
mentorship [1] 161/25	10/19 37/7 37/9 44/11 55/21	61/17 63/7 64/16 64/16 72/17
merits [1] 176/16	72/10 73/22 84/17 84/18	76/21 76/21 76/25 77/2 81/23
messaging [4] 83/4 83/5 83/9	84/19 84/19 86/10 86/23 88/1	81/24 81/24 87/3 89/8 90/5
83/17	118/16 150/2	90/6 96/12 96/13 96/14 96/14
Mestre [2] 61/9 61/17	Montgomery [1] 175/9	99/23 101/7 101/9 101/12
met [4] 62/22 65/2 120/6	month [6] 17/20 33/25 41/7	103/9 135/23 142/17 149/20
170/17	132/22 137/2 176/23	155/2 162/14 165/25 165/25
methods [3] 173/15 173/17	months [15] 21/15 30/17 32/9	166/3 170/16 170/18 174/18
173/19	37/23 39/5 82/9 101/21	179/1 179/5 179/5 179/13
Mexico [1] 62/10	115/12 115/18 115/19 115/25	Ms [3] 95/13 96/12 97/21
Miami [3] 68/17 68/18 82/15	117/4 123/8 166/25 178/21	Ms. [30] 8/21 9/12 15/9
micro [1] 162/7	Moore [1] 136/4	15/10 17/8 17/9 17/17 20/12
microphone [1] 8/21	morbidities [1] 102/11	28/4 28/4 36/4 36/6 36/8
microscope [2] 84/4 84/8	more [61] 5/19 15/17 18/8	36/13 44/4 46/11 47/2 49/21
Microsoft [1] 30/22	20/4 24/1 24/5 29/2 29/14	51/11 52/18 53/20 61/14 68/4
might [17] 24/1 85/18 85/21	33/21 34/8 34/24 35/3 35/6	72/19 72/20 74/15 76/18 90/7
86/24 95/1 96/7 97/1 97/20	38/7 39/15 45/13 48/13 49/11	95/13 135/10
98/11 99/2 124/14 135/17	52/21 53/21 60/25 61/5 61/16	Ms. Barnes [1] 28/4
136/17 158/7 161/9 173/15	66/2 70/17 71/1 71/8 71/19	Ms. Dodge [2] 52/18 95/13
177/19	74/11 76/12 77/11 77/24	Ms. Fegan [7] 8/21 9/12 17/9
mightily [1] 51/7	81/14 81/19 85/17 85/18	17/17 28/4 47/2 74/15
mike [3] 15/6 25/16 55/4	85/20 91/24 96/5 99/2 99/3	Ms. Goldenberg [2] 90/7
miles [1] 39/2	99/5 103/22 107/17 110/21	135/10
million [4] 26/25 63/24	115/8 117/16 127/7 129/6	Ms. Hyman [2] 72/20 76/18
90/18 90/23	132/12 133/4 144/4 148/10	Ms. Kelly [1] 72/19
millions [3] 26/20 93/9 93/9	149/14 155/25 156/21 156/21	Ms. Westcot [2] 61/14 68/4
mind [5] 7/17 9/6 16/25	163/21 172/18 172/19 174/8	Ms. Whitely [8] 36/4 36/6
46/13 48/7	morning [26] 2/1 8/23 15/10	36/13 44/4 46/11 49/21 51/11
mindful [1] 81/8	15/11 20/16 20/17 20/18	53/20
minds [2] 7/7 165/22	25/18 25/19 31/14 31/15 39/4	Ms. Whitely's [1] 36/8
mine [1] 145/16	39/13 39/14 44/6 50/2 50/3	Ms. Wolfson [4] 15/9 15/10
minor [1] 13/24	55/4 68/10 72/20 81/24 82/2	17/8 20/12
minority [1] 118/23	98/21 100/7 110/7 110/14	MSP [7] 65/10 65/17 66/12
minute [2] 22/5 145/12	most [34] 22/23 32/14 33/12	66/13 66/14 66/15 66/16
minutes [11] 8/14 20/23	39/9 40/10 40/20 44/12 56/9	much [82] 2/14 2/18 9/1
23/25 24/2 91/7 109/21	68/22 79/6 80/4 80/6 80/18	11/17 14/4 15/8 15/21 18/1
145/11 145/15 145/17 147/4	83/14 92/2 96/11 96/24 97/1	20/11 25/8 25/11 28/1 28/7
180/4	97/9 108/24 109/2 109/3	30/13 31/11 36/5 39/2 43/23
minutia [1] 156/14	111/25 113/5 132/14 134/20	43/25 44/19 44/21 49/21 50/3
mirrors [1] 54/3	136/19 142/23 149/4 165/17	54/25 59/2 60/13 62/23 68/7
misimpression [1] 90/1	167/22 170/23 180/8 180/14	81/19 81/22 81/23 88/3 89/15
misplaced [1] 141/15	mostly [1] 156/4	91/23 92/9 93/10 94/18 95/12
miss [1] 24/20	motion [3] 74/20 117/13	99/4 99/14 99/20 99/21
missing [2] 90/16 112/15	121/4	103/22 104/9 104/18 107/10
Missouri [2] 77/7 78/4	motions [7] 14/6 14/9 14/22	109/11 110/5 110/25 113/5
mistaken [2] 157/1 180/20	27/25 28/20 128/11 128/11	118/8 119/6 119/22 122/1
misunderstood [1] 31/18	motivated [2] 102/22 133/5	125/4 125/7 127/12 127/15
misuse [1] 92/23	Motors [1] 27/19	129/8 130/5 130/19 135/5
mitzvah [1] 136/24	move [21] 7/22 9/5 25/14	136/23 137/14 139/4 142/7
Mobile [1] 175/7	36/10 44/17 56/5 75/4 96/6	145/5 145/18 145/25 149/16
model [2] 138/12 146/4	116/13 117/11 117/16 119/20	149/20 149/25 152/2 157/18
molecular [1] 148/1	119/25 120/10 120/15 140/3	163/5 168/17 168/20 172/14
mom [5] 8/13 31/24 73/13	140/16 146/5 150/16 151/4	172/18 174/12 177/23 179/13
73/15 137/1	175/8	Muhlstock [1] 168/21
moment [9] 3/1 21/6 21/9	moved [6] 26/18 89/18 91/14	multiple [17] 10/15 75/22
52/8 57/12 95/1 145/17 158/5	115/19 141/17 170/1	79/13 80/17 106/23 117/24
	movement [1] 107/17	120/24 120/25 121/1 124/4

M multiple... [7] 126/7 132/11 142/3 153/3 166/1 168/7 173/2 Murray [1] 22/1 music [1] 94/14 must [2] 8/25 17/17 mute [5] 88/12 88/21 89/3 145/15 180/18 my [341] my mom [1] 73/15 myself [26] 2/5 6/11 11/11 13/6 16/25 18/9 19/8 20/5 29/12 29/18 57/10 61/4 79/11 79/19 82/20 83/22 89/3 90/10 108/2 110/23 110/24 125/13 127/7 154/15 164/12 172/6 Mystery [1] 61/13	negotiations [2] 133/2 179/3 neither [1] 66/9 nervous [9] 8/4 8/5 8/12 8/17 26/11 26/13 39/15 60/25 76/22 nervousness [2] 26/11 50/7 neurological [1] 154/18 never [8] 6/18 39/17 41/8 120/2 120/3 128/8 139/22 159/12 new [31] 8/9 8/10 8/24 10/7 11/7 11/19 12/2 18/7 65/18 68/17 77/17 80/23 81/7 81/15 81/25 85/13 85/25 106/4 107/14 120/5 120/6 127/5 127/13 128/7 139/18 143/23 144/6 144/7 144/19 145/4 180/19 newbie [1] 167/19 newer [1] 139/2 news [3] 109/11 164/20 170/20 next [35] 2/11 3/25 8/1 14/10 14/13 15/2 19/15 25/14 30/22 42/8 49/25 61/15 76/21 94/22 98/3 99/22 105/1 109/12 109/14 115/1 119/9 130/23 138/18 139/8 145/21 147/4 148/16 152/5 157/19 162/14 166/25 172/1 172/2 172/2 176/23 nice [20] 13/12 13/20 25/21 31/11 44/2 49/22 55/1 57/14 60/14 72/15 72/21 74/14 76/20 89/7 104/23 109/12 114/25 130/20 144/19 180/12 Nicola [1] 157/19 Nigh [3] 130/23 142/16 166/3 night [4] 113/13 154/25 173/5 178/18 nightmare [1] 109/21 nights [3] 123/8 123/17 123/20 nine [1] 64/8 Ninth [1] 89/20 nitrites [1] 166/15 nitrites [2] 155/23 166/14 no [33] 1/3 7/3 7/5 8/4 9/8 29/15 54/23 58/20 60/11 61/13 70/25 81/21 86/4 87/16 87/18 88/13 113/7 113/7 113/7 113/8 113/8 123/23 126/22 127/1 150/14 152/19 157/5 164/8 164/11 165/18 172/18 175/12 180/9 noise [2] 46/20 46/24 non [5] 2/10 49/7 49/10 102/14 147/22 non-applicants [1] 2/10 non-medical [1] 147/22 non-profit [2] 49/7 49/10 nonexistent [1] 97/22 nonlawyer [1] 173/3 nonscientist [1] 149/7 nonscientists [1] 147/20 normal [1] 29/16 Northern [1] 22/25 Norwegian [1] 96/21	nose [1] 110/20 not [192] not important [1] 113/22 notch [1] 33/15 note [5] 60/19 61/2 74/8 96/20 144/6 noted [1] 95/25 notes [3] 2/6 2/9 161/14 nothing [5] 17/23 20/6 26/17 52/21 123/19 noticed [2] 105/24 144/7 notion [1] 29/24 novel [3] 173/14 173/17 173/18 now [57] 2/4 2/5 5/19 10/18 13/7 14/24 15/1 15/18 22/24 24/7 27/14 30/13 32/3 32/15 33/4 33/9 39/7 45/1 48/15 49/10 53/11 53/15 58/13 62/20 65/21 68/4 72/18 76/21 79/3 85/11 85/23 88/8 97/22 98/24 99/2 100/23 103/21 103/25 113/24 116/20 118/11 120/7 123/12 127/25 137/1 137/18 138/10 145/8 150/15 153/5 156/14 159/17 166/22 167/7 168/9 169/23 173/4 number [39] 11/17 16/5 16/13 22/14 22/16 22/20 25/5 37/11 37/25 38/11 38/11 50/18 51/9 55/17 57/11 58/22 59/7 63/25 65/21 65/22 69/12 89/22 90/4 95/18 99/7 104/12 104/12 105/4 105/16 111/7 117/23 118/7 122/18 125/25 138/4 148/17 175/3 175/23 177/24 numbers [2] 63/24 179/14 numerical [1] 104/2 numerous [2] 147/21 153/11 nurse [6] 83/8 159/6 159/12 159/16 159/20 161/23 nursing [3] 159/20 160/1 161/21 nuts [1] 121/18
N name [16] 68/15 69/11 70/12 72/25 82/7 89/11 91/22 93/14 93/14 127/20 132/2 152/6 152/12 162/17 174/19 175/11 named [2] 71/18 152/14 names [3] 60/20 60/22 115/5 narrow [1] 92/12 narrowly [1] 67/11 NASA [2] 26/16 26/19 National [2] 42/9 62/7 nationwide [1] 6/16 natural [1] 127/17 nature [2] 8/7 34/22 navigate [2] 144/11 147/16 Navy [1] 96/23 NDMA [1] 168/10 nearing [1] 107/3 Nearly [1] 79/12 Nebraska [1] 176/3 necessarily [3] 71/3 71/8 82/1 necessary [12] 5/25 38/8 40/4 42/2 85/5 93/1 107/6 107/22 122/1 124/19 129/4 152/20 need [36] 3/3 4/14 18/19 19/5 23/17 23/19 25/18 26/14 31/5 38/3 47/8 48/10 57/25 70/3 70/4 72/5 85/23 86/16 87/22 88/23 98/4 103/24 117/7 117/8 117/10 117/17 118/18 123/14 138/7 139/25 147/18 151/1 152/11 155/9 165/12 170/24 needed [9] 6/19 34/25 59/9 120/19 122/1 124/8 124/9 127/19 152/21 needs [13] 33/15 33/18 33/22 64/19 84/22 84/23 84/24 85/1 85/2 117/5 128/16 147/17 150/4 negatives [1] 165/15 negotiate [1] 133/1 negotiated [2] 101/21 136/15 negotiating [7] 67/13 111/22 112/4 131/24 132/16 133/3 133/15		O o'clock [2] 89/1 89/4 O'Connor [1] 2/23 objections [1] 178/19 objectives [1] 107/24 obligation [2] 49/6 129/9 obligations [3] 93/17 96/3 128/25 observations [1] 50/12 observing [1] 8/2 obtain [2] 62/17 62/18 obvious [2] 19/24 52/8 obviously [3] 12/23 58/8 93/22 occasions [1] 166/1 occur [2] 71/23 80/16 Odal [1] 166/1 odd [2] 57/11 131/19 off [18] 9/3 12/15 15/6 15/7 33/11 61/21 72/1 72/11 89/13 95/14 109/24 113/8 113/13 123/12 126/9 131/1 176/18 179/14

<p>O</p> <p>offer [3] 16/24 17/24 79/7</p> <p>offered [1] 105/25</p> <p>office [5] 39/22 68/18 78/8 173/4 173/4</p> <p>officers [1] 40/2</p> <p>offices [3] 68/16 83/9 171/20</p> <p>official [3] 1/13 39/9 181/4</p> <p>often [8] 26/23 35/13 58/2 61/2 86/22 86/25 104/1 148/10</p> <p>okay [74] 2/1 14/16 15/11 25/2 25/11 25/20 30/18 36/24 37/17 38/22 42/21 48/1 48/21 54/7 54/21 59/12 60/9 65/6 67/1 67/23 70/7 70/9 71/25 72/23 75/7 75/25 76/12 79/2 80/19 81/23 84/15 85/7 86/1 87/13 88/24 89/6 91/20 93/4 95/1 98/10 99/15 99/21 105/1 108/8 115/1 117/20 122/24 125/9 130/19 130/23 134/25 135/9 141/23 143/12 145/21 152/2 152/5 157/6 157/19 159/15 160/15 160/25 161/7 161/17 162/9 165/5 167/20 168/21 172/14 174/17 177/1 178/3 179/10 180/22</p> <p>okays [1] 18/17</p> <p>old [9] 82/21 99/9 112/12 136/22 137/2 137/2 143/19 152/9 162/24</p> <p>omnibus [1] 79/23</p> <p>once [9] 7/20 14/12 43/5 47/23 81/13 85/24 85/25 91/7 93/3</p> <p>oncologist [1] 164/21</p> <p>oncology [2] 140/11 147/25</p> <p>one [160] 2/25 3/2 5/18 8/4 9/9 14/19 16/5 22/3 24/8 25/3 26/15 27/5 28/7 29/12 29/14 29/16 29/16 29/18 30/21 30/25 33/21 37/6 37/11 38/17 40/14 42/7 42/10 42/14 45/12 46/2 46/12 48/8 50/18 50/22 52/16 53/1 55/23 56/1 56/3 56/9 57/5 57/7 58/23 59/10 59/18 60/19 60/20 61/2 63/21 65/22 66/21 67/25 68/16 69/16 70/12 70/23 70/24 72/8 74/10 76/7 77/18 78/3 78/7 78/12 79/17 81/10 82/21 82/23 86/14 88/13 89/1 89/3 91/4 95/7 96/14 97/11 99/5 100/11 102/16 105/16 106/20 108/1 111/3 112/9 112/21 114/1 118/23 120/22 123/10 126/4 126/8 127/23 128/10 128/17 128/18 129/5 131/14 132/15 132/19 133/20 134/14 135/17 136/11 136/22 139/23 140/14 140/21 140/25 142/15 143/5 143/21 144/4 144/19 144/21 145/2 149/11 149/23 150/2 151/18 152/17 154/10 154/24 155/7 156/8</p>	<p>156/8 159/21 161/9 161/11 161/24 162/24 163/1 163/14 163/23 164/4 165/7 165/14 165/15 165/17 165/24 165/24 166/10 167/3 169/14 171/6 171/7 172/1 172/2 172/2 173/20 175/2 175/25 176/2 176/3 176/6 176/8 176/9 177/14 178/11 179/14 180/19</p> <p>ones [7] 14/8 18/7 24/23 36/16 57/9 92/25 134/20</p> <p>only [33] 2/23 3/14 5/22 7/7 7/10 12/9 13/19 23/10 35/20 35/23 37/14 41/6 41/12 47/25 53/13 59/18 60/20 63/1 64/21 69/23 73/5 77/18 83/13 98/14 105/21 126/1 132/21 156/22 164/4 164/9 164/22 165/8 169/19</p> <p>open [3] 7/17 10/3 16/25</p> <p>opening [29] 4/24 7/10 9/5 10/22 15/19 21/5 21/13 26/2 32/4 44/14 48/2 50/1 55/8 68/11 72/23 77/6 82/6 93/24 95/9 100/3 109/18 111/16 115/9 118/15 119/14 135/15 163/9 163/11 163/24</p> <p>opinion [4] 137/12 160/17 170/14 170/15</p> <p>opinions [2] 146/23 158/22</p> <p>opioids [3] 40/19 42/5 42/9</p> <p>opportunities [3] 69/20 139/1 144/23</p> <p>opportunity [59] 4/18 7/25 10/5 10/14 10/21 11/15 12/11 14/5 15/22 21/9 32/4 32/8 34/2 39/5 40/24 44/22 49/19 50/4 54/22 55/5 59/15 62/4 68/14 76/14 76/15 76/17 81/17 103/6 103/7 105/3 105/4 105/7 105/17 117/3 119/24 120/1 120/16 122/21 125/11 127/24 127/25 128/14 130/21 135/21 135/22 136/1 136/20 139/3 144/3 145/7 152/12 164/7 170/16 170/20 170/20 170/21 175/23 176/25 178/13</p> <p>opposed [3] 77/22 97/11 139/22</p> <p>opposing [8] 14/2 19/2 19/7 19/8 19/10 19/19 122/8 178/8</p> <p>opposite [2] 44/18 96/16</p> <p>opposition [1] 30/2</p> <p>opt [2] 78/13 78/13</p> <p>option [1] 174/9</p> <p>options [1] 174/11</p> <p>order [12] 3/24 33/14 51/16 60/16 61/7 80/25 95/25 96/7 100/2 117/10 117/11 133/4</p> <p>orders [8] 44/11 81/9 81/9 112/3 116/3 116/4 116/5 121/3</p> <p>ordinarily [1] 54/2</p> <p>ordinary [1] 33/1</p> <p>organization [3] 41/1 71/4 124/2</p> <p>organizational [1] 60/18</p>	<p>organizations [2] 63/5 64/2</p> <p>organize [1] 127/25</p> <p>organized [1] 74/4</p> <p>organizing [2] 17/4 55/16</p> <p>orientation [2] 4/22 118/19</p> <p>oriented [2] 78/2 90/13</p> <p>originally [1] 110/10</p> <p>Ortho [2] 126/21 127/9</p> <p>other [106] 2/8 3/15 6/15 9/10 9/11 13/2 13/6 18/6 19/20 22/8 22/9 22/11 23/5 25/3 31/23 35/14 36/15 37/10 38/24 39/25 40/6 40/7 40/18 40/24 41/14 42/1 42/13 43/1 43/25 44/19 47/17 55/13 59/22 62/23 66/14 69/7 70/6 70/13 71/5 71/12 71/17 71/18 75/1 79/22 84/22 85/1 85/16 87/24 90/4 91/11 93/23 93/23 94/8 94/9 95/23 96/13 100/14 105/21 106/24 107/2 107/16 107/24 108/3 108/13 112/8 112/9 112/15 113/13 113/17 118/10 121/12 122/24 124/8 126/2 126/3 126/8 126/13 126/25 127/6 127/13 128/2 129/4 129/13 132/7 134/10 135/19 136/17 137/19 138/12 143/22 149/11 149/15 151/14 151/19 161/7 167/2 167/23 173/3 175/21 176/6 176/9 176/14 177/6 177/20 178/14 180/3</p> <p>others [36] 2/10 6/6 7/1 21/6 26/5 29/7 31/19 34/13 36/13 36/16 36/20 38/9 38/25 40/19 54/11 59/13 66/20 76/25 78/18 80/10 80/21 80/21 81/14 107/11 107/13 107/15 112/13 114/21 116/18 127/24 136/4 137/17 138/15 146/1 148/15 161/10</p> <p>otherwise [3] 70/17 74/17 118/22</p> <p>ought [3] 64/12 79/10 177/21</p> <p>our [87] 2/22 3/1 5/16 8/20 10/3 10/21 11/7 12/5 12/13 12/18 20/2 20/10 25/14 33/17 33/23 33/24 35/7 46/7 47/15 49/3 54/12 67/12 67/24 70/13 73/24 76/25 77/14 78/10 85/12 88/14 88/16 89/14 96/10 96/19 98/16 100/15 101/18 102/4 102/13 104/4 114/14 119/1 119/9 119/19 119/23 122/11 126/1 126/8 126/9 126/23 126/23 128/22 130/1 130/5 133/6 134/2 134/2 134/13 136/15 138/7 139/17 139/18 142/19 145/1 145/21 148/20 151/6 152/5 153/3 153/12 157/19 162/14 164/12 167/4 171/1 173/4 173/4 173/7 173/8 175/1 175/24 176/2 176/5 176/8 177/18 178/11 179/12</p> <p>ours [1] 36/6</p> <p>ourselves [1] 96/9</p>
--	--	--

O	owning [1] 164/4	41/15 66/10 66/10 69/8 70/13 70/16 71/18 139/17 152/14 154/10 169/12 175/25 176/6
out [65] 6/2 7/15 9/18 9/23 10/11 11/3 13/5 13/7 21/19 27/25 29/17 31/7 33/20 34/16 38/11 38/18 48/10 50/11 51/6 57/14 60/16 60/23 61/6 61/18 61/22 67/21 74/16 77/2 78/13 85/13 85/24 85/25 89/16 91/20 92/1 95/4 96/17 98/17 109/22 110/11 111/19 117/1 118/24 120/12 122/7 123/11 130/13 134/16 134/19 134/21 134/22 139/12 140/14 141/9 154/1 157/12 157/14 158/16 163/2 164/18 165/9 165/11 168/3 168/25 173/3	P	parts [3] 84/3 114/16 171/15 party [20] 5/7 6/17 7/5 37/13 42/18 46/3 59/5 63/1 63/2 63/16 63/19 64/13 64/18 64/24 65/1 66/19 67/9 67/12 112/2 129/12
out-of-pocket [1] 10/11	PA's [1] 83/8	passed [1] 49/17
outcome [1] 17/4	pace [1] 115/19	passion [6] 20/1 79/9 79/14 79/20 144/23 168/19
outlines [1] 156/9	packager [1] 93/15	passionate [3] 144/13 159/6 167/17
outlying [1] 160/12	packaging [1] 83/12	passions [1] 136/11
outright [1] 61/7	Packer [1] 132/9	password [1] 180/21
outset [5] 14/20 14/23 15/3 19/4 47/22	paid [4] 37/15 63/16 66/22 83/20	past [18] 32/8 41/7 44/18 45/24 47/5 93/11 97/13 101/20 115/24 119/12 121/18 122/16 128/9 146/9 153/15 153/22 173/19 177/13
outside [2] 107/23 108/2	paint [1] 10/16	patents [1] 47/23
outstanding [4] 3/17 26/3 33/13 36/14	pair [1] 84/23	path [4] 41/21 115/9 120/5 144/19
ovarian [2] 148/3 150/24	PALM [3] 1/2 1/5 1/14	pathology [3] 147/25 151/19 155/16
over [84] 2/11 9/12 10/1 10/6 11/18 12/11 13/6 15/19 18/4 21/12 21/16 21/21 26/2 27/16 29/11 32/8 34/2 40/2 44/4 44/14 46/18 46/25 49/16 50/1 55/7 58/18 58/19 60/21 60/25 61/25 64/5 64/8 68/8 69/13 73/4 77/9 81/25 82/5 82/22 86/22 88/9 91/13 93/6 95/9 98/25 100/3 100/21 101/20 103/1 107/3 114/18 117/3 120/25 121/5 121/14 126/13 127/20 131/21 131/23 133/8 136/17 139/17 140/2 140/8 141/17 141/18 142/8 142/20 149/7 152/18 152/23 156/6 160/11 161/12 165/9 165/11 165/19 165/21 169/5 169/10 169/22 170/1 175/24 176/1	panacea [1] 92/24	patience [4] 8/2 174/13 180/8 180/15
over-the-counter [5] 10/6 46/18 46/25 64/5 69/13	Pancratic [1] 85/19	patient [2] 160/22 164/15
overall [6] 6/4 77/25 90/1 113/24 118/21 128/5	pandemic [3] 2/20 62/8 119/21	patients [4] 84/7 160/10 161/12 176/4
overcome [1] 161/3	panel [2] 102/25 165/13	patterns [1] 150/17
overlap [4] 59/24 71/23 121/13 131/25	panels [1] 171/1	Paul [2] 42/9 154/10
overlapping [1] 75/13	Papantonio [1] 133/6	Pauline [2] 1/13 181/4
overlaps [2] 51/4 121/10	paper [6] 16/21 21/20 23/6 90/25 91/20 118/1	pause [2] 21/6 21/9
overly [1] 25/8	papers [3] 115/21 124/24 173/1	pawn [1] 113/8
overseas [1] 141/12	paperwork [1] 115/5	pay [3] 63/2 63/20 64/24
overturned [1] 65/14	paralegal [2] 97/24 136/25	paying [2] 137/20 149/2
own [21] 9/1 10/3 13/16 19/12 28/15 47/25 50/7 81/4 84/9 84/9 84/23 89/2 113/4 118/15 137/6 147/2 148/24 164/4 169/9 169/12 171/20	paralegals [6] 49/17 123/12 164/1 164/2 173/3 173/9	payor [4] 46/3 63/1 63/2 65/1
owned [1] 163/1	parameters [1] 5/13	payors [11] 5/8 37/13 42/18 63/16 63/20 64/13 64/18 64/24 66/19 67/9 67/12
owner [3] 118/23 162/22 163/21	paramount [2] 16/2 159/10	payouts [2] 85/17 85/17
	paranoid [1] 100/1	pays [2] 54/19 63/18
	Pardon [1] 2/7	PEC [10] 35/11 42/10 90/2 90/3 101/15 107/2 114/18 124/6 124/12 124/14
	Parekh [2] 89/8 101/7	peer [1] 147/10
	parents [1] 136/22	pen [1] 16/20
	Parker [3] 170/3 172/3 173/1	penalized [1] 99/8
	part [34] 10/8 22/15 32/9 32/13 36/4 36/4 36/20 38/5 43/11 74/21 77/20 77/21 83/5 94/9 100/12 105/18 105/19 109/12 113/5 119/1 126/18 127/8 127/17 128/3 128/6 128/8 129/7 129/11 129/19 129/20 142/23 159/13 172/16 173/13	pending [2] 5/4 13/2
	participant [1] 109/8	people [77] 6/24 6/25 13/4 13/7 13/19 17/1 18/5 18/16 23/11 23/12 25/5 25/6 25/7 26/25 27/7 33/7 51/16 57/13 60/6 60/23 60/24 61/6 61/8 62/17 76/6 76/8 76/10 84/19 87/23 88/24 91/6 91/23 91/25 96/24 97/9 98/5 98/19 98/21 105/18 106/17 107/18 111/7 112/7 112/19 113/2 113/12 113/15 113/19 113/23 114/5 114/8 119/1 121/12 123/12 124/8 124/16 124/18 143/12 143/15 143/18 152/18 155/17 159/25 163/5 165/20 167/6 168/16 169/21 170/17 171/12
	participants [5] 3/18 4/12 8/8 88/8 180/9	
	participate [4] 4/18 16/22 19/9 108/1	
	participated [2] 102/25 105/10	
	participating [1] 36/13	
	participation [1] 8/2	
	particular [13] 24/14 37/16 44/16 93/18 97/9 109/5 121/7 141/4 142/4 142/8 143/3 148/12 170/8	
	particularizing [1] 108/17	
	particularly [5] 27/12 38/19 56/16 69/18 130/12	
	parties [10] 2/16 41/25 52/22 59/8 106/8 117/16 117/23 126/7 167/24 174/6	
	partner [13] 16/19 39/21 42/9 45/20 58/14 65/3 68/15 68/18 69/7 100/15 123/11 127/7 139/16	
	partners [15] 28/3 33/18	

P	phenomenons [1] 142/11	planning [2] 117/10 131/3
people... [7] 171/13 171/13	Phew [1] 179/19	plans [4] 42/18 64/1 64/7
171/15 171/20 172/7 174/4	philosophy [1] 118/13	111/22
176/18	phon [5] 49/16 69/25 136/19	plate [4] 12/15 53/12 172/19
people's [2] 18/9 159/22	175/22 179/1	172/20
per [3] 17/20 59/8 164/23	phone [1] 158/12	platform [1] 8/18
perceived [1] 7/4	photograph [1] 31/20	play [5] 4/3 91/16 91/19
percent [12] 63/18 63/22	phraseology [1] 99/7	92/8 178/19
64/8 64/14 73/5 73/6 94/5	physician [1] 83/5	played [2] 173/20 178/17
141/2 141/17 154/24 165/19	physicians [4] 83/6 83/6	player [9] 26/8 41/24 55/25
165/21	83/8 83/25	57/10 59/13 94/2 116/12
perfect [2] 162/9 174/1	PI [19] 74/21 74/24 75/4	148/15 168/1
performance [1] 77/19	75/14 75/19 75/20 84/23 86/2	players [3] 36/21 65/19
perhaps [6] 24/5 29/4 30/1	86/7 86/7 86/8 86/8 86/11	82/17
50/13 117/7 150/17	86/22 87/4 87/9 88/1 114/8	playing [2] 12/16 80/2
period [9] 2/14 52/12 52/16	135/2	plead [1] 64/10
117/3 120/13 142/8 143/18	pick [4] 30/2 58/23 116/23	pleadings [2] 18/25 136/4
145/14 146/2	161/9	please [4] 9/8 82/7 113/17
periods [2] 64/3 64/3	picking [1] 176/18	178/20
permanent [2] 16/13 117/8	picture [2] 135/25 149/3	pleased [2] 7/3 63/12
permission [1] 123/13	piece [2] 57/24 90/13	pleasure [4] 12/4 94/20
permit [1] 21/10	Pierce [1] 1/14	139/14 174/13
permitted [1] 62/16	Pierce/West [1] 1/14	pled [2] 63/8 64/9
person [19] 2/2 13/20 57/5	pile [2] 26/23 93/2	pledge [1] 34/17
64/21 65/4 69/8 76/10 81/13	pill [2] 114/10 154/22	plenty [1] 13/7
86/11 94/16 102/11 109/8	pills [2] 46/18 166/16	plethora [1] 83/22
114/17 127/5 127/18 129/13	pings [1] 8/14	plugged [1] 109/24
139/23 142/8 151/14	pink [1] 96/22	plus [7] 11/19 43/6 64/7
person's [2] 142/12 151/12	pinnacle [1] 9/20	64/7 64/7 64/8 146/9
personal [31] 5/8 7/20 11/1	PIP [1] 97/5	pocket [1] 10/11
11/8 14/20 16/17 18/17 27/20	pipe [1] 125/21	podium [5] 39/9 39/10 135/24
27/22 36/22 37/3 38/15 49/5	Pittsburgh [1] 162/25	157/23 157/24
55/19 55/23 57/8 63/17 79/17	pivot [1] 172/6	point [28] 12/17 13/12 15/9
86/17 98/4 110/21 129/9	pivoted [1] 172/6	37/6 38/4 38/7 50/18 51/9
131/3 136/21 137/4 140/22	place [27] 7/21 9/16 12/13	51/22 52/4 61/25 63/22 69/23
144/6 150/15 163/15 164/17	30/10 72/11 74/10 80/25	75/12 76/10 77/2 86/19 88/5
168/14	106/5 108/5 111/10 117/7	102/2 122/7 134/14 138/11
personalities [1] 32/19	117/11 117/11 118/2 120/18	143/17 166/19 175/16 177/4
personally [7] 35/24 65/15	130/1 130/6 130/18 134/11	180/11 180/18
66/1 79/17 95/3 132/13	138/16 142/4 160/21 160/22	points [4] 51/4 53/5 104/3
172/13	167/19 168/2 168/5 179/10	125/13
persons [1] 102/8	placed [2] 94/17 109/4	policy [1] 63/17
perspective [5] 69/18 75/11	places [2] 40/25 96/2	political [1] 20/1
78/7 100/13 134/5	placing [2] 7/2 94/10	Polk [1] 146/13
perspectives [5] 41/1 43/20	Plaintiff [7] 26/6 31/4	pool [2] 4/9 87/11
43/21 107/15 118/20	90/14 120/8 143/3 151/7	pop [1] 61/4
persuasive [1] 83/14	158/25	population [1] 160/4
pertain [1] 116/4	Plaintiff's [3] 120/2 125/18	portal [1] 136/15
pertaining [2] 142/11 146/25	127/25	posed [1] 113/15
pertains [1] 140/23	Plaintiffs [34] 4/16 9/20	position [52] 3/13 9/13
pervaded [1] 54/13	15/16 33/7 33/11 45/8 52/25	10/25 12/6 14/11 16/15 21/17
Petrosinelli [1] 96/13	73/1 75/22 75/23 79/24 86/3	22/23 23/22 24/24 24/25 29/9
Pfizer [2] 116/9 133/2	90/17 92/9 94/11 95/19 118/9	30/9 30/10 34/24 37/1 39/22
pharma [8] 59/17 60/2 60/4	118/12 120/17 122/22 125/2	43/17 51/25 53/10 53/17
60/7 78/5 82/3 137/6 170/22	126/16 139/19 141/5 142/25	53/17 64/20 64/22 69/5 69/6
pharmaceutical [19] 10/6	148/25 150/9 151/1 158/19	70/21 73/6 74/9 75/17 99/19
10/9 10/13 45/6 45/25 83/1	158/21 159/8 159/10 172/7	100/6 104/24 105/4 106/4
84/10 100/14 100/19 112/2	173/25	108/22 109/1 109/9 111/1
114/11 121/18 126/17 126/19	Plaintiffs' [30] 9/14 9/24	139/15 140/4 140/5 140/15
132/10 139/25 146/11 175/9	10/1 17/3 19/3 29/25 33/14	140/24 158/18 159/4 169/9
175/10	35/8 36/2 45/5 52/7 54/14	170/4 170/10 170/11 172/8
pharmaceuticals [1] 141/11	57/18 58/9 60/8 67/7 67/7	172/17
pharmacist [1] 159/12	67/8 71/7 89/17 91/11 111/21	positions [9] 23/4 34/5
pharmacists [1] 83/9	126/14 129/11 134/17 152/25	100/10 100/19 108/4 169/12
pharmacy [1] 63/18	154/21 166/23 169/22 170/2	173/3 173/4 175/24
phase [2] 171/9 171/11	plan [4] 28/25 33/20 129/25	positive [1] 154/7
phenomenal [1] 165/13	172/22	possess [1] 159/3
	planned [2] 5/15 25/22	possibility [1] 19/4

P		pretty [8]	64/21 89/15 99/14 110/25 111/2 112/11 136/23 160/10	professor [4]	32/23 110/5 155/1 155/10
possible [4]	28/1 30/7 59/3 110/25	prevent [1]	108/16	profit [2]	49/7 49/10
possibly [2]	75/19 165/7	previous [1]	136/7	profoundly [1]	16/16
post [1]	63/20	previously [6]	5/17 24/6 77/18 94/2 118/11 131/18	program [3]	118/7 133/24 155/11
poster [1]	165/17	pricing [1]	10/9	progresses [1]	105/15
potential [5]	79/23 80/17 103/19 103/24 111/5	pride [10]	9/3 11/11 13/18 16/25 18/9 19/8 20/5 90/10 108/2 149/5	prohibits [1]	54/2
powder [1]	176/5	primarily [5]	45/18 79/3 83/3 97/5 111/21	project [1]	102/24
power [6]	43/2 43/10 65/2 65/5 149/9 167/4	primary [3]	83/8 125/13 129/5	prominent [1]	118/14
powerful [1]	33/12	prime [1]	127/24	promise [1]	99/10
powers [1]	159/1	principle [1]	146/17	promote [3]	13/16 26/7 33/10
PPI [7]	120/23 123/2 123/9 123/24 124/3 156/17 156/17	principles [1]	149/8	promotes [1]	6/5
PPO's [1]	63/4	prior [2]	23/1 146/9	promoting [4]	11/12 107/12 118/14 138/18
practical [2]	90/12 90/17	priorities [2]	128/4 130/14	Prongay [1]	21/25
practice [23]	50/6 59/14 73/19 74/20 77/9 77/18 81/11 81/12 97/3 100/18 117/13 121/4 126/19 126/24 139/18 139/20 140/3 140/18 144/13 144/18 148/21 154/24 155/13	prioritization [1]	138/2	pronounce [2]	89/11 162/19
practiced [4]	16/6 143/25 154/16 175/6	prioritize [1]	137/22	pronounced [2]	113/3 152/6
practices [3]	30/24 32/9 115/11	private [1]	139/20	proof [2]	161/8 161/11
practicing [6]	33/25 65/3 100/15 115/14 140/17 144/7	privilege [3]	41/22 115/12 127/21	propel [1]	101/18
practitioners [1]	83/8	privileged [1]	3/17	properly [4]	15/16 41/2 42/20 111/10
pragmatic [1]	90/12	pro [2]	76/6 83/19	proponent [2]	171/18 171/19
pre [1]	29/24	probably [14]	21/17 59/10 60/24 60/25 64/1 94/15 101/10 111/3 112/15 122/15 138/15 142/20 156/4 178/23	proposing [1]	129/25
pre-conceived [1]	29/24	problem [7]	92/11 123/10 138/8 152/19 161/3 161/5 178/10	propounding [1]	106/16
predominate [2]	28/12 86/22	problems [6]	106/10 106/10 117/21 154/18 159/23 161/1	pros [1]	63/12
predominates [1]	86/24	procedural [1]	13/25	prosecute [1]	97/10
preemption [2]	11/5 60/1	Procedure [1]	81/2	prosecutor [1]	97/4
preemptive [2]	136/6 136/9	procedures [4]	32/9 80/25 81/4 115/11	protecting [2]	108/9 108/12
prefer [1]	29/9	proceed [4]	88/18 88/18 120/20 158/8	protection [2]	31/5 166/22
preferably [1]	156/21	proceeding [7]	2/7 4/1 8/7 38/15 38/16 62/13 180/16	protections [1]	86/16
prejudice [2]	137/18 138/3	proceedings [3]	117/18 169/14 181/1	protocol [4]	111/24 113/8 116/7 137/16
preliminary [1]	47/4	process [23]	6/5 22/19 31/3 36/10 44/25 77/20 77/22 80/1 80/5 90/22 100/23 106/8 114/13 130/1 130/5 132/17 136/14 138/22 147/10 147/11 161/6 171/24 177/5	protocols [1]	131/24
prematurely [1]	134/15	produce [1]	117/14	protracted [2]	52/11 117/13
premium [1]	96/2	product [13]	13/1 55/19 56/17 58/23 59/3 97/8 106/9 117/25 122/4 124/5 160/16 160/21 162/4	protracting [1]	97/14
preparation [1]	180/14	production [3]	101/22 116/8 117/11	proud [8]	32/13 33/17 40/21 56/9 57/1 58/10 58/12 165/17
prepare [5]	3/25 19/1 41/21 146/21 146/23	products [11]	1/5 10/6 10/14 37/10 47/25 97/6 106/4 120/25 121/1 121/9 121/13	prove [5]	81/17 127/14 151/11 151/16 151/16
prepared [6]	2/7 16/22 35/15 98/13 135/19 171/8	profession [1]	154/4	provided [1]	76/9
preparing [2]	131/11 163/24	professional [4]	6/15 68/21 73/14 105/6	providing [1]	156/9
prescription [4]	63/15 63/19 63/23 64/7	professionalism [6]	16/2 43/13 90/10 96/2 96/8 107/24	PSC [63]	10/24 11/15 11/21 11/24 12/21 14/11 17/10 18/4 29/5 29/9 29/10 29/19 35/10 35/14 37/25 38/1 38/3 39/22 57/23 58/1 58/24 70/10 73/3 74/2 87/21 100/19 102/14 108/21 108/22 108/25 109/6 109/8 112/10 113/25 114/18 117/8 124/5 124/12 124/18 127/6 127/13 127/20 129/18 129/20 140/6 140/18 140/24 140/25 146/7 152/14 153/19 153/19 156/7 156/7 159/2 161/5 167/8 169/8 170/9 173/13 175/20 175/25 178/12
prescriptions [1]	63/25	professionals [1]	159/9	provided [1]	76/9
presence [2]	126/22 126/23			providing [1]	156/9
present [8]	14/8 16/21 19/13 30/9 77/6 146/24 147/19 162/11			PSC [63]	10/24 11/15 11/21 11/24 12/21 14/11 17/10 18/4 29/5 29/9 29/10 29/19 35/10 35/14 37/25 38/1 38/3 39/22 57/23 58/1 58/24 70/10 73/3 74/2 87/21 100/19 102/14 108/21 108/22 108/25 109/6 109/8 112/10 113/25 114/18 117/8 124/5 124/12 124/18 127/6 127/13 127/20 129/18 129/20 140/6 140/18 140/24 140/25 146/7 152/14 153/19 153/19 156/7 156/7 159/2 161/5 167/8 169/8 170/9 173/13 175/20 175/25 178/12
presentation [4]	99/18 135/6 151/17 157/7			PSC's [2]	153/16 169/10
presented [2]	77/21 166/6			psychology [1]	83/9
presenting [2]	168/18 180/13			public [1]	102/25
preservation [3]	112/5 116/5 133/4			pull [1]	68/7
president [1]	62/7			pulled [1]	66/6
presumably [1]	88/25			pulling [2]	95/14 134/22
presume [2]	50/15 171/6			pulls [1]	156/2
pretesting [1]	2/24				
pretrial [1]	95/25				

P purchase [1] 37/10 purchased [2] 33/8 161/12 purchases [2] 37/16 47/16 purely [1] 116/11 purpose [2] 106/21 110/24 purposeful [1] 162/18 purposes [4] 35/25 89/24 90/20 98/25 pursue [2] 34/11 175/9 pursuing [2] 77/10 80/15 pursuit [1] 34/7 push [1] 31/1 pushed [1] 68/8 pushing [1] 9/20 put [35] 5/19 12/13 25/13 26/20 31/9 44/24 45/4 47/19 53/12 56/12 59/6 80/25 86/17 92/22 96/16 109/2 112/20 113/9 114/22 115/5 124/24 130/15 130/18 132/15 134/1 134/11 141/6 153/24 154/4 154/21 158/16 160/21 164/6 165/5 180/15 putative [5] 5/6 33/7 37/15 43/9 63/6 putting [7] 13/5 69/1 78/10 114/3 137/14 152/19 159/22	radiology [1] 147/25 raise [2] 6/21 81/15 raised [1] 162/24 raising [1] 39/1 Ramen [1] 22/25 range [5] 5/4 37/22 91/21 93/2 143/17 ranging [1] 92/4 RANITIDINE [3] 1/4 106/4 155/23 ranks [2] 171/25 173/7 rapport [1] 120/10 rare [2] 50/6 131/20 Rasmussen [3] 94/23 97/21 101/9 rather [6] 4/25 6/19 53/14 75/21 90/12 92/5 Raton [2] 39/22 42/15 RE [1] 1/4 reach [3] 7/15 57/19 102/17 reaching [1] 38/18 read [8] 9/8 26/4 55/10 82/16 136/23 137/9 155/2 155/4 reading [3] 20/9 115/7 148/10 readmitted [1] 88/23 ready [15] 2/2 18/23 30/4 30/7 39/4 43/7 88/24 115/22 121/21 136/9 161/25 161/25 166/20 168/3 178/19 real [6] 31/17 31/18 39/10 56/17 78/8 79/9 Realistically [1] 30/15 realize [4] 4/1 10/24 28/12 141/11 realized [1] 139/24 really [35] 7/17 9/25 18/2 30/15 41/7 47/8 64/13 77/12 84/13 86/12 86/19 88/4 91/16 97/2 111/5 111/14 112/14 113/3 113/6 126/3 127/11 129/14 130/5 134/14 138/8 141/4 146/4 151/22 163/14 165/2 168/5 177/8 178/10 179/11 180/2 reap [1] 109/3 reason [3] 63/14 128/13 170/21 reasons [6] 16/4 86/15 105/17 120/22 140/14 140/21 reassure [1] 122/25 recall [3] 20/19 25/23 134/18 recalled [1] 33/9 receive [1] 129/6 received [1] 70/2 recent [2] 73/3 147/22 recently [5] 22/23 78/2 98/24 106/3 176/21 recess [4] 76/25 89/5 145/19 174/22 recognize [4] 14/3 41/20 76/2 107/17 recognized [1] 140/16 recognizes [3] 5/2 14/7 32/20 recognizing [4] 37/3 38/4	54/4 54/12 recommend [3] 23/21 56/23 57/1 recommended [4] 56/10 56/11 56/22 73/17 record [5] 2/19 96/20 115/19 173/11 181/1 records [2] 164/15 176/14 recover [2] 66/20 66/24 recovery [6] 34/9 66/12 66/13 66/14 66/15 66/17 recreate [1] 91/10 recruited [1] 126/18 recruiting [1] 146/20 recurring [1] 98/15 Reddy [1] 69/25 reduces [1] 104/11 refer [5] 35/25 36/21 37/25 38/1 148/9 reference [3] 83/25 170/18 179/4 referenced [1] 66/15 referral [1] 165/21 referred [3] 122/16 142/17 153/8 referring [1] 148/20 reflected [1] 5/5 reflects [1] 118/18 refreshing [2] 44/19 50/5 refugees [1] 20/1 regard [13] 126/3 126/12 127/11 128/25 136/10 140/5 141/21 142/10 142/21 143/2 143/8 144/2 153/14 regarding [3] 28/8 40/11 179/4 regardless [4] 64/22 95/20 109/9 124/18 regards [2] 35/17 75/3 register [1] 178/2 registered [1] 159/6 registry [13] 103/14 103/23 104/1 104/3 104/14 104/17 133/13 133/14 177/9 177/11 177/11 177/19 178/1 regular [1] 98/15 regularly [1] 61/2 regulators [1] 59/25 regulatory [3] 106/2 121/10 121/13 rehab [1] 160/4 rehash [1] 164/6 reimbursed [1] 37/15 reimbursement [1] 46/4 reinvent [1] 48/18 rejoin [1] 103/6 related [3] 8/11 36/19 168/8 relates [2] 37/18 138/4 relating [1] 62/15 relations [1] 96/4 relationship [8] 19/7 62/24 78/16 120/14 120/19 122/8 122/10 154/7 relationships [6] 11/11 14/1 101/11 105/13 110/22 127/4 relative [1] 4/1 relatively [3] 2/14 51/18 128/5
Q qualified [5] 16/4 36/15 100/9 108/6 120/21 qualifies [1] 96/22 qualities [1] 52/19 quality [3] 33/22 141/12 166/12 quantity [1] 119/13 question [28] 6/21 10/19 13/18 14/15 19/14 19/15 31/25 35/4 35/17 62/5 65/16 67/10 86/15 97/20 99/5 110/14 111/17 113/15 113/16 137/25 149/23 150/12 154/11 167/25 168/9 168/16 178/4 178/6 questions [48] 7/11 7/16 7/16 9/10 11/16 17/6 17/15 24/19 28/8 30/19 31/19 34/20 34/21 46/9 68/12 70/6 78/25 81/25 91/9 92/5 97/16 99/16 99/18 103/10 105/22 106/17 107/8 110/4 110/11 110/13 113/18 116/19 122/22 129/21 133/10 135/17 137/10 141/22 143/6 147/18 151/12 152/16 155/14 167/2 167/3 169/16 169/17 172/11 quick [1] 109/22 quicker [1] 134/23 quickly [3] 12/13 15/3 49/2 quintessential [1] 26/8 quite [14] 6/16 21/21 24/21 26/3 36/7 48/14 61/22 86/6 88/25 107/2 121/10 129/24 156/11 172/4		
R race [2] 4/21 118/19		

<p>R</p> <p>relax [3] 8/18 15/7 20/11</p> <p>released [1] 73/4</p> <p>relentless [1] 34/6</p> <p>relevant [1] 169/17</p> <p>reliable [1] 128/24</p> <p>relied [1] 164/23</p> <p>relief [2] 18/16 85/8</p> <p>rely [3] 6/7 47/20 164/1</p> <p>rely greatly [1] 6/7</p> <p>remarkable [2] 112/11 116/25</p> <p>remarks [7] 15/17 15/20 44/15 135/15 135/19 136/21 163/11</p> <p>remember [1] 4/9</p> <p>remind [2] 46/22 88/6</p> <p>Reminder [1] 88/12</p> <p>reminiscent [1] 169/15</p> <p>remission [1] 85/21</p> <p>remote [1] 173/22</p> <p>remotely [6] 21/3 69/21 167/15 173/21 174/3 174/4</p> <p>repeat [2] 26/8 29/6</p> <p>repeatedly [1] 106/3</p> <p>repetitive [1] 99/17</p> <p>report [2] 7/3 165/9</p> <p>reporter [4] 1/13 46/22 181/4 181/5</p> <p>reporting [2] 126/6 143/13</p> <p>reports [1] 146/21</p> <p>represent [14] 22/3 33/6 42/16 42/17 42/18 45/8 86/6 111/11 115/23 119/2 126/23 133/8 141/21 142/25</p> <p>representation [8] 5/3 23/19 51/23 52/2 87/10 140/1 152/15 158/20</p> <p>representative [6] 4/15 5/20 28/17 70/3 80/8 80/14</p> <p>representatives [3] 79/23 79/25 87/6</p> <p>represented [9] 5/21 33/12 46/4 64/19 73/20 73/21 76/11 119/2 132/13</p> <p>representing [9] 64/23 66/13 86/2 119/3 125/20 126/16 139/19 146/15 153/9</p> <p>reps [3] 83/21 83/21 83/23</p> <p>reputation [8] 40/21 43/18 54/8 54/9 54/10 54/14 106/14 133/7</p> <p>request [2] 74/11 120/16</p> <p>requested [1] 70/19</p> <p>requests [7] 59/7 70/2 70/14 94/8 101/22 101/23 101/25</p> <p>require [2] 6/10 88/16</p> <p>required [5] 6/11 34/11 47/20 53/9 172/16</p> <p>requirement [1] 180/10</p> <p>requirements [1] 28/24</p> <p>requires [5] 16/17 74/5 78/8 96/2 112/21</p> <p>research [8] 56/20 66/4 69/3 69/9 70/15 71/2 79/14 162/6</p> <p>residency [1] 155/11</p> <p>resolution [9] 19/4 52/24 74/5 96/7 101/15 132/16</p>	<p>150/19 150/19 167/24</p> <p>resolutions [3] 19/5 100/20 107/3</p> <p>resolve [4] 30/10 171/8 177/17 177/23</p> <p>resolved [7] 19/5 61/13 65/25 132/22 171/5 176/21 177/22</p> <p>resource [2] 35/16 148/13</p> <p>resources [20] 11/9 15/15 34/23 34/25 35/2 35/2 35/3 35/7 35/20 36/1 38/13 38/14 38/19 40/1 68/19 107/6 117/7 133/7 137/23 141/19</p> <p>respect [4] 12/21 27/6 27/9 41/9</p> <p>respects [1] 25/15</p> <p>responders [1] 157/15</p> <p>response [1] 142/7</p> <p>responsibilities [11] 12/20 40/7 40/7 40/9 42/13 100/22 122/18 123/24 128/4 129/5 129/5</p> <p>responsibility [9] 34/16 56/18 59/4 78/22 99/12 123/21 126/11 126/22 129/15</p> <p>responsible [4] 116/9 126/4 126/8 138/13</p> <p>rest [11] 31/11 44/2 49/22 55/1 60/14 63/20 72/15 104/23 128/22 180/1 180/12</p> <p>Restaino [3] 148/16 152/5 152/13</p> <p>restaurant [5] 162/22 163/2 163/3 163/9 163/23</p> <p>restrictions [3] 94/10 108/16 146/6</p> <p>restrictive [1] 108/11</p> <p>result [6] 37/10 40/18 54/1 60/17 118/8 118/19</p> <p>resulting [1] 133/9</p> <p>results [4] 54/20 77/25 149/11 165/6</p> <p>resume [1] 82/17</p> <p>retailer [2] 47/6 118/4</p> <p>retailers [5] 48/12 48/17 101/24 133/3 138/11</p> <p>retained [1] 102/5</p> <p>retainer [1] 153/7</p> <p>retaining [1] 153/11</p> <p>retired [1] 146/13</p> <p>return [1] 30/24</p> <p>review [17] 28/19 90/18 90/22 91/5 91/7 91/15 92/11 101/1 102/19 113/8 138/24 147/10 156/9 156/10 162/2 164/23 174/7</p> <p>reviewed [2] 101/8 115/21</p> <p>reviewers [1] 91/18</p> <p>revisiting [1] 10/21</p> <p>Richardson [2] 2/23 95/13</p> <p>RICO [2] 45/20 112/1</p> <p>rid [1] 179/16</p> <p>ridiculous [1] 31/24</p> <p>right [56] 2/5 2/6 2/12 8/13 13/7 21/24 24/14 25/23 25/24 29/1 30/18 38/22 39/3 49/12 55/3 60/6 60/19 60/21 60/22</p>	<p>61/3 61/10 61/13 66/15 67/23 72/12 72/19 76/12 85/11 85/11 85/23 88/3 92/14 97/22 98/24 99/1 100/1 100/2 104/18 106/16 106/16 106/17 106/18 106/19 106/21 123/12 124/13 130/19 153/5 156/14 158/9 167/7 167/13 168/17 171/14 171/16 171/17</p> <p>rights [1] 20/2</p> <p>rise [1] 146/16</p> <p>risk [4] 102/10 104/11 151/14 159/12</p> <p>road [1] 179/9</p> <p>Robbins [5] 35/23 36/1 36/12 39/21 40/2</p> <p>ROBIN [2] 1/10 1/13</p> <p>Rodal [3] 162/14 170/16 170/18</p> <p>role [51] 4/3 4/18 6/2 6/3 11/21 11/24 11/24 17/13 17/24 17/25 22/19 24/5 24/12 29/2 29/6 48/21 53/7 55/25 56/2 56/18 57/10 58/25 66/7 68/22 69/6 69/11 70/11 71/6 71/8 71/10 71/14 71/16 71/16 71/17 71/19 72/2 76/2 79/25 80/7 98/25 101/4 108/22 120/17 120/22 123/9 127/1 129/4 143/4 144/24 147/7 172/15</p> <p>roles [12] 12/17 29/8 41/14 69/8 70/18 108/6 113/24 122/24 127/20 129/18 132/12 173/20</p> <p>room [5] 21/10 91/11 96/16 167/19 179/24</p> <p>Roopal [1] 115/1</p> <p>Rosemarie [1] 139/8</p> <p>ROSENBERG [3] 1/3 1/10 1/13</p> <p>Rotman [5] 145/20 145/22 149/20 153/23 155/2</p> <p>roughly [1] 43/5</p> <p>rounded [2] 125/16 127/18</p> <p>Roundup [1] 111/5</p> <p>Rueb [1] 152/17</p> <p>rule [1] 21/23</p> <p>rules [5] 6/15 6/16 81/2 81/3 81/3</p> <p>ruling [1] 178/18</p> <p>rulings [2] 13/11 21/24</p> <p>run [6] 59/4 98/18 136/9 136/11 136/12 174/8</p> <p>running [8] 18/2 18/3 18/4 50/23 72/11 112/10 112/16 121/11</p> <p>ruptured [1] 154/19</p> <p>S</p> <p>sadly [2] 155/18 155/19</p> <p>safe [5] 141/10 141/13 141/14 141/15 157/16</p> <p>safely [1] 31/1</p> <p>safety [1] 31/9</p> <p>said [48] 2/12 8/11 8/12 8/13 9/8 21/17 24/17 26/11 26/12 26/17 26/18 29/6 29/15 29/21 31/24 38/22 39/15</p>
---	---	---

<p>S</p> <p>said... [31] 39/16 39/17 39/20 47/22 53/21 57/15 61/16 76/5 83/1 87/15 89/2 97/15 97/24 98/2 98/6 99/14 101/9 110/1 112/10 120/8 120/16 122/20 137/8 138/7 170/16 172/24 175/9 175/10 175/11 178/20 179/11</p> <p>sail [1] 95/7</p> <p>sake [1] 76/24</p> <p>sale [1] 63/22</p> <p>sales [3] 83/3 83/21 83/23</p> <p>same [32] 6/10 12/1 12/23 18/3 19/2 31/9 39/19 39/20 43/1 55/2 61/14 65/4 96/14 100/1 102/20 102/21 110/10 113/11 113/16 119/22 128/4 137/3 138/16 147/14 168/10 169/8 170/12 173/22 180/20 180/20 180/21 180/21</p> <p>sample [1] 149/8</p> <p>samples [1] 84/2</p> <p>San [3] 45/20 64/24 68/17</p> <p>sanctioned [1] 66/11</p> <p>sanctions [2] 65/13 66/6</p> <p>Sanofi [1] 101/12</p> <p>Sarah [1] 68/15</p> <p>Saturday [1] 121/15</p> <p>Saunders [1] 159/17</p> <p>save [1] 48/18</p> <p>saw [3] 164/13 166/7 178/10</p> <p>say [58] 2/4 7/23 17/17 32/13 33/17 38/1 38/5 38/23 43/24 49/14 50/15 51/15 56/23 57/21 64/17 67/3 72/12 74/14 82/8 83/12 83/17 83/17 84/12 86/4 91/20 94/11 94/12 95/12 96/16 98/7 99/2 99/6 100/8 100/21 101/13 101/13 101/20 102/22 111/4 112/19 112/25 113/15 132/19 138/14 145/12 149/15 154/25 156/13 156/13 158/5 159/11 163/11 164/7 164/13 165/16 165/20 166/5 179/2</p> <p>saying [2] 80/13 96/18</p> <p>sayings [1] 155/8</p> <p>says [1] 168/13</p> <p>scale [2] 9/1 137/3</p> <p>scenes [6] 69/9 69/11 70/14 71/12 71/16 100/25</p> <p>schedule [3] 88/6 145/9 165/9</p> <p>scheduled [1] 5/17</p> <p>scheduling [1] 40/9</p> <p>school [16] 9/18 20/22 20/25 22/6 24/7 61/20 81/2 82/25 123/16 123/17 129/15 160/6 162/5 163/19 173/5 173/5</p> <p>science [42] 48/19 50/20 71/23 83/4 85/12 105/24 112/7 116/11 116/15 121/10 130/12 131/16 133/1 140/4 140/19 140/20 141/23 141/25 143/5 146/8 146/20 147/5 147/8 148/4 149/5 149/23</p>	<p>150/4 150/5 150/18 153/1 153/13 156/8 156/11 164/22 165/25 166/2 166/3 166/4 166/5 166/10 166/14 168/10</p> <p>sciences [1] 157/9</p> <p>scientific [12] 105/22 106/11 106/15 134/12 134/13 146/24 148/6 148/9 149/2 149/11 165/25 168/8</p> <p>scientist [1] 131/11</p> <p>scope [4] 131/10 134/10 134/15 134/15</p> <p>score [6] 102/12 103/25 104/8 104/9 104/10 104/11</p> <p>scores [1] 78/14</p> <p>scoring [9] 102/16 102/18 103/13 103/17 103/21 133/25 134/3 134/8 142/16</p> <p>Scott [3] 10/22 10/23 105/1</p> <p>scratch [1] 166/9</p> <p>scratching [1] 46/24</p> <p>screen [7] 2/8 60/18 61/3 68/8 97/17 97/19 151/6</p> <p>screened [1] 142/20</p> <p>screening [5] 141/25 142/1 142/3 142/6 142/18</p> <p>scroll [1] 60/21</p> <p>se [1] 76/6</p> <p>seamlessly [1] 179/24</p> <p>search [3] 92/11 101/21 101/25</p> <p>seasoned [6] 4/12 21/19 121/24 122/6 128/2 170/13</p> <p>seat [2] 165/14 169/10</p> <p>Seattle [3] 30/22 30/25 31/8</p> <p>second [9] 26/22 43/7 89/21 89/21 98/11 109/22 128/13 132/14 158/2</p> <p>Secondly [2] 83/25 121/15</p> <p>seconds [2] 24/2 157/12</p> <p>section [1] 175/1</p> <p>securely [1] 31/4</p> <p>securities [2] 43/3 89/17</p> <p>see [70] 2/5 11/14 12/7 15/11 16/19 24/24 25/5 26/4 27/22 28/10 29/2 29/7 29/12 29/18 36/18 41/17 41/18 44/19 48/24 68/3 70/9 71/8 72/21 72/22 74/19 75/13 76/18 76/20 77/2 81/25 82/2 86/2 86/5 88/13 89/3 94/22 99/25 101/12 101/17 105/4 109/23 110/1 110/6 111/2 117/2 125/5 130/12 141/8 143/12 143/15 144/2 148/16 149/13 149/23 150/17 151/18 155/21 156/24 158/13 158/14 160/11 161/11 167/11 167/15 170/1 173/7 176/17 177/15 177/21 179/6</p> <p>seeing [4] 21/1 114/14 155/23 180/13</p> <p>seek [2] 37/14 43/17</p> <p>seeking [5] 11/21 37/9 39/22 100/11 104/24</p> <p>seems [1] 59/13</p> <p>seen [16] 44/18 56/24 64/2 72/2 72/3 76/5 81/10 86/14</p>	<p>86/21 86/21 94/8 143/20 145/3 151/19 155/22 177/6</p> <p>select [5] 3/25 23/10 74/11 88/2 99/11</p> <p>selected [12] 4/2 4/8 6/6 23/11 29/8 74/2 76/16 77/20 78/7 81/17 82/13 108/10</p> <p>selecting [1] 6/25</p> <p>selection [5] 103/11 130/2 141/24 153/13 177/4</p> <p>selections [1] 130/9</p> <p>self [1] 63/4</p> <p>semi [1] 154/25</p> <p>seminal [1] 16/10</p> <p>send [1] 91/20</p> <p>sending [1] 178/24</p> <p>senior [4] 12/6 17/1 45/19 145/2</p> <p>sense [12] 16/13 30/12 62/22 77/8 92/13 112/25 113/1 114/17 114/18 114/18 120/24 138/13</p> <p>sent [1] 154/11</p> <p>separate [13] 27/23 63/8 63/11 70/5 72/10 87/2 87/3 87/9 98/23 118/4 151/15 168/13 168/14</p> <p>separately [1] 66/2</p> <p>separating [1] 72/9</p> <p>September [3] 102/24 154/17 164/14</p> <p>serious [1] 155/19</p> <p>seriously [7] 77/16 99/12 99/13 122/19 123/21 129/1 149/5</p> <p>serve [20] 15/22 29/19 34/24 44/22 45/5 49/10 51/5 51/11 51/16 53/17 77/20 87/16 108/6 119/20 138/22 139/2 139/25 144/24 150/8 175/20</p> <p>served [8] 41/13 70/17 72/1 76/2 101/15 128/8 140/25 165/8</p> <p>serves [1] 106/20</p> <p>service [3] 116/4 136/14 141/3</p> <p>services [1] 49/20</p> <p>serving [8] 4/4 6/2 78/21 86/3 90/3 115/13 127/21 140/17</p> <p>session [9] 2/22 2/24 2/24 80/21 89/7 89/14 179/12 179/19 180/5</p> <p>set [13] 14/21 18/9 19/9 41/11 45/3 86/12 87/8 90/1 103/14 106/13 113/4 123/4 127/9</p> <p>sets [2] 7/6 32/18</p> <p>setting [4] 87/4 87/11 146/4 177/9</p> <p>settings [1] 105/11</p> <p>settled [3] 10/17 46/6 69/14</p> <p>settlement [20] 9/23 52/24 62/20 74/25 75/3 75/3 85/22 86/17 87/6 87/11 102/17 108/10 109/6 133/15 133/16 133/19 134/7 158/20 171/4 176/17</p>
--	--	---

<p>S</p> <p>settlements [2] 69/14 108/14</p> <p>settling [2] 108/16 176/23</p> <p>seven [2] 65/9 82/8</p> <p>Seventh [2] 65/23 66/6</p> <p>several [15] 10/18 32/8 44/18 46/5 80/6 86/8 126/21 136/9 148/2 159/20 169/10 175/13 175/18 175/21 176/8</p> <p>severe [3] 85/17 85/18 85/21</p> <p>sexual [2] 4/22 118/19</p> <p>sexual orientation [1] 4/22</p> <p>share [21] 3/10 4/24 7/18 8/1 29/20 35/7 35/12 46/14 48/5 48/6 63/16 76/13 80/20 81/20 87/14 97/19 98/5 116/22 157/25 161/17 177/5</p> <p>shared [3] 3/19 68/1 119/5</p> <p>sharing [6] 53/5 104/20 114/23 145/6 149/21 152/3</p> <p>sharp [1] 54/15</p> <p>she [31] 3/6 8/11 8/13 8/21 29/16 29/17 31/24 39/17 53/21 58/13 58/14 58/15 58/16 58/17 62/1 68/4 68/5 73/15 74/11 97/25 97/25 98/2 98/3 98/6 98/8 98/8 98/9 98/9 105/11 105/12 154/19</p> <p>sheer [1] 117/23</p> <p>sheet [3] 129/10 129/11 130/8</p> <p>sheets [3] 67/7 67/7 67/8</p> <p>Sheffield [1] 179/1</p> <p>shift [1] 91/14</p> <p>shine [1] 111/14</p> <p>ship [2] 164/14 164/18</p> <p>shipping [2] 106/9 135/3</p> <p>short [8] 2/14 68/19 98/3 120/13 145/9 145/14 145/19 146/2</p> <p>shortly [2] 35/22 69/4</p> <p>shot [1] 14/13</p> <p>should [43] 2/12 11/25 22/20 24/23 29/13 30/8 30/16 31/23 34/23 36/15 36/25 50/18 51/23 61/1 63/8 75/8 75/10 75/11 75/17 80/13 88/12 88/13 100/8 101/10 108/9 109/9 111/19 112/10 124/20 124/23 134/5 150/8 156/10 160/20 160/21 165/3 167/5 167/7 170/16 174/10 179/20 179/23 179/23</p> <p>shoulder [4] 35/7 35/12 35/13 35/15</p> <p>shouldered [1] 12/20</p> <p>shout [2] 157/12 157/14</p> <p>show [7] 92/14 92/15 137/2 165/1 165/5 165/5 165/6</p> <p>showcased [1] 4/20</p> <p>showed [2] 73/7 166/6</p> <p>showing [2] 166/17 177/10</p> <p>shown [2] 4/6 33/24</p> <p>shows [1] 166/14</p> <p>shredding [1] 92/17</p> <p>side [68] 9/18 9/20 11/8 11/9 13/24 14/20 27/7 27/12</p>	<p>27/20 27/20 28/11 29/5 29/25 31/4 31/4 34/25 35/16 36/1 36/2 36/14 36/18 36/22 36/22 37/4 37/19 38/10 38/15 38/15 41/19 43/1 51/12 52/23 58/6 58/7 58/9 59/1 79/10 80/2 82/3 83/11 84/23 86/7 86/11 88/1 88/1 90/14 90/14 94/8 94/9 96/13 96/16 97/4 113/24 120/8 120/9 125/18 126/14 127/25 134/17 137/15 137/19 150/16 160/5 169/20 169/22 169/24 170/2 172/7</p> <p>sides [9] 27/18 36/23 74/6 87/6 94/13 94/17 94/18 108/16 137/23</p> <p>signature [3] 151/21 155/23 181/5</p> <p>signatures [1] 95/7</p> <p>signed [1] 167/13</p> <p>significance [1] 149/9</p> <p>significant [12] 23/14 42/11 46/16 46/18 48/25 49/9 55/22 63/25 129/7 132/19 151/22 152/20</p> <p>significantly [1] 100/23</p> <p>silicone [1] 154/19</p> <p>similar [6] 50/22 80/12 120/23 124/4 138/12 176/10</p> <p>similarities [2] 45/12 48/4</p> <p>similarity [1] 36/8</p> <p>similarly [2] 17/10 139/1</p> <p>simplification [1] 149/7</p> <p>simultaneously [2] 31/10 142/12</p> <p>since [18] 2/13 16/6 22/1 26/7 40/7 45/23 63/25 80/19 83/18 86/20 102/24 115/15 127/16 136/23 146/18 154/23 159/19 175/20</p> <p>single [5] 80/15 124/16 139/22 139/22 165/24</p> <p>singular [1] 110/25</p> <p>sit [4] 9/22 15/6 60/15 172/8</p> <p>site [1] 12/16</p> <p>sitting [3] 21/15 90/25 91/11</p> <p>situation [9] 39/19 57/5 69/19 69/25 80/16 81/15 120/6 127/2 141/7</p> <p>situations [1] 127/3</p> <p>six [6] 8/13 66/10 101/20 115/18 145/9 160/25</p> <p>size [8] 36/6 38/2 124/2 124/4 124/10 124/18 149/8 171/22</p> <p>skill [3] 32/18 45/3 90/1</p> <p>skills [13] 4/6 18/3 18/10 18/12 26/16 34/14 55/17 79/6 79/7 93/23 116/17 124/19 159/3</p> <p>skin [1] 84/2</p> <p>skipped [3] 60/24 61/7 61/7</p> <p>slate [3] 77/20 77/22 154/2</p> <p>slightly [2] 4/17 37/24</p> <p>Sloan [1] 130/13</p> <p>small [5] 15/15 51/5 56/14</p>	<p>77/9 128/5</p> <p>smaller [7] 9/1 36/5 78/8 79/15 127/23 158/19 158/23</p> <p>smoked [1] 166/16</p> <p>smoothly [2] 2/18 136/12</p> <p>so [221]</p> <p>so-called [1] 78/5</p> <p>solar [1] 114/20</p> <p>solid [5] 15/5 19/7 59/7 102/1 120/10</p> <p>some [72] 2/3 3/19 7/11 9/10 12/25 13/1 23/18 24/2 25/15 27/7 33/11 38/7 38/12 38/13 45/2 48/2 48/3 48/4 49/7 52/19 61/6 61/25 64/4 64/6 66/4 67/2 67/4 68/12 70/4 71/5 81/16 85/13 87/23 96/19 97/16 99/3 99/6 101/2 105/20 106/24 113/15 122/9 129/24 130/6 130/14 130/14 134/10 136/5 136/13 136/18 138/3 138/22 142/3 152/15 154/8 155/7 156/11 156/13 159/3 162/2 164/10 164/16 164/19 168/10 169/12 169/16 173/10 175/16 176/4 176/21 177/2 180/10</p> <p>somebody [7] 8/14 21/8 32/1 46/22 122/13 127/13 158/11</p> <p>Somehow [2] 60/23 153/24</p> <p>someone [14] 2/12 16/8 20/3 21/14 85/19 85/20 87/20 109/7 113/22 144/20 160/12 164/3 165/14 175/11</p> <p>something [35] 9/2 11/13 25/7 26/13 27/2 33/16 33/23 46/19 56/9 56/20 57/22 65/8 69/21 77/8 77/15 79/25 80/10 81/5 81/6 81/7 85/22 90/16 95/14 96/24 103/11 104/15 110/23 111/20 124/22 161/15 164/10 164/11 168/15 173/1 174/10</p> <p>sometimes [7] 45/13 86/22 86/24 98/17 112/24 129/17 156/21</p> <p>somewhat [6] 52/4 54/14 78/12 100/25 103/17 169/7</p> <p>somewhere [1] 71/3</p> <p>son [1] 82/22</p> <p>soon [2] 30/7 51/19</p> <p>sorry [1] 158/15</p> <p>sort [5] 51/6 51/15 78/23 94/1 103/14</p> <p>sorts [2] 84/3 95/6</p> <p>sought [2] 6/14 140/14</p> <p>sounded [1] 176/10</p> <p>soup [1] 121/18</p> <p>sour [1] 143/19</p> <p>South [3] 59/22 100/17 166/20</p> <p>SOUTHERN [1] 1/1</p> <p>Spanish [1] 62/10</p> <p>spanning [1] 120/25</p> <p>sparked [2] 162/4 163/18</p> <p>speak [13] 19/12 44/10 58/21 62/2 81/12 82/11 103/5 103/7 110/4 125/12 139/5 157/24</p>
--	--	--

<p>S</p> <p>speak... [1] 180/3</p> <p>speaking [4] 6/17 103/2 142/9 150/15</p> <p>speaks [1] 27/8</p> <p>special [13] 3/7 6/12 9/21 32/22 41/5 44/12 44/20 56/1 66/2 119/19 146/3 146/14 149/17</p> <p>specialties [1] 147/22</p> <p>specific [11] 67/8 143/7 146/25 147/18 150/10 151/4 151/5 151/16 151/16 151/23 151/24</p> <p>specifically [9] 6/17 48/11 60/4 68/22 95/25 112/1 158/24 159/25 168/8</p> <p>specificity [1] 14/17</p> <p>spectrum [2] 3/2 90/9</p> <p>spend [11] 9/7 9/9 12/22 22/5 40/4 42/1 42/19 117/3 132/21 148/10 176/24</p> <p>spending [1] 25/8</p> <p>spent [12] 10/4 13/1 15/2 20/20 40/8 40/20 42/11 84/6 120/22 136/2 136/5 140/8</p> <p>spiel [1] 78/23</p> <p>Spirit [1] 73/21</p> <p>spoke [11] 13/14 43/12 55/25 102/24 131/18 132/1 138/1 158/12 164/23 167/6 167/14</p> <p>spoken [6] 19/20 48/2 59/12 103/12 161/18 169/21</p> <p>spot [3] 94/25 124/21 178/12</p> <p>spots [1] 38/13</p> <p>spread [2] 100/16 113/18</p> <p>square [1] 33/11</p> <p>squeeze [1] 21/4</p> <p>staff [10] 12/15 95/13 123/10 123/14 152/19 153/3 173/11 173/11 175/1 175/3</p> <p>staffed [2] 68/19 117/6</p> <p>staffing [4] 37/18 37/19 37/20 124/1</p> <p>stage [7] 15/2 30/16 48/15 129/25 132/5 157/10 171/6</p> <p>stages [4] 67/18 67/18 123/5 126/20</p> <p>stagger [1] 118/3</p> <p>staggering [2] 111/2 111/7</p> <p>stake [1] 64/18</p> <p>stakeholders [1] 6/23</p> <p>stance [1] 106/3</p> <p>stand [3] 14/5 14/10 171/23</p> <p>standards [3] 6/22 63/21 147/17</p> <p>standing [1] 80/15</p> <p>standpoint [2] 34/23 93/6</p> <p>start [15] 17/15 32/16 41/18 50/23 84/11 88/7 94/25 131/1 131/13 138/15 150/21 156/16 162/23 179/20 180/19</p> <p>started [35] 8/25 9/18 20/6 21/19 40/6 45/17 45/19 61/20 73/15 78/2 84/9 89/1 89/13 89/16 91/1 97/23 100/24 109/20 120/9 123/15 125/24</p>	<p>136/22 138/8 138/16 139/21 139/24 140/1 154/17 162/3 169/19 169/20 170/5 173/3 178/21 180/4</p> <p>starting [8] 9/3 9/16 12/2 12/13 102/2 134/20 141/1 143/16</p> <p>starts [1] 174/19</p> <p>startup [1] 94/4</p> <p>state [15] 28/9 28/10 28/11 28/19 28/22 28/23 28/24 46/3 46/4 46/7 117/17 117/18 156/25 157/3 169/14</p> <p>stated [2] 94/1 166/4</p> <p>statement [22] 4/24 7/24 9/6 15/17 21/5 21/13 26/3 32/4 50/2 55/8 72/24 77/6 82/6 93/24 95/10 96/5 100/3 100/8 109/19 111/22 115/9 119/14</p> <p>statements [1] 7/11</p> <p>states [21] 1/1 1/10 28/18 28/19 28/20 30/3 30/3 30/4 30/5 47/13 47/14 47/16 47/17 47/18 53/25 54/4 59/22 62/11 96/23 152/18 159/21</p> <p>statistical [1] 149/9</p> <p>stay [6] 65/5 88/10 145/15 157/16 158/11 180/10</p> <p>stayed [2] 162/5 180/8</p> <p>staying [2] 97/11 113/12</p> <p>steer [1] 53/15</p> <p>steering [17] 9/14 21/17 22/2 23/15 23/21 24/21 24/24 38/6 45/5 51/19 68/22 68/23 71/7 107/2 139/15 152/25 154/21</p> <p>step [4] 70/20 71/9 71/19 132/7</p> <p>stepping [1] 144/16</p> <p>Steve [7] 23/22 25/15 145/20 145/21 153/23 154/5 154/12</p> <p>sticking [1] 110/20</p> <p>still [8] 13/21 63/23 65/3 65/4 107/1 145/14 158/13 174/17</p> <p>Stipes [2] 1/13 181/4</p> <p>Stoller [2] 152/17 154/10</p> <p>stomach [2] 143/20 150/24</p> <p>stones [1] 144/16</p> <p>stop [5] 88/22 89/3 145/16 149/14 180/18</p> <p>stopped [1] 94/25</p> <p>storage [3] 101/8 106/9 135/3</p> <p>store [1] 162/25</p> <p>stories [1] 163/17</p> <p>storing [1] 176/10</p> <p>story [7] 39/15 98/3 111/15 111/16 157/25 159/16 163/14</p> <p>straight [1] 114/19</p> <p>straightforward [1] 35/3</p> <p>stranger [2] 70/25 96/15</p> <p>strategic [3] 51/16 85/4 116/14</p> <p>strategizing [1] 40/11</p> <p>strategy [6] 40/14 93/5 116/10 117/1 128/15 140/19</p> <p>streak [2] 68/11 152/8</p>	<p>streamline [1] 116/4</p> <p>streamlining [1] 136/14</p> <p>strength [7] 60/3 60/4 60/5 70/22 146/8 155/25 156/6</p> <p>strengthen [1] 14/10</p> <p>strengthens [1] 118/21</p> <p>strengths [3] 30/9 70/24 125/1</p> <p>stress [6] 8/8 50/17 51/22 52/20 158/15 158/15</p> <p>stressful [1] 9/4</p> <p>strikes [1] 81/3</p> <p>strive [2] 148/21 159/10</p> <p>stroke [1] 16/21</p> <p>strong [12] 54/16 57/14 72/5 116/12 128/13 129/14 134/2 134/6 140/17 141/18 153/16 171/16</p> <p>strong/weak [1] 134/6</p> <p>strongly [2] 30/25 124/24</p> <p>struck [2] 110/14 110/15</p> <p>structure [19] 3/20 3/22 29/3 47/8 50/14 50/19 51/10 52/9 57/4 72/6 114/17 124/2 124/12 125/15 138/1 138/4 144/4 144/22 171/10</p> <p>structures [2] 111/14 124/22</p> <p>structuring [1] 47/2</p> <p>struggled [1] 31/7</p> <p>stuck [1] 173/19</p> <p>student [1] 160/7</p> <p>students [3] 21/2 99/8 156/23</p> <p>studies [10] 85/13 85/25 134/13 134/14 134/20 134/21 140/10 149/10 156/20 168/8</p> <p>study [7] 26/17 73/3 73/7 130/13 148/12 149/11 166/17</p> <p>stuff [1] 92/17</p> <p>stumbling [1] 13/5</p> <p>stupid [1] 31/25</p> <p>style [6] 7/17 27/5 27/6 27/10 178/7 178/8</p> <p>sub [1] 4/4</p> <p>sub-committee [1] 4/4</p> <p>subclass [1] 18/16</p> <p>subcommittee [1] 68/24</p> <p>subject [4] 6/14 6/16 113/23 147/14</p> <p>submission [1] 50/12</p> <p>submissions [2] 55/10 164/6</p> <p>submit [2] 33/21 168/18</p> <p>submitting [2] 4/7 139/12</p> <p>subpoenas [2] 129/12 165/11</p> <p>subsequently [1] 32/10</p> <p>substance [2] 102/20 166/6</p> <p>substantial [7] 16/5 49/6 113/22 113/24 121/13 153/17 177/2</p> <p>substantially [1] 93/6</p> <p>substantive [3] 13/25 18/1 24/15</p> <p>substantively [3] 12/8 17/14 119/13</p> <p>subsuming [1] 93/2</p> <p>succeed [1] 173/7</p> <p>success [5] 16/11 30/6 30/11 42/22 51/13</p>
---	---	--

<p>S</p> <p>successful [10] 29/22 29/23 29/24 29/25 41/3 101/14 110/9 114/4 126/24 173/24</p> <p>successfully [7] 10/17 42/3 43/21 52/22 116/13 162/10 173/13</p> <p>such [9] 2/14 16/9 25/9 27/6 46/1 81/13 105/17 120/12 129/19</p> <p>sudden [1] 177/10</p> <p>suffered [1] 18/17</p> <p>Suffice [1] 98/7</p> <p>sufficiency [1] 30/3</p> <p>sufficient [1] 167/24</p> <p>suggest [2] 57/5 57/10</p> <p>suggesting [1] 38/8</p> <p>suit [1] 57/14</p> <p>suitable [2] 97/1 165/22</p> <p>sum [1] 88/21</p> <p>SummaCare [2] 65/19 66/20</p> <p>summary [2] 23/2 67/18</p> <p>summer [3] 123/4 123/5 136/25</p> <p>sums [1] 114/4</p> <p>sun [1] 94/12</p> <p>super [1] 105/16</p> <p>supervising [1] 91/25</p> <p>supplement [1] 36/16</p> <p>supplemental [1] 64/4</p> <p>suppliers [2] 114/11 114/11</p> <p>support [11] 3/3 11/7 12/15 70/16 71/18 74/9 107/14 122/5 172/21 173/12 175/1 42/10 79/18 79/18</p> <p>supported [5] 41/14 41/17</p> <p>supports [1] 74/12</p> <p>suppose [2] 4/2 82/20</p> <p>supposed [2] 66/23 141/16</p> <p>Supreme [2] 10/19 54/1</p> <p>sure [40] 2/25 8/12 11/14 13/4 17/16 17/22 25/7 46/23 56/4 60/6 65/7 65/15 67/22 71/20 72/11 72/19 79/20 79/21 81/14 85/10 86/5 87/10 87/10 89/15 92/19 94/14 98/22 99/25 100/2 103/16 107/18 108/3 118/18 119/5 138/6 138/21 158/16 160/10 160/12 163/23</p> <p>surface [1] 4/20</p> <p>surgery [2] 154/16 162/7</p> <p>surgical [1] 155/10</p> <p>surprised [1] 177/9</p> <p>survive [1] 14/21</p> <p>survived [1] 128/11</p> <p>suspect [2] 105/14 114/16</p> <p>sustain [1] 96/4</p> <p>sustainable [1] 114/2</p> <p>sustaining [4] 43/10 65/2 65/5 167/4</p> <p>sweet [1] 38/10</p> <p>swiftly [1] 96/6</p> <p>swirling [1] 170/19</p> <p>switched [1] 45/24</p> <p>symptom [1] 156/16</p> <p>symptoms [3] 151/9 151/10</p>	<p>156/18</p> <p>sync [1] 67/25</p> <p>synergies [2] 13/3 18/18</p> <p>synergy [2] 10/25 12/24</p> <p>system [12] 20/3 103/13 114/20 133/25 134/3 134/8 142/16 153/6 160/20 166/19 176/12 176/13</p> <p>systems [2] 12/11 103/17</p> <p>T</p> <p>tab [1] 72/19</p> <p>table [7] 108/24 109/9 114/5 117/25 125/1 125/17 128/24</p> <p>tabs [2] 61/3 179/13</p> <p>tack [1] 109/19</p> <p>tailor [2] 6/12 93/12</p> <p>tailored [1] 67/12</p> <p>tailoring [1] 93/18</p> <p>take [54] 3/1 7/20 7/22 12/4 12/14 13/18 18/3 24/25 34/8 35/2 52/8 56/18 59/4 61/16 61/25 68/20 68/21 76/25 77/15 88/25 95/1 95/3 96/8 96/15 98/22 99/11 99/12 103/12 106/5 113/17 119/25 122/18 123/21 127/19 128/19 128/25 130/22 132/7 135/9 139/7 140/2 145/8 145/11 146/22 149/4 149/5 157/11 163/10 164/25 166/11 171/21 173/13 177/23 178/2</p> <p>takeaway [1] 48/5</p> <p>taken [12] 8/25 46/23 48/14 83/22 89/5 127/15 143/18 143/19 145/19 153/1 176/11 179/8</p> <p>takes [6] 20/3 96/17 103/21 131/2 155/7 158/21</p> <p>taking [23] 34/22 69/9 77/23 88/9 89/22 101/2 104/9 104/17 114/22 119/22 121/20 126/5 135/6 139/5 139/11 142/17 156/17 156/17 161/14 162/11 168/18 176/1 176/22</p> <p>talc [6] 111/4 153/19 153/21 155/15 155/20 164/10</p> <p>talcum [1] 176/5</p> <p>talent [4] 4/6 4/9 17/3 33/13</p> <p>talented [1] 149/18</p> <p>talents [3] 18/5 108/24 140/2</p> <p>talk [21] 13/22 35/2 62/25 64/17 66/2 82/6 82/14 83/5 83/23 91/8 91/19 98/8 108/8 132/7 147/4 149/14 158/5 165/18 171/9 172/9 175/5</p> <p>talked [5] 58/4 136/7 164/21 168/4 178/20</p> <p>talking [19] 19/24 20/24 22/10 22/11 46/25 56/13 57/12 60/3 65/2 65/11 83/15 85/17 91/12 92/8 134/7 163/22 165/15 166/24 176/10</p> <p>talks [1] 168/2</p> <p>tall [1] 174/21</p> <p>Tampa [3] 57/17 82/15 103/1</p>	<p>tandem [2] 13/5 47/10</p> <p>tangential [1] 24/12</p> <p>Tar [5] 92/9 92/21 92/21 92/23 92/24</p> <p>target [2] 125/20 151/2</p> <p>task [3] 30/4 127/19 128/16</p> <p>tasks [2] 40/17 129/13</p> <p>taught [2] 138/24 155/10</p> <p>Taxotere [2] 160/16 160/18</p> <p>TEA [1] 91/21</p> <p>teacher [4] 20/22 22/6 22/12 24/7</p> <p>teachers [2] 21/1 21/2</p> <p>teaching [7] 20/20 20/21 20/24 24/4 155/12 156/11 156/22</p> <p>team [111] 3/25 4/15 4/15 4/17 5/3 5/20 6/13 9/21 10/8 11/5 11/7 16/1 16/4 18/2 18/6 19/3 26/5 26/6 27/3 27/17 27/17 32/11 32/14 32/19 33/17 33/19 33/22 34/18 35/8 35/11 35/18 35/19 35/20 36/4 36/13 36/17 38/1 38/7 38/19 39/25 40/9 41/24 42/13 43/11 44/23 44/25 45/3 45/7 49/5 49/15 50/16 52/1 56/10 56/19 56/20 59/2 59/6 60/5 62/22 75/16 78/6 78/21 79/16 79/19 82/13 83/3 114/22 115/11 115/13 116/10 116/11 116/11 116/12 116/17 117/7 118/16 118/25 119/19 122/2 127/8 128/3 128/14 128/23 129/19 129/20 129/20 131/9 135/23 136/2 136/3 148/15 159/13 165/10 165/22 166/3 166/4 168/1 168/2 168/5 170/12 171/10 171/14 171/16 172/20 172/23 172/25 173/13 173/17 175/16 177/8 178/14</p> <p>teams [13] 18/19 32/10 33/23 34/4 40/5 41/7 41/8 45/1 73/23 79/21 82/3 120/18 171/12</p> <p>tears [1] 18/15</p> <p>tease [1] 155/2</p> <p>tech [1] 3/3</p> <p>technical [1] 92/5</p> <p>technically [1] 5/11</p> <p>technological [1] 69/20</p> <p>technology [6] 8/9 8/17 39/16 69/19 70/7 174/10</p> <p>teen [1] 92/4</p> <p>teen-agers [1] 92/4</p> <p>teens [2] 143/16 143/20</p> <p>tell [25] 4/25 8/19 9/15 12/7 24/10 28/8 29/5 29/23 30/19 39/14 48/22 58/24 66/9 66/16 84/16 93/25 98/19 104/4 124/3 131/6 156/25 158/9 163/13 163/17 165/4</p> <p>teller [1] 12/5</p> <p>telling [6] 22/5 24/18 24/19 84/6 94/24 161/13</p> <p>tells [1] 43/15</p> <p>temperament [1] 34/14</p>
--	--	--

<p>T</p> <p>temporarily [1] 94/4</p> <p>ten [14] 17/19 40/2 43/6 53/12 64/14 89/18 100/15 140/1 145/17 152/9 165/19 165/21 171/7 178/14</p> <p>tenant [1] 156/1</p> <p>tens [2] 26/20 105/18</p> <p>tension [1] 86/25</p> <p>Tenth [1] 89/20</p> <p>term [7] 4/1 45/25 114/2 135/21 159/24 160/3 160/3</p> <p>terms [33] 11/4 16/17 18/22 22/10 27/5 37/21 58/25 78/9 92/11 96/9 96/10 96/21 96/25 97/3 101/21 101/25 112/8 118/6 118/24 124/4 125/14 126/12 130/1 130/14 130/14 131/18 133/7 133/25 134/7 134/16 135/1 135/3 138/1</p> <p>terrible [1] 114/13</p> <p>terrific [9] 25/20 67/23 104/18 108/8 119/4 128/2 133/11 145/5 174/12</p> <p>Terry [1] 122/10</p> <p>test [6] 2/2 30/3 40/23 92/16 93/1 171/23</p> <p>testament [2] 26/15 126/25</p> <p>testicular [1] 104/6</p> <p>testimony [2] 78/17 173/23</p> <p>testing [3] 2/22 2/24 134/19</p> <p>text [1] 154/11</p> <p>texting [1] 65/24</p> <p>texts [1] 93/10</p> <p>Thai [3] 162/21 163/5 163/9</p> <p>than [32] 4/25 9/1 9/10 14/4 22/9 29/14 29/16 31/16 34/9 35/6 35/14 38/24 39/15 43/25 53/12 60/25 74/12 75/21 85/18 85/20 90/12 92/5 95/23 107/16 113/17 132/12 134/10 136/15 147/9 148/11 149/15 180/3</p> <p>thank [153] 3/1 3/6 3/12 5/10 8/1 11/17 14/14 15/7 15/21 15/23 16/1 17/8 20/10 20/11 20/11 20/13 21/14 24/4 25/12 25/25 26/10 28/7 31/6 31/11 32/5 34/21 36/24 37/17 39/4 39/6 39/12 42/4 43/23 43/25 44/2 44/8 44/16 44/22 46/11 48/1 49/21 49/21 49/24 50/3 50/4 53/4 53/4 54/23 54/25 55/5 55/6 55/9 58/20 60/13 61/18 67/23 67/25 68/13 72/13 72/16 72/25 74/13 74/14 76/15 76/18 76/20 79/9 81/19 81/22 81/23 84/15 86/1 88/3 89/12 93/4 94/18 94/19 95/11 95/12 95/15 95/21 99/17 99/17 99/20 100/4 103/9 104/18 104/22 104/23 104/25 105/2 107/10 109/11 109/13 114/21 115/2 115/4 115/10 115/12 116/21 119/6 119/8 119/10 119/18 125/4 125/5 125/7</p>	<p>125/11 130/19 130/20 130/21 131/5 133/11 135/5 135/8 135/11 135/13 135/14 135/15 135/20 139/4 139/11 145/5 145/7 145/25 149/20 150/14 152/2 152/12 157/11 157/15 157/17 157/18 157/22 162/9 162/10 162/12 164/7 167/20 168/17 169/6 172/14 174/12 174/12 174/15 177/1 179/13 179/15 179/16 179/18 179/25 180/7 180/7</p> <p>thanking [1] 131/1</p> <p>thanks [6] 72/15 99/21 139/6 145/17 152/2 168/24</p> <p>that [984]</p> <p>that's [1] 170/19</p> <p>the American [1] 73/21</p> <p>their [52] 6/2 6/7 16/2 18/5 19/12 36/19 37/10 37/15 47/21 47/24 47/25 49/20 50/7 61/20 66/25 78/16 78/17 79/24 80/9 81/15 82/18 96/3 108/4 110/8 113/3 122/6 122/19 126/18 126/19 137/20 143/7 143/11 143/16 144/18 144/20 144/24 146/1 146/21 148/19 151/15 151/15 153/4 158/25 161/13 164/24 165/20 166/14 166/15 171/20 171/20 176/16 178/2</p> <p>them [76] 7/15 14/10 16/3 18/8 22/14 24/18 24/19 26/4 31/10 32/14 35/23 35/24 38/13 41/10 45/4 48/11 55/15 57/1 65/18 76/9 76/9 78/18 82/12 82/14 82/14 83/19 84/3 91/12 91/25 92/6 96/16 103/1 103/6 105/6 105/7 108/24 111/6 112/13 112/13 112/24 112/24 116/13 116/20 121/20 122/9 122/23 127/14 128/25 131/10 137/20 139/3 140/3 143/9 144/25 146/20 146/21 146/21 148/20 151/6 154/8 155/12 159/19 159/23 159/24 161/9 162/6 165/11 165/11 165/24 166/6 166/15 167/14 169/1 169/2 169/9 179/6</p> <p>themes [1] 179/12</p> <p>themselves [5] 20/6 24/18 108/5 127/14 155/13</p> <p>then [14] 45/16 45/23 83/18 97/1 102/3 126/15 127/7 127/7 143/16 151/4 154/23 169/21 170/6 175/20</p> <p>theories [4] 10/9 40/15 106/6 106/7</p> <p>theory [1] 116/14</p> <p>there [181] 4/12 9/19 10/4 10/5 10/6 10/10 10/14 10/25 13/3 13/7 13/7 13/12 14/3 14/7 14/11 17/20 18/11 18/19 18/23 19/5 20/15 21/22 22/1 22/13 22/20 23/18 25/5 26/13 26/17 26/23 27/25 28/18 29/13 30/1 31/7 36/15 36/20 38/11 38/11 39/9 45/3 45/12</p>	<p>45/12 45/14 45/14 45/15 45/15 46/20 46/23 48/3 50/18 51/4 51/12 51/23 52/2 52/21 52/23 53/21 54/1 54/14 54/15 56/3 60/7 60/9 60/20 61/10 61/23 62/8 63/10 63/12 63/19 64/17 65/20 67/6 67/8 67/20 68/24 70/1 70/1 70/3 70/4 74/10 75/2 75/15 76/6 76/12 78/25 79/21 80/6 81/13 82/16 82/17 83/3 83/22 83/22 84/1 84/12 84/24 84/24 84/25 85/1 85/4 85/10 85/16 85/21 85/22 87/13 87/22 92/23 93/22 95/2 95/7 95/23 97/7 98/5 99/5 105/17 105/21 107/17 108/13 109/4 111/4 113/6 113/7 114/6 117/24 118/24 120/1 121/8 121/9 123/6 124/9 124/12 124/13 124/15 130/13 130/17 132/3 133/15 134/21 138/25 142/10 142/20 143/17 144/8 144/15 144/18 147/12 148/25 149/25 149/25 150/4 150/22 151/11 151/19 152/6 152/7 154/13 155/19 156/3 158/7 160/15 160/16 160/20 161/1 161/1 161/7 161/9 161/21 163/2 164/7 164/16 170/7 170/21 171/12 171/13 175/11 177/19 177/20 178/16 180/9</p> <p>thereby [1] 6/5</p> <p>therefore [1] 23/18</p> <p>Thereupon [3] 89/5 145/19 180/23</p> <p>these [45] 5/24 7/15 7/20 13/12 15/25 16/1 22/22 27/15 32/25 40/17 43/21 50/16 53/5 64/13 66/21 66/21 66/24 73/25 81/25 83/5 86/9 86/11 95/6 100/10 100/22 106/15 106/15 107/7 111/12 112/22 119/25 121/9 121/13 133/23 136/9 140/23 141/13 147/5 147/9 148/7 149/10 150/20 153/18 155/16 160/24</p> <p>they [146] 3/4 3/14 3/23 5/12 6/21 7/14 10/4 11/1 14/10 14/13 15/1 23/18 24/19 26/25 27/1 34/9 35/24 36/14 36/21 38/13 40/23 41/15 47/10 47/19 47/20 47/24 49/16 49/17 49/17 49/18 50/17 54/1 56/11 57/20 60/25 61/21 61/23 61/23 61/25 64/2 66/18 66/20 66/22 67/16 67/17 70/19 70/20 71/20 75/1 75/20 75/23 76/7 76/9 80/9 80/9 80/15 82/17 84/7 87/18 91/24 91/25 91/25 92/5 92/7 92/12 92/13 92/22 93/3 93/13 93/14 93/14 93/15 93/16 93/16 93/19 94/15 98/20 102/8 104/4 104/7 104/8 104/8 104/9 104/10 108/6 108/25 110/9 110/9 111/18 114/9 114/10 122/10 122/12</p>
--	---	--

T		
they... [53]	122/14 122/17 122/18 124/20 124/21 124/21 137/3 138/7 141/8 141/8 141/9 141/9 141/14 141/16 142/15 143/1 143/8 143/9 143/10 143/14 143/18 145/1 145/3 147/11 147/12 151/2 154/3 156/16 156/17 156/20 158/11 160/7 160/21 161/12 164/1 164/1 164/2 164/3 165/16 166/5 166/7 167/14 167/16 170/13 171/25 175/8 175/9 175/10 176/16 176/21 177/17 179/7 179/24	127/14 127/16 128/9 128/24 129/13 129/22 130/10 130/11 130/16 130/16 131/13 132/4 134/9 136/19 138/1 140/21 141/24 144/1 145/3 145/8 148/19 149/2 151/6 155/8 157/6 158/2 158/3 161/7 161/24 164/8 165/22 167/3 168/11 169/14 170/21 171/6 171/10 176/9 179/2 179/7 179/10 179/14
thick [1]	167/9	thinking [8]
thing [26]	26/22 27/5 30/21 30/25 33/21 39/20 51/2 60/24 80/7 80/12 88/15 92/2 92/4 98/4 98/11 114/13 132/19 137/3 137/13 142/13 142/15 151/18 166/16 173/22 178/1 180/7	14/22 37/4 37/5 108/18 148/22 151/5 167/21 173/18
things [64]	5/15 12/14 12/16 12/25 14/6 19/13 21/20 27/15 40/16 45/14 45/16 48/9 48/10 57/14 60/1 70/15 71/2 72/6 72/7 78/7 78/12 79/11 80/3 80/6 80/18 83/23 84/4 91/4 91/16 91/23 95/6 95/24 108/2 110/12 112/9 112/15 112/21 113/13 114/12 116/13 120/8 120/9 126/13 127/18 132/16 134/7 134/10 136/12 136/13 143/5 151/6 160/5 161/2 161/22 163/23 165/17 166/10 166/19 167/10 168/3 168/4 169/15 176/8 178/17	third [23]
think [176]	8/7 9/14 11/25 12/11 13/9 13/12 13/22 14/19 14/23 16/24 19/2 20/1 23/14 23/23 23/25 24/6 24/15 25/3 25/10 26/6 27/8 28/2 28/11 28/14 29/3 29/23 31/19 34/25 36/25 37/18 37/25 38/3 42/21 42/25 43/13 43/18 50/11 50/13 50/17 51/22 52/13 52/16 54/9 54/11 54/18 55/17 56/7 56/22 57/2 57/11 57/11 57/13 58/1 59/6 59/10 60/11 60/17 64/12 64/13 64/22 65/4 65/11 67/16 68/21 69/17 70/3 70/22 72/13 74/23 74/24 75/5 75/7 75/8 75/10 75/11 75/15 75/15 75/16 77/13 78/20 79/6 79/11 79/22 80/4 80/12 80/18 82/15 82/17 85/4 85/10 85/11 86/4 86/4 86/16 87/3 87/3 88/18 90/15 91/18 92/7 93/4 93/21 95/4 95/5 95/18 96/5 96/19 96/22 97/12 97/13 97/20 99/5 101/25 103/10 104/15 107/11 107/21 108/9 110/17 110/21 111/15 112/11 114/1 114/18 116/11 116/23 117/5 119/6 120/14 120/18 121/6 122/3 124/13 126/24	5/7 6/17 7/5 37/13 39/17 42/18 46/3 51/22 59/5 59/8 63/1 63/2 63/15 63/19 64/13 64/18 64/24 64/25 66/19 67/9 67/12 112/2 129/12
		third-party [7]
		5/7 6/17 7/5 37/13 42/18 46/3 59/5
		Thirdly [1]
		129/2
		this [406]
		thorough [3]
		3/14 128/23 157/7
		thoroughly [1]
		16/21
		those [93]
		3/20 7/7 11/3 11/3 11/9 12/16 12/19 13/21 14/6 16/12 19/5 26/9 28/5 28/6 28/23 30/3 30/3 30/18 34/2 37/8 38/19 43/21 45/17 47/3 47/14 47/15 47/17 47/25 48/10 48/19 51/6 52/19 53/25 60/24 63/24 70/5 75/18 80/2 80/17 81/3 81/3 81/18 83/13 84/4 85/19 86/25 88/24 90/18 90/22 92/20 95/7 97/9 101/22 105/19 105/21 105/23 106/22 106/23 107/4 108/12 109/2 109/10 110/13 114/11 121/1 127/23 128/6 128/9 128/12 137/22 142/11 142/14 142/17 144/16 144/19 144/21 155/7 159/10 165/9 166/19 167/23 168/3 168/4 169/11 171/24 171/25 174/11 176/8 176/23 177/3 178/17 178/19 179/12
		though [2]
		163/6 165/18
		thought [22]
		4/23 50/16 63/13 65/16 70/20 74/22 85/7 86/22 93/7 111/19 129/3 130/5 130/9 152/7 154/19 161/10 165/2 167/5 171/2 171/15 171/17 180/15
		thoughtful [3]
		3/13 7/13 53/5
		thoughts [16]
		7/18 7/20 8/1 19/20 37/20 77/5 113/14 113/20 114/23 130/1 130/6 138/3 145/6 150/17 173/14 177/5
		thousand [1]
		113/3
		thousands [3]
		55/23 105/18 153/1
		three [15]
		16/4 19/16 21/15 23/25 57/5 68/16 98/1 100/16
		114/17 123/3 123/17 125/13 163/16 176/2 180/5
		three-person [1]
		57/5
		through [24]
		2/19 9/22 9/24 44/11 46/2 47/8 49/4 55/12 76/5 92/1 94/12 129/14 132/17 141/8 143/21 149/22 159/20 162/10 171/4 171/4 171/7 171/8 171/25 173/7
		throughout [6]
		48/6 85/12 85/24 106/5 108/23 143/6
		throw [1]
		141/9
		thrown [2]
		14/16 60/17
		Thursday [1]
		3/24
		Thursday's [1]
		2/24
		thus [6]
		4/7 51/14 60/10 69/3 129/8 131/7
		thyroid [1]
		104/7
		tied [1]
		168/8
		tiers [2]
		85/16 85/21
		Tim [1]
		10/22
		time [143]
		2/15 2/16 2/21 3/7 3/8 3/9 3/25 4/19 5/22 9/7 11/20 11/23 12/5 12/7 12/9 12/22 12/23 13/1 13/9 14/10 14/13 15/2 17/11 19/2 20/12 23/7 23/8 24/3 25/8 25/9 25/12 25/13 30/13 31/16 36/19 37/6 38/3 38/4 40/4 40/8 40/8 42/1 42/11 42/19 43/7 43/18 48/18 48/22 48/23 48/24 48/25 49/3 49/8 49/10 49/11 49/22 50/10 52/12 52/16 53/7 58/13 59/18 59/19 60/12 61/17 69/5 71/13 71/21 75/12 77/18 77/23 78/16 81/13 81/21 83/20 84/6 95/19 98/23 100/6 106/20 107/1 107/4 107/9 108/25 109/3 111/6 114/22 118/1 119/7 119/8 120/13 122/25 123/7 125/7 126/10 126/20 127/8 127/16 127/16 127/20 128/4 129/3 129/24 132/20 133/14 133/18 135/6 136/3 136/5 137/4 139/5 139/7 139/11 141/1 142/8 143/18 145/6 145/7 145/14 146/2 146/5 148/10 149/13 149/16 152/3 154/6 157/16 160/19 162/11 164/19 168/18 169/8 171/21 171/23 172/16 173/8 173/9 175/2 176/23 176/24 178/24 180/8 180/14
		times [7]
		2/6 15/25 35/13 86/25 133/15 156/20 163/16
		Timez [1]
		49/15
		timing [4]
		61/18 67/24 74/20 163/7
		title [1]
		170/4
		titles [1]
		113/21
		today [40]
		3/8 8/2 8/6 20/11 21/1 31/24 32/25 33/24 37/24 39/1 39/5 52/9 54/24 55/15 96/22 114/23 125/12 135/7 136/8 139/5 139/14 152/4 162/11 162/12 168/19 169/4 169/16 169/18 169/21 170/1

<p>T</p> <p>today... [10] 172/8 172/10 175/6 175/22 178/6 179/11 179/12 179/14 179/25 180/21</p> <p>today's [2] 2/7 179/19</p> <p>together [36] 5/20 7/21 10/22 11/2 11/3 11/4 11/12 13/4 27/18 27/21 27/23 44/24 45/4 47/19 49/16 55/14 56/4 56/12 56/25 57/13 57/16 57/18 59/6 60/5 69/1 74/6 75/5 91/7 92/22 97/10 113/4 134/23 137/14 148/17 153/24 174/4</p> <p>told [10] 21/11 21/14 22/7 26/24 60/20 79/2 97/23 98/6 135/23 147/3</p> <p>tolling [1] 64/10</p> <p>tomorrow [6] 33/1 174/18 179/20 179/21 180/14 180/19</p> <p>ton [1] 144/8</p> <p>too [37] 8/4 8/18 11/25 18/24 20/11 25/8 26/23 56/2 72/16 72/22 78/25 83/7 83/15 83/16 83/22 83/24 84/22 84/23 85/6 85/13 86/7 87/5 88/24 92/12 92/12 92/13 114/19 129/17 130/5 130/10 130/11 135/15 136/8 171/18 174/15 179/8 180/7</p> <p>took [15] 5/22 9/2 10/4 28/7 63/21 70/20 73/2 73/24 84/20 101/3 159/8 160/7 164/24 175/16 178/12</p> <p>tool [1] 107/22</p> <p>tools [1] 60/18</p> <p>tooting [1] 147/2</p> <p>top [4] 33/15 38/2 48/5 60/21</p> <p>top-notch [1] 33/15</p> <p>topics [1] 11/18</p> <p>torch [1] 103/5</p> <p>tort [10] 57/8 121/18 139/21 140/16 152/17 169/8 169/20 170/6 170/6 175/1</p> <p>torts [8] 125/19 139/24 141/2 141/17 148/2 154/23 154/24 167/18</p> <p>total [3] 37/19 37/20 37/25</p> <p>totaling [1] 64/10</p> <p>touch [4] 47/12 69/15 95/24 131/3</p> <p>touched [5] 37/18 46/12 84/22 93/21 177/2</p> <p>touching [1] 20/9</p> <p>toward [1] 18/11</p> <p>town [1] 77/9</p> <p>toxic [1] 140/10</p> <p>toxicology [3] 147/25 153/11 155/6</p> <p>Toyota [1] 26/16</p> <p>toys [1] 10/16</p> <p>TPP [3] 51/24 52/2 65/7</p> <p>TPP's [1] 65/18</p> <p>track [12] 2/13 70/5 75/2 75/14 75/14 78/24 84/23 85/2 85/2 86/10 168/13 173/11</p>	<p>tracks [2] 74/24 87/5</p> <p>Tracy [3] 119/9 131/12 166/3</p> <p>trades [1] 99/6</p> <p>traditional [1] 63/3</p> <p>traditionally [1] 165/14</p> <p>trained [5] 58/13 58/14 83/16 83/16 157/14</p> <p>trajectory [1] 107/12</p> <p>trans [1] 158/24</p> <p>transcript [1] 180/25</p> <p>transfer [1] 128/12</p> <p>transferred [1] 126/13</p> <p>transition [2] 24/7 40/6</p> <p>transitioned [3] 126/15 162/22 169/22</p> <p>transitioning [5] 42/12 79/3 80/19 161/21 161/22</p> <p>translates [1] 113/10</p> <p>transparency [3] 6/4 118/10 118/12</p> <p>transport [1] 136/16</p> <p>treat [4] 12/1 122/14 143/22 156/17</p> <p>treated [2] 54/17 54/18</p> <p>treating [1] 54/11</p> <p>tremendous [5] 4/9 36/3 49/18 67/17 105/12</p> <p>trial [41] 18/23 19/1 30/4 30/7 30/8 30/14 43/7 45/20 46/6 55/20 58/7 67/19 73/23 85/3 86/9 86/12 86/12 87/8 87/8 90/20 111/12 111/14 117/14 117/15 117/16 121/20 121/20 127/8 127/10 138/9 152/23 152/24 171/4 171/7 173/15 173/22 176/3 177/18 178/13 178/18 178/22</p> <p>trials [10] 9/19 9/20 19/13 87/12 89/21 153/2 173/19 174/8 174/8 175/18</p> <p>tried [12] 12/13 27/21 43/4 45/21 62/9 86/8 91/14 91/15 93/11 98/19 113/2 134/5</p> <p>trigger [2] 117/9 156/3</p> <p>trivia [1] 91/19</p> <p>true [4] 4/21 34/2 39/11 97/22</p> <p>truly [4] 3/17 5/20 71/22 120/3</p> <p>trust [7] 7/2 7/9 52/6 68/5 96/17 99/9 120/13</p> <p>trusting [1] 141/14</p> <p>try [5] 30/7 34/3 91/23 97/15 177/14</p> <p>trying [23] 12/17 15/25 16/1 19/17 21/7 26/14 28/17 32/20 59/2 65/5 77/12 78/24 90/13 95/4 111/12 113/10 113/18 134/13 134/15 134/21 153/18 176/2 179/7</p> <p>Tuesday [1] 62/19</p> <p>tune [1] 161/6</p> <p>turn [28] 9/12 15/6 15/9 15/19 21/12 25/16 25/18 26/2 31/12 31/12 39/7 44/4 44/5 44/14 49/25 50/1 55/4 55/7 58/18 58/19 60/23 82/5 88/12 95/9 100/3 145/16 169/5</p>	<p>174/23</p> <p>turned [2] 165/9 165/10</p> <p>turning [1] 2/5</p> <p>twice [1] 155/3</p> <p>two [55] 12/20 12/24 13/12 16/13 18/4 18/19 20/23 27/19 27/20 29/15 29/17 35/1 37/5 37/12 37/23 39/5 43/5 46/12 49/6 51/9 51/12 61/8 61/19 62/15 62/16 65/22 74/23 76/25 78/7 80/3 80/18 84/1 84/4 89/7 90/7 92/20 93/8 98/21 103/10 115/11 115/18 115/24 117/15 123/8 123/11 126/8 132/21 137/1 140/8 152/13 156/15 163/16 165/1 167/14 179/12</p> <p>two-year [1] 49/6</p> <p>type [29] 16/16 53/7 67/10 67/11 73/12 78/4 83/7 86/16 87/6 93/18 96/1 103/22 106/15 106/18 106/19 118/10 130/15 131/19 134/3 141/6 142/5 143/1 144/9 147/23 150/10 151/10 151/21 170/24 177/21</p> <p>types [24] 5/13 5/21 12/14 12/16 14/6 85/18 102/7 104/5 104/8 106/10 106/23 111/12 124/5 133/23 135/1 137/25 140/23 148/5 149/24 150/10 150/21 150/23 150/23 151/1</p> <p>typical [2] 143/20 177/21</p> <p>typically [3] 55/18 59/18 175/4</p> <p>U</p> <p>ugly [1] 179/2</p> <p>ulcers [1] 134/22</p> <p>ultimately [9] 10/17 11/5 65/13 138/2 153/8 173/24 174/8 175/18 176/17</p> <p>Um [1] 19/22</p> <p>Um-m-m [1] 19/22</p> <p>unable [2] 43/8 62/18</p> <p>uncomfortable [2] 2/4 69/22</p> <p>under [10] 12/18 22/4 32/20 84/2 84/8 94/11 144/4 144/4 145/1 153/6</p> <p>undercurrent [1] 170/19</p> <p>underneath [1] 84/3</p> <p>understand [30] 7/12 7/20 13/8 17/9 18/5 21/22 23/10 24/9 27/14 29/1 34/11 39/24 41/19 42/4 66/6 77/24 80/8 82/2 91/25 94/9 94/13 109/17 109/25 137/14 143/1 149/6 150/3 155/15 160/5 160/15</p> <p>understandable [1] 147/20</p> <p>understanding [14] 5/13 46/3 81/7 98/16 125/24 140/8 140/11 140/11 142/21 148/7 159/18 166/1 168/4 168/5</p> <p>undertaking [2] 116/1 173/24</p> <p>underway [1] 3/11</p> <p>undivided [1] 34/18</p> <p>undoubtedly [3] 50/24 105/24 106/6</p>
---	--	--

<p>U</p> <p>unduly [1] 108/11</p> <p>unfairness [1] 54/4</p> <p>unfortunately [1] 167/13</p> <p>unified [1] 118/9</p> <p>unintelligible [4] 26/21 27/13 158/22 158/25</p> <p>unique [21] 4/22 19/25 40/23 40/23 40/25 43/20 69/5 69/18 69/25 77/8 78/12 80/25 81/4 82/18 84/9 96/24 100/13 117/3 150/17 155/16 157/9</p> <p>uniquely [1] 120/21</p> <p>unit [1] 160/3</p> <p>united [6] 1/1 1/10 7/21 62/11 96/23 152/18</p> <p>university [1] 155/3</p> <p>unkind [1] 54/16</p> <p>unknown [1] 166/25</p> <p>unless [2] 21/8 179/13</p> <p>unlimited [1] 117/7</p> <p>unnecessarily [1] 97/13</p> <p>unpaid [1] 87/25</p> <p>unparalleled [1] 40/1</p> <p>unprofessional [1] 179/3</p> <p>unravel [1] 48/14</p> <p>unruly [1] 118/6</p> <p>until [5] 33/4 34/18 63/14 121/20 175/12</p> <p>unusual [2] 30/21 78/14</p> <p>unwanted [1] 54/14</p> <p>up [72] 2/21 12/4 13/24 14/5 14/10 17/22 20/6 20/10 26/1 26/17 30/6 34/3 39/2 39/3 43/5 49/7 52/9 61/16 67/24 68/7 72/19 78/22 88/7 91/10 92/14 92/15 93/9 96/17 97/25 98/9 98/21 98/24 100/7 103/14 106/13 112/3 113/12 118/2 118/15 121/20 128/6 129/13 131/9 131/20 132/20 133/21 137/22 144/6 152/23 163/9 163/16 163/19 165/1 166/2 167/1 167/13 168/3 169/22 170/22 171/25 174/22 176/1 176/22 176/24 177/9 177/10 177/17 178/13 178/18 178/20 179/6 180/10</p> <p>upbringing [1] 169/16</p> <p>updates [1] 76/10</p> <p>upheld [2] 47/24 65/21</p> <p>upon [14] 6/7 21/2 38/14 38/19 40/5 72/17 103/18 103/25 104/16 132/4 132/6 153/15 158/15 162/5</p> <p>upstate [1] 139/18</p> <p>urge [2] 51/14 74/25</p> <p>us [35] 2/3 8/9 10/4 12/20 17/21 28/16 30/5 30/10 31/8 32/12 36/3 38/14 39/9 48/14 50/8 91/10 92/10 103/20 104/4 104/20 114/5 120/14 131/10 134/23 135/14 152/14 152/19 153/8 173/2 173/6 173/8 173/9 173/11 178/18 179/20</p> <p>usage [2] 79/13 150/17</p>	<p>use [15] 37/10 88/23 99/6 102/11 102/14 102/16 137/23 143/10 143/13 143/14 148/10 148/13 149/10 151/15 177/19</p> <p>used [13] 12/4 22/12 33/8 82/3 92/22 102/19 103/13 134/17 147/12 163/2 163/2 163/16 180/21</p> <p>using [6] 8/9 33/9 133/12 136/15 143/15 176/14</p> <p>usually [2] 39/15 143/19</p> <p>Utah [1] 176/3</p> <p>utility [5] 36/21 55/25 57/10 59/13 94/2</p> <p>utilize [1] 18/10</p> <p>utmost [1] 7/9</p> <p>V</p> <p>Valdez [1] 58/12</p> <p>Valsartan [57] 36/8 45/11 46/17 48/3 48/5 48/9 48/21 48/22 48/23 49/1 49/14 50/20 50/21 50/23 50/25 51/6 51/10 51/18 53/7 53/13 62/21 63/9 63/10 64/23 67/6 68/10 68/23 69/12 70/10 71/12 71/14 71/16 71/17 71/18 72/3 85/2 90/3 93/12 101/18 102/1 102/6 102/17 131/15 131/22 131/25 132/1 132/3 134/1 137/12 138/2 138/7 138/16 140/5 140/15 140/24 142/6 142/16</p> <p>valuable [5] 67/17 79/6 148/9 164/5 166/2</p> <p>value [8] 3/20 104/2 104/11 104/13 109/5 109/8 124/12 124/19</p> <p>values [1] 109/4</p> <p>varied [1] 122/3</p> <p>variety [3] 83/2 83/18 120/22</p> <p>various [15] 45/1 65/17 66/19 78/17 84/14 85/16 102/10 104/3 112/6 152/15 152/25 155/12 159/21 175/14 176/11</p> <p>varying [1] 108/24</p> <p>vast [4] 78/1 79/12 102/18 170/24</p> <p>vehicles [1] 166/17</p> <p>vein [2] 6/10 77/17</p> <p>vendor [1] 116/6</p> <p>vendors [1] 6/11</p> <p>venture [1] 174/1</p> <p>verdict [2] 23/2 45/21</p> <p>Vermont [3] 45/10 139/18 144/7</p> <p>versed [4] 16/10 81/1 116/15 166/4</p> <p>versus [6] 13/25 14/22 74/21 93/19 134/2 155/17</p> <p>very [124] 2/18 3/5 6/25 8/5 11/17 11/24 15/7 16/8 16/8 19/6 20/9 20/13 24/6 25/10 25/11 28/7 28/21 29/17 30/5 42/12 43/16 43/23 43/25 44/21 45/21 47/4 49/21 50/3</p>	<p>50/22 51/21 52/15 55/13 55/14 55/18 56/9 56/15 57/7 57/7 57/21 57/24 58/7 58/12 59/3 59/5 59/17 59/18 60/13 62/21 62/23 67/10 67/14 68/7 75/5 75/22 80/8 80/12 81/1 81/5 81/25 84/11 95/12 98/4 99/12 99/20 100/9 104/19 105/5 108/6 109/11 110/19 111/23 112/12 113/2 113/2 113/24 118/24 119/12 120/9 120/10 122/3 122/18 123/21 124/7 126/11 126/24 127/15 127/18 128/9 128/24 129/3 129/8 129/18 133/5 134/2 137/23 140/6 140/7 145/25 147/3 147/9 149/5 149/16 149/17 149/20 153/10 155/5 157/9 160/19 160/19 164/5 168/20 169/17 171/16 172/14 172/25 172/25 173/24 173/25 175/15 175/17 176/5 176/12 179/13 180/17</p> <p>vet [2] 102/19 103/19</p> <p>veteran [1] 169/7</p> <p>vets [1] 122/13</p> <p>vetting [4] 79/22 80/5 134/4 177/4</p> <p>viable [2] 143/3 174/11</p> <p>victims [3] 33/7 34/9 34/12</p> <p>video [20] 1/9 8/21 15/7 15/10 25/17 31/12 44/5 55/4 61/11 68/4 88/12 88/22 89/3 94/25 120/4 145/16 158/11 178/16 179/17 180/18</p> <p>view [7] 3/19 7/22 7/23 35/19 112/12 124/1 147/7</p> <p>viewpoint [1] 113/21</p> <p>vilify [1] 101/3</p> <p>Vioxx [5] 10/10 175/13 176/12 177/13 178/16</p> <p>Virginia [1] 155/1</p> <p>virtual [5] 31/17 31/19 31/22 31/23 33/5</p> <p>virtually [2] 2/2 50/4</p> <p>virus [1] 157/14</p> <p>visibly [1] 70/17</p> <p>vision [13] 3/16 14/17 14/19 18/22 27/17 30/13 72/3 103/15 110/15 110/17 111/15 117/1 133/12</p> <p>vital [1] 158/20</p> <p>voice [3] 158/25 170/13 170/14</p> <p>voices [1] 108/4</p> <p>Volkswagen [1] 40/19</p> <p>voluntarily [1] 138/3</p> <p>volunteer [2] 81/16 154/14</p> <p>volunteered [2] 83/20 127/2</p> <p>volunteering [1] 58/21</p> <p>vow [1] 34/16</p> <p>vulnerability [1] 54/12</p> <p>W</p> <p>Waichman [3] 170/3 172/4 173/1</p> <p>wait [4] 73/4 168/15 168/25 169/1</p>
---	--	--

<p>W</p> <p>waiting [7] 13/10 21/10 21/10 167/15 168/11 174/13 179/23</p> <p>walk [1] 39/3</p> <p>Walker [1] 159/18</p> <p>walkers [1] 165/1</p> <p>want [120] 2/15 3/1 3/6 3/8 3/12 5/10 7/17 7/19 7/25 8/12 8/16 8/19 8/24 9/7 11/20 13/6 15/13 15/23 15/25 17/14 20/11 22/5 25/12 26/19 26/22 29/1 29/15 30/19 44/22 46/14 46/23 51/9 53/21 54/21 58/20 59/15 62/25 66/16 69/15 72/6 72/12 76/1 76/3 76/15 78/25 81/19 82/8 83/23 87/18 87/23 88/6 88/18 89/25 90/18 92/7 94/11 95/11 95/24 98/11 98/20 98/22 99/7 99/25 108/18 108/21 109/18 110/10 110/11 115/12 115/20 119/5 119/15 119/18 119/22 122/4 122/7 123/20 123/22 124/14 124/18 124/21 125/12 128/23 130/12 131/1 131/6 132/7 135/15 135/24 136/11 139/12 140/17 142/24 145/15 145/25 149/1 151/6 156/19 157/11 157/12 157/14 158/9 158/16 159/13 160/11 161/17 163/10 164/6 164/12 165/18 168/6 169/3 171/1 172/12 173/15 175/9 176/21 179/18 179/22 179/23</p> <p>wanted [20] 6/24 11/18 19/18 21/6 38/23 60/9 62/17 65/8 76/13 77/2 83/21 96/20 124/7 140/15 163/4 163/5 170/4 170/4 170/11 177/17</p> <p>wanting [1] 108/15</p> <p>wants [2] 43/20 144/20</p> <p>Wardwell [1] 146/13</p> <p>warehouses [1] 90/25</p> <p>warnings [1] 83/13</p> <p>warrants [1] 2/17</p> <p>warranty [1] 10/7</p> <p>was [156] 2/13 6/18 6/24 8/5 9/2 9/20 9/24 10/6 10/8 10/8 10/15 15/16 20/9 20/13 20/21 21/20 22/6 22/15 22/15 24/2 25/22 27/12 31/20 31/20 39/1 42/9 43/3 45/21 45/21 46/6 49/9 53/19 56/13 56/24 57/12 59/4 59/22 63/15 63/23 65/15 65/16 65/20 65/20 66/22 67/12 69/8 70/10 73/2 73/5 73/13 73/14 74/14 76/10 77/19 77/20 77/20 77/21 77/25 79/16 82/9 82/11 82/12 82/25 89/5 90/6 94/4 95/3 95/19 96/22 98/8 99/16 99/16 100/25 101/1 102/7 111/6 115/7 116/3 116/6 116/9 116/10 123/16 123/16 123/17 123/18 126/4 126/5 126/16 126/17 126/19 126/20 126/22</p>	<p>126/24 127/5 127/9 127/24 128/5 128/5 131/14 136/22 136/23 136/24 136/25 138/23 138/24 142/4 142/6 145/19 146/11 146/12 146/14 146/16 148/18 150/2 151/9 152/9 154/20 154/21 155/10 159/21 160/20 162/2 162/7 162/18 163/3 163/7 163/7 163/15 163/21 164/20 165/1 165/7 165/25 169/24 170/2 170/11 172/4 173/21 173/23 173/24 173/25 175/12 175/15 175/17 175/25 176/6 176/9 176/22 178/16 178/18 178/23 178/24 178/25 179/2 179/19 180/23</p> <p>washing [1] 163/24</p> <p>wasn't [4] 12/16 66/1 66/22 175/11</p> <p>waste [1] 9/21</p> <p>wasting [1] 106/20</p> <p>watch [3] 9/22 60/15 81/5</p> <p>watched [1] 25/9</p> <p>watching [2] 180/1 180/9</p> <p>water [1] 73/21</p> <p>Watts [1] 179/5</p> <p>way [46] 2/13 11/10 12/25 13/4 22/21 24/23 31/9 32/15 51/5 51/21 52/11 54/15 56/5 56/24 60/20 60/21 63/9 64/14 78/22 79/13 85/4 85/5 88/9 88/18 88/22 92/15 92/20 97/13 111/2 111/10 120/12 124/13 126/2 129/14 133/20 134/8 140/2 140/20 147/20 150/18 154/1 161/23 170/12 171/4 171/4 174/5</p> <p>Wayland [1] 73/1</p> <p>ways [9] 14/11 23/18 35/1 53/1 92/15 108/5 124/13 142/10 147/11</p> <p>we [514]</p> <p>we'll [7] 31/12 44/4 49/25 88/7 117/13 117/21 153/8</p> <p>we're [2] 66/24 131/11</p> <p>weak [1] 134/6</p> <p>weaken [1] 158/23</p> <p>weakest [2] 102/13 134/2</p> <p>weakness [1] 71/3</p> <p>weaknesses [1] 30/9</p> <p>wear [1] 139/12</p> <p>wearing [1] 96/22</p> <p>week [9] 2/11 7/9 8/1 30/23 42/8 91/7 107/19 157/13 163/17</p> <p>week's [1] 3/25</p> <p>weekends [4] 123/8 123/17 123/19 123/20</p> <p>weekly [1] 91/5</p> <p>weeks [4] 44/18 47/5 47/5 119/12</p> <p>weigh [1] 14/23</p> <p>weighed [1] 136/3</p> <p>Weiss [1] 121/16</p> <p>welcome [12] 8/20 11/15 26/8 32/3 39/10 55/6 70/6 76/17 95/9 127/13 129/20 141/22</p> <p>welfare [1] 42/18</p>	<p>well [110] 2/20 3/7 3/20 4/22 6/13 9/19 11/8 12/20 13/20 16/10 17/2 18/1 19/10 19/22 22/8 23/24 26/12 27/21 29/4 29/4 29/17 36/5 36/11 36/15 38/15 44/8 45/2 47/4 47/17 48/8 49/2 49/4 49/20 50/8 60/8 61/18 61/22 64/7 66/18 72/21 75/1 75/18 75/19 77/5 79/4 81/1 81/25 83/7 83/24 84/23 85/6 85/25 86/7 87/5 87/7 90/15 94/8 94/21 100/9 105/4 106/2 106/25 108/20 113/4 114/25 115/5 115/6 116/15 117/5 117/6 118/9 118/12 120/19 120/20 121/16 123/25 124/3 124/7 124/11 125/16 125/25 126/2 126/3 126/21 126/25 127/6 127/16 127/18 128/2 128/20 133/6 134/24 135/13 136/3 136/5 136/13 137/23 139/3 143/15 145/9 148/17 157/6 157/22 158/8 162/17 164/14 166/4 172/23 174/16 179/10</p> <p>well-known [1] 133/6</p> <p>well-rounded [2] 125/16 127/18</p> <p>went [10] 15/5 29/16 127/3 127/8 138/25 160/1 160/6 162/25 173/5 173/5</p> <p>were [56] 3/13 3/14 5/17 6/25 10/2 10/23 21/7 24/9 26/25 33/8 37/1 37/15 38/17 43/6 43/8 45/9 46/25 49/16 51/6 57/15 57/20 58/15 59/23 61/10 61/21 62/18 65/13 67/8 82/17 83/6 83/13 84/3 87/21 96/12 121/9 125/22 125/22 126/1 127/23 133/14 133/15 137/21 142/15 143/8 152/7 154/19 160/15 160/24 161/21 164/14 164/19 164/22 164/24 173/10 179/14 180/10</p> <p>weren't [3] 65/24 76/10 137/20</p> <p>WEST [4] 1/2 1/5 1/14 25/23</p> <p>Westcot [3] 61/14 68/4 68/15</p> <p>what [217]</p> <p>whatever [9] 37/25 39/23 50/19 86/24 96/7 99/6 104/7 128/16 150/19</p> <p>whatsoever [1] 127/1</p> <p>wheel [2] 48/19 171/11</p> <p>when [64] 3/23 7/15 8/11 8/25 12/12 13/22 13/23 14/7 14/10 21/19 26/13 30/13 34/6 35/25 52/23 55/25 57/17 61/4 61/10 61/21 63/17 64/21 83/14 84/9 90/6 91/13 94/11 100/24 101/3 102/8 102/17 110/23 123/16 123/16 123/17 123/18 129/16 129/22 130/2 130/4 136/22 139/24 141/7 141/11 142/5 142/15 145/12 146/5 151/8 151/9 151/9 154/11 160/6 160/12 162/3 163/3 163/25 167/17 169/24</p>
---	---	---

<p>W</p> <p>when... [5] 170/1 171/9 174/19 174/22 176/13</p> <p>where [52] 30/10 47/18 48/15 49/6 51/6 51/15 52/16 52/22 53/25 62/15 64/12 71/4 71/5 72/11 72/18 75/20 78/21 80/17 86/25 91/1 91/6 91/19 93/13 93/16 97/7 98/2 101/17 110/9 110/15 111/10 111/14 112/1 112/16 127/2 136/2 137/1 137/16 138/8 138/9 138/11 141/25 144/18 146/23 147/11 149/3 151/24 151/25 160/8 164/13 169/4 171/23 177/10</p> <p>where-with-all [1] 171/23</p> <p>wherever [1] 56/3</p> <p>whether [35] 4/3 10/19 12/2 23/20 35/10 48/16 58/23 79/4 86/10 102/14 106/8 108/22 108/25 112/7 113/25 124/21 126/5 143/2 156/7 157/3 164/16 165/3 167/5 168/13 168/13 168/14 170/4 170/8 170/11 170/13 171/7 174/5 174/5 174/7 177/5</p> <p>which [61] 6/10 8/18 14/22 18/3 22/24 24/9 31/10 40/21 41/17 41/19 45/20 45/21 46/6 47/7 50/11 50/21 53/2 59/24 60/19 60/20 63/3 63/15 63/21 64/14 67/14 67/17 69/13 71/5 74/10 77/23 78/3 78/8 83/4 83/11 91/1 104/11 106/5 109/5 109/21 116/8 116/25 122/3 126/9 126/16 126/19 129/6 130/15 131/19 134/5 134/17 137/6 140/2 140/20 147/9 151/10 153/3 155/16 155/24 173/23 175/2 176/24</p> <p>while [14] 5/15 9/19 10/4 10/14 13/21 61/2 61/3 73/2 74/1 83/3 123/8 128/4 156/2 159/2</p> <p>white [2] 73/1 91/20</p> <p>Whitely [8] 36/4 36/6 36/13 44/4 46/11 49/21 51/11 53/20</p> <p>Whitely's [1] 36/8</p> <p>who [108] 3/3 6/7 7/7 7/8 14/4 18/16 20/3 21/10 22/3 22/5 24/8 31/12 32/1 32/13 33/7 33/12 33/21 35/22 36/4 36/18 36/20 36/21 37/8 37/15 39/7 40/2 42/10 42/16 42/24 43/1 43/10 43/16 43/17 43/19 44/4 48/13 48/15 50/24 53/15 62/17 64/21 65/24 69/8 70/17 71/18 73/18 74/12 81/18 84/20 85/19 85/20 87/20 91/6 91/25 93/12 97/1 98/5 98/6 98/6 101/7 101/12 105/19 108/9 109/2 109/7 111/7 112/23 113/2 113/24 120/7 121/25 122/13 125/21 127/7 127/18 128/12 128/17 128/18 141/7 144/20 144/21 144/23</p>	<p>146/1 146/14 150/16 152/14 153/23 154/4 154/10 155/17 156/20 159/8 159/9 159/25 160/14 161/12 165/14 165/25 169/21 171/12 171/13 171/13 171/20 171/21 175/11 175/24 180/1 180/13</p> <p>whoever [1] 24/25</p> <p>whole [6] 8/9 37/22 114/15 124/25 141/6 173/9</p> <p>wholesaler [1] 93/15</p> <p>wholesalers [1] 48/17</p> <p>wholesalers' [1] 48/12</p> <p>whom [5] 7/2 7/14 25/14 38/12 38/12</p> <p>why [24] 8/11 22/17 26/11 39/3 42/21 54/9 56/11 61/10 92/8 92/16 93/1 94/12 94/12 113/1 122/15 125/14 127/17 128/13 141/17 145/11 145/12 158/5 158/8 158/14</p> <p>wide [2] 69/14 143/17</p> <p>wife [3] 39/15 62/1 65/3</p> <p>wifi [1] 109/25</p> <p>will [144] 2/5 2/5 2/20 3/24 4/3 6/7 6/12 7/9 7/21 7/22 7/22 7/25 8/20 9/4 13/18 14/10 14/15 14/23 16/10 16/21 19/10 19/20 21/23 21/24 23/11 25/14 28/12 28/18 28/21 31/5 32/25 33/15 34/18 35/1 35/7 35/11 35/20 35/22 36/9 37/14 38/18 39/7 39/25 40/4 41/20 42/1 42/22 48/10 55/3 57/4 59/3 59/18 60/15 60/20 61/14 61/25 64/9 67/20 68/10 68/12 68/22 74/2 75/25 76/16 76/25 78/20 81/16 81/17 82/20 84/12 84/12 85/12 85/13 85/13 87/5 87/7 87/9 87/23 88/10 88/16 88/18 89/1 89/2 89/3 94/15 99/11 103/23 104/12 105/14 105/18 106/5 106/6 106/7 106/24 110/12 111/20 114/1 117/9 117/11 117/18 118/8 120/14 122/23 123/3 123/23 127/18 128/18 128/18 129/22 129/24 130/4 130/13 131/25 133/10 135/1 138/14 145/8 145/16 145/17 149/3 149/19 151/16 152/14 152/15 155/16 155/24 158/9 161/20 162/21 162/23 168/12 168/16 169/5 170/3 172/20 176/17 176/19 176/23 178/2 179/16 179/24 180/4 180/13 180/19</p> <p>Williamson [5] 99/22 99/23 103/9 131/17 142/17</p> <p>willing [5] 29/19 107/5 113/4 113/9 115/22</p> <p>willingness [3] 108/1 113/9 127/12</p> <p>win [1] 149/1</p> <p>wisdom [4] 121/24 122/5 122/6 124/25</p> <p>wise [1] 56/24</p> <p>wish [2] 49/22 60/14</p>	<p>Wisner [3] 90/6 109/14 165/25</p> <p>within [12] 7/11 7/14 13/17 67/13 79/15 79/24 81/3 104/3 104/13 144/15 156/21 171/23</p> <p>without [19] 7/1 13/1 41/22 54/16 55/7 56/23 58/22 74/9 80/13 90/22 95/15 108/11 108/17 137/17 138/3 141/12 149/7 164/9 180/16</p> <p>withstand [1] 171/21</p> <p>witness [3] 89/23 147/8 147/14</p> <p>witnesses [7] 31/4 101/3 106/17 126/5 126/6 173/21 173/23</p> <p>woke [2] 39/3 100/7</p> <p>Wolfson [4] 15/9 15/10 17/8 20/12</p> <p>woman [4] 73/4 108/1 144/1 154/18</p> <p>women [11] 11/13 49/18 73/3 73/6 73/9 73/9 73/10 74/13 107/18 108/3 123/11</p> <p>won't [6] 56/16 88/25 107/20 113/7 136/8 169/3</p> <p>wonderful [5] 95/18 97/25 110/3 115/3 144/22</p> <p>Woodson [3] 174/18 174/24 179/13</p> <p>word [5] 4/1 92/13 92/14 156/14 165/10</p> <p>words [2] 92/22 108/13</p> <p>work [179] 2/14 3/6 4/5 10/12 13/1 13/5 13/9 14/25 17/22 18/11 18/13 20/2 20/5 20/8 20/24 22/21 22/22 23/7 23/8 23/12 24/5 24/21 25/4 25/6 25/7 29/4 30/15 30/24 31/6 32/9 33/23 33/24 34/3 36/19 40/16 40/24 43/20 44/9 44/13 44/17 44/19 45/17 45/22 45/24 46/13 47/4 47/6 47/10 49/19 52/11 53/16 54/17 54/18 55/18 56/12 56/17 56/19 57/18 58/15 58/21 58/23 58/24 59/3 59/5 59/18 59/19 59/23 60/14 61/2 62/12 62/12 65/1 69/10 70/14 70/25 71/2 71/10 71/11 71/19 74/3 75/4 75/16 76/16 77/24 78/3 78/10 78/14 79/17 79/19 81/2 81/16 82/13 87/23 87/23 88/2 88/10 90/8 90/11 93/7 95/12 95/14 97/5 97/9 105/7 109/7 112/20 113/3 113/22 114/22 115/18 116/1 116/12 116/22 116/24 117/1 119/11 119/13 119/20 119/24 120/2 120/13 121/21 122/4 123/6 123/20 124/11 124/19 124/20 125/5 126/25 127/1 127/2 127/3 128/14 128/18 128/18 129/14 129/16 131/18 132/15 135/5 135/16 135/22 136/18 136/20 137/4 137/5 137/5 138/23 144/2 144/10 144/21 145/1 146/2 148/8 149/16</p>
--	---	---

<p>W</p> <p>work... [23] 149/19 153/16 154/3 159/5 162/1 162/2 162/4 165/23 166/7 169/20 170/3 170/12 172/23 174/3 175/2 175/10 175/14 175/16 175/17 175/17 175/23 178/13 180/2</p> <p>worked [87] 9/23 23/4 27/21 28/4 29/4 29/10 29/17 35/23 41/8 42/5 48/10 48/12 49/15 49/16 53/14 55/13 56/12 56/15 56/16 56/25 57/16 58/6 59/5 59/20 61/18 61/22 69/12 82/25 83/1 83/2 83/3 83/4 83/7 83/9 83/11 83/13 83/18 83/19 83/25 84/1 90/4 90/5 90/6 94/16 101/13 105/9 111/18 111/23 112/15 116/15 116/16 120/2 120/3 121/20 123/16 123/17 124/7 125/17 126/3 127/5 127/20 128/2 129/14 132/9 132/9 133/19 136/13 136/23 146/13 146/19 147/21 147/23 148/2 148/16 148/17 153/22 154/1 155/11 159/2 159/15 159/20 160/2 170/10 173/2 173/6 176/11 179/1</p> <p>workers [1] 157/15</p> <p>working [86] 11/11 11/12 12/23 13/4 13/19 13/20 13/23 14/9 14/19 14/25 18/6 23/12 23/23 27/18 27/23 30/25 35/18 41/7 44/12 45/1 46/17 48/9 52/17 52/21 54/8 56/4 56/14 56/19 62/23 69/1 69/7 74/4 74/6 78/7 79/24 82/9 82/12 84/13 96/4 100/25 101/3 101/10 101/23 105/13 111/13 112/3 115/13 116/10 120/14 120/19 120/23 121/16 122/10 122/21 123/7 123/11 123/16 123/18 123/19 128/6 129/12 131/8 131/10 132/12 144/3 144/4 146/19 146/19 146/20 148/15 149/18 152/14 152/18 156/7 156/12 158/24 159/17 159/19 160/2 160/8 162/23 164/14 164/18 166/2 178/7 178/23</p> <p>works [2] 9/23 94/9</p> <p>workup [1] 128/19</p> <p>world [12] 26/8 27/16 30/23 33/12 42/24 42/25 69/19 88/16 92/2 144/8 144/21 170/23</p> <p>worn [1] 168/24</p> <p>worried [1] 100/7</p> <p>worries [1] 61/13</p> <p>worry [3] 61/5 128/17 158/16</p> <p>worst [1] 88/15</p> <p>worth [2] 25/3 165/23</p> <p>worthy [1] 154/3</p> <p>would [177] 3/10 3/20 4/5 6/1 6/10 8/22 9/15 11/14 12/14 17/6 17/10 17/14 18/19</p>	<p>19/21 21/5 21/15 21/17 22/19 23/8 23/13 23/21 23/24 24/15 26/2 27/6 27/17 29/4 29/9 30/1 30/13 32/3 32/7 32/17 32/22 33/21 36/16 37/6 37/24 38/1 38/4 39/2 43/9 44/16 46/9 47/12 47/22 47/24 47/24 48/6 49/12 49/14 49/19 50/10 50/24 51/7 51/22 52/1 52/5 53/8 55/17 56/22 56/23 56/23 57/9 58/16 58/24 63/16 66/1 66/4 69/17 70/20 71/19 71/20 71/23 72/8 72/18 74/8 74/11 74/18 76/1 76/3 76/16 78/6 78/17 78/21 79/1 79/5 79/17 79/19 79/19 80/2 80/3 80/23 81/8 82/18 82/20 83/14 83/24 84/16 85/8 85/20 86/4 87/14 87/16 87/21 87/25 89/16 91/12 92/7 93/25 96/3 98/4 99/17 100/21 101/13 101/20 102/22 103/13 106/11 107/13 107/23 108/18 108/20 108/21 108/25 109/7 110/17 114/16 116/12 116/23 118/4 121/6 122/20 124/11 125/14 127/24 128/13 129/19 135/23 138/13 140/24 141/5 143/22 144/2 144/3 144/21 144/22 144/24 145/4 146/7 147/4 147/23 147/23 149/16 150/1 150/5 151/1 151/20 154/13 157/25 158/3 161/24 163/13 163/17 163/18 164/7 164/13 165/14 165/22 166/17 167/22 168/6 169/15 171/21 172/16 176/24 179/2</p> <p>wouldn't [5] 38/8 68/5 109/6 118/22 161/4</p> <p>wrap [2] 13/18 135/18</p> <p>wrapped [4] 17/12 29/8 98/24 137/24</p> <p>write [1] 161/23</p> <p>writer [1] 79/11</p> <p>writers [1] 79/21</p> <p>writing [3] 79/14 149/5 149/6</p> <p>written [1] 101/5</p> <p>wrong [4] 26/17 57/23 92/24 124/13</p> <p>wrongful [3] 5/8 55/19 57/8</p> <p>wrote [1] 4/13</p> <p>X</p> <p>Xarelto [1] 177/13</p> <p>Y</p> <p>Yahoo [2] 24/9 24/12</p> <p>year [17] 2/12 12/18 33/25 49/6 50/23 51/5 82/21 82/22 84/1 123/19 131/22 136/22 137/2 143/19 152/9 156/21 170/13</p> <p>years [67] 10/4 12/11 16/15 20/20 21/21 22/6 29/11 34/2 41/25 43/4 43/6 49/16 50/5 52/22 53/11 53/15 54/17 58/10 58/15 64/12 65/1 65/3</p>	<p>73/2 77/9 84/1 89/17 89/18 90/6 91/13 99/9 100/15 112/11 115/15 117/15 117/25 120/23 120/25 121/10 121/14 121/19 123/4 126/15 132/9 134/18 139/17 140/1 140/3 140/8 143/25 146/9 147/22 148/17 153/1 155/11 156/6 156/15 160/11 160/25 162/24 163/8 163/20 166/22 169/22 172/3 173/6 175/6 175/13</p> <p>Yechezkel [1] 162/20</p> <p>yes [24] 46/15 47/1 48/25 61/7 65/11 70/8 70/19 71/22 75/10 76/24 82/4 88/18 89/12 94/24 108/13 125/11 150/20 155/15 156/1 157/20 159/19 161/24 162/18 165/10</p> <p>yesterday [3] 2/25 98/9 153/6</p> <p>yet [9] 37/8 72/2 74/2 76/2 84/20 129/25 132/23 167/16 169/8</p> <p>York [7] 10/8 23/1 65/18 68/17 139/18 144/6 144/7</p> <p>you [843]</p> <p>you'd [1] 68/12</p> <p>you've [1] 28/13</p> <p>young [19] 14/3 22/13 22/14 27/24 49/18 58/7 58/10 82/21 107/18 143/12 143/14 144/1 144/3 144/11 144/16 169/24 170/1 172/24 175/5</p> <p>younger [15] 4/17 14/8 14/12 17/2 22/20 23/12 24/17 32/2 38/20 69/16 69/17 82/24 100/11 170/25 171/24</p> <p>youngest [1] 82/23</p> <p>your [276]</p> <p>yours [2] 9/1 39/11</p> <p>yourself [7] 8/19 12/7 17/13 26/4 29/2 29/7 81/17</p> <p>Z</p> <p>ZANTAC [29] 1/4 22/2 37/10 51/1 63/22 70/2 101/19 103/2 105/19 132/25 133/9 134/17 143/13 148/20 149/24 153/5 155/17 155/22 156/17 157/2 160/10 160/17 161/2 161/3 164/11 164/13 166/18 168/9 177/21</p> <p>zealous [1] 13/21</p> <p>Zicam [1] 69/13</p> <p>zone [1] 114/20</p> <p>Zoom [24] 2/19 5/1 8/12 8/13 8/14 21/15 21/18 25/5 32/1 32/6 39/10 39/17 82/1 91/6 91/17 92/8 94/15 100/5 120/4 131/2 157/24 167/6 172/9 173/21</p>
---	---	--